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1. INTRODUCTION 
1.1 NEURODEGENERATIVE DISORDERS 
Neurodegenerative disorders are categorized by progressive and irreversible 
loss of neurons from particular regions of the brain. Prototypical neurodegenerative 
disorders include Parkinson's disease (PD) and Huntington's disease (HD), results in 
deviations in the control of drive due to the loss of neurons from structures of the basal 
ganglia1, 2. Alzheimer's disease (AD), results in the loss of cortical and hippocampal 
neurons with impairment of memory and cognitive ability and amyotrophic lateral 
sclerosis (ALS), producing muscular weakness due to degeneration of bulbar, spinal, 
and cortical motor neurons3, 4.  
Neurodegenerative disorders are comparatively common and represent a 
substantial societal and medical problem. They are principal disorders of later life, 
developing in individuals who are neurologically normal, although childhood-onset 
forms of each of the disorders are known. PD is detected in more than 1% of population 
above the age of 655, 6, whereas AD affects as many as 10% of the same individuals7. 
HD, which is a genetically stable autosomal dominant disorder, is less common in the 
population as a whole but disturbs, on average, 50% of each generation in families 
booming the gene. ALS also is moderately rare but sometimes leads to disability and 
death8, 9.   
At present, the pharmacological therapy of neurodegenerative disorders is 
restricted mostly to symptomatic treatments that do not change the course of the 
underlying disease. Symptomatic management for PD, where the neurochemical deficit 
created by the disease is well defined. The available treatments for AD, HD, and ALS 
are much more limited in effectiveness, and there is a need for new strategies10, 11.  
1.1.1 Overview of dementia 
Dementia is a depleting disorder, which gradually declines the cognitive 
functions including memory, language, speech, orientation, judgement and learning 
capacity. More than 47 million people are currently living with dementia worldwide 
and about 75% of this population that is, 27 million people, are estimated to be affected 
by AD12. It may be due to therapeutic drug use (atropine and phenytoin), metabolic 
disorders (hypoglycemia, acid base disorders, hematological disorders, hyperglycemia, 
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hypopituitarism, pulmonary insufficiency, cardiac dysfunction and hepatolenticular 
degeneration), deficiency states (vitamin B12, niacin and folate deficiency), collagen 
(vascular disorders, systemic lupus erythematous, Behcet’s syndrome, temporal arteritis 
and sarcoidosis), intracranial disorders (tumor, epilepsy, neurosyphilis, encephalitis, 
multiple sclerosis and cerebrovascular insufficiency) and exogenous intoxication 
(alcohol, lead, carbon monoxide, organophosphates, mercury, manganese and toluene). 
It is not a part of normal aging and constantly turns as pathological process.  
Alzheimer’s is the most common cause of dementia13-15. 
1.2 TYPES OF DEMENTIA  
1.2.1 Alzheimer’s disease 
Alzheimer’s disease is a chronic, progressive and disabling organic brain 
disorder characterized by disturbances of multiple cortical functions including memory, 
comprehension, orientation, language and learning capacity16. AD is accompanied by 
three main structural changes in the brain including neuronal loss, formation and 
accumulation of hyperphosphorylated tau protein termed neurofibrillary tangles (NFT) 
and aggregation of β-amyloid (Aβ) peptides termed senile or amyloid plaques17. These 
changes are most protruding in the cholinergic system, primarily in cortex and 
hippocampus, which is closely associated with memory loss and cognitive dysfunction 
in AD18.  
1.2.2 Vascular dementia 
Earlier known as post stroke or multi-infract dementia, for about 10% of 
population associated with vascular dementia and it is less common as a cause of 
dementia than Alzheimer’s disease. In most of the cases, the infarct dementia co-occurs 
with Alzheimer’s pathology. Vascular dementia occurs most commonly from damage 
leading to infarcts or blood vessel blockages or bleeding in the brain19, 20. 
1.2.3 Dementia with Lewy bodies (DLB) 
Lewy bodies are abnormal aggregations of the protein alpha-synuclein that 
accumulate in neurons and dementia can result when they develop in cortex region of 
the brain. Aggregation of alpha-synuclein in the brains of people with Parkinson’s 
disease (PD), in which it is produced by extreme neuronal loss in a part of the brain 
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called the substantia nigra. While people with dementia with Lewy bodies DLB and PD 
both have Lewy bodies, the onset of the disease is marked by cognitive impairment in 
DLB and motor impairment in PD20. 
1.2.4 Fronto-temporal lobar degeneration (FTLD) 
FTLD includes dementias such as behavioural-variant FTLD, primary 
progressive aphasia, corticobasal degeneration, Pick’s disease and progressive 
supranuclear palsy. Initial symptoms include marked changes in behaviour and 
personality and difficulty with comprehending language. Nerve cells in the frontal lobe 
and temporal lobes of the brain are affected, and these regions become significantly 
shrunken. In addition, the upper layers of the cortex typically become spongy and soft 
and have protein insertions (tau protein or the transactive DNA-binding protein) 21. 
1.2.5 Mixed dementia 
Mixed dementia is characterized by the hallmark abnormalities of more than 
one cause of dementia most commonly Alzheimer’s combined with vascular dementia, 
followed by Alzheimer’s with DLB, and Alzheimer’s with vascular dementia and DLB. 
Vascular dementia with DLB is less common. Recent studies suggest that mixed 
dementia is more common than previously recognized, with about half of those with 
dementia having pathologic evidence of more than one cause of dementia 20, 22. 
1.2.6 Creutzfeldt-Jakob disease 
This is very rare fatal disorder and rapidly impairs memory and coordination 
and causes behaviour changes, results from a misfolding protein (prion) that causes 
other proteins throughout the brain to misfold and malfunction. It may be hereditary 
sporadic or caused by a known infection. A specific form called variant Creutzfeldt-
Jakob disease is believed to be caused by consumption of products from cattle affected 
by mad cow disease23. 
1.2.7 Parkinson’s disease (PD) dementia 
Problems with movement (slowness, rigidity, tremor and changes in gait) are 
common symptoms of PD. In PD, alpha-synuclein aggregates appear in an area deep in 
the brain called the substantia nigra. The aggregates are thought to cause degeneration 
of the nerve cells that produce dopamine. The incidence of PD is about one-tenth that 
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of Alzheimer’s. As PD progresses, it often results in dementia secondary to the 
accumulation of Lewy bodies in the cortex (similar to DLB) or the accumulation of 
beta-amyloid clumps and tau tangles24, 25. 
1.2.8 Normal pressure hydrocephalus 
Symptoms include difficulty in walking, memory loss and inability to control 
urination. Accounts for less than 5% of dementia cases and caused by impaired 
reabsorption of cerebrospinal fluid and the consequent build-up of fluid in the brain, 
increasing pressure in the brain. People with a history of brain haemorrhage 
(particularly subarachnoid haemorrhage) and meningitis are at increased risk. It can 
sometimes be corrected with surgical installation of a shunt in the brain to drain excess 
fluid26. 
1.3 ALZHEIMER'S DISEASE (AD)  
AD produces an impairment of cognitive abilities that is gradual in onset but 
relentless in progression. Impairment of short-term memory usually is the first clinical 
feature, whereas retrieval of distant memories is preserved relatively well into the 
course of the disease. As the condition progresses, additional cognitive abilities like, the 
ability to calculate, exercise visuospatial skills, and use common objects and tools 
(ideomotor apraxia) are impaired27. The level of arousal or alertness of the patient is not 
affected until the condition is very advanced, nor is there motor weakness, although 
muscular contractures are an almost universal feature of advanced stages of the disease. 
Death, most often from a complication of immobility such as pneumonia or pulmonary 
embolism, usually ensues within 6 to 12 years of onset. The diagnosis of AD is based 
on careful clinical assessment of the patient and appropriate laboratory tests to exclude 
other disorders that may mimic AD; at present, no direct antemortem confirmatory test 
exists28.  
1.3.1 History of Alzheimer’s disease 
AD, the most common form of dementia, is an increasing medical, social and 
public health concern29. AD is characterized by deficits in the cholinergic system and 
the deposition of β-amyloid (Aβ) protein30. The cholinergic system has been targeted 
for the design of anti-Alzheimer’s drugs. Cholinesterase inhibitors increase both the 
level and duration of action of acetylcholine. In addition, it has been demonstrated that 
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both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) play an important 
role in Aβ-aggregation during plaque formation31. Many research papers published in 
the last decade have indicated that the structures of compounds that exhibit 
cholinesterase inhibitory activity are diverse32, 33. 
1.3.2 Neurotransmitters in AD 
The brain, in AD, shows the loss of cholinergic neurons in the basal forebrain, 
decreased acetylcholine (ACh) levels, and a decrease in the acetylcholine synthesizing 
enzyme choline acetyltransferase (CHAT) in the cerebral cortex. Animal models show 
that ACh plays a crucial role in information processing and memory34. Although other 
neurotransmitters (noradrenaline, serotonin, somatostatin and other peptides) are also 
deficient in AD, the cognitive impairment correlates best with the loss of cholinergic 
input. AChE inhibitors (tacrine) and ACh receptor agonists, including nicotine, have 
been used to treat AD. The marginal success of this approach suggests that, in addition 
to ACh deficiency, there are other profound alterations that contribute to the cognitive 
dysfunction35. 
The relation between accumulation of plaques in brain and dementia was first 
identified by Dr. Alois Alzheimer in the year 1906. Later Emil Kraepelin, a German 
psychiatrist coined this disease as Alzheimer’s disease in 1910. Dr. Alois Alzheimer 
described the case of a 51-year-old woman, Auguste D in the year 1906. The patient 
was admitted to a hospital for 5 years with a cluster of unusual symptoms with loss of 
memory, inability to speak, disorientation, behavioral problems, and hallucinations. 
After the death, Dr. Alzheimer examined her brain tissue and found two hallmarks of 
Alzheimer’s disease (AD): Beta-amyloid plaques and neuroﬁbrillary tangles. Hence the 
name of this neurodegenerative disorder delivers his name36, 37. 
1.3.3 Signs of AD 
The first sign of AD is generally related to memory loss. The person may 
replicate the things many times, have trouble in naming items, may lose things like 
their wallet, glasses, keys, or get lost themselves. These changes may become more 
pronounced with time. Simple tasks can prove difficult for the person with 
Alzheimer’s, such as dressing, preparing meals, using the phone, or playing a game38. 
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The Alzheimer's Association has identified ten warning signs concerned someone 
might have Alzheimer's or dementia: 
 Memory loss; 
 Problems with abstract thinking; 
 Difficulty performing familiar tasks; 
 Changes in mood or behavior; 
 Disorientation to time and place; 
 Misplacing things in unusual places; 
 Poor or decreased judgment; 
 Changes in personality;  
 Problems with language; and,  
 Loss of initiative. 
1.3.4 Clinical facts of AD 
The possibility of AD is 6% to 10% for men and 12% to 19% for women after 
65 years of age. About 47% of individuals develop AD beyond the age of 80 years. 
This disease last for 20 years and the persons would survive around 8 years after initial 
diagnosis39. 
1.3.5 Etiology of AD 
1.3.5.1 Genetic etiology of AD 
The genetic etiology of AD includes apolipoprotein E gene polymorphism, 
amyloid-β protein precursor and presenilin I and II40. 
1.3.5.2 Non-genetic etiology of AD 
Non- genetic etiology of AD includes age, tauopathy and other risk factors like 
hyperlipidemia, hypertension, diabetes mellitus, stroke, smoking, traumatic head injury 
and familial history39, 41.  
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1.3.6 Stages of AD 
Different stages of AD are: 
1. Mild cognitive decline 
2. Moderate cognitive decline 
3. Severe cognitive decline 
 
Fig 1: Brain image showing different stages of AD 
1.3.6.1 Mild cognitive decline 
People suffering from mild Alzheimer’s disease may appear to be healthy, but 
they actually have trouble making sense of their surroundings. Because mild 
Alzheimer’s is commonly mistaken for normal aging, it may take time to realize the 
condition of mild Alzheimer’s disease42. 
1.3.6.2 Moderate cognitive decline 
In the moderate stages of Alzheimer’s disease, the degeneration of the brain 
worsens and spreads to other areas that control language, reasoning, sensory processing 
and thought. The signs of the disease become more pronounced and behavioral 
problems often occur43. 
1.3.6.3 Severe cognitive decline 
Damage to the brain’s nerve cells is widespread in severe stages of AD. People 
may lose motor coordination and the ability to walk, speak, feed themselves, and 
recognize others (Fig. 1). Typically at this stage, full time care is required20, 43. 
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Each of the three stages; mild, moderate and severe, can be further broken down 
into seven levels: 
Level 1 is considered to be a normal adult with no decline in function or of their 
memory. 
Level 2 is a slight decline from stage 1. A person in stage 2 will complain of 
deficits in recalling familiar names and places. This stage is often overlooked because 
forgetfulness is assumed to be a natural process associated with aging. 
Level 3 is characterized by a mild decline defined as early Alzheimer’s disease. 
In stage 3, anxiety and denial are large features under intensive interviews. Some signs 
include getting lost when traveling to unknown locations, low performance in the 
workplace and loss of words or vocabulary.  
Level 4 is identified when the person needs assistance in complicated tasks such 
as handling individual’s finances. In this stage people tend to exhibit problems 
remembering their past events such as family vacations. 
Level 5 brings a severe decline in a person’s ability to do everyday activities. In 
this stage one will need constant assistance by another individual to do simple tasks of 
picking out cloths, preparing meals and even starting a car. They will have difficultly 
recalling current information, but will still remember major information involving 
themselves and their families. 
Level 6 is when there is a moderately severe decline in the disease. By this 
stage, Alzheimer’s patients forget significant amount of information including personal 
facts. When this stage approaches, a person needs assistance getting dressed and going 
to the bathroom, and has disturbed sleep patterns. The individual’s personality change 
becomes highly apparent and noticeable. Feeling frustrated and acting out with violence 
may occur because of the person’s inability to remember or process information long 
enough to react to their own thoughts. 
Level 7 is the last stage in Alzheimer’s disease. This is when there is a severe 
decline in vocabulary, emotions and the connection of the brain to body parts. Patients 
are now limited to six or seven words at a time. They lose the ability to walk, sit up 
straight, hold up their head, and even smile. In this stage there is no ability to have a 
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hand-to-mouth motion, to place one foot in front of another, or even to urinate on their 
own. 
1.3.7 Pathophysiology of AD  
AD is driven by two processes: extracellular deposition of beta amyloid-Aβ and 
intracellular accumulation of tau protein. Both these compounds are insoluble. Aβ is the 
main component of senile plaques and tau is the component of neurofibrillary tangles. 
Aβ deposition is specific for AD and is thought to be primary. Tau accumulation is also 
seen in other degenerative diseases and is thought to be secondary44, 45. 
1.3.7.1 Beta Amyloid hypothesis 
Aβ is a 36 to 43 amino acid peptide, which is part of a larger protein, 
the Amyloid Precursor Protein (APP). APP is a transmembrane protein, made by 
neurons and other brain cells. It is also found in extraneural tissues and is especially 
abundant in platelets. Its function is unknown. The Aβ amyloid residue includes part of 
the transmembrane domain of APP and is derived from cleavage of APP by the 
enzymes β-and γ-secretase. Aβ monomers and oligomers are further degraded by other 
enzymes46. Defective clearance of Aβ from aberrant cleavage of APP and other 
mechanisms results in its accumulation (Fig. 2). Aβ monomers polymerize initially into 
soluble oligomers and then into larger insoluble fragments such as Aβ42, which 
precipitate as amyloid fibrils. 
 
Fig 2: Cascade of pathophysiological events in AD 
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The beta amyloid hypothesis is the basis of a novel prevention and treatment 
method for AD that was reported recently in transgenic mice that overexpress a mutant 
APP and develop AD neuropathology. Active immunization of young animals with Aβ 
and passive immunization with Aβ antibodies prevented the development of AD; 
immunization of older animals reduced the extent and severity of AD pathology. Based 
on these findings, a human vaccine consisting of synthetic Aβ was developed. Phase I 
trials went uneventfully but phase II studies were terminated because some patients 
developed an autoimmune meningoencepalitis47, 48. 
1.3.7.2 Tau protein aggregation  
Neurofibrillary degeneration is characterized by the deposition in the neuronal 
body and processes of insoluble polymers of over-phosphorylated microtubule 
associated protein tau. Tau aggregates as pairs of filaments that are twisted around one 
another (paired helical filaments). These deposits interfere with cellular functions by 
displacing organelles (Fig. 3).  
 
Fig. 3: Aggregation of tau protein cascade events 
By distorting the spacing of microtubules, they impair the axonal transport thus 
affecting the nutrition of axon terminals and dendrites. No mutations of the tau gene 
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occur in AD. Abnormal tau first appears in the entorhinal cortex, then in the 
hippocampus, and at later stages in association cortex. Recent observations in 
transgenic mice suggest that the spread of the pathology to anatomically linked areas 
occurs by passage of abnormal tau across synapses49, 50. 
1.3.7.3 Cholinergic deficiency 
Neuronal and pharmacological evidences correlate the severity of memory 
impairment with cholinergic hypo function. Cholinergic neurotransmitter plays an 
important role in patients with AD. AChE is an enzyme that hydrolyzes the 
acetylcholine to acetate and choline at the cholinergic synapses51. Reduction in the level 
of acetylcholine in the brain produces memory and learning impairment. ACh binds to 
postsynaptic receptors such as muscarinic and nicotinic receptors (Fig. 4). Presynaptic 
nicotinic receptors are responsible for the release of neurotransmitters important for 
memory and mood (acetylcholine, glutamate, serotonin and norepinephrine). Loss of 
nicotinic receptor subtypes in the hippocampus and cortex has been observed in AD. 
Muscarinic receptors are not involved in the development of dementia, but blocking of 
this receptor produces confusion52, 53.  
 
Fig 4: Synthesis, release and binding of ACh to its receptors 
The function of BuChE is less clearly defined, and it can hydrolyze 
acetylcholine as well as other esters. Membrane bound form of AChE decreases the 
acetylcholine level in the brain of patients with AD whereas the BuChE remains 
unchanged or even increased. But ACh level can be maintained by selective BuChE 
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inhibitors. Drugs that inhibit both enzymes may be preferably used for treating AD.  In 
AD, there is an involvement of pyramidal neurons there by neuronal loss, synapse loss, 
reduced glutamate concentration and tangle formation leads to the formation of 
neurofibrillary tangles. Glutamate is the neurotransmitter of pyramidal neurons54-56. 
1.3.7.4 Glutamatergic pathway 
Glutamate is the primary excitatory neurotransmitter present in the brain. In the 
central nervous system, it is ubiquitous and involved roughly 66% of all brain synapse. 
Glutamatergic neurons are critical, because they form projections to other areas of brain 
including cholinergic neurons and the cholinergic neurons help for cognition and 
memory. (N-methyl-D-aspartate) (NMDA) receptor undergoes sustained low level 
activation in AD brains and produce sustained low level neurotransmission56. This 
dysregulation of NMDA glutamate receptor leads to neuronal damage and the 
continuous activation of the receptor leads to the chronic calcium influx within the 
neuron. This interfere the normal signal transduction pathway of glutamate and leads to 
increased production of amyloid precursor protein (APP). APP increases the plaque 
development and hyperphosporylation of tau protein (Neurofibrillary tangle (NFT) 
formation) followed by neuronal toxicity. AD patients appeared to have reduced 
number of glutamate reuptake receptor sites and abnormal expression of glutamate 
transporter leads to the formation of NFT and these tangles are pathogenic55. 
Other neurotransmitters like serotonin and norepinephrine levels become altered 
in brain which affect wide spread areas of cerebral cortex and produce behavioral and 
psychological symptoms of dementia57. 
1.3.7.5 Oxidative stress 
In AD brains, Aβ induces lipid peroxidation and generate reactive nitrogen and 
reactive oxygen species. The reactive nitrogen and oxygen molecules contain unpaired 
electrons in the outer shell. These unpaired electrons react with other molecules to 
achieve a stable configuration and produce free radicals. These free radicals cause 
cellular and molecular damage. This reaction is permanent and occurs in all types of 
neuronal macromolecules such as proteins, lipids, carbohydrates and nucleic acids. 
Brain is unprotected to damage from oxidative stress, because of high oxygen 
consumption rate, high lipid content and relative loss (paucity) of anti-oxidant enzymes 
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compared to other organs. Neuronal oxidation can cause numerous problems such as 
irreparable DNA damage and up-regulation of pro inflammatory cytokines57, 58. 
1.3.7.6 Chronic inflammation 
Senile plaques, NFT and damaged neurons may stimulate inflammation and 
leads to cell damage. Microglia is a type brain cells and it includes neurons, astrocytes 
and oligodendrocytes. These are involved in the infection or injury within the brain. 
Microglia gets activated and release cytotoxic molecules like pro-inflammatory 
cytokines, reactive oxygen species (ROS), complement proteins and proteinases during 
AD pathogenesis. Cytokines stimulate inflammatory process and promote apoptosis of 
neurons and oligodendrocytes and induce myelin damage55, 59.  
1.3.8 Acetylcholine 
Acetylcholine (ACh) is a neurotransmitter present in the cholinergic synapses 
and neuroeffector junctions in the central and peripheral nervous systems. 
Acetylcholine acts through muscarinic and nicotinic cholinergic receptors. With the 
help of these receptors, signals will transduce via different mechanisms. Cholinergic 
agonists are drugs, which mimics the effects of acetylcholine at these receptors60. 
N +CH 3
C H 3
C H 3
O
C H 3
O . Cl- 
Fig 5: Structure of acetylcholine chloride 
1.3.9 Synthesis, storage and release of acetylcholine 
In the synthesis of acetylcholine, Acetyl CoA (Acetyl co-enzyme A) is derived 
from pyruvate via multistep pyruvate dehydrogenase reaction. Choline is taken up from 
the extracellular fluid into the axoplasm by active transport mechanism.  In the 
presence of choline acetyltransferase, choline and acetyl CoA gets converted to 
acetylcholine. After its synthesis, ACh is taken up by storage vesicles present in the 
nerve terminals. The vesicles contain both ACh and ATP in the ratio of 10:1 and the 
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release of ACh and other neurotransmitters takes place through calcium-mediated 
exocytosis. Release of ACh inhibited by botulinum and tetanus toxins from 
clostridium60, 61. 
1.3.10 Management of AD 
Several pathogenic pathways are involved in the progression of AD via senile 
plaques, NFT, oxidative stress, inflammatory cascade, glutamatergic and cholinergic 
deficiency. Based on the pathological mechanism, several pharmacological treatments 
are available. Currently available drug therapy for AD consist of cholinesterase 
inhibitors and NMDA receptor antagonists approved by the U.S. Food and Drug 
Administration (FDA) and some neuroprotective agents improve the psychological and 
behavioral symptoms of AD62. 
A major approach to the treatment of AD has involved attempts to augment the 
cholinergic function of the brain63. An early approach was the use of precursors of 
acetylcholine synthesis, such as choline chloride and phosphatidyl choline (lecithin). 
Physostigmine, a rapidly acting, reversible AChE inhibitor, produces improved 
responses in animal models of learning, and some studies have demonstrated mild 
transitory improvement in memory following physostigmine treatment in patients with 
AD. The use of physostigmine has been limited because of its short half-life and 
tendency to produce symptoms of systemic cholinergic excess at therapeutic doses64. 
Four inhibitors of AChE currently approved by the FDA for treatment of 
Alzheimer's disease are tacrine (1,2,3,4-tetrahydro-9-aminoacridine; COGNEX), 
donepezil (ARICEPT), rivastigmine (EXCELON), and galantamine (RAZADYNE)65.  
Tacrine is a potent centrally acting inhibitor of AChE66. Studies of oral tacrine 
in combination with lecithin have confirmed that there is indeed an effect of tacrine on 
some measures of memory performance, but the magnitude of improvement observed 
with the combination of lecithin and tacrine is modest at best67. The side effects of 
tacrine often are significant and dose-limiting; abdominal cramps, anorexia, nausea, 
vomiting, and diarrhoea are observed in up to one-third of patients receiving therapeutic 
doses, and elevations of serum transaminases are observed in up to 50% of those 
treated. Because of significant side effects, tacrine is not clinically widely used68.  
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Donepezil is a selective inhibitor of AChE in the CNS with little effect on 
AChE in peripheral tissues. It produces modest improvement in cognitive scores in 
Alzheimer's disease patients and has a long half-life, allowing once-daily dosing. 
Rivastigmine and galantamine are dosed twice daily and produce a similar degree of 
cognitive improvement. Adverse effects associated with donepezil, rivastigmine, and 
galantamine are similar in character but generally less frequent and less severe than 
those observed with tacrine; they include nausea, diarrhea, vomiting, and insomnia. 
Donepezil, rivastigmine, and galantamine are not associated with the hepatotoxicity 
that limits the use of tacrine69.  
An alternative strategy for the treatment of AD is the use of the NMDA 
glutamate-receptor antagonist memantine. Memantine produces a use-dependent 
blockade of NMDA receptors. In patients with moderate to severe AD, use of 
memantine is associated with a reduced rate of clinical deterioration. Whether this is 
due to a true disease-modifying effect, possibly reduced excitotoxicity, or is a 
symptomatic effect of the drug is unclear. Adverse effects of memantine usually are 
mild and reversible and may include headache or dizziness70. 
1.3.10.1 Cholinesterase inhibitor 
Donepezil, rivastigmine, galantamine and tacrine are cholinesterase inhibitors. 
These drugs prevent the breakdown of acetylcholine in the brain by inhibition of 
acetylcholinesterase enzyme and increase the expression of nicotinic receptors. These 
drugs help in maintaining the acetylcholine level in brain and compensate the loss of 
functioning of brain cells. Cholinesterase inhibitors are used for the treatment of mild, 
moderate and severe AD and the side effects observed are nausea, vomiting, loss of 
appetite and increased frequency of bowel movement71. 
1.3.10.2 NMDA receptor antagonist 
Memantine is a NMDA receptor antagonist. It is used for the treatment of 
moderate to severe AD. Memantine restores the function of damaged nerve cells and 
reduce abnormal excitatory signals by modulating the NMDA receptor activity. Some 
compounds are mainly under preclinical and clinical evaluations based on the 
mechanism of β-amyloid (Aβ) cascade and tau protein hyperphosporylation72. 
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1.3.10.2.1 Aβ-targeting strategies 
 α secretase activators/ modulators 
 β secretase inhibitors (GSK188909, PMS777) 
 γ secretase inhibitors/ modulators (BMS299897,MRK-560) 
 Aβ- aggregation inhibitors 
 M1 muscarinic agonists (AF102B, AF267B) 
 Immunotherapy 
 Apo lipoprotein (ApoE) promotes Aβ clearance 
 Aβ-degrading enzyme 
 Drugs influencing Aβ blood- brain barrier transport 
1.3.10.2.2 Treatment based on tau pathology 
 Prevention of phosphorylation of tau 
 Prevention of the aggregation of tau 
 Tau immunotherapy 
 Prevent the misfolding of tau 
1.3.10.2.3 Non-steroidal anti-inflammatory drugs (NSAIDs) 
 Trials with COX-2 selective inhibitors 
1.3.10.2.4 Antioxidants nutrients and agents: Vitamins C and E, oestrogen, statins, 
omega-3 polyunsaturated fatty acids. 
1.3.11 Alzheimer’s disease inducing agents 
 Alzheimer’s disease or learning impairment was induced by drugs and 
chemicals such as: scopolamine, benzodiazepines, phencyclidine, monosodium 
glutamate, aluminium chloride and colchicines73. 
1.3.11.1 Scopolamine and neurotoxicity 
Scopolamine, a muscarinic cholinergic receptor antagonist, has been widely 
adopted to study cognitive deficits in experimental animals. After intraperitoneal (i.p.) 
injection of scopolamine, the cholinergic neurotransmission is blocked, leading to 
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cholinergic dysfunction and impaired cognition in rats74. Recently, it has been reported 
that Indigofera tinctoria Linn (Fabaceae) attenuates cognitive and behavioral deficits in 
scopolamine-induced amnesic mice75. Munshi et al., 2016 reported the efficacy of 
Brahmi ghrita against scopolamine induced amnesia in rats76. 
 
Fig. 6: Mechanism of scopolamine induced AD 
The administration of the antimuscarinic agent scopolamine to young human 
volunteers produces transient memory deficits77. Analogously, scopolamine has been 
shown to impair memory retention when given to mice shortly before training in a dark 
avoidance task78-80. The ability of a range of different cholinergic agonist drugs to 
reverse the amnesic effects of scopolamine is now well documented in animals and 
human volunteers. However, the neuropathology of dementia of the Alzheimer type is 
not confined to the cholinergic system81. 
Nabeshima et al., studied the antagonism against phencyclidine-induced 
retrograde amnesia in mice82. Lenegre et al., investigated the effects of piracetam on 
amnesia induced by scopolamine, diazepam and electroconvulsive shock83. Yamaoto et 
al., studied the effect of drugs on the impairment of working memory produced by 
scopolamine, ethylcholine aziridinium (AF64A) or cerebral ischemia using a repeated 
acquisition procedure in a three-panel runway apparatus84. Braida et al., investigated 
the short (120 min) and long-lasting (360 min) antagonism of scopolamine- induced 
amnesia in rats in an eight-arm radial maze by a cholinesterase inhibitor85. 
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1.3.11.2 Aluminum and neurotoxicity 
The hypothesis that there is a link between aluminum and AD was first brought 
out in the 1960s by Terry and Pena and by Klatzo and collaborators in 196586. Early in 
1976, high levels of aluminum have been found in brain lesions, such as plaques and 
tangles, in patients with Alzheimer’s disease and also in other conditions such as 
Parkinson’s disease (PD), pre-senile dementia, amyotrophic lateral sclerosis, neuro 
fibrilar degeneration, dialysis encephalopathy syndrome and nigro striatal syndrome87 
(Fig. 7). 
 
Fig. 7: Mechanism of Aluminium chloride induced AD 
Elevated aluminum levels have been reported in other less common 
neurological disorders such as the Guamanian Parkinsonian-amylotrophic lateral 
sclerosis constellation and Hallervorden-Spatz Disease. The most common 
neurostructural alterations induced by high levels of aluminum in the brain is: brain 
ventricle dilatation and thinning of the corpus callosum reduce neural cell density, 
degenerative changes like picnosis, vacuolization, chromatin condensation increase 
neural filaments in neuron from the spinal cord and brainstem, axonal cerebellar 
disorder with degeneration of the Purkinje cells. There is some experimental evidence 
that aluminium chloride exposure can adversely affect the dopaminergic system88. 
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Extended exposure to 100 mM Al lactate increased striatal levels of the dopamine 
metabolite in turns, suggests that exposure to Al may cause increased turnover of 
dopamine. The development of an encephalopathy, characterized by cognitive deficits, 
in-coordination, tremor and spinocerebellar degeneration, among workers in the 
aluminum industry also indicates that exposure to the metal can be profoundly 
deleterious89.  
Abnormal neurological symptoms have been observed in several patients 
receiving intramuscular injections of Al-containing vaccines. There have been many 
experimental studies on animals and on isolated cells showing that aluminum has toxic 
effects on the nervous system. In 1991, Guy showed that the uptake of aluminum by 
human neuroblastoma cells display an epitope associated with Alzheimer's diseases. 
Chronic exposure of animals to aluminum is associated with behavioral, 
neuropathological and neurochemical changes90. Among them, deficits of learning and 
behavioral functions are most evident. Several metals interact with β-amyloid (Aβ) in 
senile plaques. It is interesting to note that, compared to other Aβ-metal complexes 
(Aβ-Fe, Aβ-Zn, Aβ-Cu), Aβ-Al is unique in promoting a specific form of Aβ 
oligomerization that has marked neurotoxic effects91. There are a lot of ways by which 
Al can damage neural cells:  
 Interfering with glucose metabolism, leading to low amounts of ACh 
precursors. 
 Inhibiting the binding of Ca++ ions 
 Increasing the production of cAMP 
 Changes in the cytoskeleton protein, leading to phosphorylation, proteolysis, 
transport and synthesis disruption 
 Inducing oxidative damage by lipid peroxidation 
 Interacting directly to genomic structures 
Being involved in the production of reactive oxygen species (ROS), aluminum 
may cause impairment in mitochondrial bioenergetics and may lead to the generation of 
oxidative stress which may lead to a gradual accumulation of oxidatively modified 
cellular proteins, lipids and affects endogenous antioxidant enzyme activity, leading to 
degeneration of neuronal cells92, 93. In this way, aluminum is a strong candidate for 
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consideration as a subtle promoter of events typically associated with brain aging and 
neurodegenerative disorders. 
1.4 DRUG DISCOVERY AND DEVELOPMENT 
 Drug discovery process was started in the beginning of nineteenth century, by 
John Langley in the year of 1905. It is considered as the fastest developing directions of 
the high-tech investigations that depend on the achievements of molecular chemistry, 
information technologies, quantum physics, biology and bio-informatics94.  
Drug discovery process involves the identification of target, target validation, 
lead identification, lead optimisation, synthesis, screening for its therapeutic efficacy 
(Fig. 8). Once the testing is completed, drug development process will started prior to 
the clinical trials95, 96. 
                     
 
Fig 8: Different phases of drug discovery cycle 
 
1.4.1 Drug design 
 Rational drug design uses different computational methods to identify novel 
compounds. The compounds having maximum efficacy, safety and selectivity towards 
the target will be identified. In rational drug design the biological and physical 
properties of the target was studied97. 
1.4.2 Types of drug design 
 There are two types of drug design: 
Structure based drug design  
Ligand based drug design  
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1.4.2.1 Structure based drug design 
 Structural based virtual screening is being with the identification of a potential 
ligand binding site on the target molecule (Fig. 9). Target site possesses a variety of 
hydrogen bond donors and acceptors, hydrophobic characteristics, and molecular 
adherence surfaces. The structure of a target protein is determined by NMR, X-ray 
crystallography and initialization of the target is the key steps in the structure based 
drug design98, 99. The experimental structures of ligands bound to the enzymes, provide 
ideas for analog design and intern useful for the docking studies100. 
 
Fig. 9 Various steps involved in structure based drug design  
1.4.2.2 Ligand based drug design  
 It is a most effective method used in the absence of the structural information of 
the target. Ligand based method is used to know about the inhibitors of the target 
receptor101.  The active lead molecule is detected by using structural properties or 
topological similarity properties. Several criteria for structure similarity comparisons 
are shape of an individual fragment or electrostatic properties of the molecule. The lead 
molecules are generated by ranked based on their function score obtained by using 
different algorithms98.  
In this method, the known active molecules (ligands) and the potential hit 
molecules are compared using pre-defined mathematical expressions (grids) to quantify 
molecular similarity (Fig. 10). These approaches essentially neglect any information 
about the target biomolecule as well as the 3D structure of the ligand compounds. 
Ligand based drug design is efficient method and applied in combination with 
structure-based approaches to identify potential bioactive leads that can be fed into 
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docking experiments101.    
 
 
Fig. 10 Difference between structure based drug design and ligand based drug 
design 
1.4.3 Molecular docking 
 Molecular docking may be defined as an optimization problem, which would 
describe the “best-fit” orientation of a ligand that binds to a particular protein of 
interest. The aim of molecular docking is to achieve an optimized conformation for 
both the protein and ligand and relative orientation between protein and ligand such that 
the free energy of the overall system is minimized102. 
 In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to a second when bound to each other to form a 
stable complex. Knowledge of the preferred orientation may be used to predict the 
binding affinity between two molecules or strength of association (scoring functions). 
During the docking process, the ligand and the protein adjust their conformation to 
achieve an overall “best-fit” and this kind of conformational adjustments results in the 
overall binding and can be referred to as “induced-fit”103. 
1.4.4 Identification of right target and active site 
 Target is a protein molecule and it is closely related to disease. It plays an 
important role in signal transduction pathway that often disrupted in the diseased 
condition. Enzymes are one of the targets as they have binding pockets for inhibition as 
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well as substrates104.  
1.4.5 Lipinski’s rule of Five 
            This rule was postulated by Christopher A. Lipinski in 1997, based on the 
observation that most of the drugs are relatively small and lipophilic in nature. 
Lipinski's rule of five is a rule of thumb to evaluate druglikeness. This rule states that, 
an orally active "drug-like" molecule has: 
 Partition coefficient (log P) less than 5  
 Molecular weight below 500 daltons 
 Not more than 10 hydrogen bond acceptors (O and Ngroup) 
 Not more than 5 hydrogen bond donors (OH and NH group) 
 Number of violations less than 5 
 All the numbers should be multiples of 5, which is the basis for the 
rules name. 
 The rule describes about pharmacokinetic properties of a drug in the human 
body, including their absorption, distribution, metabolism, and excretion (ADME). But 
this rule does not predict if a compound is pharmacologically active or not105. This set 
of rules suggests that the necessary properties for good oral bioavailability and reflects 
the notion that pharmacokinetics, toxicity and other adverse effects are directly linked 
to the chemical structure of a drug106.  
1.4.6 Types of docking107  
1.4.6.1 Rigid docking 
 The rigid docking is suitable position for the ligand in receptor environment 
obtained while maintaining its rigidity. 
1.4.6.2 Flexible docking 
 In this process, receptor-ligand interaction was obtained by changing internal 
torsions of ligand into the active site while receptor remains fixed.  
 
1.4.7 Docking approaches108 
 Two approaches mainly popular in molecular docking. 
1.4.7.1 Shape complementarity: This technique is used to describe the matching  of 
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ligand and protein as complementarity surfaces. 
1.4.7.2 Simulation: It is the actual docking process additionally calculating the 
interaction energies between ligand and protein molecule. 
1.4.8 Mechanics of docking 
 To perform a docking screen, the first requirement is a structure of a protein. 
Protein structure has been determined by using x-ray crystallography or NMR 
spectroscopy. The protein structure and database of potential ligands serve as inputs to 
a docking programme. The success of docking program depends on: search algorithm 
and scoring function109. 
1.4.8.1 Search algorithm 
 A strict search algorithm would completely elucidate all possible binding modes 
between ligand and receptor. Various searching algorithms have been developed and 
widely used in molecular docking software.  But it would be too expensive to 
computationally generate all the possible conformations. Some commonly used 
searching algorithms are: Monte Carlo (MC) methods, fragment based method, distance 
geometry, matching method, ligand fit method, point complementarity method, blind 
docking, inverse docking, genetic algorithms and molecular dynamics110. 
1.4.8.2 Monte Carlo (MC) method 
 MC methods are among the most established and widely used stochastic 
optimization techniques. These methods use sampling technique and are able to 
generate states of low energy conformations. The system makes random moves and 
accepts or rejects each conformation based on Boltzmann probability. Simulated 
annealing is a generalization of a Monte Carlo method for examining the equations of 
state and frozen states of n-body systems. The initial state of the system has random 
thermal motion within a specified potential force field. The effective temperature of the 
system (the degree of random motion) is decreased overtime, until a final stable docked 
position is obtained. The random motion of the ligand allows for exploration of the 
local search space, and the decreasing temperature of the system acts to drive it to a 
minimum energy111. One of the most widely used simulated annealing procedures is the 
Metropolis Monte Carlo simulated annealing algorithm. 
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1.4.8.3 Matching method 
 This method focuses on complementarity. Ligand atom is placed at the ‘best’ 
position in the site, generating a ligand receptor configuration that may require 
optimization103. 
1.4.8.4 Distance geometry 
 Many types of structural information can be expressed as intra or intermolecular 
distances. The distance geometry formalism allows these distance to be assembled and 
3 dimensional structures consistent with them to be calculated. The fast sampling of the 
conformational space do not always results in reliable results. An example of a program 
using distance geometry in docking problem is Dock It102. 
1.4.8.5 Fragment based method 
 Fragment based methods can be described as dividing the ligand into separate 
protons or fragments, docking the fragments and finally linking these fragments 
together with target protein. Some mainly used fragment based methods are FlexX104. 
1.4.8.6 Ligand fit method 
 Ligand fit term provide a rapid accurate protocol for docking small molecules 
ligand into protein active sites for considering shape complimentarity between ligand 
and protein active sites103. 
1.4.8.7 Inverse docking 
 This method uses computer for finding toxicity and side effects of protein 
targets on a small molecule. Knowledge of these targets combined with that of 
proteomics pharmacokinetic profile can facilitate the assessment of potential toxicities 
side effect of drug candidate. One of these protocols is selected for docking studies of 
particular ligand108. 
1.4.8.8 Genetic algorithm (GA) 
 It is adaptive heuristic search technique premised on the evolutionary ideas of 
natural selection and genetics. The basic concept of GA is designed to simulate 
processes in natural system necessary for evolution. As such they represent an 
intelligent exploitation of a random search within a defined search space to solve a 
problem. In a genetic algorithm, there is a population of solutions that undergo 
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mutation and crossover transformations. The algorithm maintains a selective pressure 
towards an optimal solution, with a randomized information exchange permitting 
exploration of the search space. A range of programs implements GA for docking110. 
1.4.8.9 Molecular dynamics (MD) 
 Molecular dynamics (MD) is widely used as a powerful simulation method in 
many fields of molecular modeling. In the context of docking, by moving each atom 
separately in the field of the rest atoms, MD simulation represents the flexibility of both 
the ligand and protein more effectively than other algorithms. The disadvantage of MD 
simulations is that they progress in very small steps and thus have difficulties in 
stepping over high energy conformational barriers, which may lead to inadequate 
sampling. MD simulations are often efficient at local optimization. Thus a current 
strategy is to use random search in order to identify the conformation of the ligand, 
followed by the further subtle MD simulations106. 
1.4.9 Scoring functions 
 The purpose of the scoring function is to delineate the correct poses from 
incorrect poses, or binders from inactive compounds in a reasonable computation time. 
Scoring functions involve estimating, rather than calculating the binding affinity 
between the protein and ligand and through these functions, adopting various 
assumptions and simplifications104. Scoring functions can be divided into: 
i. Force-field-based scoring functions 
ii. Knowledge-based scoring functions. 
iii. Empirical based scoring functions 
1.4.9.1 Force-field-based scoring functions 
 Classical force-field-based scoring functions assess the binding energy by 
calculating the sum of the non-bonded (electrostatics and van der Waals) interactions. 
The electrostatic terms are calculated by a Columbic formulation. Force-field-based 
scoring functions also have the problem of slow computational speed. Thus cut-off 
distance is used to handle the non-bonded interactions106.  
 Extensions of force-field-based scoring functions consider the hydrogen bonds, 
solvation’s and entropy contributions. Software programs, such as DOCK, GOLD and 
AutoDock, offer users such functions. They have some differences in the treatment of 
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hydrogen bonds, the form of the energy function etc. The results of docking with force-
field-based functions can be further refined with other techniques, such as linear 
interaction energy and free-energy perturbation methods (FEP) to improve the accuracy 
in predicting binding energies109. 
1.4.9.2 Knowledge-based scoring functions 
 Knowledge based scoring functions use statistical analysis of ligand-protein 
complexes crystal structures to obtain the inter-atomic contact frequencies and 
distances between the ligand and protein. The scoring is done by statistically observing 
the intermolecular relation between the ligand and the biological target protein using 
“Potential of Mean Force”. The intermolecular interactions are mainly taken into 
account for the functional group or atoms that occur frequently. The result of this 
method is evaluated based on the binding interactions. PMF, Drug Score, SMoG and 
Bleep are examples of knowledge-based functions110. 
1.4.9.3 Empirical scoring functions 
            In empirical scoring functions, binding energy decomposes into several energy 
components, such as hydrogen bond, ionic interaction, hydrophobic effect and binding 
entropy. Each component is multiplied by a coefficient and then summed up to give a 
final score. Coefficients are obtained from regression analysis fitted to a test set of 
ligand-protein complexes with known binding affinities. Empirical scoring functions 
may be treated in a different manner by different software, and the numbers of the 
terms included are also different. LUDI, PLP, Chem Score are examples derived from 
empirical scoring functions112. 
1.4.10 Various docking software’s used for molecular docking 
 Over 60 docking software systems and more than 30 scoring functions are 
reported. Molecular docking is implemented as part of software packages for molecule 
design and simulation. More than one search method and scoring functions are 
provided in order to increase the accuracy of the simulations113. Only some of the 
software was made available and a limited number of them are widely used.  
Commonly used software’s are: 
 
 
28 
 
1.4.10.1 DOCK 
           DOCK is one of the oldest and best known ligand-protein docking programs. It 
systematically describes the geometries of ligands and binding sites by sets of spheres, 
attempting to fit each compound from a database into the binding site and the spheres 
could be overlapped by means of an approximate clique-detection procedure. The 
initial version used rigid ligands and edibility was later incorporated via incremental 
construction of the ligand in the binding pocket of the target protein.  In the recent 
version of DOCK, steric matching-scores with electrostatic and molecular mechanics 
interaction energies are considered for the ligand-receptor complex.  In scoring, the 
docked orientations of atomic hydrophobicity descriptors are being considered114, 115. 
1.4.10.2 GOLD (Genetic Optimization for Ligand Docking) 
 GOLD uses a flexible docking mode for small molecules into protein binding 
site which utilizes genetic algorithm for the conformational search that forms a 
powerful tool for screening and identification of novel lead compounds. It provides 
docking of flexible ligand and protein with flexible hydroxyl groups. Otherwise the 
protein is considered to be rigid. This makes it a good choice when the binding pocket 
contains amino acids that form hydrogen bonds with the ligand. Gold is very highly 
regarded within the molecular modeling community for its accuracy and reliability and 
its genetic algorithm parameters are optimized for wide range of virtual screening 
applications. GOLD has one of the most comprehensive validation test sets114, 116. 
1.4.10.3 GLIDE (Grid Based Ligand Docking with Energetics) 
 GLIDE approximates a close and complete systematic search for the 
conformational, orientation and positional space of the docked ligand. Glide uses a 
series of hierarchical filters to search for possible locations of the ligand in the active-
site region of the receptor. A grid representation for the shape and properties of the 
receptor is used that progressively scores for ligand posing114.  
1.4.10.4 FlexX (Future Leaders Exchange) 
 A pose-clustering algorithm is used to classify the docked ligand conformers, 
where the placement of rigid core fragment is based on interaction geometry between 
fragment and receptor groups. Prior to docking, FlexX cuts the ligand at rotatable bonds 
into pieces, places a base fragment into the active site, and incrementally builds up the 
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ligand again, using the other pieces. For a protein with known three dimensional 
structures and a small ligand molecule, FlexX predicts the geometry of the protein-
ligand complex and estimates the binding affinity. It has a bit lower hit rate than DOCK 
but provides better estimates of Root Mean Square Distance for compounds with 
correctly predicted binding mode117.  
1.4.10.5 SLIDE (Screening for ligands by induced-fit docking) 
 SLIDE represents a general approach to organic and peptidyl database 
screening. It can handle large binding-site templates and uses multi-stage indexing to 
identify feasible subsets of template points for ligand docking. An optimization 
approach based on mean-field theory is applied to model induced-fit complementarities, 
balancing flexibility between the ligand and the protein side chains. SLIDE can screen 
100,000 compounds within a few days and returns a ranked list of sterically feasible 
ligand candidates, ranked by complementarities to the protein's binding site114.  
1.4.10.6 Hammerhead 
           Hammerhead is suitable for screening large databases of flexible molecules by 
binding to a protein of known structure. It precisely docks a variety of known flexible 
ligands, and it spends an average of only a few seconds on each compound during a 
screen. The approach is completely automated, from the elucidation of protein binding 
sites, through the docking of molecules, to the final selection of compounds for 
assay114. 
1.4.10.7 FRED 
           FRED takes a multi-conformer library or database of one or more ligands, a 
target protein structure, a box defining the active site of the protein and several optional 
parameters. Various options are available for optimization with respect to the built-in 
scoring functions: optimization of hydroxyl group rotamers, rigid body optimization, 
torsion optimization, and reduction of the number of poses that are passed on to the 
next scoring function. The ligand conformers and protein structure are treated as rigid 
during the majority of the docking process. FRED's docking strategy is to exhaustively 
score all possible positions of each ligand in the active site. The exhaustive search is 
based on rigid rotations and translations of each conformer. This novel strategy 
completely avoids the sampling issues associated with stochastic methods used by most 
other docking programs (such as Gold, FlexX, Dock and Glide). FRED jobs can also be 
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easily distributed over multiple processors to further reduce docking time115. 
1.4.10.8 AutoDock 
 AutoDock is a script driven flexible automated and random search docking 
technique operated by altering the ligand or a subset of ligand with several rotatable 
bonds to predict the binding interaction between small molecules to the known receptor 
three-dimensional structure. The robustness of AutoDock can be attributed to the 
Monte Carlo simulated annealing, evolutionary, genetic and Lamarckian genetic 
algorithm methods. The prediction of bound conformations such as enzyme-inhibitor 
complexes, peptide-antibody complexes and even protein-protein interactions has 
shown a great success through AutoDock. Possible orientations are evaluated with 
AMBER force field model in conjunction with free energy scoring functions and a 
large set of protein-ligand complexes with known protein-ligand constants. The newest 
unreleased version 4 contains side chain flexibility. AutoDock has more informative 
web pages than its competitors; because of its free academic license118. 
1.4.10.9 AutoDock 4.2 
 Auto Dock 4.2 uses a semi-empirical free energy force field to evaluate 
conformations during docking simulations. The force field evaluates binding in two 
steps. The ligand and protein start in an unbound conformation. In the first step, the 
intra molecular energies are estimated for the transition from these unbound states to 
the conformation of the ligand and protein in the bound state. The second step then 
evaluates the intermolecular energies of combining the ligand and protein in their 
bound conformations. The parameters are based on the amber force field119. 
Computer-aided drug design (CADD) is a key component in the process of drug 
discovery and development, as it offers great promise to drastically reduce cost and 
time120. It belongs to pre-clinical phase and it plays a key role in identifying new 
investigational drug-likes and developing new potential inhibitors related to a 
determinate target. Computational strategy protocol characterized by the use of 
bioinformatics tools for lead optimization which reduce the cycle time and cost121. 
AutoDock 4.2 is the most recent version which has been widely used for virtual 
screening, due to its enhanced docking speed122.  
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1.4.11 Applications of drug design 
 
Use of computational techniques in drug discovery and development process is 
rapidly gaining in implementation, popularity, and appreciation. Different terms are 
being applied to this area, including computer-aided drug design (CADD), computer-
aided molecular modeling (CAMM), computational drug design, computer-aided 
molecular design (CAMD), computer-aided rational drug design, and in silico drug 
design. Both computational and experimental techniques have important roles in drug 
discovery and development and represent complementary approaches123, 124. CADD 
entails: 
 Streamline drug discovery and development process 
 Leverage of chemical and biological information about ligands and/or 
targets to identify and optimize new drugs 
 Design of in silico filters to eliminate compounds with undesirable 
properties (poor activity and/or poor absorption, distribution, metabolism, 
excretion and toxicity, ADMET) and develop most promising drug 
candidates. 
 1.5 FLAVONOIDS 
 Flavonoids are the large group of biologically active water-soluble plant 
compounds that include pigments present naturally in fruits, vegetables, and herbs. 
Flavonoids are inherent part of human and animal diet however, these are not 
synthesized within the body of animals including human125.  
 Flavonoids are present in different parts of plant materials include leaves, fruits, 
vegetables, herbs and beverages such as tea and red wine. Flavonoids are associated 
with a broad spectrum of health promoting effects126-128. They are an indispensable 
component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic 
applications129-130. Most of them are present in our everyday’s life. 
1.5.1 Structure of flavonoids 
 Flavonoids occur in aglycones, glycosides and methylated derivatives131. 
Glycosylation makes it less active, more water soluble and permits its storage in the cell 
vacuole. Chemically flavonoids may be defined as a group of polyphenolic compounds 
consisting of two substituted benzene rings (Ring A and C) connected by the side chain 
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of three carbon atoms and an oxygen bridge (Ring B)132 (Fig. 11).  
 
Fig. 11 Basic structure of flavonoids  
 All flavonoids share a basic C6-C3-C6 phenyl-benzopyran backbone. Ring A 
usually shows a phloroglucinol substitution pattern133. 
1.5.2 Classification of flavonoids 
 Over 5000 naturally occurring flavonoids have been characterized from various 
plants sources134 (Fig. 12). 
 
Fig. 12 Classification of flavonoids 
1.5.3 Pharmacological activity of flavonoids 
 Flavonoids exhibit several biological effects such as: 
1.5.3.1 Antimicrobial activity 
 Flavonoids are esters of phenolic acids; it has antibacterial, antifungal and 
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antiviral activities. Naringin, quercetin, hesperetin and catechin possess various 
spectrum of antiviral activity. It affects the replication and infectivity of certain RNA 
and DNA viruses. Flavones selectively inhibit HIV-1 and HIV-2 or similar 
immunodeficiency virus infections. Quercetin and apigenin exhibit antibacterial 
activity135. 
1.5.3.2 Hepatoprotective activity 
Flavonoids have also been found to possess hepatoprotective activity. In a study 
carried out to investigate the flavonoid derivatives silymarin, apigenin, quercetin, and 
naringenin, as putative therapeutic agents against microcrystin LR-induced 
hepatotoxicity, silymarin was found to be the most effective one. The flavonoid, rutin 
and venoruton, showed regenerative and hepatoprotective effects in experimental 
cirrhosis131. 
1.5.3.3 Anti-oxidant activity 
 Flavonoids possess antioxidant potential due to its structural characteristics. 
They protect cells against the damaging effects of reactive oxygen species. Anti-
oxidant activity of flavonoids is due to their ability to reduce free radical formation, 
scavenge free radicals, and chelate metal ions. Flavonoids require a hydroxyl group at 
carbon 3 of the C- ring and two hydroxyl groups at carbons 3' and 4' of the B- ring for 
their anti-oxidant activity. Luteolin, genistein, daidzein, kaempferol, morin, naringenin, 
quercetin, apigenin, myricetin, robinin and cyanidin are possess antioxidant activity. 
Catechins are a most powerful flavonoid for protecting the body against reactive 
oxygen species131, 134. 
1.5.3.4 Antidiabetic activity 
 Flavonoids, especially quercetin, have been reported to possess antidiabetic 
activity. Quercetin brings about the regeneration of pancreatic islets and probably 
increases insulin release in streptozotocin-induced diabetic rats. Quercetin stimulates 
insulin release and enhanced Ca2+ uptake from isolated islets cell which suggest a place 
for flavonoids in noninsulin-dependent diabetes135. 
1.5.3.5 Anti-inflammatory activity 
 Flavonoids possess the anti-inflammatory activity. Hesperidin possesses 
significant anti-inflammatory and analgesic effect. Recently apigenin, luteolin and 
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quercetin have been reported to exhibit anti-inflammatory activity. Kaempferol, 
quercetin, myricetin, fisetin can modulate arachidonic acid metabolism via the 
inhibition of cyclooxygenase (COX) and lipoxygenase activity (LOX) activities131.  
1.5.3.6 Antiulcer activity 
 Flavonoids possess anti-ulcerogenic activity. Flavonoid glycosides decreased 
ulcer and inhibited gastric acid and pepsin secretions. Quercetin, rutin, and 
kaempferolare used for the treatment of peptic ulcer132, 134.  
1.5.3.7 Cardioprotective effects 
 Flavonoids have been stimulated by the potential health benefits arising from 
the antioxidant activity. It results in the high propensity to transfer electrons, chelate 
ferrous ions, and scavenge reactive oxygen species. Because of these properties, 
flavonoids have been considered as potential protectors against chronic cardiotoxicity 
caused by the cytostatic drug doxorubicin. Doxorubicin is a very effective antitumor 
agent but its clinical use is limited by the occurrence of a cumulative dose-related 
cardiotoxicity, resulting in, for example, congestive heart failure (negative inotropic 
effect) In a recent report, the cardiotoxicity of doxorubicin on the mouse left atrium has 
been inhibited by flavonoids, 7- monohydroxyethylrutoside and 7’,3’,4’-
trihydroxyethylrutoside131. 
1.5.3.8 Anticancer effect  
 Dietary flavonoid reduces the risk of cancer. Flavonoids are dietary 
antioxidants, which act as nutritional supplements during treatment of cancer or during 
inflammatory disorders. Flavonoids and their synthetic analogues are used in the 
treatment of ovarian, breast, cervical, pancreatic, and prostate cancer. Daidzein and 
genistein inhibit both hormonal and non-hormonal types of cancer. Tangeritin is a citrus 
flavonoid and inhibit cancer cell proliferation. Flavonoids such as 3-hydroxyflavone, 
3',4' dihydroxy flavone, 2',3'-dihydroxy flavone, fisetin, apigenin, and luteolin are 
potential inhibitors of tumour cell proliferation. Quercetin and apigenin inhibit 
melanoma growth. Kaempferol, catechin, toxifolin and fisetin also suppressed cell 
growth136. 
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1.5.3.9 Immunomodulatory activity  
 Certain flavonoids act as immune boosters. Flavonoids help in the homeostasis 
within the immune system and also affect the functions of inflammatory cells. 
Quercetin helps to inhibit several initial process of inflammation and stimulate immune 
functions137. 
1.5.3.10 Neuroprotective property  
 Neurodegenerative disorders were developed by the combined effect of 
oxidative stress, inflammation and transition metal accumulation. Alzheimer’s and 
dementias are the major disorder of neurodegeneration. Flavonoids have attracted 
potential interest for their neuroprotective properties, because of their antioxidant, anti-
inflammatory and metal chelating properties. Flavones and flavonones play an effective 
role in the treatment of neurodegenerative diseases138.  
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2. LITERATURE REVIEW 
2.1 RELATED TO DOCKING STUDIES 
Hamulakova et al., 2017 synthesized a novel series of acridine-coumarin 
hybrids and biologically evaluated their inhibitory potential of AChE and BuChE. The 
newly synthesized derivatives 9a-d have shown higher activity against human AChE 
compared with 7-MEOTA as the standard drug. Among them derivative 9b exhibited 
the most potent AChE inhibitory activity, with an IC50 value of 5.85μM compared with 
7-MEOTA (IC50=15μM). Molecular modelling studies were performed to predict the 
binding modes of compounds 9b, 9c and 9f with hAChE/hBuChE139.  
Park et al., 2017 studied the AChE and BuChE inhibitory potential of 3,4-
dihydroquinazoline derivatives. In particular, compound 8b and 8d were the most active 
compounds in the series against BuChE with IC50 values of 45nM and 62nM, as well as 
146- and 161-fold higher affinity to BuChE, respectively. Molecular docking 
simulations were performed to get better insights into the mechanism of binding of 3,4-
dihydroquinazoline derivatives. As expected, compound 8b and 8d bind to both 
catalytic anionic site (CAS) and peripheral site (PS) of BuChE with better interaction 
energy values than AChE. Furthermore, the non-competitive/mixed-type inhibitions of 
both compounds confirmed their dual binding nature in kinetic studies140. 
Sehgal et al., 2016 carried out detailed screening analyses by 2-D similarity 
search against prescribed antidepressant drugs using their physicochemical properties. 
Ligand Scout was employed to ascertain novel molecules and pharmacophore 
properties. In this study, three novel compounds showed maximum binding affinity 
with HSPB8. Docking analysis elucidated that Met37, Ser57, Ser58, Trp60, Thr63, 
Thr114, Lys115, Asp116, Gly117, Val152, Val154, Leu186, Asp189, Ser190, Gln191, 
and Glu192 are their critical residues for ligand-receptor interactions. Site-directed 
mutagenesis could be significant for further analysis of the binding pocket. The novel 
findings based on an in silico approach may be momentous for potent drug design 
against depression and Charcoat Marie Tooth disease141. 
Sehgal et al., 2015 performed two-dimensional similarity search with selected 
inhibitor, keeping in view the physiochemical properties of the inhibitor. Docking 
studies revealed that Glu-53, Thr-54, Lys-58, Val-85, Ser-86, Tyr-87, Leu-88, Glu-90, 
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Leu-95, Val-98, Ser-100, Glu-112, Tyr-116, Lys-120, Asp-121, and Arg-122 were 
critical residues for receptor-ligand interaction. The C-terminal of selected isoforms is 
conserved, and binding was observed on the conserved region of isoforms. Further 
analysis of this inhibitor through site-directed mutagenesis could be helpful for 
exploring the details of ligand-binding pockets142.  
Ahmad et al., 2014 generated the ligand based pharmacophore model using the 
Discovery studio 2.0 software. In addition to this a structure based approach has been 
used to validate the developed pharmacophoric features to gain a deeper insight into its 
molecular recognition process. This validated pharmacophore and the docking model 
was then implemented as a query for pharmacophore based virtual screening to 
prioritize the probable hits for the caspase-3. Two ligands, ZINC12405015 and 
ZINC12405043 were finally selected on the basis of their fit values and docking scores. 
This study also reveals the vital amino acids His-121, Ser-205, Arg-207 which were 
found to be playing crucial role in the binding of the selected compounds within the 
active site of caspase-3143. 
Jalkute et al., 2013 performed molecular dynamics simulation of crystal 
structure complex of testis truncated version of ACE (tACE) and its inhibitor lisinopril 
along with Zn2+ to understand the dynamic behavior of active site residues of tACE. 
Root mean square deviation results revealed the stability of tACE throughout 
simulation. The residues Ala 354, Glu 376, Asp 377, Glu 384, His 513, Tyr 520 and 
Tyr 523 of tACE stabilized lisinopril by hydrogen bonding interactions. Using this 
information, in subsequent part of study, molecular docking of tACE crystal structure 
with Aβ-peptide was investigated and the interactions of Aβ-peptide with enzyme 
tACE was explored. The residues Asp 7 and Ser 8 of Aβ-peptide were found in close 
contact with Glu 384 of tACE along with Zn2+. This study has demonstrated that the 
residue Glu 384 of tACE might play key role in the degradation of Aβ-peptide by 
cleaving peptide bond between Asp 7 and Ser 8 residues. Molecular basis generated by 
this attempt could provide valuable information towards designing of new therapies to 
control Aβ concentration in Alzheimer’s patient144. 
Spilovska et al., 2013 designed, synthesized and evaluated a structural series of 
7-MEOTA-adamantylamine thioureas as inhibitors of human AChE and human 
BuChE. The compounds were prepared based on the multi-target-directed ligand 
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strategy with different linker lengths (n = 2–8) joining the well-known NMDA 
antagonist adamantine and the hAChE inhibitor 7-methoxytacrine (7-MEOTA). Based 
on in silico studies, these inhibitors proved dual binding site character capable of 
simultaneous interaction with the peripheral anionic site (PAS) of human AChE and the 
catalytic active site (CAS). These structural derivatives exhibited very good inhibitory 
activity towards human BuChE resulting in more selective inhibitors of this enzyme. 
The most potent cholinesterase inhibitor was found to be thiourea analogue 14 (with an 
IC50 value of 0.47 µM for human AChE and an IC50value of 0.11 µM for hBuChE, 
respectively). Molecule 14 is a suitable novel lead compound for further evaluation 
proving that the strategy of dual binding site inhibitors might be a promising direction 
for development of novel AD drugs145. 
Grover et al., 2012 elucidated the ChE inhibitory potential of withanolide A 
and its associated binding mechanism. Binding interactions of the ligand to the receptor 
were predicted with the help of computational docking studies. Ligand interaction with 
the human AChE residues was found to be Thr78, Trp81, Ser120 and His442 as active 
sites, it could be responsible for its inhibitory activity. The study further proved the 
evidence for consideration of withanolide A as a potential molecule in prevention and 
management of AD146.  
Dayangac-Erden et al., 2009 found that (E)-resveratrol, inhibited histone 
deacetylase activity in a concentration-dependent manner and half-maximum inhibition 
was observed at 650 μm. Molecular docking studies showed that (E)-resveratrol had 
more favorable free energy of binding (−9.09 kcal/mol) and inhibition constant values 
(0.219 μm) than known inhibitors. To evaluate the effect of (E)-resveratrol on survival 
motor neuron (SMN2) expression, spinal muscular atrophy type I fibroblast cell lines 
was treated with (E)-resveratrol. The level of full-length SMN2 mRNA and protein 
showed 1.2 to 1.3 fold increases after treatment with 100 μm (E)-resveratrol in only one 
cell line. These results indicated that response to (E)-resveratrol treatment was variable 
among cell lines. This data demonstrated a novel activity of (E)-resveratrol and that it 
could be a promising candidate for the treatment of spinal muscular atrophy147. 
Tatar et al., 2009 tested 33 carboxylic acid derivatives to understand the 
structural requirements for histone deacetylase (HDAC) inhibition activity. Several 
modifications were applied to develop the structure–activity relationships of carboxylic 
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acid HDAC inhibitors. HDAC inhibition activities were investigated in vitro by using 
HeLa nuclear extract in a fluorimetric assay. Molecular docking was also carried out 
for the human HDAC8 enzyme in order to predict inhibition activity and the 3D poses 
of inhibitor–enzyme complexes. Among the compounds tested caffeic acid derivatives 
chlorogenic acid and curcumin were found to be highly potent compared to sodium 
butyrate, a well-known HDAC inhibitor148. 
2.2 ENZYME INHIBITION ASSAY 
Lan et al., 2017 developed novel family of cinnamic acid derivatives and 
evaluated cholinesterase inhibitory activity by fusing N-benzyl pyridinium moiety and 
different substituted cinnamic acids. In vitro studies showed that most compounds were 
endowed with a noteworthy ability to inhibit cholinesterase, self-induced Aβ (1-42) 
aggregation, and to chelate metal ions. Especially, compound 5l showed potent 
cholinesterase inhibitory activity (IC50, 12.1 nM for eeAChE, 8.6 nM for human AChE, 
2.6 μM for eqBuChE and 4.4 μM for hBuChE) and the highest selectivity toward AChE 
over BuChE. It also showed good inhibition of Aβ (1-42) aggregation (64.7% at 
20 μM) and good neuroprotection on PC12 cells against amyloid-induced cell toxicity. 
Finally, compound 5l could penetrate the BBB, as forecasted by the PAMPA-BBB 
assay and proved in OF1 mice by ex vivo experiments. Overall, compound 5l seems to 
be a promising lead compound for the treatment of Alzheimer's disease149. 
Saeedi et al., 2017 evaluated the in vitro ChEI activity of various plants 
including betel nuts (Areca catechu L.), clove buds (Syzygium aromaticum L.), aerial 
parts of dodder (Cuscuta chinensis Lam.), common polypody rhizomes (Polypodium 
vulgare L.) and turpeth roots (Ipomoea turpethum R. Br.) which were recommended for 
the treatment of AD symptoms in Iranian traditional medicine (ITM). Among them, 
aqueous extract of A. catechu L. was found to be potent anti-AChE 
(IC50 = 32.00 μg/mL) and anti-BuChE (IC50 = 48.81 ± 0.1200 μg/mL) agent150. 
Singh et al., 2016 evaluated the anti-amnesic effect of Ocimum basilicum L., 
Ocimum sanctum L. and Ocimum gratissimum L. extracts using in-vitro and in-vivo 
models. In-vitro AChE inhibitory and antioxidant activities of hydro-methanol extracts 
of plants were evaluated using Ellman and DPPH and FRAP assays, respectively. Brain 
AChE activity, oxidative profile and histopathological studies were assessed to outline 
the anti-amnesic mechanism of the extract. Significant antioxidant and AChE 
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inhibition activity was observed with all prepared extracts and however, Ocimum 
basilicum extract (OBE) showed most marked free radical scavenging, reducing power 
and AChE inhibition (IC50 0.65±0.15mg/ml) activity. The in-vivo studies showed that 
OBE pre-treatment (200 and 400 mg/kg, p.o.) reversed the memory deficit induced by 
scopolamine in mice, evident by significant (p<0.05) decrease in the transfer latency 
time and increase in step down latency in elevated plus maze and passive shock 
avoidance task, respectively. These biochemical changes were responsible for the anti-
amnesic and neuroprotective activities of Ocimum basilicum which may be attributed to 
the presence of phenolic and flavonoid compounds and can be developed as an 
effective anti-amnesic drug151. 
Hajlaoui et al., 2016 investigated the chemical composition and evaluated the 
antioxidant, antimicrobial, cytotoxic and anti-acetylcholinesterase properties of 
Tunisian Origanum majorana essential oil. The findings showed that the oil exhibited 
high activity, particularly in terms of reducing power and β-carotene bleaching, 
inducing higher IC50 values than butylated hydroxyl toluene. The oil showed an 
important antimicrobial activity against 25 bacterial and fungal strains. In fact, the 
inhibitory zone, minimum inhibitory concentration and minimum bactericidal 
concentration values were recorded. A low cytotoxic effect was observed against 
cancer (Hep-2 and HT29) and continuous cell lineage (Vero), with cytotoxic 
concentration (CC50) values ranging from 13.73 to 85.63 mg/mL. The oil was also 
evaluated for anti-AChE effects, which showed that it exhibited 
significant activity with IC50 values reaching 150.33 ± 2.02 μg/mL152. 
Formagio et al., 2015 investigated the in vitro antiproliferative and 
anticholinesterase activities of 11 extracts from 5 Annonaceae species. Antiproliferative 
activity was assessed using 10 human cancer cell lines. Thin-layer chromatography and 
a microplate assay were used to screen the extracts for AChE inhibitory activity. The 
chemical compositions of the active extracts were investigated using high performance 
liquid chromatography. Eleven extracts obtained from five Annonaceae plant species 
were active and were particularly effective against the UA251, NCI-470 lung, HT-29, 
NCI/ADR, and K-562 cell lines with growth inhibition (GI50) values of 0.04-0.06, 
0.02-0.50, 0.01-0.12, 0.10-0.27, and 0.02-0.04 mg/mL, respectively. The Annona 
cacans extract displayed the lowest activity. Based on the microplate assay, the percent 
AChE inhibition of the extracts ranged from 12 to 52%, and the Annona coriacea seed 
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extract resulted in the greatest inhibition (52%). Caffeic acid, sinapic acid, and rutin 
were present at higher concentrations in the Annona crassiflora seed samples153.  
Ali-Shtayeh et al., 2014 investigated the in vitro AChEI in herbal medicines 
traditionally used in Palestine to treat cognitive disorders. The effect on AChE activity 
of 92 extracts belonging to 47 medicinal plants were evaluated using micro-well plate 
AChE activity  (NA-FB)  and  Ellman’s assays and antioxidant activity using DPPH 
assay.67.4% and 37% of extracts inhibited AChE by >50% using the NA-FB and 
Ellman’s assays. Using NA-FB assay, 84 extracts interacted reversibly with the 
enzyme, of which Mentha spicata (94.8%), Foeniculum vulgare (89.81), and Oxalis 
pes-caprae (89.21) were most potent, and 8 showed irreversible inhibitions of leaves of 
Lupinus pilosus (92.02%) were most active. Antioxidant activity was demonstrated by 
73 extracts Majorana syriaca (IC50 0.21mg/ml), and Rosmarinus officinalis (0.38) were 
the most active.  Palestinian flora has shown to be a rich source for, new and promising 
agents (AChEIs) for the treatment of AD154. 
Liu et al., 2014 focused on the synthesis and anti-cholinesterase evaluation of 
new donepezil like analogs. A new series of phthalimide derivatives (compounds 4a-4j) 
were synthesized via Gabriel protocol and subsequently amidation reaction was 
performed using various benzoic acid derivatives. Then, the corresponding anti-
acetylcholinesterase activity of the prepared derivatives (4a-4j) was assessed by 
utilization of the Ellman’s test and obtained results were compared to donepezil. 
Besides, docking study was also carried out to explore the likely in silico binding 
interactions. According to the obtained results, electron withdrawing groups (Cl, F) at 
position 3 and an electron donating group (methoxy) at position 4 of the phenyl ring 
enhanced the AChE inhibitory activity. Compound 4e (m-Fluoro, IC50 = 7.1 nM) and 4i 
(p-Methoxy, IC50 = 20.3 nM) were the most active compounds in this series and exerted 
superior potency than donepezil (410 nM). Moreover, a similar binding mode was 
observed in silico for all ligands in superimposition state with donepezil into the active 
site of AChE155.  
Alipour et al.,  2013 synthesised a novel series of coumarin and 3-coumaranone 
derivatives encircling the phenacyl pyridinium moiety and assessed their AChE and 
BuChE inhibitory activity by Ellman's method. All compounds exhibited AChE and 
BuChE inhibitory activity in the µM concentrations. The computational docking studies 
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revealed that the selected compounds were inhibitors of AChE dual binding site. A 
kinetic study was carried out and mixed type of enzyme inhibition was found. The 
compounds were evaluated for their antioxidant activity and no significant activity was 
witnessed156. 
2.3 SCOPOLAMINE INDUCED AMNESIA 
Akinyemi et al., 2017 assessed the combined pretreatment effect of curcumin, 
the major polyphenolic compound of turmeric (Curcuma longa) rhizomes, with 
donepezil, a ChE inhibitor, on cognitive function in scopolamine-
induced memory impairment in rats. Rats were pretreated with curcumin (50 mg/kg) 
and/or donepezil (2.5 mg/kg) via oral administration (p.o.) for seven successive days. 
Dementia was induced at the end of the treatment period by a single i.p. injection 
of scopolamine (1 mg/kg). Thereafter, the changes in spatial and episodic memory were 
conducted; then, the estimation of some biochemical parameters associated with 
cognitive function was determined. Scopolamine-treated rats showed 
impaired learning and memory and increased activities of AChE and BuChE, adenosine 
deaminase (ADA), and lipid peroxidation with a concomitant decrease in levels of 
nitric oxide (NO) and reduced glutathione (GSH), superoxide dismutase (SOD), and 
catalase when compared with control. Thus, the observed anti-amnestic effect could be 
linked to their inhibitory effect on key enzyme of cholinergic system associated with 
memory function157. 
Erfanparast et al., 2017 investigated the effects of microinjection of vitamin 
B12 into the hippocampus on the orofacial pain and memory impairments induced by 
scopolamine and orofacial pain. The memory impairment induced by orofacial pain 
was improved by vitamin B12 and physostigmine used alone. Naloxone prevented, 
whereas physostigmine enhanced the memory improving effect of vitamin B12 in the 
pain-induced memory impairment. All the above-mentioned chemicals did not alter 
locomotor activity. The results of the present study showed that at the level of the 
dorsal hippocampus, vitamin B12 modulated orofacial pain through a mu-opioid 
receptor mechanism. In addition, vitamin B12 contributed to hippocampal cholinergic 
system in processing of memory. Moreover, cholinergic and opioid systems may be 
involved in improving effect of vitamin B12 on pain-induced memory impairment158. 
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Imam et al., 2017 investigated the neuro-cognitive implications of oral 
cannabis use in rats. Cannabis significantly reduced rearing frequencies in the OFT and 
EPM, and increased freezing period in the OFT. It also reduced percentage alternation 
similar to scopolamine in the Y maze, and these effects were coupled with alterations in 
the cortico-hippocampal neuronal architectures. These results pointed the detrimental 
impacts of cannabis on cortico-hippocampal neuronal architecture and morphology, and 
consequently cognitive deficits159.  
Rahmati et al., 2017 studied the effects of L. officinalis extract in scopolamine-
induced memory impairment, anxiety and depression-like behaviour. Memory 
impairment was assessed by Y-maze task, while, elevated plus maze and forced 
swimming test were used to measure anxiolytic and antidepressive-like activity. 
Spontaneous alternation percentage in Y maze is reduced by scopolamine (36.42 ± 
2.60) (p ≤ 0.001), whereas lavender (200 and 400 mg/kg) enhanced it (83.12 ± 5.20 and 
95 ± 11.08, respectively) (p ≤ 0.05). Also, lavender pretreatment in 200 and 400 mg/kg 
enhanced time spent on the open arms (15.4 ± 3.37 and 32.1 ± 3.46, respectively) 
(p ≤ 0.001). On the contrary, while immobility time was enhanced by scopolamine 
(296 ± 4.70), 100, 200 and 400 mg/kg lavender reduced it (193.88 ± 22.42, 73.3 ± 8.25 
and 35.2 ± 4.22, respectively) in a dose-dependent manner (p ≤ 0.001). Lavender 
extracts improved scopolamine-induced memory impairment and also reduced anxiety 
and depression-like behaviour in a dose-dependent manner160. 
Kim et al., 2016 investigated the cognition-enhancing effects of aqueous extract 
of Indigofera tinctoria Linn. (ITE, Fabaceae) in experimental amnesic mice. The 
cognitive-enhancing activity of the ITE (5, 10 and 20 μg/mL) was studied by passive 
avoidance response, elevated plus maze and Y-maze behavioral paradigm in normal 
and scopolamine-induced amnesic mice. Antioxidant activities were also determined 
based on the ability of ITE to inhibit lipid peroxide, superoxide and hydroxyl radicals.  
Scopolamine-induced cognitive deficits were significantly reversed by ITE (p < 0.001 
at 20 mg/kg) in a dose-dependent fashion in all the behavioral paradigms tested. 
Furthermore, ITE dose dependently scavenged lipid peroxide, superoxide and hydroxyl 
free radicals with 50 % inhibition concentration (IC50) of 7.28 ± 0.37, 5.25 ± 0.28 and 
7.62 ± 0.43 μg/mL, respectively. ITE possesses cognitive-enhancing properties in 
amnesic mice due to its potent antioxidant action75. 
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Pandareesh et al., 2016 evaluated the cognition-enhancing activity of Bacopa 
monniera extract (BME) against scopolamine-induced amnesic rats by novel object 
recognition test (NOR), elevated plus maze (EPM) and Morris water maze (MWM) 
tests.  BME administration also ameliorated scopolamine effect by down-regulating 
AChE and up-regulating BDNF, muscarinic M1 receptor and CREB expression in brain 
hippocampus confirms the potent neuroprotective role and these results are in 
corroboration with the earlier in vitro studies. BME administration showed significant 
protection against scopolamine-induced toxicity by restoring the levels of antioxidant 
and lipid peroxidation. These results indicate that, cognition-enhancing and 
neuromodulatory propensity of BME is through modulating the expression of AChE, 
BDNF, MUS-1, CREB and also by altering the levels of neurotransmitters in 
hippocampus of rat brain161. 
Setorki, 2016, observed the effect of Ziziphus spina-christi extract against 
anxiety related behavior induced by scopolamine. Experimental groups received Z. 
spina-christi extract (50, 100 and 200 mg/kg IP) 30 min after scopolamine injection. 
Anxiety related behaviors were assessed using the elevated plus maze. The rotarod test 
was used to evaluate motor coordination. Administration of Z. spina-christi extract (200 
mg/kg) significantly increased the time spent in the open arm of elevated plus maze. 
The extract also reduced the percentage of closed arms entries and time spent in the 
closed arms. Different concentration of Z. spina-christi extract didn’t affect motor 
coordination and balance. Hydro-alcoholic extract of Z. spina-christi significantly 
ameliorated scopolamine-induced anxiety162.  
He et al., 2015 examined the effect on scopolamine-induced memory 
impairment mice and APP/PS1 transgenic mice using Morris water maze test. Results 
showed that harmine (20 mg/kg) administered by oral gavage for 2 weeks could 
effectively enhance the spatial cognition of C57BL/6 mice impaired by intraperitoneal 
injection of scopolamine (1 mg/kg). Meanwhile, long-term consumption of harmine (20 
mg/kg) for 10 weeks also slightly benefited the impaired memory of APP/PS1 mice. 
Furthermore, harmine could pass through blood brain barrier, penetrate into the brain 
parenchyma shortly after oral administration, and modulate the expression of Egr-1, c-
Jun and c-Fos. Molecular docking assay disclosed that harmine molecule could directly 
dock into the catalytic active site of acetylcholinesterase, which was partially confirmed 
by its in vivo inhibitory activity on AChE. Results suggested that harmine impaired 
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memory by enhancement of cholinergic neurotransmission via inhibiting the activity of 
AChE, which may contribute to its clinical use in the therapy of neurological diseases 
characterized with AChE deficiency163. 
Lee et al., 2015 evaluated the neuropharmacological effects of 30% ethanolic 
pine needle extract (PNE) on memory impairment caused by scopolamine injection in 
mice hippocampus. Mice were orally pretreated with PNE (25, 50, and 100 mg/kg) or 
tacrine (10 mg/kg) for 7 days, and scopolamine (2 mg/kg) was injected 
intraperitoneally, 30 min before the Morris water maze task on first day. To evaluate 
memory function, the Morris water maze task was performed for 5 days 
consecutively. Scopolamine increased the escape latency and cumulative path-length 
but decreases the time spent in target quadrant, which were ameliorated by pre-
treatment with PNE. These findings suggest that PNE could be a potent neuro 
pharmacological drug against amnesia, and its possible mechanism might be 
modulating cholinergic activity via CREB-BDNF pathway164. 
2.4 ALUMINIUM CHLORIDE INDUCED AMNESIA 
Lee et al., 2017 investigated the effect of the ethanol extract of 
Acanthopanax koreanum (EEAK) on cholinergic blockade-
induced memory impairment in mice. The phosphorylation levels of both Akt and 
CaMKII were significantly increased by approximately two-fold compared with the 
control group because of the administration of EEAK (100 or 200 mg/kg) (p < 0.05). 
Moreover, the phosphorylation level of CREB was also significantly increased 
compared with the control group by the administration of EEAK (200 mg/kg) 
(p < 0.05). The study suggested that EEAK ameliorates the cognitive 
dysfunction induced by the cholinergic blockade, in part, via several memory-
associated signalling molecules and may hold therapeutic potential against cognitive 
dysfunction, such as that presented in neurodegenerative diseases165.  
Pahaye et al., 2017 assessed memory improvement and neuroprotective and 
antioxidant effects of Mitragyna inermis leaf decoction on the central nervous system.  
Oxidative stress enzymes-catalase, superoxide dismutase, and the thiobarbituric acid 
reactive substance, a product of lipid peroxidation-were quantified. The time spent in 
target quadrant in morris water maze increased while the transfer latency decreased in 
mice treated by M. inermis at the dose of 196.5 mg/kg. The activity levels of 
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superoxide dismutase and catalase were significantly increased, whereas the 
thiobarbituric acid reactive substance was significantly decreased after 8 consecutive 
days of treatment with M. inermis at the dose of 393 mg/kg.  These results suggest 
that M. inermis leaf extract possess potential anti-amnesic effects166. 
Thenmozhi et al., 2017 reported that hesperidin, a citrus bioflavonoid reversed 
memory loss caused by aluminium intoxication through attenuating acetylcholine 
esterase activity and the expression of amyloid β biosynthesis related markers. 
Intraperitoneal injection of AlCl3 (100 mg/kg., b.w.) for 60 days significantly enhanced 
the learning and memory deficits, levels of thiobarbituric acid reactive substances and 
diminished the levels of reduced glutathione, activities of enzymatic antioxidants and 
the expression of B-cell lymphoma-2 as compared to control group in the hippocampus, 
cortex, and cerebellum. Co administration of hesperidin (100 mg/kg., b.w. oral) for 60 
days prevented the cognitive deficits, biochemical anomalies and apoptosis induced by 
AlCl3 treatment. Results of the study demonstrated that hesperidin could be a potential 
therapeutic agent in the treatment of oxidative stress and apoptosis associated 
neurodegenerative diseases including AD18. 
Al-Amin et al., 2016 investigated the effect of astaxanthin on AlCl3-exposed 
behavioral brain function and neuronal oxidative stress. Aluminum exposed group 
showed a significant reduction in spatial memory performance and anxiety-like 
behavior. Moreover, aluminium group exhibited a marked deterioration of oxidative 
markers; lipid peroxidation (MDA), nitric oxide (NO), glutathione (GSH) and advanced 
oxidation of protein products (AOPP) in the brain. To the contrary, co-administration of 
astaxanthin and aluminium has shown improved spatial memory, locomotor activity, 
and reduced OS. These results indicate that astaxanthin improves aluminium-induced 
impaired memory performances presumably by the reduction of OS in the distinct brain 
regions167.  
Azza et al., 2016 evaluated the influence of caffeine and nicotine co-
administration against aluminium-induced neurotoxicity that mimics AD in rats. Five 
groups of rats were used and received daily for five weeks: Saline for control, 
aluminium chloride (AlCl3) (70 mg/kg, i.p.) for AD mimic group, while treated groups 
received together with AlCl3, either caffeine (5 mg/kg, i.p.), nicotine (1 mg/kg, s.c.) or 
their combination. Three behavioral experiments were performed: Forced swimming 
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test (FST), Morris water maze (MWM) task and conditioned-avoidance and learning 
(CAL) test. Histo pathological changes in the brain and biochemical changes in AChE 
as well as oxidative parameters; malondialdehyde (MDA), superoxide dismutase 
(SOD), total antioxidant capacity (TAC) were also evaluated for all groups. Results of 
the behavioral tests showed that caffeine and nicotine co-administration had more 
pronounced protecting effect from learning and memory impairment induced by AlCl3 
than each one alone. Caffeine and nicotine co-administration also prevented neuronal 
degeneration in the hippocampus and the eosinophilic plagues in the striatum induced 
by AlCl3 while nicotine alone showed mild gliosis in striatum. The marked protection 
of caffeine and nicotine co-administration was also confirmed by the significant 
increase in TAC and SOD and decrease in MDA and AChE in brain tissue. Co-
administration of caffeine and nicotine reduced the risk of neuronal degeneration in the 
hippocampus and attenuated the impairment of learning and memory associated with 
AD16. 
Jayant et al., 2016 investigated the ameliorative role of selective modulator of 
cannabinoid receptor type 2 (CB2), 1-phenylisatin in experimental AD condition. Intra 
cerebro ventricular (i.c.v.) administration of streptozotocin (STZ) and AlCl3+d-
galactose were given to animals. Morris water maze (MWM) and attentional set 
shifting test (ASST) were used to assess learning and memory. Hematoxylin-eosin and 
Congo red staining were used to examine the structural variation in brain. Brain 
oxidative stress (thiobarbituric acid reactive substance and glutathione), nitric oxide 
levels (nitrites/nitrates), AChE activity, myeloperoxidase and calcium levels were also 
estimated. i.c.v. STZ as well as AlCl3+d-galactose have impaired spatial and reversal 
learning with executive functioning, increased brain oxidative and nitrosative stress, 
cholinergic activity, inflammation and calcium levels. Furthermore, these agents have 
also enhanced the burden of Aβ plaque in the brain. Treatment with 1-phenylisatin and 
donepezil attenuated i.c.v. STZ as well as AlCl3+d-galactose induced impairment of 
learning-memory, brain biochemistry and brain damage. Hence, this study concludes 
that CB2 receptor modulation can be a potential therapeutic target for the management 
of AD168. 
Kiuji et al., 2016 explored the neuroprotective effect of CA on chronic 
aluminium chloride (AlCl3) exposure induced neurotoxicity in rat brain regions 
(cerebral cortex, striatum, hypothalamus and hippocampus). Wistar albino rats were 
48 
 
segregated into four groups: group 1-control rats, group 2- rats received AlCl3 (300 
mg/kg b.w. every day orally) for 60 days, rats in group 3-received CA (500 mg/kg b.w. 
orally) and group 4 rats were initiated with both AlCl3 and CA treatment. 
Administration of AlCl3 developed behavioral deficits, triggered lipid peroxidation 
(LPO), compromised acetylcholine esterase (AChE) activity, and reduced the levels of 
superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and 
glutathione-S-transferase (GST) and caused histologic aberrations. AlCl3–induced 
alterations in the activities of SOD, CAT, GSH and GST, levels of LPO, activity of 
AChE, behavioral deficits and histologic aberrations were attenuated on treatment with 
CA. Results of the study demonstrate neuroprotective potential of CA against AlCl3- 
induced oxidative damage and cognitive dysfunction169. 
de Vargas et al., 2016 evaluated the in vitro antioxidant and anti-peroxidases 
potential of the ethanol extracts of five plants from the Brazilian Amazon. 2,2-
diphenyl-1-picrylhydrazyl (DPPH) assay, 2,2’-azinobis(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS) assay, superoxide anion radical, singlet oxygen and the β-
carotene bleaching methods were employed for characterization of free radical 
scavenging activity and total polyphenols were determined. Antioxidant activities were 
evaluated using murine fibroblast NIH3T3 cell. The stem bark extracts of 
Calycophyllum spruceanum and Mytella guyanensis provided the highest free radical 
scavenging activities. C. spruceanum exhibited IC50 = 7.5 ± 0.9, 5.0 ± 0.1, 18.2 ± 3.0 
and 92.4 ± 24.8 μg/mL for DPPH(•), ABTS(+•), O2 (-•) and O2 assays, respectively. 
Ptychopetalum olacoides and C. spruceanum extracts also inhibited free radicals 
formation in the cell-based assay. At a concentration of 100 μg/mL, the extracts of C. 
spruceanum, Byrsonima japurensis inhibited horseradish peroxidase by 62 and 50 %, 
respectively. C. spruceanum, M. guyanensis, B. japurensis also inhibited 
myeloperoxidase in 72, 67 and 56 %, respectively170. 
Kasbe et al., 2016 studied protective effect of mangiferin against AlCl3-
induced neurotoxicity and cognitive impairment in male Swiss albino mice. AlCl3 (100 
mg/kg) was administered once daily through oral gavage for 42 days. Mangiferin (20 
and 40 mg/kg, p.o.) was given to mice for last 21 days of the study. Cognitive 
dysfunction in AlCl3-treated group was assessed by Morris water maze test, and novel 
object recognition test. AlCl3-treated group showed elevated level of oxidative stress 
markers, proinflammatory cytokines level and lowered hippocampal brain-derived 
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neurotrophic factor (BDNF) content. Mangiferin (40 mg/kg) prevented the cognitive 
deficits, hippocampal BDNF depletion, and biochemical anomalies induced by AlCl3-
treatment. Mangiferin offered neuroprotection in AlCl3-induced neurotoxicity and 
reduced oxido-nitrosative stress and inflammation-associated neurotoxicity171. 
Li et al., 2016 explored the therapeutic effect of ginseng protein (GP) on 
Alzheimer's disease and its correlation with the PI3K/Akt signaling pathway to 
understand the mechanism underlying the neuroprotective effect of ginseng. The 
expression of mRNAs and proteins of PI3K, Akt, phosphorylated Akt (p-Akt), Bcl-2, 
and Bax in the hippocampus was detected by real-time quantitative reverse 
transcription polymerase chain reaction and Western blot assay. GP was found to 
significantly improve the memory ability of AD rats and prolong the times of crossing 
the platform and the percentage of residence time in the original platform quadrant of 
spatial probe test. GP also reduced the content of Aβ1-42 and p-tau and improved the 
mRNA and protein expression of PI3K, p-Akt/Akt, and Bcl-2/Bax in the hippocampus. 
GP improved the memory ability and reduced the content of Aβ1-42 and p-tau in AD 
rats. The anti-AD effects of GP were in part mediated by PI3K/Akt signaling pathway 
activation172. 
Mahboob et al., 2016 evaluated the neuroprotective effect of alpha-lipoic acid 
(ALA) in AlCl3-induced neurotoxicity mouse model. Effect of ALA (25mg/kg/day) 
was evaluated in the AlCl3-induced neurotoxicity (AlCl3 150 mg/kg/day) mouse model 
on learning and memory using behaviour tests and on the expression of muscarinic 
receptor genes (using RT-PCR), in hippocampus and amygdala. ALA enhanced fear 
memory (p<0.01) and social novelty preference (p<0.001) comparative to the AlCl3-
treated group. Fear extinction memory was remarkably restored (p<0.001) in ALA-
treated group demonstrated by reduced freezing response as compared to the AlCl3-
treated group which showed higher freezing. In-silico analysis showed that racemic 
mixture of ALA has higher binding affinity for M1 and M2 compared to acetylcholine. 
These novel findings highlight the potential role of ALA in cognitive functions and 
cholinergic system enhancement thus presenting it an enviable therapeutic candidate for 
the treatment of neurodegenerative disorders173. 
Prema et al., 2016 explored the neuroprotective effect of fenugreek seed 
powder (FSP) against AlCl3-induced experimental AD model. Administration of 
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germinated FSP (2.5, 5 and 10% mixed with ground standard rat feed) protected AlCl3 
induced memory and learning impairments, Al overload, AChE hyperactivity, amyloid 
β (Aβ) burden and apoptosis via activating Akt/GSK3β pathway. Further these results 
could lead a possible therapeutics for the management of neurodegenerative diseases 
including AD in future12. 
Lakshmi et al., 2015 evaluated the effect of selenium on AlCl3-
induced Alzheimer's disease in rats. The animals showed increase in time to reach 
platform in Morris water maze and decreased step-down latencies in passive avoidance 
test indicating learning and memory impairment in AlCl3-treated group, but 
administration of selenium decreased time to reach platform in Morris water maze, 
increased step-down latencies, and strengthened its memory action in drug-treated 
animals. There was decrease in muscle strength measured by rotarod test indicating 
motor incoordination and decrease in locomotor activity assessed by actophotometer 
test in AlCl3 control group, whereas in selenium-AlCl3 group, there was improvement 
in muscle strength and locomotion. Biochemical analysis of the brain revealed that 
chronic administration of AlCl3 significantly increased lipid peroxidation and decreased 
levels of AChE, catalase, reduced glutathione and glutathione reductase, an index of 
oxidative stress process. Administration of selenium attenuated lipid peroxidation and 
ameliorated the biochemical changes. There were marked changes at subcellular level 
observed by histopathology studies in AlCl3 group, and better improvement in these 
changes was observed in selenium + AlCl3 group. Therefore, this study strengthened the 
hypothesis that selenium helped to combat oxidative stress produced by accumulation 
of AlCl3 in the brain and helped in prophylaxis of Alzheimer's diseases175. 
Huma et al., 2013 analyzed thirteen plant-derived alkaloids, 
namely pleiocarpine, kopsinine, pleiocarpamine, oliveroline, noroliveroline, liridonine, 
isooncodine, polyfothine, darienine and eburnamine, eburnamonine, eburnamenine and 
geissoschizol for their anti-cholinergic action through docking with AChE as target. 
Among the alkaloids, pleiocarpine showed promising anti-cholinergic potential, while 
its amino derivative showed about six-fold higher anti-cholinergic potential than 
pleiocarpine. Pleiocarpine and its amino derivative were found to be better inhibitors of 
AChE, as compared to commonly used drugs tacrine and rivastigmine, suggesting 
development of these molecules as potential therapeutics in future174. 
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Thippeswamy et al., 2013 evaluated the synergistic activity of Bacopa 
monniera with rivastigmine against AlCl3-induced cognitive impairment in rats. 
Chronic administration of AlCl3 caused significant memory impairment associated with 
increased RL in the Morris water maze task and increased TL in the elevated plus maze 
test. Interestingly, animals treated with oral administration of B. monniera (100 and 200 
mg/kg), rivastigmine (5 mg/kg) or a combination of B. monniera (100 mg/kg) with 
rivastigmine (5 mg/kg) showed significant protection against AlCl3-
induced memory impairment compared to animal treated with AlCl3 alone. 
Additionally, the neuroprotective effect of B. monniera (100 and 200 mg/kg) was 
significantly improved when supplemented with rivastigmine (5 mg/kg). These findings 
suggest that treatment with a combination of B. monniera with rivastigmine highly 
beneficial compared to their AlCl3 alone treated animals176. 
Thirunavukkarasu et al., 2012 examined the neuroprotective effect of 
Manasamitra vatakam (MMV) against aluminum (Al)-induced memory impairment and 
oxidative damage in rats. Neurotoxicity was induced by the administration of Al [100 
mg/kg body weight (b.w.) per oral (p.o.)/day] to Wistar albino rats for 90 days. It was 
observed that the administration of MMV (100 mg/kg b.w./p.o./day) along with AlCl3 
improved memory performance and antioxidant activity against Al-induced 
neurotoxicity in rats. These data suggest that MMV can prevent brain damage from Al-
induced neurotoxicity in rats and thus can be used as a neuroprotective agent177. 
Kumar et al., 2011 explored the possible role of carvedilol, an adrenergic 
antagonist against AlCl3-induced neurotoxicity in rats. AlCl3 (100 mg/kg) administered 
daily for six weeks, significantly increased cognitive dysfunction in the Morris water 
maze and oxidative damage as indicated by a rise in lipid peroxidation and nitrite 
concentration and depleted reduced glutathione, superoxide dismutase, catalase and 
glutathione S-transferase activity compared to sham treatment. Chronic aluminium 
chloride treatment also significantly increased acetylcholinesterase activity and the 
aluminium concentration in brain compared to sham. Chronic administration of 
carvedilol (2.5 and 5 mg/kg, po) daily to rats for a period of 6 weeks significantly 
improved the memory performance tasks of rats in the Morris water maze test, 
attenuated oxidative stress (reduced lipid peroxidation, nitrite concentration and 
restored reduced glutathione, superoxide dismutase, catalase and glutathione S-
transferase activity), decreased acetylcholinesterase activity and aluminium 
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concentration in aluminium-treated rats compared to control rats (p < 0.05). Results of 
this study demonstrated the neuroprotective potential of carvedilol in aluminium 
chloride-induced cognitive dysfunction and oxidative damage178. 
Butler et al., 2010 tested tubastatin A, in primary cortical neuron cultures in 
which it was found to induce elevated levels of acetylated α-tubulin, but not histone, 
consistent with its HDAC6 selectivity. Tubastatin A also conferred dose-dependent 
protection in primary cortical neuron cultures against glutathione depletion-induced 
oxidative stress. Importantly, when given alone at all concentrations tested, this 
hydroxamate-containing HDAC6-selective compound displayed no neuronal toxicity, 
thus, forecasting the potential application of this agent and its analogues to 
neurodegenerative conditions179. 
Bihaqi et al., 2009 investigated neuroprotective effects of aqueous extract 
from Convolvulus pluricaulis (CP) against AlCl3-induced neurotoxicity in rat cerebral 
cortex. Daily administration of CP (150 mg/kg) for 3 months along with AlCl3 
(50 mg/kg) decreased the elevated enzymatic activity of AChE and also inhibited the 
decline in Na+/K+ATPase activity which resulted from aluminium intake. Oral 
administration of CP preserved the mRNA levels of muscarinic receptor 1 (M1 
receptor), choline acetyltransferase (ChAT) and Nerve growth factor-tyrosine kinase A 
receptor (NGF-TrkA). The potential of CPE to inhibit aluminium induced toxicity was 
compared with rivastigmine tartrate (1 mg/kg), which was taken as standard. The 
potential of the extract to prevent aluminium-induced neurotoxicity was also reflected 
at the microscopic level, indicative of its neuroprotective effects. C. 
pluricaulis possesses neuroprotective potential, thus validating its use in alleviating 
toxic effects of aluminium180. 
Kumar et al., 2009 demonstrated the protective effect of chronic curcumin 
administration against aluminium-induced cognitive dysfunction and oxidative damage 
in rats. AlCl3 (100 mg/kg, p.o.) was administered to rats daily for 6 weeks. Rats were 
concomitantly treated with curcumin (per se; 30 and 60 mg/kg, p.o.) daily for a period 
of 6 weeks. On the 21st and 42nd day, behavioral studies to evaluate memory (Morris 
water maze and elevated plus maze task) and locomotion (actophotometer) were done. 
The rats were sacrificed on 43rd day following the last behavioral test and various 
biochemical tests were performed to assess the extent of oxidative damage. Chronic 
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aluminium chloride administration resulted in poor retention of memory in Morris 
water maze, elevated plus maze task paradigms and caused marked oxidative damage. 
It also caused a significant increase in the acetylcholinesterase activity and aluminium 
concentration in aluminium treated rats. Chronic administration of curcumin 
significantly improved memory retention in tasks, attenuated oxidative damage, AChE 
activity and aluminium concentration in aluminium treated rats (P < 0.05). Curcumin 
has neuroprotective effects against aluminium-induced cognitive dysfunction and 
oxidative damage181. 
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3. AIM & OBJECTIVES 
In the light of literature review, the study was aimed to evaluate the possible 
neuroprotective effects of commercially available flavonoids using in silico, in vitro 
and in vivo approaches. 
The objectives of the present study are to 
 Evaluate drug likeness properties of the flavonoids  
 Carry out in silico docking studies of the selected flavonoids using AutoDock 
4.2 
 Perform in vitro AChE and BuChE enzyme inhibitory assay for the selected 
flavonoids 
 Carry out the acute toxicity studies for the selected flavonoids 
 Assess the selected flavonoids against scopolamine and aluminium chloride 
induced Alzheimer models 
 Carry out various behavioural studies using selected flavonoids using in vivo 
models 
 Explore the biochemical alterations after induction of learning impairment and 
correction of biochemical parameters after drug treatment. 
 Perform histopathological studies to corroborate the results of in vivo studies. 
 To correlate the results obtained using statistical tools using GraphPad Prism 
software. 
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4. PLAN OF WORK 
STEP I 
 Selection of flavonoids and determination of acetylcholinesterase inhibitory 
activity. 
STEP II 
Determination of drug likeness score by using MedChem Designer software. 
STEP III 
To carry out the molecular docking studies using AutoDock 4.2 against AChE 
and BuChE based on the bioactive score. 
STEP IV 
Selection of flavonoids based on their docking score and drug likeness 
properties. 
STEP V 
In vitro screening of selected flavonoids by AChE and BuChE inhibitory assay.  
STEP VI 
Acute toxicity studies following OECD guidelines-420 (fixed dose procedure) 
for selected flavonoids based on the in vitro results. 
STEP VII 
In vivo screening of the flavonoids by acute scopolamine-induced learning 
impairment in mice. 
STEP VIII 
In vivo screening of the flavonoids by chronic aluminium chloride-induced 
learning impairment in mice. 
STEP IX 
Assessment of neuroprotective activity using various behavioral experiments. 
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STEP X 
Dissection and preparation of tissue homogenates using brain for biochemical 
estimations. 
STEP XI 
Histopathological studies for both scopolamine and aluminium chloride-induced 
models. 
STEP XII 
 Tabulation, compilation of results and statistical analysis of data obtained. 
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Fig.13 Schematic representation of the plan of work 
In silico prediction of neuroprotective potential of certain commercially 
available flavonoids 
• Acetylcholinesterase  Butyrylcholinesterase  
In vitro enzyme inhibition Assay 
• Acetylcholinesterase inhibitory activity  
• Butyrylcholinesterase inhibitory activity  
Behavioural Assessments  
 
 Rectangular maze test  
 Morris water maze test  
 Attention in a 5 choice serial 
reaction time task 
 Assessment of gross behavioral 
activity 
 Pole climbing test 
Statistical analysis 
Tabulation and compilation of results 
Literature review 
Acute toxicity studies 
Biochemical Estimations 
 Estimation of cholinesterase activity 
 Estimation of protein  
 Enzymatic antioxidants 
o Catalase activity 
o SOD assay  
o Estimation of glutathione 
reductase 
o Estimation of glutathione 
peroxidase 
 Non-Enzymatic antioxidants 
 Estimation of reduced 
glutathione  
 TBARS assay 
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5. MATERIALS AND METHODS 
5.1 Evaluation of drug likeness properties 
 The pharmacologically active substituents are characterized by calculating 
steric, hydrophobic, electronic, and hydrogen bonding properties as well as by the drug-
likeness score. The theory of drug-likeness score helps to optimize pharmaceutical and 
pharmacokinetic properties, for example, chemical stability, solubility, distribution 
profile and bioavailability. The molecular descriptors have developed as rationally 
predictive and informative, for example, the Lipinski's Rule-of-Five182.  
The better oral absorption of the ligands and drug likeness scores are 
constructed by getting information about the solubility, diffusion, log P, molecular 
weight etc. The theory of drug-likeness score helps to optimize pharmaceutical and 
pharmacokinetic properties. Lipinski’s rule of five describes the important molecular 
properties required for the drug’s pharmacokinetics183. Lipinski’s rule states that, the 
drug to have good pharmacokinetic profile, should not have more than one violation of 
the following criteria: 
 Not more than 5 hydrogen-bond donors  
 Not more than 10 hydrogen-bond acceptors 
 Molecular weight should be less than 500 daltons 
 The partition coefficient (log P) not greater than 5 
Two hundred and forty five flavonoids were evaluated for their pharmacokinetic 
profile based on Lipinski’s rule of five using MedChem Designer software. 
5.1.1 Lipinski’s rule of five calculations 
 Open the MedChem designer home page. 
 Click calculation of molecular properties of drug likeness 
 Draw the structure of flavonoids in the active window. 
 Click and calculate properties. 
 Save the properties. 
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5.2 In silico docking binding interaction studies 
5.2.1 Softwares used 
 AutoDock 4.2 which combines 
 AutoDock Tools 1.5.4 
 Python Molecule Viewer 1.5.4 
 Vision 1.5.4 
 Python 2.7 
 Cygwin 
 Accerlys discovery studio viewer 
 ChemSketch 
 RCSB protein data bank 
 Online SMILES translator 
5.2.2 In silico docking study on AChE enzyme using AutoDock 4.2 
5.2.2.1 Identification of target enzyme and selection of flavonoids and related 
compounds 
The crystal structures of acetylcholinesterase (AChE) (PDB ID: 5HCU) and 
butyrylcholinesterase (BuChE) (PDB ID: 4BDS) were obtained from the research 
collaboratory for structural bioinformatics (RCSB) protein data bank and refined 
proteins were further used for in silico studies.  
 
Fig. 14 Refined crystal structure of mouse acetylcholinesterase (5HCU) 
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A total of 245 flavonoids were taken for the study and the structures were drawn 
using ChemSketch and optimized using “Prepare Ligands” in the AutoDock 4.2 for 
docking studies184. 
 
 
Fig. 15 Human butyrylcholinesterase in complex with tacrine (4BDS) 
5.2.2.2 Docking studies for the selected flavonoids185 
Step I - Protein structure refinement  
 The proteins downloaded from PDB have to be refined for docking. The steps 
involved in the protein structure refinement are, 
 Open                 Accelrys discovery studio viewer  
 Select                Target protein PDB file              
 Click    View,  and then click                Hierarchy. 
 Click water molecules  
 Ctrl + shift and click the last water molecule (select all water molecules) 
 Give right click and cut 
 Select ligand, which is unnecessary, give right click and cut. 
 Save the molecule in our desired area.  
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Step II - Ligand file format conversion 
 The ligands which are desired are drawn in Chem Sketch. 
 Select tools and click generate, finally click SMILES notation [simplified 
molecular input line entry system, which is a file format] 
 Save the SMILES in a word document 
 Open the online smiles translator – cactus.nci.nih.gov/services/translate/ 
 Upload the SMILES. 
 By choosing the required file format we can save the file (pdb file). 
 Online smiles translator allows the user to convert SMILES format into PDB, 
MOL, SDF and smile text file format. Thus the selected ligand molecule of 
canonical smile formats was converted to pdb formats. The protein and ligand files 
which are prepared by above said procedures are selected for docking. 
Step III - Docking with AutoDock 4.2 
Docking calculation in AutoDock 4.2 was performed using the refined protein 
and the desired ligand in pdb format. 
Preparing the protein  
 At first give the right click on the PMV molecules for to open the file. 
 Choose the particular refined enzyme file. 
 Click under atom to give color to the atoms. 
  The elimination of the water is carried by the following steps.  
 press select option 
 click select from string option   
  then write HOH* in the residue line & * in the atom line     
  click add and then dismiss.          
  After that click edit option and delete and then delete atom set. 
 Addition of  hydrogens is take placed by, 
 Press  edit  option 
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 Click the hydrogens 
  Then click add         
  Finally choose hydrogens and no bond order, and finally yes to 
renumbering. 
 Next add the Kollmann charges which is present in  the edit option 
 For to hide the protein click on the gray under show molecules.   
Preparing the ligand 
 Confirm that all the hydrogens are added in the ligand. 
 Toggle the Autodock tools button 
 For to open the ligand file press the Input option and click open and then all 
files finally choose the suitable ligand file and finally open 
  AutoDock tools itself computes Gasteiger charges, and merges nonpolar 
hydrogens, and finally assigns AutoDock type to each atom. 
  The torsions are designed by following steps, 
 In the ligand option select torsion tree  
 Select detect root option 
  Click torsion tree 
  Then select the choose torsions option 
 Amide bonds should not be active. 
 After that click the torsion tree and select set number of torsions. 
 Number of rotatable bonds is choosen. 
 Finally save the ligand files by selecting the output option (pdbqt file). 
 Hide the ligand. 
Conversion of pdb files of protein into pdbqt file  
  Select the grid option and open the macromolecule pdb file              
 AutoDock adds the charges and itself merges the hydrogens. 
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 Save the object as pdbqt in desired area. 
Running AutoGrid Calculation (glg file) 
 Open the grid and click macromolecule option and choose the rigid protein then 
yes to preserve the existing charges.    
  The preparation of grid parameter file is carried out by, 
 Open grid  
  Select the set map types         
  Choose ligand           
  Accept it. 
 Setting of  grid properties 
 Open grid 
 Select the grid box 
 Set the proper grid dimensions 
 Adjust the spacing 
 Select the file and click close saving current. 
 Save the grid settings as gpf file in the output option (gpf file). 
 Make sure the AutoGrid is in the same directory as like of the other input files. 
 Select the run option and click run AutoGrid for to launch. 
 It will be saved as glg file. 
Running AutoDock (dlg file) 
 The rigid molecule specification is carried out by, 
 Select the docking option 
 Click the macromolecule  
 Set rigid file name. 
  The ligand specification is carried out by, 
 Click the docking option 
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 Select the ligand  
 And then accept it. 
  In the next step, click docking option and select search parameters in that click 
genetic algorithm and finally accept it. 
  In the docking options select docking parameters and choose the defaults. 
  After that, in the docking option clicks output and adds Lamarckian genetic 
algorithm. 
 The confirmation is required that whether all the files (macromolecule, ligand, 
gpf, dpf ) are in the  same directory. 
 Finally select the run command and click run AutoDock and then launch. 
Step IV - Viewing docking results  
Reading the docking log file .dlg 
 Toggle the AutoDock tools  button 
 Click analyze and dockings then open it. 
 In the next step, click analyze option and conformations then load. 
 Double click on the conformation for to view it. 
Visualizing docked conformations 
 Click analyze and dockings then play. 
 Load dlg file  
 Choose the suitable conformations 
 In the next step, click analyze and docking then show interactions. 
Obtaining snap shots of docked pose  
 Open the file and read the molecule  
 Open analyze option click dockings and open dlg file  
 Open analyze option click macromolecule and choose pdbqt file. 
  Open analyze option click conformations and load  
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  Double click the desired conformation 
 In the next step, click analyze and docking then show interactions. 
 Lamarckian genetic algorithm (LGA) for ligand conformational searching is 
used for the docking, which is a hybrid of genetic algorithm and local search algorithm. 
This algorithm first builds a population of individuals, each being a different random 
conformation of the docked molecule. Each individual is then mutated to acquire a 
slightly different translation and rotation and the local search algorithm then performs 
energy minimizations on a user-specified proportion of the individuals. The individuals 
with the low resulting energy are transferred to the next generation and the process is 
then repeated. The algorithm is called lamarckian genetic algorithm because every new 
generation of individuals is allowed to inherit the local search adaptations of their 
parents186.  
The preparation of the target protein 5HCU and 4 BDS with the AutoDock tools 
software involved adding all hydrogen atoms to the macromolecule, which is a step 
necessary for correct calculation of partial atomic charges. Gasteiger charges are 
calculated for each atom of the macromolecule in AutoDock 4.2 instead of kollman 
charges which were used in the previous versions of the program. Three-dimensional 
affinity grids of size 277 × 277 × 277 Å with 0.6 Å spacing were centered on the 
geometric center of the target protein and were calculated for each of the following 
atom types: HD, C, A, N, OA, and SA, representing all possible atom types in a protein. 
Additionally, an electrostatic map and a desolvation map were also calculated187. 
Rapid energy evaluation was achieved by precalculating atomic affinity 
potentials for each atom in the ligand molecule. In the AutoGrid procedure, the target 
enzyme was embedded on a three dimensional grid point. The energy of interaction of 
each atom in the ligand was encountered. The selected important docking parameters 
for the LGA as follows: population size of 150 individuals, 2.5 million energy 
evaluations, maximum of 27000 generations, number of top individuals to 
automatically survive to next generation of 1, mutation rate of 0.02, crossover rate of 
0.8, 10 docking runs, and random initial positions and conformations. The probability 
of performing local search on an individual in the population was set to 0.06. AutoDock 
was run several times to get various docked conformations, and used to analyze the 
predicted docking energy. The binding sites for these molecules were selected based on 
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the ligand-binding pocket of the templates. AutoDock Tools provide various methods 
to analyze the results of docking simulations such as, conformational similarity, 
visualizing the binding site and its energy and other parameters like intermolecular 
energy and inhibition constant. For each ligand, ten best poses were generated and 
scored using AutoDock 4.2 scoring functions188.  
5.3 REAGENTS AND CHEMICALS 
Donepezil, acetylcholinesterase, butyrylcholinesterase, apigenin, baicalein, 
catechin, chrysin, diosmin, epigallocatechin, hesperetin, hesperidin, kaempferol, morin, 
myrecetin, naringenin, robinetin, rutin, scopoletin, silibinin, taxifolin, tetra 
hydroflavone, theaflavin and tricetin were purchased from Sigma Aldrich, St. Louis, 
MO. All other drugs and chemicals used in the study were obtained commercially and 
were of analytical grade. Bovine serum albumin (BSA),  p-nitro benzaldehyde, p- fluro 
benzaldehyde,  p-chloro benzaldehyde, p-methyl benzaldehyde, p-methoxy 
benzaldehyde, p-hydroxy benzaldehyde ethanol, potassium phosphate, Folin phenol 
reagent, 5,5'-dithiobis-2-nitro benzoic acid, acetylthiocholine iodide, carboxy methyl 
cellulose and tris hydrochloride were purchased from Hi Media Laboratories, Mumbai. 
Sodium thiosulphate, sodium hydroxide, hydrochloric acid, sodium potassium tartarate, 
sodium carbonate, copper sulphate, hydrogen peroxide, potassium dichromate, glacial 
acetic acid and sodium citrate were purchased from SD Fine chem limited, Mumbai. 
Scopolamine and aluminium chloride were purchased from Sigma Aldrich, USA. All 
other chemicals and solvents used were of AR grade.  
5.4 INSTRUMENTS USED 
 Digital Balance (Sartorius Ltd., USA), Eppendorff minispin, incubator 
(Technico), Jasco FTIR-420 series, Mass spectrometer, Shimadzu-Jasco V-530 UV/Vis 
spectrophotometer, ELCO 1/27 pH meter.  
5.5 In vitro enzyme inhibition assay 
5.5.1 In vitro acetylcholinesterase inhibition 
Based on in silico results, twenty compounds were selected for their AChE 
inhibitory activities189. About 1.3 ml of the Tris-HCl buffer (pH 8.0; 50 mM) was 
treated with 0.4 ml of different concentrations (2 to 128 µg/ml) of the compounds and 
0.1 ml of the AChE (0.28 U/ml) was added. This mixture was incubated for 15 minutes 
and 0.3 ml of acetylthiocholine iodide (0.023mg/ml) and 1.9 ml (5,5'-dithiobis-(2-
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nitrobenzoic acid) DTNB (3 mM) solution were added. This final reaction mixture (4.0 
ml) was kept for further incubation at room temperature for 30 minutes and the 
absorbance of the reaction mixture was measured at 405 nm. The assay was done in 
triplicate and the results were expressed as mean±SEM. Donepezil was used as 
standard190. The percentage inhibition was calculated for the selected flavonoids using 
the following formula,  
 
A0= Absorbance of the control 
A1= Absorbance of the standard/compounds. 
5.5.2 In vitro butyrylcholinesterase inhibition 
In our work, 20 flavonoids were examined for their BuChE inhibitory activities 
at various concentrations (1 to 128 µg/ml) and were dissolved in 1.3 ml of the Tris-HCl 
buffer (pH 8.0; 50 mM) following the spectrophotometric method189. In this method, 
0.1 ml of the BuChE (0.377 U/ml) solution were added to the initial mixture, to start the 
reaction and then the absorbance was determined. 0.3 ml of s-butyrylthiocholine iodide 
(1.5 mM) and 1.9 ml DTNB (3 mM) solution and 0.4 ml of drug solution at the 
different concentrations evaluated, which were mixed and incubated for 15 min at 30ºC. 
Then, the mixture was monitored spectrophotometrically at 405 nm. The control sample 
contained all components except the test compounds and rivastigmine was used as 
standard190. The percentage of BuChE inhibitory activity was calculated by using the 
following equation: 
 
A0 = Absorbance of the control 
A1 = Absorbance of the standard/ compounds. 
5.6 ACUTE TOXICITY STUDIES 
5.6.1 Experimental animals 
Acute toxicity studies were performed for the baicalein and scopoletin 
according to organization for economic co-operation and development (OECD) 
guidelines 420 (fixed dose procedure) 191. Healthy young adult female rats (200-250 g) 
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used for the acute toxicity studies were procured from Kerala Veterinary and Animal 
Sciences University, Mannuthy, Thrissur, Kerala, India. Animals were 8-12 weeks old 
and weight was not deviated from ± 20%. Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA) approval number for experimental 
protocols for the toxicological studies was COPSRIPMS/IAEC/PhD/P’CHEMISTRY/ 
03/ 2012-2013.  
5.6.2 Acute toxicity study procedure 
Due to absence of toxicity information for flavonoids, in the sighting study, one 
animal was administered with 5 mg/kg dose and in the absence of toxicity 50mg/kg 
dose was given to second animal to check for toxicity. If no mortality was observed for 
50mg/kg dose then the next dose of 300 mg/kg was given to third animal and if no 
mortality was observed then the fourth animal was administered with 2000 mg/kg dose. 
If no mortality was observed for upper dose limit of 2000 mg/kg, then the specific dose 
was selected for main study. Keen observations were done to determine the onset of 
signs, onset of recovery and time to death.  
In main study a total of 5 animals of one sex was used. The 5 animals would be 
made of one animal from the sighting study dosed at the selected dose level together 
with an additional four animals. Dose of 2000 mg/kg dose of the drug was administered 
and food was withheld for further 3-4 hours. Animals were observed individually at 
least once during the first 30 minutes after dosing, periodically during the first 24 hours 
(with special attention during the first 4 hours) and daily thereafter for a period of 14 
days. Once daily cage side observations included changes in skin and fur, eyes and 
mucous membrane (nasal), and also changes in respiratory rate, circulatory parameters 
(heart rate and blood pressure), autonomic parameters (salivation, lacrimation, 
perspiration, piloerection, urinary incontinence and defecation) and CNS parameters 
(ptosis, drowsiness, gait, tremors and convulsions)192. 
5.7 IN VIVO EXPERIMENTAL DESIGN 
5.7.1 Experimental animals 
Male swiss albino mice (20-25 g) were procured from Kerala Veterinary and 
Animal Sciences University, Mannuthy, Thrissur, Kerala, India. Animals were fed with 
commercial pellet diet and drinking water ad libitum and maintained at an ambient 
temperature of 22 ± 2°C with a 12-h light: dark cycle. The experiments were conducted 
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in accordance with guidelines of Institutional animal ethical committee (IAEC) 
governed by CPCSEA guidelines, Government of India. All the readings were taken 
during the same time of the day that is between 10.00 am and 2.00 pm. CPCSEA 
approval number for experimental protocols for the pharmacological studies was 
COPSRIPMS/IAEC/PhD/P’CHEMISTRY/ 03/ 2012-2013.  
5.7.2 In vivo scopolamine-induced amnesia model 
Animals were classified into six groups (n=6, Swiss albino mice). Treatments 
were given p.o. for seven successive days. Group I served as control received only 
normal saline (10ml/kg). Animals in group II were treated with baicalein (100 
mg/kg/day) and group III mice were treated with baicalein (200 mg/kg/day). Animals in 
group IV received scopoletin (100 mg/kg/day) and group V mice were administered 
with scopoletin (200 mg/kg/day). Group VI mice were treated with donepezil (5 mg/kg, 
p.o.). For all the groups, treatments were given for 7 consecutive days. One hour after 
the last dose of test agents, all animals were i.p. injected with scopolamine 
hydrobromide (1 mg/kg) except the control group193. The values for the negative 
control group were taken from archives163. The neuroprotective effects of the selected 
flavonoids were studied using various behavioral assessments such as rectangular maze 
test, Morris water maze, gross behavioral activity, 5 choice serial reaction time task and 
pole climbing test during the treatment period.  
On day 8, after behavioral assessments, animals were sacrificed by excess of 
anesthesia. The brain was removed and each brain had been separately kept after 
rinsing with ice-cold isotonic saline. A (10% w/v) homogenate was prepared with 
0.1 M phosphate buffer (pH 7.4) and centrifuged at 3000 rpm for 15 minutes and 
aliquots of supernatant had separated and used for the various biochemical estimations 
{cholinesterase activity, protein estimation, enzymatic (Catalase activity, 2,2-diphenyl-
1-picrylhydrazyl assay, superoxide dismutase assay, glutathione reductase, glutathione 
peroxidase) and non-enzymatic antioxidant activities (reduced glutathione) and lipid 
peroxidation indices with thiobarbituric acid reactive substances assay}. 
5.7.3 Aluminium-induced learning impairment 
Swiss albino mice were divided into 6 different groups, each comprising of six 
animals. Group I served as control which received normal saline. In group II mice were 
treated with baicalein (100 mg/kg/day) and group III were administered with baicalein 
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(200 mg/kg/day). In group IV mice received scopoletin (100 mg/kg/day), group V 
received scopoletin (200 mg/kg/day). Group VI mice were treated with donepezil (5 
mg/kg, p.o.) for 3 months. All the groups were treated for a period of 3 months. Groups 
III to VII received Aluminum chloride (AlCl3) dissolved in water at a dose of 50 
mg/kg/day194, 195, for a period of 3 months. The values for the negative control group 
were taken from archives. The values for the negative control group were taken from 
archives18. The effects of the selected flavonoids were studied using various behavioral 
assessments such as rectangular maze test, Morris water maze, gross behavioral 
activity, 5 choice serial reaction time task and pole climbing test during the treatment 
period.  
After treatment period, animals were sacrificed by excess of anesthesia. The 
brain of the each animal was removed and rinsed with ice-cold isotonic saline. A (10% 
w/v) homogenate was prepared with 0.1 M phosphate buffer (pH 7.4) and centrifuged at 
3000 rpm for 15 minutes and aliquots of supernatant separated and used for various 
biochemical estimations {cholinesterase activity, protein estimation, enzymatic 
(Catalase activity, 2,2-diphenyl-1-picrylhydrazyl assay, superoxide dismutase assay, 
glutathione reductase, glutathione peroxidase} and non-enzymatic antioxidant activities 
(reduced glutathione) and lipid peroxidation by thiobarbituric acid reactive substances 
assay}. 
5.8 BEHAVIORAL ASSESSMENTS 
5.8.1 Rectangular maze test 
The maze consists of completely enclosed rectangular box with an entry and 
reward chamber partitioned with wooden slots into blind passages leaving just twisting 
corridor leading from the entry to the reward chamber (Fig. 16). All the mice were 
familiarized with the rectangular maze. Well trained animals were taken for the 
experiment. The time taken for the mouse to reach the reward chamber was taken as the 
transfer latency. Lower scores of assessment indicate efficient learning while higher 
scores indicate poor learning in animals. The time taken by the animals to reach the 
reward chamber from the entry chamber was tabulated196. All the values were 
calculated in seconds. 
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Fig. 16 Rectangular maze 
5.8.2 Morris water maze test 
This test was carried out in circular pool (150 cm in diameter and 60 cm in 
height) of water with ten centimeter hidden platform (Fig. 17). In the water maze 
experiments, the day prior to the experiment the animals were trained to swim for 60 s 
in the absence of the platform. In the following days, the mice were given the trial 
session each day for four consecutive days. During each trial, the escape latencies of 
mice were recorded. The point of entry of the mouse into the pool and the location of 
the platform for escape between trials changed each day thereafter. During acquisition, 
trial escape latency time (ELT), measure to locate the hidden platform, was noted as an 
index of acquisition. Escape latency time was calculated in seconds. All mice were 
tested for spatial memory 30 minutes after the last dose of the treatment197. 
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 Fig. 17 Morris water maze  
 
5.8.3 Assessment of gross behavioral activity (Locomotor activity) 
Most of the CNS drugs influence the locomotor activity in man and animals. 
The locomotor activity of drug was studied using actophotometer which operates on 
photoelectric cells which are connected in circuit with a counter (Fig. 18). When the 
beam of light falling on photocell was cut off by the animal, then a count was recorded. 
Animals were placed individually in the activity cage for 10 min and the activity was 
monitored. The photo cell count was noted and a decrease or increase in locomotor 
activity was calculated198. 
 
Fig. 18 Actophotometer 
5.8.4 Pole climbing test 
This test was used to study the neuroprotective and nootropic effect of test 
drugs. The mice were trained for conditioned avoidance response (CAR) by using pole 
climbing apparatus. Prior to the experiment, animals were trained in a 25 × 25 × 40 cm 
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chamber that was enclosed in a dim light, sound attenuated box (Fig. 19). Each mouse 
was allowed to acclimatize for 2 min and then exposed to a buzzer noise. After 10 sec 
of putting on the buzzer, mild electric shocks were given through the grid floor. The 
magnitude of the voltage was adequate (30v) to stimulate the mice to escape from the 
floor and climb the pole. As soon as the mice climbed the pole, both the buzzer and 
foot-shock were switched off. At least 10 such trails were given to each mouse at an 
interval of 1 min. per day for 3 days. After training schedule, most of the mice learned 
to climb the pole within 10 sec of starting the buzzer to avoid the electric foot shocks. 
On the test days, after 2 min of acclimatization period, each mouse was exposed to the 
buzzer for 10 sec; ten such trails were given at an interval of 1 min, without giving any 
shock. Mice, responding by climbing the pole when exposed to the buzzer noise, were 
considered to have retained the conditional avoidance response198. 
 
Fig. 19 Pole climbing apparatus 
5.8.5 Attention in a 5 choice serial reaction time task (5-CSRT) 
 The 5 choice serial reaction time task (5-CSRT) tests specific types of attention, 
including sustained, divided, and selected attention. The 5-CSRT was implemented in a 
specifically designed operant chamber with multiple response locations using light 
source (Fig. 20). The usual paradigm requires the mice to detect brief flashes of light 
presented in a pseudorandom order in one of five locations over a large number of 
trials. The response time of the animals were calculated in seconds199.     
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Fig. 20 Five choice serial reaction time task apparatus 
5.9 BIOCHEMICAL ESTIMATIONS 
5.9.1 Estimation of AChE in mice brain 
 The cholinergic marker, acetylcholinesterase, was estimated in the whole brain 
using Ellman method. Ellman’s reagent is 5,5’-dithiobis(2-nitrobenzoate) and is also 
abbreviated as DTNB. Ellman’s reagent is the mixture of 19.8 mg of DTNB in 100 ml 
of 0.1% sodium citrate solution. About 0.1 ml of brain homogenate was incubated for 
5 min with 2.7 ml of phosphate buffer and 0.1 ml of DTNB. Then, 0.1 ml of freshly 
prepared acetylthiocholine iodide (pH 8) was added and the absorbance was measured 
at 412 nm200. 
5.9.2 Estimation of total protein content  
The amount of total protein present in the tissue homogenate was estimated 
using bovine serum albumin as the standard. To 0.1 ml of tissue homogenate, 4.0 ml of 
alkaline copper tartarate solution was added and allowed to stand for 10 min. To the 
mixture 0.4 ml of phenol reagent was added rapidly, mixed quickly and incubated at 
room temperature for 30 min for colour development. Reading was taken against blank 
prepared with distilled water at 610 nm in an UV-visible spectrophotometer. The 
protein content was calculated from the standard curve prepared with bovine serum 
albumin (BSA) (1 mg/ml) and expressed as mmoles/min/mg brain tissue201. 
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5.9.3 Enzymatic anti-oxidants 
5.9.3.1 Estimation of catalase  
Catalase (hydrogen peroxide oxidoreductase) enzyme is involved in the 
decomposition of hydrogen peroxide into water and oxygen molecules. Catalase 
activity is measured either by decomposition of H2O or by liberation of O2. The 
decrease in the absorbance by H2O2 as a function of time is used to follow the 
hydrogen-peroxide reaction. The spectral region for hydrogen peroxide is 210-240 nm. 
The difference in absorbance per minute is a measure of catalase activity. Catalase 
plays a major role in cellular antioxidant defense system by decomposing H2O2, thereby 
preventing the generation of hydroxyl radical through the Fenton reaction202. 
About 0.1 ml of tissue homogenate was added to 1.0 ml of 0.01 M phosphate 
buffer of pH 7.0 and was incubated at 37C for 15 min. The reaction was started by the 
addition of 0.4 ml of 2M H2O2. The reaction was then stopped by the addition of 2 ml 
of dichromate - acetic acid reagent (a mixture of 5% potassium dichromate and glacial 
acetic acid in a ratio of 1:3). CAT was assayed colorimetrically at 620 nm. Unit of 
catalase activity is expressed as the amount of enzyme causing the decomposition of 
µmoles H2O2/mg protein/min203.  
5.9.3.2 Estimation of superoxide dismutase (SOD) 
The first enzyme involved in the antioxidant defense is superoxide dismutase. It 
is a metalloprotein found in both prokaryotic and eukaryotic cells. The oxygen-derived 
free radicals generated by the interaction of Fe2+ and H2O2 are the species responsible 
for the oxidation of epinephrine and they were strongly inhibited by the enzyme, 
superoxide dismutase204. 
About 0.1 ml of tissue homogenate was mixed with sodium pyrophosphate 
buffer, and nitroblue tetrazolium (NBT). The reaction was initiated by the addition of 
NADH. The reaction mixture was incubated at 30°C for 90 seconds and it was stopped 
by the addition of 1 ml of glacial acetic acid. The absorbance of the chromogen formed 
was measured at 560nm.  SOD activity is expressed as nmoles/min/mg protein205.    
5.9.3.3 Estimation of glutathione reductase (GSSH) 
The reaction mixture contained 2.1 ml of 0.25 mM potassium phosphate buffer 
of pH 7.6, 0.1ml of 0.001M NADPH, 0.2 ml of 0.0165 M oxidized glutathione and 0.1 
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ml of bovine serum albumin (10 mg/ml). The reaction was started by the addition of 0.2 
ml of tissue homogenate with mixing and the decrease in the absorbance at 340 nm was 
measured for 3 minutes against the blank. Glutathione reductase activity is expressed as 
nmoles NADPH oxidized /min/mg protein205.  
5.9.3.4 Estimation of glutathione peroxidase (GPx) 
Glutathione peroxidase (GPx) has a major role in degrading the levels of H2O2 
in cells. Since GPx acts on the hydroperoxides of unsaturated fatty acids, this enzyme 
plays an important role in protecting membrane lipids, and thus the cell membranes 
from oxidative disintegration206. 
The reaction mixture consisted of 0.2 ml of 0.4 M Tris-HCl buffer, 0.1 ml of 
sodium azide, 0.1 ml of hydrogen peroxide, 0.2 ml of glutathione and 0.2 ml of 
supernatant. The mixture was incubated at 37C for 10 min. The reaction was arrested 
by the addition of 10 % trichloro acetic acid and the absorbance was measured at 340 
nm.  GPx activity is expressed as nmoles/min/mg protein207. 
5.9.4. Non-enzymatic antioxidants 
5.9.4.1 Estimation of reduced glutathione (GSH) 
The most widely used method for the determination of GSH in biological 
samples is by Ellman reagent (DTNB), which reacts with sulfydryl compounds to give 
a relatively stable yellow colour. About 1 ml of supernatant was treated with 0.5 ml of 
Ellman’s reagent (19.8 mg of 5, 5’-dithiobis-(2-nitro) benzoic acid (DTNB) in 100 ml 
of 0.1% sodium citrate solution) and 3.0 ml of 0.2 M phosphate buffer of pH 8.0. The 
absorbance was read at 412 nm using a spectrophotometer. The activity of GSH was 
expressed as nmoles/min/mg protein204. 
5.9.5 Estimation of lipid peroxidation (LPO) 
Lipid peroxidation as evidenced by the formation of malondialdehyde was 
measured by the method of Niehaus and Samuelson, 1986. About   0.1 ml of tissue 
homogenate was treated with 2 ml of (1:1:1 ratio) TBA-TCA-HCl reagent (0.37% 
thiobarbituric acid, 15% trichloroacetic acid and 0.25 N hydrochloric acid) placed in a 
water bath for 15 min, cooled and centrifuged at room temperature for 10 min at 3000 
rpm.  The absorbance of the clear supernatant was measured against a reference blank 
at 535 nm.  The values are expressed as nmoles of MDA formed /min/mg protein208. 
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5.9.6 (2,2-Diphenyl-1-picrylhydrazyl) (DPPH) assay 
DPPH is a stable, nitrogen-centered free radical which produces violet colour in 
ethanol solution. It was reduced to a yellow colored product, diphenylpicryl hydrazine, 
with the addition of the fractions in a concentration-dependent manner. The reduction 
in the number of DPPH molecules can be correlated with the number of available 
hydroxyl groups. About 1 ml of tissue homogenate was mixed with 4 ml of 0.004% 
methanolic solution of DPPH solution. After 30 min incubation, absorbance was read at 
517 nm. Percentage of inhibition was calculated 209. 
5.10 Histopathological studies 
Brain of animals in different groups was perfusion-fixed with 4% 
paraformaldehyde in 0.1 M phosphate buffer. The brain was removed and post fixed in 
the same fixative overnight. The brain was embedded in paraffin and stained with 
hematoxylin-eosin. The hippocampal lesions were assessed microscopically at 40 X 
magnification210. 
5.11 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 4.0 by One-way 
Analysis of Variance (ANOVA) followed by Dunnett’s test. Results are expressed as 
mean±SEM from six mice in each group. P values < 0.05 were considered significant. 
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6. RESULTS AND ANALYSIS 
6.1 Drug likeness properties of the flavonoids 
In the present study, two hundred and forty five flavonoids were identified and 
the structures were drawn with the help of MedChem designer. The drug likeness 
properties of the flavonoids were evaluated with the help of MedChem designer. All the 
245 flavonoids showed excellent score (partition coefficient, molecular weight, 
hydrogen bond donors and acceptors) which indicate that these compounds have no 
violations or acceptable violations in Lipinski’s rule of 5 (Fig. 21). Based on the drug 
likeness score, all the 245 flavonoids exhibited considerable pharmacokinetic profile 
and were selected for in silico biological screening against AChE and BuChE using 
AutoDock 4.2. 
 
Fig. 21 Drug likeness properties of the flavonoids 
6.2 In silico docking studies against AChE and BuChE 
Totally 245 flavonoids selected were subjected to in silico docking studies based 
on drug likeness properties. In the docking studies of the flavonoids, the following 
docking parameters such as binding energy, inhibition constant and intermolecular 
energy were evaluated against AChE and BuChE enzymes. The selected flavonoids 
showed excellent docking parameters and orientations when compared with the 
standard (donepezil) against AChE and BuChE.  
All the selected flavonoids when docked with AChE target protein showed 
binding energy ranging between -6.95 kcal/mol to -3.90 kcal/mol as compared to 
donepezil (standard) which showed binding energy of -3.87 kcal/mol (Table 1). 
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Scopoletin and baicalein showed remarkably excellent binding energy (-6.95 kcal/mol 
and -6.93 kcal/mol) when compared to other flavonoids (Fig. 22). The minimum 
binding energy indicated that the selected flavonoids have excellent inhibitory potential 
toward AChE protein. 
Inhibition constant is an important score to consider, by which the effectiveness 
of the compounds were evaluated through both virtual screening and in vitro 
pharmacological experimental studies. In silico studies proved that, the flavonoids 
could exhibit excellent inhibition constant toward the AChE ranging between 8.37 µM 
to 990.45 µM when compared with standard (994.14 µM). Scopoletin and baicalein 
showed remarkably excellent inhibition constant (8.37 µM and 8.32 µM) when 
compared to other flavonoids. 
Intermolecular energy is also directly proportional to binding energy. We found 
a decrease in intermolecular energy of all the flavonoids with a simultaneous decrease 
in binding energy. The flavonoids showed intermolecular energy towards the AChE 
ranging from -8.94 kcal/mol to -5.51 kcal/mol when compared with standard (-5.46 
kcal/mol). Scopoletin and baicalein showed remarkably excellent intermolecular energy 
(-8.94 kcal/mol and -8.91 kcal/mol) when compared to other flavonoids. This further 
proved the inhibitory potential of scopoletin and baicalein against AChE.  
The ligand scopoletin interacted with the binding sites of AChE at the amino 
acid residues Tyr 124, Trp 286, Leu 289, Ser 293, Ile 294, Phe 295, Tyr 341 and it was 
in correlation with the donepezil Tyr 72, Tyr 124, Trp 286, Phe 295 and Tyr 341 (Fig. 
23).  
 
Fig. 22 Binding energy of the flavonoids against AChE 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Acacatechin -4.84 287.59 -7.37 -2.97 134.85 -4.81 
Acacetin -4.54 335.28 -6.92 -2.79 156.98 -4.54 
Afzelechin -5.26 136.28 -7.80 -3.20 71.63 -5.09 
Angoletin -5.14 162.14 -7.73 -3.12 80.92 -5.06 
Annulatin -4.86 282.94 -7.40 -2.98 131.50 -4.85 
Apigenin -6.33 39.87 -8.67 -3.88 19.08 -5.68 
Apometzgerin -5.31 114.42 -7.87 -3.26 54.77 -5.16 
Aromadedrin, Dihydro Kaempferol -5.37 90.21 -7.96 -3.29 43.32 -5.23 
Aurantinidin -5.46 84.04 -8.10 -3.35 39.25 -5.25 
Aureusidin -5.54 80.12 -8.19 -3.40 37.76 -5.37 
Ayanin -5.63 74.78 -8.24 -3.45 35.09 -5.41 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Azaleatin -4.24 730.98 -6.30 -2.60 342.77 -4.11 
Baicalein -6.93 8.32 -8.91 -4.51 2.12 -6.11 
Baicalin mono hydrate -3.94 964.84 -5.64 -2.41 459.96 -3.66 
Baptigenin -5.34 98.84 -7.94 -3.26 51.69 -5.21 
Bavachinin -4.04 914.52 -5.84 -2.47 439.08 -3.77 
Biochanin A -4.36 368.66 -6.62 -2.68 170.41 -4.33 
Bis Hydroxy Coumarin -5.68 70.32 -8.35 -3.48 33.11 -5.46 
Bracteatin -5.46 83.74 -7.99 -3.33 39.69 -5.25 
Buceracidin-B -5.54 80.56 -8.18 -3.40 37.96 -5.36 
Butein -4.92 276.36 -7.45 -3.02 126.27 -4.87 
Calycopterin -4.30 581.36 -6.41 -2.63 320.78 -4.20 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Calycosin -4.67 321.84 -7.14 -2.85 150.65 -4.66 
Candidone -5.05 200.12 -7.62 -3.09 102.49 -4.95 
Cannflavin -4.77 298.34 -7.30 -2.92 142.95 -4.77 
Capensinidin -4.50 339.68 -6.89 -2.75 160.72 -4.50 
Carajuflavone -4.23 729.36 -6.24 -2.60 341.73 -4.07 
Carpachromene -3.96 954.36 -5.71 -2.42 451.12 -3.68 
Casticin -4.69 315.64 -7.16 -2.87 150.86 -4.69 
Catechin -5.34 136.44 -6.99 -3.28 45.30 -5.21 
Chrysin -6.30 45.39 -8.64 -3.83 25.37 -5.65 
Chrysoeriol -4.59 328.45 -6.97 -2.79 157.16 -4.54 
Chrysosplenetin -5.43 84.68 -7.99 -3.33 40.58 -5.23 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Cirsililol -4.16 832.21 -6.01 -2.52 399.50 -3.91 
Cirsilineol -5.63 74.86 -8.24 -3.45 35.76 -5.40 
Cirsimaritin -5.72 69.92 -8.38 -3.49 32.93 -5.48 
Cladrin -5.80 68.84 -8.44 -3.53 32.46 -5.53 
Combretol -4.23 729.64 -6.23 -2.59 339.48 -4.07 
Cyanidin -4.50 338.64 -6.87 -2.75 160.37 -4.49 
Cyclocommunol -4.77 298.81 -7.29 -2.92 142.72 -4.77 
Daidzein -5.04 218.24 -7.58 -3.08 109.86 -4.95 
Datin -5.31 118.42 -7.86 -3.26 54.04 -5.15 
Datiscetin -4.24 731.26 -6.30 -2.60 343.07 -4.10 
Delphinidin -3.94 962.38 -5.61 -2.41 459.45 -3.64 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Demethylbellidifolin -4.64 321.62 -7.12 -2.83 151.89 -4.59 
Desmethoxycentaureidin -5.58 79.05 -8.20 -3.42 37.00 -5.38 
Dihydrobaicalein -5.84 67.86 -8.50 -3.57 31.99 -5.55 
Dihydroflavonol -4.77 298.72 -7.27 -2.91 143.73 -4.77 
Dihydrokaempferide -5.04 218.64 -7.54 -3.08 108.39 -4.94 
Dihydromyricetin -5.31 116.84 -7.86 -3.24 57.58 -5.14 
Dihydrorobinetin -5.58 78.94 -8.20 -3.42 36.88 -5.38 
Dihydrotricetin -4.54 334.98 -6.92 -2.77 157.71 -4.53 
Dihydrowogonin -4.34 396.44 -6.55 -2.65 197.60 -4.27 
Diosmetin -6.03 60.86 -8.57 -3.66 29.87 -5.61 
Diosmin -6.03 36.86 -7.84 -3.69 28.66 -5.61 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Dorsilurin-F -5.68 70.26 -8.34 -3.52 32.57 -5.51 
Epicatechin -5.74 69.64 -8.42 -3.52 32.64 -5.53 
Epicatechin Gallate -5.80 68.98 -8.44 -3.17 73.26 -5.09 
Epigallocatechin -5.24 124.12 -7.04 -3.24 58.29 -5.13 
Epigallocatechin Gallate -5.31 115.28 -7.84 -3.40 37.56 -5.38 
Eriocitrin -5.58 78.68 -8.20 -3.57 31.95 -5.55 
Eriodictyol -5.84 67.24 -8.48 -2.68 172.81 -4.35 
Ermanin -4.37 357.45 -6.67 -2.69 164.74 -4.42 
Esculetin -4.38 354.98 -6.75 -3.12 79.86 -5.05 
Eupafolin -5.09 168.42 -7.72 -3.39 38.31 -5.34 
Eupalitin -5.53 81.12 -8.17 -3.44 36.51 -5.39 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Eupatilin -5.60 77.94 -8.21 -3.47 33.24 -5.44 
Eupatolitin -5.67 70.64 -8.32 -3.52 32.59 -5.52 
Eupatorin -5.75 69.24 -8.43 -3.42 36.85 -5.38 
Europetin -5.60 77.89 -8.21 -3.38 38.42 -5.32 
Europinidin -5.52 81.72 -8.13 -3.30 42.29 -5.23 
Farobin-A -5.39 89.12 -7.97 -3.23 63.88 -5.12 
Fisetin -5.28 122.84 -7.83 -3.15 76.00 -5.07 
Fisetinidol -5.17 156.28 -7.75 -3.09 102.30 -4.98 
Flavoxate -5.05 198.89 -7.67 -3.02 126.66 -4.88 
Formononetin -4.94 264.69 -7.45 -2.95 136.96 -4.79 
Fustin -4.82 290.86 -7.32 -2.87 148.82 -4.69 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Galangin -4.71 312.28 -7.18 -2.81 155.39 -4.56 
Gallocatechin -4.60 326.54 -6.97 -3.36 38.85 -5.32 
Gallocatechin Gallate -5.51 81.96 -8.11 -3.44 36.53 -5.39 
Ganhuangenin -5.62 76.28 -8.23 -3.51 32.78 -5.50 
Gardenin B -5.74 69.47 -8.39 -3.56 32.27 -5.54 
Gartanin -5.82 68.24 -8.46 -2.65 197.10 -4.22 
Genistein -4.32 421.54 -6.50 -2.50 412.75 -3.87 
Genistin -4.08 886.24 -5.94 -2.58 338.97 -4.06 
Geraldone -4.22 724.23 -6.20 -2.97 134.81 -4.84 
Gericudranin-B -4.86 283.16 -7.40 -2.77 157.50 -4.53 
Glabridin -4.54 334.20 -6.92 -2.69 165.22 -4.40 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Glaziovianin-A -4.38 352.12 -6.74 -2.91 144.53 -4.75 
Glycitein -4.76 304.95 -7.27 -2.38 464.27 -3.62 
Gnetifolin E -3.92 981.25 -5.58 -2.98 132.73 -4.86 
Gomphrenol -4.88 278.98 -7.42 -2.96 136.34 -4.81 
Gossypetin -4.84 289.64 -7.34 -2.50 413.84 -3.86 
Guibourtinidol -4.08 884.16 -5.93 -2.63 311.37 -4.19 
Helmon -4.28 698.28 -6.41 -3.70 27.38 -5.63 
Herbacetin -6.08 57.96 -8.58 -3.22 25.63 -5.11 
Hesperedin -5.28 148.38 -7.08 -4.15 8.09 -5.72 
Hesperetin -6.72 17.02 -8.81 -3.83 24.67 -5.64 
Hibiscetin -6.28 48.42 -8.63 -3.56 32.33 -5.54 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Hirsutidin -5.82 68.16 -8.45 -3.52 32.56 -5.51 
Hispudulin -5.74 69.53 -8.41 -3.35 38.98 -5.32 
Homoeriodictyol -5.48 82.87 -8.10 -3.26 53.63 -5.17 
Homoorientin -5.32 110.28 -7.94 -2.82 153.96 -4.58 
Hydrangenol -4.61 324.03 -6.99 -2.73 163.43 -4.48 
Hypolaetin -4.46 345.24 -6.84 -2.63 316.01 -4.20 
Icaritin -4.30 561.28 -6.41 -2.69 164.18 -4.40 
Irigenin -4.38 350.92 -6.74 -2.93 140.03 -4.77 
Isalpinin -4.77 298.36 -7.30 -2.97 135.77 -4.82 
Isoetin -4.86 284.31 -7.38 -2.50 413.50 -3.88 
Isoimperatorin -4.11 852.26 -5.96 -2.58 338.62 -4.06 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Isokaempferide -4.23 728.14 -6.22 -2.74 161.83 -4.49 
Isookanin -4.48 344.23 -6.85 -2.76 158.74 -4.51 
Isopongaflavone -4.52 336.45 -6.90 -2.65 196.09 -4.22 
Isoquercitrin -4.32 421.28 -6.48 -3.73 27.17 -5.63 
Isorhamnetin -6.22 57.28 -8.58 -3.06 114.78 -4.92 
Isosakuranetin -5.02 236.24 -7.54 -3.04 119.75 -4.90 
Isoscutellarein -4.98 244.87 -7.50 -2.95 136.61 -4.81 
Isosilybin -4.84 287.31 -7.34 -3.03 124.07 -4.89 
Isothymusin -4.96 252.36 -7.48 -2.65 195.11 -4.21 
Isovitexin -4.32 420.84 -6.46 -2.74 161.80 -4.48 
Isoxanthohumol -4.48 342.86 -6.85 -2.99 130.77 -4.87 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Jaceidin -4.92 272.38 -7.44 -3.11 85.53 -5.04 
Kaempferide -5.08 172.63 -7.71 -3.85 22.70 -5.68 
Kaempferol -6.32 42.90 -8.65 -3.06 112.98 -4.92 
Kumatakenin -5.02 234.36 -7.54 -2.68 171.17 -4.33 
Ladanein -4.36 364.28 -6.61 -2.71 163.76 -4.43 
Laricitrin -4.42 349.84 -6.81 -2.50 412.54 -3.85 
Leptosidin -4.08 882.14 -5.91 -2.69 166.40 -4.43 
Leucoanthocyanidin -4.42 349.21 -6.79 -3.14 77.49 -5.07 
Leucocyanidin -5.16 160.76 -7.74 -2.71 163.99 -4.47 
Leucodelphinidin -4.46 345.18 -6.83 -2.69 164.29 -4.40 
Leucofisetinidin -4.38 351.44 -6.73 -2.60 341.89 -4.10 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Leucomalvidin -4.24 731.04 -6.30 -2.90 145.70 -4.75 
Leucopelargonidin -4.76 304.46 -7.27 -2.93 139.86 -4.79 
Leucopeonidin -4.81 291.44 -7.32 -2.99 130.04 -4.86 
Leucorobinetinidin -4.92 270.21 -7.43 -2.83 152.19 -4.58 
Leukoefdin -4.64 321.38 -7.10 -2.62 346.13 -4.18 
Licoflavonol -4.28 674.16 -6.40 -2.63 327.32 -4.21 
Limocitrin -4.31 454.26 -6.42 -2.67 180.12 -4.33 
Limocitrol -4.36 362.18 -6.61 -2.69 165.06 -4.42 
Liquiritigenin -4.42 349.12 -6.77 -2.71 163.69 -4.46 
Luteoforol -4.46 345.02 -6.83 -2.66 188.85 -4.29 
Luteolin -4.35 384.26 -6.59 -2.58 338.73 -4.06 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Luteolinidin -4.23 729.02 -6.20 -2.48 428.68 -3.83 
Maesopsin -4.08 880.54 -5.89 -2.50 415.43 -3.90 
Malvidin -4.12 842.15 -5.99 -2.60 342.02 -4.09 
Maritimetin -4.24 731.24 -6.26 -2.61 343.32 -4.14 
Matteucinol -4.26 734.22 -6.34 -2.65 197.27 -4.24 
Mearnsitrin -4.33 402.89 -6.53 -2.69 164.10 -4.39 
Meciadanol -4.38 352.46 -6.70 -2.58 339.12 -4.06 
Melacacidin -4.21 722.38 -6.19 -2.71 163.65 -4.44 
Melanoxetin -4.45 348.65 -6.82 -2.68 170.76 -4.34 
Mesquitol -4.37 359.12 -6.67 -4.44 3.92 -5.74 
Morin -6.92 8.29 -8.90 -3.88 18.69 -5.69 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Myricetin -6.34 38.96 -8.68 -4.21 6.18 -5.72 
Naringenin -6.76 17.26 -8.84 -3.59 31.52 -5.57 
Naringin -5.88 65.86 -8.51 -3.45 35.05 -5.41 
Natsudaidain -5.64 72.68 -8.28 -3.31 41.78 -5.23 
Negletein -5.42 86.56 -7.97 -3.12 78.95 -5.07 
Nepetin -5.16 160.32 -7.73 -2.97 134.68 -4.82 
Nobiletin -4.86 280.53 -7.38 -2.89 146.38 -4.71 
Nodifloretin -4.73 310.83 -7.23 -2.68 167.55 -4.38 
Norathyriol -4.38 350.25 -6.70 -2.84 151.38 -4.66 
Norwogonin -4.67 321.15 -7.14 -2.93 140.07 -4.79 
Okanin -4.80 292.19 -7.30 -2.50 414.45 -3.89 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Ombuin -4.12 840.14 -5.98 -2.60 341.32 -4.08 
Ononin -4.24 731.88 -6.25 -2.48 427.71 -3.82 
Orientin -4.08 882.85 -5.88 -2.64 212.93 -4.21 
Orobol -4.32 420.48 -6.43 -2.55 390.10 -3.95 
Oroxylin-A -4.18 784.46 -6.13 -2.68 168.34 -4.38 
Osajin -4.38 350.48 -6.70 -2.87 150.54 -4.69 
Pachypodol -4.68 318.65 -7.15 -2.62 346.42 -4.16 
Patuletin -4.28 684.33 -6.39 -2.43 447.36 -3.75 
Pectolinarigenin -4.04 912.44 -5.82 -2.43 448.38 -3.73 
Pedalitin -4.02 934.27 -5.76 -2.64 263.10 -4.21 
Pelargonidin -4.32 418.33 -6.43 -2.53 394.76 -3.94 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Penduletin -4.18 782.15 -6.12 -3.94 17.01 -5.70 
Peonidin -6.42 36.28 -8.71 -2.60 342.65 -4.14 
Persicarin -4.26 735.08 -6.33 -2.75 161.36 -4.50 
Persicogenin -4.52 336.01 -6.90 -2.81 155.24 -4.56 
Petunidin -4.61 324.68 -6.98 -2.74 161.73 -4.48 
Pinoquercetin -4.48 342.12 -6.84 -2.87 149.37 -4.69 
Platanetin -4.71 311.88 -7.19 -2.64 272.51 -4.21 
Pomiferin -4.32 416.24 -6.42 -2.53 393.82 -3.92 
Pratensein -4.18 780.14 -6.03 -2.65 197.48 -4.25 
Pratol -4.34 398.78 -6.55 -2.42 452.27 -3.70 
Primetin -4.02 936.71 -5.74 -2.61 344.17 -4.16 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Propolin B -4.28 664.26 -6.38 -2.21 488.27 -2.92 
Prosogerin E -3.92 980.16 -5.55 -2.18 508.27 -2.82 
Prunetin -3.90 990.45 -5.51 -2.47 437.94 -3.78 
Prunin -4.08 880.08 -5.86 -2.79 157.02 -4.54 
Pulchellidin -4.58 331.18 -6.95 -2.82 153.07 -4.58 
Quercetagetin -4.63 322.94 -7.10 -2.57 367.72 -4.02 
Quercetagetinidin -4.21 722.62 -6.18 -3.26 55.51 -5.16 
Ranupetin -5.32 108.12 -7.90 -3.09 102.36 -4.99 
Retusin -5.06 182.46 -7.68 -2.93 139.85 -4.79 
Rhamnazin -4.81 291.25 -7.31 -3.04 118.74 -4.89 
Rhamnetin -4.98 241.02 -7.50 -2.66 185.83 -4.30 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Rhusflavanone -4.36 363.55 -6.60 -2.76 159.23 -4.52 
Rhynchosin -4.54 334.89 -6.91 -1.25 231.18 -2.41 
Robinetin -6.45 24.25 -8.73 -3.96 11.37 -5.71 
Robinetinidin -5.66 70.96 -8.30 -3.45 34.93 -5.42 
Robinetinidol -5.02 231.24 -7.52 -3.04 118.29 -4.91 
Rosinidin -5.08 170.15 -7.69 -3.10 93.23 -5.04 
Rutin -6.51 23.27 -8.76 -4.03 9.23 -5.72 
Sakuranetin -4.96 255.46 -7.47 -3.02 129.54 -4.89 
Salvigenin -4.84 287.68 -7.33 -2.95 136.52 -4.80 
Santal -5.08 170.36 -7.69 -3.10 93.81 -5.00 
Santin -5.28 124.36 -7.82 -3.20 70.46 -5.10 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Scopoletin -6.95 8.37 -8.94 -4.62 1.29 -6.23 
Scutellarein -5.72 69.87 -8.38 -3.49 32.96 -5.48 
Scutevulin -5.12 165.31 -7.72 -3.12 79.76 -5.05 
Selagin -4.96 253.31 -7.45 -3.02 127.68 -4.88 
Silibinin -5.66 70.92 -7.45 -3.46 34.07 -5.44 
Silybin -5.74 69.48 -8.40 -3.51 32.75 -5.50 
Sinensetin -5.04 218.36 -7.60 -3.08 110.74 -4.95 
Skullcapflavone Ii -4.75 306.62 -7.26 -2.90 145.79 -4.73 
Sorbifolin -4.37 358.98 -6.64 -2.68 169.77 -4.34 
Sternbin -4.26 736.24 -6.32 -2.60 342.78 -4.14 
Sterubin -4.42 349.36 -6.75 -2.69 164.49 -4.42 
100 
 
Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Syringetin -4.36 365.16 -6.59 -2.66 186.93 -4.30 
Tamarixetin -4.68 317.48 -7.15 -2.85 150.76 -4.67 
Tambulin -4.74 308.32 -7.24 -2.89 146.19 -4.72 
Tanetin -4.58 331.49 -6.95 -2.79 156.66 -4.54 
Tangeritin -6.24 56.62 -8.59 -3.82 26.19 -5.63 
Taxifolin -5.22 150.32 -7.01 -3.17 75.36 -5.08 
Tectorigenin -4.21 723.14 -6.18 -2.57 366.63 -4.02 
Tephrosin -4.92 269.38 -7.42 -2.98 132.63 -4.86 
Teracacidin -4.72 311.02 -7.20 -2.88 147.96 -4.70 
Ternatin -4.88 277.42 -7.40 -2.98 133.27 -4.85 
Tetra Hydroflavone -6.38 37.08 -8.70 -3.89 18.26 -5.70 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Texasin -5.34 96.64 -7.94 -3.26 50.68 -5.19 
Theaflavin -5.88 66.25 -8.52 -3.59 31.81 -5.58 
Theaflavin-3-Gallate -5.58 78.62 -8.20 -3.42 37.05 -5.38 
Thunberginol A -4.27 738.41 -6.36 -2.61 345.11 -4.15 
Tomentin -4.21 723.46 -6.18 -2.57 365.69 -3.96 
Topazolin -4.38 350.08 -6.68 -2.68 168.27 -4.36 
Tricetin -4.27 739.02 -6.06 -2.61 344.57 -4.16 
Tricin -5.36 92.42 -7.96 -3.28 46.33 -5.21 
Veronicoside -4.25 732.41 -6.31 -2.60 342.68 -4.14 
Viscidulin Ii -5.46 83.16 -8.10 -3.35 39.39 -5.32 
Vitexin -5.96 63.72 -8.54 -3.61 30.87 -5.59 
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Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE (Cont.) 
Flavonoids 
Acetylcholinesterase Butyrylcholinesterase 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Binding 
Energy 
(kcal/mol) 
Inhibition 
constant 
(µM) 
Intermolecular 
Energy 
(kcal/mol) 
Vitexycarpin -6.01 61.15 -8.54 -3.61 31.05 -5.59 
Wogonin -6.86 9.48 -8.87 -4.25 4.81 -5.73 
Wogonoside -5.54 80.98 -8.17 -3.39 38.03 -5.36 
Xanthohumol -5.21 152.82 -7.75 -3.17 75.15 -5.07 
Donepezil -3.87 994.14 -5.46 -3.47 33.26 -5.45 
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Fig. 23 Molecular interactions of scopoletin and donepezil against AChE 
In silico studies with BuChE revealed that all the flavonoids showed good 
binding energy ranging between -4.62 to -2.18 kcal/mol. The scopoletin binding energy 
was found to be -4.62 kcal/mol as compared to donepezil (standard) -1.25 kcal/mol 
(Fig. 24). In case of BuChE target, inhibition constant of the flavonoids were found to 
be 1.29 µM to 508.27 µM when compared to the standard (231.18 µM). The results of 
inhibition constant coincide with the binding energy scores (Table 1).  
 
Fig. 24 Binding energy of the flavonoids against BuChE 
The flavonoid molecules having 2D structure were converted to energy 
minimized 3D structures and were further used for in silico protein–ligand docking. 
The active pocket of the BuChE for the scopoletin was found to be His 77, Lys 131, 
Gln 279, Val 204, Ile 272, Ser 287, Thr 346, Pro 449, Arg 515 and for donepezil were 
His 77, Pro 102, Lys 131, Val 204, Ser 287, Thr 346 (Fig. 25).  
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Fig. 25 Molecular interactions of scopoletin and donepezil against BuChE 
These amino acid residues were dynamically involved in the formation of 
hydrophilic and hydrophobic contacts and they were initiated to play an important role 
in the binding site of target. This proves that the flavonoids possess potential ChE 
inhibitory binding sites when compared to the standard. These molecular docking 
analyses could lead to the further development of potent acetylcholinesterase inhibitors 
for the treatment of AD.    
The in silico ChE (AChE and BuChE) inhibitory activities of the 245 flavonoid 
compounds decreased in the order of Scopoletin > Baicalein > Morin > Wogonin > 
Naringenin > Hesperetin > Rutin > Robinetin > Peonidin > Tetra Hydroflavone > 
Myricetin > Apigenin > Kaempferol > Chrysin > Hibiscetin > Tangeritin > 
Isorhamnetin > Herbacetin > Diosmin > Diosmetin > Vitexycarpin > Vitexin > 
Theaflavin > Naringin > Dihydrobaicalein > Eriodictyol > Gartanin > Hirsutidin > 
Cladrin > Epicatechin Gallate > Eupatorin > Epicatechin > Hispudulin > Silybin > 
Gardenin B > Scutellarein > Cirsimaritin > Bis Hydroxy Coumarin > Dorsilurin-F > 
Eupatolitin > Silibinin > Robinetinidin > Natsudaidain > Ayanin > Cirsilineol > 
Ganhuangenin > Eupatilin > Europetin > Theaflavin-3-Gallate > 
Desmethoxycentaureidin > Dihydrorobinetin > Eriocitrin > Aureusidin > Buceracidin-
B > Wogonoside > Eupalitin > Europinidin > Gallocatechin Gallate > Homoeriodictyol 
> Viscidulin II > Aurantinidin > Bracteatin > Chrysosplenetin > Negletein > Farobin-A 
> Aromadedrin > Tricin > Catechin > Baptigenin > Texasin > Homoorientin > 
Ranupetin > Apometzgerin > Datin > Dihydromyricetin > Epigallocatechin Gallate > 
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Fisetin > Hesperedin > Santin > Afzelechin > Epigallocatechin > Taxifolin > 
Xanthohumol > Fisetinidol > Leucocyanidin > Nepetin > Angoletin > Scutevulin > 
Eupafolin > Kaempferide > Rosinidin > Santal > Retusin > Flavoxate > Candidone > 
Sinensetin > Daidzein > Dihydrokaempferide > Isosakuranetin > Kumatakenin > 
Robinetinidol > Isoscutellarein > Rhamnetin > Isothymusin > Sakuranetin > Selagin > 
Formononetin > Butein > Jaceidin > Leucorobinetinidin > Tephrosin > Gomphrenol > 
Ternatin > Annulatin > Gericudranin-B > Isoetin > Nobiletin > Acacatechin > 
Gossypetin > Isosilybin > Salvigenin > Fustin > Leucopeonidin > Rhamnazin > Okanin 
> Isalpinin > Cannflavin > Cyclocommunol > Dihydroflavonol > Glycitein > 
Leucopelargonidin > Skullcapflavone II > Tambulin > Nodifloretin > Teracacidin  > 
Platanetin > Galangin > Casticin > Pachypodol > Tamarixetin > Calycosin > 
Norwogonin > Demethylbellidifolin > Leukoefdin > Quercetagetin > Hydrangenol > 
Petunidin > Gallocatechin > Chrysoeriol > Pulchellidin > Tanetin > Acacetin > 
Dihydrotricetin > Glabridin > Rhynchosin > Isopongaflavone > Persicogenin > 
Capensinidin > Cyanidin > Isookanin > Isoxanthohumol > Pinoquercetin > Hypolaetin 
> Leucodelphinidin > Luteoforol > Melanoxetin > Laricitrin > Leucoanthocyanidin > 
Liquiritigenin > Sterubin > Esculetin > Glaziovianin-A > Irigenin > Leucofisetinidin > 
Meciadanol > Norathyriol > Osajin > Topazolin > Ermanin > Mesquitol > Sorbifolin > 
Biochanin A  > Ladanein > Limocitrol > Rhusflavanone > Syringetin > Luteolin > 
Dihydrowogonin > Pratol > Mearnsitrin > Genistein > Isoquercitrin > Isovitexin > 
Orobol > Pelargonidin > Pomiferin > Limocitrin > Icaritin > Calycopterin > Helmon > 
Licoflavonol > Patuletin > Propolin B > Tricetin > Thunberginol A > Matteucinol > 
Persicarin > Sternbin > Veronicoside > Azaleatin > Datiscetin > Leucomalvidin > 
Maritimetin > Ononin  > Carajuflavone > Combretol > Isokaempferide > Luteolinidin 
> Geraldone > Melacacidin > Quercetagetinidin > Tectorigenin > Tomentin > 
Oroxylin-A > Penduletin > Pratensein > Cirsililol > Malvidin > Ombuin > 
Isoimperatorin > Genistin > Guibourtinidol > Leptosidin > Maesopsin > Orientin > 
Prunin > Bavachinin > Pectolinarigenin > Pedalitin > Primetin > Carpachromene > 
Delphinidin > Gnetifolin E > Prosogerin E > Prunetin > Donepezil. 
6.3 In vitro AChE and BuChE inhibitory assay 
An increase in AChE leads to an increase in breakdown of ACh to acetate and 
choline, leading to the development of AD. Recent findings suggest that the occurrence 
of AD is increasing worldwide, possibly due to life style modifications. AChE 
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inhibitors are commonly employed in the treatment of AD. Inhibition of AChE results 
in a decreased breakdown of acetylcholine into acetate and choline, when measured 
spectroscopically. Out of 245 flavonoids taken for in silico docking studies, 20 
flavonoids were selected for the in vitro enzyme inhibitory assay. The selection of the 
flavonoids was based upon the predicted docked score and the compounds were divided 
conventionally into those of high, moderate and low neuroprotective activity against the 
targets.  
Hence, to prove the reliability of in silico studies the fourteen flavonoids with 
highest activity (Scopoletin > Baicalein > Morin > Diosmin > Naringenin > Catechin > 
Hesperetin > Silibinin > Rutin > Robinetin > Taxifolin > Tetra hydroflavone > 
Hesperidin > Myrecetin), three with moderate (Apigenin > Kaempferol > Tricetin) and 
three with lowest (Chrysin > Epigallocatechin > Theaflavin) neuroprotective activities 
were selected for the in vitro enzyme inhibition studies (Fig. 26). 
 
Fig. 26 Selection of flavonoids for in vitro enzyme inhibition studies 
The absorbance of all the selected flavonoids decreased upon increasing the 
concentrations in a dose dependent manner. The percentage inhibition was calculated 
for all the flavonoids and for standard. A dose dependent increase in percentage of 
inhibition was observed for standard.  
6.3.1 Role of flavonoids in AChE inhibitory activity 
Among the different flavonoids tested, scopoletin and baicalein exhibited the 
highest AChE inhibitory activity. The inhibition constant (IC50) of scopoletin was 
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.  
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 considered as significant (One way ANOVA followed by Dunnett’s test). 
Fig. 27 In vitro AChE enzyme inhibitory assay of the selected flavonoids 
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Values are expressed as mean ± SEM; n = 6. 
*P <0.05 considered as significant (One way ANOVA followed by Dunnett’s test). 
Fig. 28 In vitro BuChE enzyme inhibitory assay of the selected flavonoids 
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found to be 10.18 ± 0.68 µg/ml and for baicalein 10.92 ± 0.38 µg/ml when compared to 
the standard donepezil showed 22.14 ± 0.56 µg/ml. All the selected flavonoids showed 
AChE inhibitory activity at a concentration below 100 µg/ml, with IC50 values ranging 
from 10.18 to 21.48 µg/ml (Fig. 27).  
6.3.2 Role of flavonoids in BuChE inhibitory activity 
The inhibitory activity of the flavonoids against BuChE was determined by 
Ellman’s method with some modifications. This method estimates BuChE using s-
butyrylythiocholine iodide (substrate) and DTNB. The enzymatic activity was 
measured by the yellow color compound produced by thiocholine when it reacts with 
dithiobisnitro benzoate ion. The inhibitory activity of the flavonoids increased with 
increasing concentration. All the flavonoids selected showed BuChE inhibitory activity 
at a concentration below 100 µg/ml, with IC50 values ranging from 28.18 to 6.12 µg/ml. 
Noteworthy IC50 values were found for scopoletin and baicalein against BuChE. 
Scopoletin showed the IC50 value 28.18 ± 0.92 µg/ml and for baicalein 31.24 ± 1.12 
µg/ml against BuChE when compared to that of donepezil was found to be 64.38± 0.42 
µg/ml (Fig. 28). 
The order of potency of flavonoids to ChE (AChE and BuChE) inhibitory 
activities of the compounds decreased in the order of Scopoletin > Baicalein > Morin > 
Diosmin > Naringenin > Catechin > Hesperetin > Silibinin > Rutin > Robinetin > 
Taxifolin > Tetra hydroflavone > Hesperidin > Myrecetin > Apigenin, Kaempferol > 
Tricetin > Chrysin > Epigallocatechin > Theaflavin > Donepezil. 
Among the selected flavonoids, scopoletin and baicalein showed excellent 
inhibition constant (IC50) values against AChE and BuChE and thereby proved that 
these compounds possess potential cholinesterase inhibitory activity. The inhibitory 
activity of scopoletin and baicalein against cholinesterase enzymes were found to be 
greater than the standard, donepezil (22±0.56 µg/ml). Hence, the compounds scopoletin 
and baicalein were further selected for the in vivo studies to prove its neuroprotective 
activity against scopolamine and aluminium induced learning impairment in mice. 
6.4 Acute toxicity studies and selection of dose for in vivo studies  
Among the twenty compounds selected for in vitro AChE inhibitory assay two 
flavonoids (scopoletin and baicalein) were found to possess excellent activity in 
inhibiting the AChE and BuChE enzymes and these compounds were selected and used 
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for further in vivo studies. Acute toxicity was determined as per OECD guidelines (420) 
employing fixed dose procedure for selecting the dose for biological activity. For acute 
toxicity studies 10 female Wistar rats weighing 150-200 g were used and they were 
fasted overnight before the experimental day.  
The animals were observed no toxic effect and after sufficient interval of time 
(2-3 days) the second animal was administered with 50 mg/kg dose of test flavonoids. 
Similar observations were made as before and since the dose was non-toxic the third 
animal was administered with 300 mg/kg. This dose also did not exhibit any toxic 
effects or morbidity and therefore the last and highest dose in fixed dose procedure of 
2000 mg/kg was administered to fourth animal and no toxicity was noticed for highest 
dose (Table 2, 3).  
Signs and symptoms of toxicity and death if any were observed individually for 
each rat at 0, 0.5, 1, 2, 3 and 4h for first 24 h and thereafter daily for 14 days. Food was 
given to the animals after 4 h of dosing. The animals were observed twice daily for 14 
days and body weight changes, food and water consumption, etc., were noted. In acute 
toxicity studies, it was found that the animals were safe up to a maximum dose of 2000 
mg/kg of body weight. There were no changes in normal behavioural pattern and no 
signs and symptoms of toxicity and mortality were observed (Table 4, 5).  
As per the OECD 420 guidelines, selected flavonoids can be included in the 
category 5 or unclassified category of globally harmonized classification system 
(GHS). Hence, based on these results, the flavonoids baicalein and scopoletin were 
considered non-toxic and 1/10th and 1/20th of the maximum tolerated (2000 mg/kg) 
dose was used for the biological evaluation (memory enhancing activity) and thus the 
studies were conducted at dose levels of 100 and 200 mg/kg body weight.   
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Table 2: Observations done for the acute oral toxicity study- Baicalein 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 
Day 
14 
Respiratory 
Dyspnea - - - - - - - - - - - - 
Apnea - - - - - - - - - - - - 
Nostril discharges - - - - - - - - - - - - 
Motor activity 
Tremor - - - - - - - - - - - - 
Hyper activity - - - - - - - - - - - - 
Hypo activity - - - - - - - - - - - - 
Ataxia - - - - - - - - - - - - 
Jumping - - - - - - - - - - - - 
Catalepsy - - - - - - - - - - - - 
Locomotor activity  - - - - - - - - - - - 
Reflexes 
Corneal reflex - - - - - - - - - - - - 
Pinna reflex - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - 
Convulsion Tonic and clonic convulsion - - - - - - - - - - - - 
Muscle tone Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - 
Ocular sign 
Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - 
Mydriasis - - - - - - - - - - - - 
Ptosis - - - - - - - - - - - - 
Skin 
Edema - - - - - - - - - - - - 
Skin and fur - - - - - - - - - - - - 
Erythema - - - - - - - - - - - - 
Cardiovascular signs Bradycardia - - - - - - - - - - - - Tachycardia - - - - - - - - - - - - 
Piloerection Contraction of erectile tissue of hair 
- - - - - - - - - - - - 
- - - - - - - - - - - - 
Gastro intestinal signs Diarrhoea - - - - - - - - - - - - 
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Note: Acute toxicity study of baicalein and scopoletin was performed and it was non-toxic up to 2000 mg/kg dose 
Live phase animals Observations  
1. Body weight every day Normal 
2. Food consumption daily Normal  
3. Water consumption daily Normal  
4. Home cage activity Normal  
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Table 3: Mortality record for baicalein in acute oral toxicity study 
 
Dose Sighting study Main study (2000 mg/kg) 5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg      
No. of animals 1 2 3 4 5 6 7 8 9 
Body weight (g) 170 174 168 172 172 196 186 170 184 
Sex Female Female Female Female Female Female Female Female Female 
30 min Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
2 h Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
3 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 2 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 4 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 5 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 6 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 8 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 10 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 12 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 13 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Mortality 0/1 0/1 0/1 0/1 0/5 
Note: Acute toxicity study of baicalein compound was performed and it was non-toxic up to 2000 mg/kg dose  
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Table 4: Observations done for the acute oral toxicity study- Scopoletin 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 Day 14 
Respiratory 
Dyspnea - - - - - - - - - - - - 
Apnea - - - - - - - - - - - - 
Nostril discharges - - - - - - - - - - - - 
Motor activity 
Tremor - - - - - - - - - - - - 
Hyper activity - - - - - - - - - - - - 
Hypo activity - - - - - - - - - - - - 
Ataxia - - - - - - - - - - - - 
Jumping - - - - - - - - - - - - 
Catalepsy - - - - - - - - - - - - 
Locomotor activity  - - - - - - - - - - - 
Reflexes 
Corneal reflex - - - - - - - - - - - - 
Pinna reflex - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - 
Convulsion Tonic and clonic convulsion - - - - - - - - - - - - 
Muscle tone Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - 
Ocular sign 
Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - 
Mydriasis - - - - - - - - - - - - 
Ptosis - - - - - - - - - - - - 
Skin 
Edema - - - - - - - - - - - - 
Skin and fur - - - - - - - - - - - - 
Erythema - - - - - - - - - - - - 
Cardiovascular signs Bradycardia - - - - - - - - - - - - Tachycardia - - - - - - - - - - - - 
Piloerection Contraction of erectile tissue of hair 
- - - - - - - - - - - - 
- - - - - - - - - - - - 
Gastro intestinal signs Diarrhoea - - - - - - - - - - - - 
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Note: Acute toxicity study of baicalein and scopoletin was performed and it was non-toxic up to 2000 mg/kg dose 
 
Live phase animals Observations  
1. Body weight every day Normal 
2. Food consumption daily Normal  
3. Water consumption daily Normal  
4. Home cage activity Normal  
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Table 5: Mortality record for scopoletin in acute oral toxicity study 
 
Dose 
Sighting study Main study (2000 mg/kg) 
5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg      
No. of animals 1 2 3 4 5 6 7 8 9 
Body weight (g) 184 166 182 174 196 168 172 196 183 
Sex Female Female Female Female Female Female Female Female Female 
30 min Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
2 h Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
3 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 2 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 4 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 5 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 6 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 8 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 10 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 12 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 13 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Mortality 0/1 0/1 0/1 0/1 0/5 
Note: Acute toxicity study of scopoletin compound was performed and it was non-toxic up to 2000 mg/kg dose  
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6.5 NEUROPROTECTIVE EFFECTS OF BAICALEIN AND SCOPOLETIN IN 
SCOPOLAMINE-INDUCED MODEL  
6.5.1 Behavioural assessment of baicalein and scopoletin in scopolamine treated 
mice  
6.5.1.1 Effect on transfer latency in the rectangular maze  
In this test, baicalein and scopoletin treated mice showed significant (P<0.01) 
decrease in latency time (LT) when compared to scopolamine treated group on the 7th 
day. Moreover the higher LT induced by scopolamine was significantly reversed by 
scopoletin and baicalein treated groups than the standard donepezil treated group. 
Administration of scopolamine resulted in learning impairment as evidenced by a 
significant (P<0.05) increase in the LT from 124.45±1.15 on the 1st day to 174.88±0.76 
on the 7th day in the negative control group when compared to the control group 
(120.34±1.18 on 1st day and 118.34±0.68 on the 7th day). Treatment with the scopoletin 
and baicalein for seven days reversed the LT significantly (P<0.01) when compared 
with negative control group (Fig. 29).  The potency of the reduction in LT was 
produced by the scopoletin 200mg/kg followed by baicalein 200 mg/kg among the 
flavonoids treated groups (77.92±0.63 sec, 82.35±0.78 sec on the 7th day). Donepezil, at 
a dose of 10 mg/kg treated for successive 7 days acts as positive control, elicited a 
significant (P<0.01) reduction in LT from 122.44±1.05 sec to 92.81±0.67 sec compared 
to the negative control group using Dunnet’s test. 
6.5.1.2 Effect on escape latency time in the Morris water maze  
The Morris water maze (MWM) plays an important role in the validation of 
rodent models for neurocognitive disorders such as Alzheimer’s disease. In MWM, 
escape latency time (ETL) was calculated, i.e., the time taken by an animal to find the 
platform. The scopolamine administration group showed increased ELT from 
64.53±0.94 sec to 86.78±1.14 sec, whereas the control group was found to be 
56.35±0.84. This relative increase in ELT when compared to the control group 
indicated a spatial memory deficit in the scopolamine treated mice. It was found that 
baicalein and scopoletin treated mice significantly (P<0.01) reduced ELT when 
compared with the scopolamine treated group.  
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Fig. 29 Effect of baicalein and scopoletin on latency time using rectangular maze test in scopolamine-induced amnesia 
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Fig. 30 Effect of baicalein and scopoletin on escape latency time using Morris water maze test in scopolamine-induced amnesia 
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In the treatment groups, higher dose of scopoletin and baicalein successfully 
reversed the scopolamine-induced memory deficits compared to other flavonoids 
treated groups and standard. The significant reduction of ELT was produced by the 
scopoletin and baicalein (200 mg/kg) among the flavonoids treated groups on the 7th 
day was found to be 24.18±0.63 sec, 31.26±1.18. Donepezil (10 mg/kg) treated 
animals, produced a significant (P<0.01) decrease in ELT 36.42±0.84 sec on the 7th day 
compared to the negative control group (Fig. 30). 
6.5.1.3 Locomotor activity in scopolamine treated mice 
Reduction of metabolic rate occurs in rodents in response to intoxication with 
several neurotoxic agents.  Scopolamine decreased locomotor activity as compared to 
control mice indicating locomotor deficits. Scopolamine-treated group showed lower 
locomotion values on the 7th day 164.85±0.82 sec when compared to control group 
280.46±0.64 sec which in turn replicate the learning impairment in negative control 
group.  
The locomotor activity of the flavonoids treated groups significantly (P<0.01) 
increased when compared to the negative control group. A significant (P<0.01) increase 
in the values of locomotion 346.17±1.04 sec on the 7th day was observed in the 
standard group. In the treatment groups, scopoletin (200 mg/kg and 100 mg/kg) treated 
mice significantly increased the locomotor values (P<0.01), 380.78±0.82 sec and 
368.52±1.02 sec respectively and baicalein (200 mg/kg and 100 mg/kg) significantly 
elevated locomotor values 356.32±0.78 and 352.43±0.62 on the 7th day compared to the 
scopolamine-treated group (Fig. 31).  
6.5.1.4 Conditioned avoidance response in scopolamine treated mice 
In pole climbing method, the percentage of conditioned avoidance response 
(CAR) were calculated based on the number of successful events and number of errors 
produced by each groups. Scopolamine treated mice showed significantly decreased 
percentage of CAR activity 48.21±0.51 sec as compared to control group 74.15±0.58 
sec on the 7th day and donepezil treated animals exhibited significant (P<0.05) increase 
in percentage of CAR activity 88.92±0.38. Scopoletin (100 mg/kg and 200 mg/kg) 
treated animals significantly (P<0.01) increased CAR activity to 92.15±0.26 and 
96.84±0.62 and baicalein (100 mg/kg and 200 mg/kg) significantly (P<0.01) elevated 
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CAR values to 88.08±0.64 and 92.62±0.82 compared to negative control group (Fig. 
32).  
6.5.1.5 Effect of scopoletin and baicalein response time in 5-choice serial time task 
method  
Five-choice serial reaction time task (5-CSRTT) is an operant based task and 
was used to study attention and impulse control in rodents. The 5-CSRTT can be used 
to explore aspects of both attentional and inhibitory control mechanisms. The basic test 
design involves training animals to respond to a brief visual stimulus presented 
unpredictably in one of five locations. Increasingly, the test is also used to examine 
aspects of response control. Increasingly this test is being applied in drug discovery 
efforts, primarily to identify novel drug treatments for conditions associated with 
attention deficits. 
Administration of scopolamine resulted in learning impairment as evidenced by 
significant delayed response values (68.24±0.84) when compared to control group 
(36.18±0.44). In treatment groups, scopoletin (100 mg/kg and 200 mg/kg) showed 
quicker responses (23.12±1.08 and 18.54±0.72) and baicalein (100 mg/kg and 200 
mg/kg) treated animals also showed significant (P<0.01) improved responses time 
(25.74±0.56 and 22.32±0.44). Standard drug, donepezil administered animals exhibited 
significantly improved responses (19.42±0.63) (Fig. 33).  
These observations made the scopolamine-induced mice as a useful learning 
impairment model for studying neuroprotective effects of the baicalein and scolpoletin. 
It has been found that higher dose of scopoletin followed by baicalein treated mice 
effectively reversed the cognitive impairments produced by the scopolamine when 
compared to the lower dose of flavonoids treated animals. These results further 
augmented the neuroprotective effect of the scopoletin against the Alzheimer's disease.   
6.5.2 Biochemical estimations in scopolamine induced mice   
6.5.2.1 Estimation of AChE activity in the brain 
AChE is a key enzyme involved in cholinergic neurotransmission and is a 
marker of extensive loss of cholinergic neurons in the brain. A significant increase 
(P<0.01) in the level of AChE was observed in the scopolamine treated mice.  
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Fig. 31 Effect of baicalein and scopoletin on locomotor activity using Actophotometer in scopolamine-induced amnesia 
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Fig. 32 Effect of baicalein and scopoletin on percentage of conditioned avoidance response using Pole climbing test in scopolamine-
induced amnesia 
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Administration of baicalein and scopoletin significantly (P<0.01) attenuated 
AChE levels and no change was observed in control group. Scopoletin (100 mg/kg and 
200 mg/kg) exhibited the percentage AChE inhibition in the brain homogenate as 
70.48% and 85.22%, which were significantly (P<0.01) increased values when 
compared to scopolamine treated mice (22.14%).  Administration of baicalein (100 
mg/kg and 200mg/kg) exhibited the percentage AChE inhibition as 57.18% and 
72.14%.  Donepezil significantly (P<0.05) reduced the level of AChE into 66.72%. 
Scopoletin (200 mg/kg) effectively inhibited the AChE and thereby it increased the 
level of acetylcholine in the brain (Fig. 34).  
 
Fig. 34 Percentage of AChE inhibition in the mice brain in scopolamine-induced 
amnesia 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative 
control (One way ANOVA followed by Dunnett’s test). 
6.5.2.2 Determination of total protein content 
The total protein content was significantly reduced to 0.34±1.32 units/mg tissue 
protein in negative control group compared to control (1.08±1.26 units/mg tissue 
protein). Scopoletin (100 mg/kg and 200 mg/kg, p.o.) treated mice significantly 
reversed the protein content values (1.22±1.08 and 1.31±0.82 µmoles/min/mg protein) 
and administration of baicalein (100 mg/kg and 200 mg/kg, p.o.) significantly increased 
the values (1.16±0.84 and 1.25±1.23 µmoles/min/mg protein) when compared to 
negative control.   
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Fig. 33 Effect of baicalein and scopoletin on response time using 5 CSRT model in scopolamine-induced amnesia
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Treatment with donepezil (5 mg/kg, p.o.) resulted in a significant increased 
protein content level (1.12±0.96 µmoles/min/mg protein) in the brain (Table 6). The 
total protein content was greatly increased in higher dose of scopoletin (200 mg/kg) 
treated group when compared to all other groups. 
Table 6: Effect of baicalein and scopoletin on protein content in scopolamine 
treated mice 
Groups Protein Content (mmoles/min/mg) 
Control 1.08±1.26 
Negative Control (Scopolamine) 0.34±1.32* 
Baicalein (100 mg/kg) 1.16±0.84** 
Baicalein (200 mg/kg) 1.25±1.23** 
Scopoletin (100 mg/kg) 1.22±1.08** 
Scopoletin (200 mg/kg) 1.31±0.82** 
Standard (Donepezil) 1.12±0.96** 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control 
(One way ANOVA followed by Dunnett’s test). 
6.5.2.3 Enzymatic antioxidant levels   
Administration of scopolamine caused marked oxidative stress, which was 
evident by the decrease in the antioxidant enzyme levels marking the occurrence of 
AD. The role of baicalien and scopoletin in the antioxidant level (CAT, SOD, GSSH, 
GPx and GSH) in the brain homogenate were estimated.  
6.5.2.3.1 Estimation of catalase  
A significant (P<0.05) reduction in the catalase level was found in scopolamine 
treated mice (1.24±0.48 µmoles/min/mg protein) compared to the control group 
(3.18±0.62 µmoles/min/mg protein). Scopoletin (100 mg/kg and 200 mg/kg, p.o.) 
treated mice resulted in significant (P<0.01) increase in the level of catalase (3.34±1.08 
and 3.46±0.38 µmoles/min/mg protein) and administration of baicalein (100 mg/kg and 
200 mg/kg, p.o.) significantly (P<0.01) increased the catalase level to 3.26±0.72 and 
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3.38±0.64 µmoles/min/mg protein when compared to negative control.  Treatment with 
donepezil (5 mg/kg) showed significant (P<0.05) increased in the level of catalase to 
3.30±0.52 µmoles/min/mg protein in the brain (Table 7). The catalase level was greatly 
increased in higher dose of scopoletin treated group animals compared to other groups 
used in the study. 
6.5.2.3.2 Estimation of superoxide dismutase  
Superoxide dismutase is an enzymatic antioxidant which scavenges the 
superoxide anion to hydrogen peroxide, hence diminishing the toxic effect caused by 
this radical. The SOD level was significantly (P<0.01) reduced to 0.98±1.08 units/mg 
tissue protein in negative control when compared to control (2.96±0.58 units/mg tissue 
protein). Scopoletin (100 mg/kg and 200 mg/kg, p.o.) treated group significantly 
(P<0.01) increased the SOD level to 3.28±0.82 and 3.42±0.74 µmoles/min/mg protein 
and treatment with baicalein (100 mg/kg and 200 mg/kg, p.o.) significantly (P<0.01) 
elevated the SOD level to 3.08±0.64 and 3.36±1.12 µmoles/min/mg protein when 
compared to negative control.  Donepezil treated mice (5 mg/kg, p.o.) resulted in a 
significant (P<0.05) elevation of SOD level (3.28±0.88 µmoles/min/mg protein) in the 
brain (Table 7). The SOD level was greatly increased in higher dose of scopoletin 
group treated animals compared to all other groups. 
6.5.2.3.3 Estimation of glutathione peroxidase  
The GPx level was significantly decreased (P<0.05) in negative control group to 
0.42±0.48 when compared to the control group (1.48±0.36) and enzymatic activity of 
GPx in donepezil treated group showed elevation of GPx level (1.62±0.34). It reveals 
that in baicalein treated mice (100 and 200 mg/kg) restoration of the activity of the 
glutathione peroxidase enzyme was noticed to 1.52±0.28 and 1.66±0.32 and scopoletin 
(100 and 200 mg/kg) treatment elevated GPx values significantly to 1.58±0.40 and 
1.76±0.36 respectively and possibly this could be due to reduced generation of free 
radicals and subsequent neuronal damage (Table 7). This suggests that the higher dose 
of scopoletin has greater capability to restore level of GPx and reduced formation of 
free radicals and associated oxidative stress. 
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Table 7: Effect of baicalein and scopoletin on enzymatic and non-enzymatic 
antioxidant level in scopolamine treated mice 
Groups CAT SOD GSSH GPx GSH 
Control 3.18±0.62 2.96±0.58 22.45±1.32 1.48±0.36 3.88±0.46 
Negative 
Control 
(Scopolamine) 
1.24±0.48* 0.98±1.08* 11.31±1.43* 0.42±0.48* 1.28±0.28* 
Baicalein   
(100 mg/kg) 3.26±0.72** 3.08±0.64** 21.08±1.61** 1.52±0.28** 3.74±0.24** 
Baicalein  (200 
mg/kg) 3.38±0.64** 3.36±1.12** 24.82±1.17** 1.66±0.32** 3.98±0.48** 
Scopoletin 
(100 mg/kg) 3.34±1.08** 3.28±0.82** 25.03±1.72** 1.58±0.40** 4.14±0.54** 
Scopoletin 
(200 mg/kg) 3.46±0.38** 3.42±0.74** 27.21±1.54** 1.76±0.36** 4.32±1.08** 
Standard 
(Donepezil) 3.30±0.52** 3.28±0.88** 23.13±1.38** 1.62±0.34** 3.96±0.32** 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.5.2.3.4 Estimation of glutathione reductase (GSSH)  
The glutathione reductase level was significantly reduced (P<0.05) in negative 
control group to 11.31±1.43 when compared to control group (22.45±1.32) and 
enzymatic activity in donepezil resulted in an increased level of glutathione reductase 
(23.13±1.38). Administration of baicalein (100 and 200 mg/kg) could reverse the level 
of the glutathione reductase to 21.08±1.61 and 24.82±1.17 and scopoletin (100 and 200 
mg/kg) increased GR significantly (P<0.01) to 25.03±1.72 and 27.21±1.54 respectively 
(Table 7). This suggests that the higher dose of scopoletin has the capability to reverse 
the level of glutathione reductase. 
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6.5.2.4 Non enzymatic antioxidant activity 
6.5.2.4.1 Estimation of reduced glutathione  
Glutathione is an important tripeptide which can remove the free radical species 
such as H2O2, O2·, alkoxy radical and maintain the membrane protein thiols and acts as a 
substrate for glutathione peroxidase and glutathione transferase. The level of reduced 
glutathione in the brain was reduced in the negative control group (1.28±0.28 
nmoles/min/mg tissue protein) when compared to the control (1.28±0.28 
nmoles/min/mg tissue protein).  Treatment with baicalein (100 and 200 mg/kg) resulted 
in a significant (P<0.01) elevation of reduced glutathione level to 3.74±0.24 and 
3.98±0.48 and administration of scopoletin (100 and 200 mg/kg) significantly (P<0.01) 
elevated the reduced glutathione levels to 4.14±0.54 and 4.32±1.08 respectively. 
Donepezil (5mg/kg, p.o.) significantly (P<0.01) increased the level (3.96±0.32 
nmoles/min/mg tissue protein) of reduced glutathione in the brain (Table 7). The 
present research depicts that scopoletin (100 mg and 200 mg/kg) reduced oxidative 
stress by replenishing the levels of catalase, SOD, GPx, and GSH in mice.  
6.5.2.5 DPPH assay 
 DPPH is a stable, nitrogen-centered free radical which produces violet colour. It 
was reduced to a yellow colored product, diphenylpicryl hydrazine, with the addition of 
the fractions in a concentration-dependent manner. The reduction in the number of 
DPPH molecules can be correlated with the number of available hydroxyl groups. The 
DPPH scavenging activity was significantly decreased (P<0.05) in negative control 
group to 7.24±1.89 when compared to the control group (12.18±1.58). The highest 
DPPH radical scavenging activity was detected in the higher concentration of 
scopoletin (200 mg/kg) 15.48±1.15, followed by the scopoletin 100 mg/kg, baicalein 
(200 mg/kg, 100mg/kg) showed the values 14.12±0.84, 13.98±1.06 and 12.48±0.81 
respectively. These activities were less than that of the standard, donepezil 
(13.08±0.98) (Table 8). Scopoletin and baicalein treated mice showed significantly 
(P<0.01) higher DPPH scavenging values compared to negative control group. 
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Table 8: Effect of baicalein and scopoletin on DPPH and MDA level in 
scopolamine-induced mice 
Groups DPPH (nmoles/min/mg) 
MDA 
(nmoles/min/mg) 
Control 12.18±1.58 5.86±0.24 
Negative Control (Scopolamine) 7.24±1.89* 13.88±0.64* 
Baicalein (100 mg/kg) 12.48±0.81** 5.63±0.34** 
Baicalein (200 mg/kg) 13.98±1.06** 5.48±0.28** 
Scopoletin (100 mg/kg) 14.12±0.84** 4.52±0.46** 
Scopoletin (200 mg/kg) 15.48±1.15** 4.03±0.38** 
Standard (Donepezil) 13.08±0.98** 6.26±0.73** 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.5.2.6 Estimation of lipid peroxidation 
Lipid peroxidation (LPO) is one of the main manifestations of oxidative damage, 
which implicates free radical oxidative cell injury in mediating the toxicity of 
scopolamine. Effect of baicalein and scopoletin on the levels of malondialdehyde 
(MDA) during scopolamine-induced neurotoxicity was observed. Increase in the level 
of lipid peroxides in the brain reflects the neuronal damage. Elevated level of MDA 
was observed in scopolamine-treated mice (13.88±0.64 nmoles/min/mg tissue protein), 
whereas it was significantly (P<0.01) reversed in flavonoids-treated groups (scopoletin 
and baicalein).  
Administration of baicalein (100 and 200 mg/kg) significantly (P<0.01) 
decreased (5.63±0.34 and 5.48±0.28 nmoles/min/mg tissue protein) MDA level in brain 
and scopoletin (100 and 200 mg/kg) treated group also reduced the level of MDA 
significantly to 4.52±0.46 and 4.03±0.38 when compared to the negative control group. 
Donepezil (5 mg/kg, p.o) significantly (P<0.01) decreased the level (6.26±0.73 
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nmoles/min/mg tissue protein) of MDA in the brain (Table 8). The results revealed that 
scopoletin and baicalein possess antioxidant property with concentration gradient and 
thereby it reduces the oxidative stress induced membrane lipid peroxidation. 
6.5.3 Histopathological studies of the baicalien and scopoletin in acute 
scopolamine induced amnesia in mice 
The results for the histopathological studies in the brains (H&E x 400) of control 
group showed normal histological architecture without any degenerative changes and 
scopolmine induced mice indicated severe neurodegenerative changes and also resulted 
in the formation of neurofibrillary tangles. Administration of baicalein (100 mg/kg) 
with scopolamine showed faintly appearing neurofibrillary tangles suggesting moderate 
therapeutic efficacy of the flavonoids and baicalein (200 mg/kg) resulted in mild 
infiltration of inflammatory cells indicating the repair mechanism. Treatment with 
scopoletin (100 mg/kg) showed moderately appearing neurofibrillary tangles 
representing the minimal efficacy and scopoletin (200 mg/kg) resulted in normal 
histological architecture with mild infiltration of inflammatory cells which indicates the 
effective repair mechanism at the high dose of scopoletin. Administration of standard 
donepezil exhibited minimal neuro degenerative changes indicating neuroprotective 
effect of the standard drug (Fig. 35). 
6.6 NEUROPROTECTIVE EFFECT OF BAICALEIN AND 
SCOPOLETIN ON BEHAVIOURAL CHANGES IN AlCl3-INDUCED MODEL  
6.6.1 Effect of baicalein and scopoletin on behavioural changes in AlCl3 
treated mice  
6.6.1.1 Evaluation of transfer latency in the rectangular maze  
In this test, latency time (LT) of the animals was calculated for all (Group I to 
VII) the groups. Administration of AlCl3 to mice for 3 months resulted in learning 
impairment by a significant (P<0.05) increase in the LT (175.32±0.98) in the negative 
control group when compared to the control group (112.21±0.54). Baicalein and 
scopoletin treated mice resulted in reversal of LT significantly (P<0.01) when 
compared with negative control.  
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Fig. 35 The demonstration of the effects of baicalein and scopoletin  in scopolamine-induced amnesia (SCP-scopolamine)(A-Normal 
histological architecture without any degenerative changes; B-Severe neurodegenerative changes; C-Formation of neurofibrillary tangles; D-
Faintly appearing neurofibrillary tangles; E-Mild infiltration of inflammatory cells indicating the repair mechanism; F-Moderately appearing 
neurofibrillary tangles; G-normal histological architecture with mild infiltration of inflammatory cells; H-minimal neuro degenerative changes) 
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The LT was effectively decreased by scopoletin (200 mg/kg, 100 mg/kg) treated 
mice among the all other groups tested showing the values of 46.72±0.38 and 54.48 
±0.82 respectively. Donepezil resulted in significant (P<0.01) decrease in LT 
72.54±0.64 compared to the negative control group using Dunnet’s test (Fig. 36). 
6.6.1.2 Estimation of escape latency time in the Morris water maze  
In MWM, escape latency time (ETL) was calculated, which was the time taken 
by an animal to find the platform. AlCl3 treated animals showed significantly (P<0.01) 
increased ETL values on 90th day (76.38±1.18) as compared to control group 
(49.48±0.72) and it indicates the impairment in learning and memory. Baicalein (100 
mg/kg and 200 mg/kg) treated mice significantly (P<0.01) decreased ETL, 31.54±0.84 
and 27.06±0.78 and scopoletin (100 mg/kg and 200 mg/kg) significantly (P<0.01) 
decreased ETL, 30.82±1.02 and 21.42±0.62 when compared to negative control. 
Administration of donepezil significantly (P<0.01) decreased ETL values (32.18±0.48). 
Among the treatment groups, scopoletin (200 mg/kg) treated mice effectively reduced 
ETL values when compared to all other groups (Fig. 37). 
6.6.1.3 Locomotor activity in AlCl3 treated mice 
AlCl3 treated mice exhibited significantly (P<0.05) decreased locomotor activity 
on 90th day (176.46±1.38) as compared to control group (286.53±0.82) and it indicates 
the learning and memory impairment in mice. Baicalein (100 mg/kg and 200 mg/kg) 
treated mice significantly (P<0.01) elevated locomotor values 386.76±0.46 and 
448.54±0.68 and scopoletin (100 mg/kg and 200 mg/kg) significantly (P<0.01) 
increased the locomotion to 426.34±0.92 and 492.54±1.08 when compared to negative 
control. Donepezil significantly (P<0.01) elevated the locomotor values (394.38±0.62) 
on the 90th day. Higher dose of scopoletin resulted in effective increase in locomotor 
activity which in turns results in its neuroprotective activity (Fig. 38). 
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Fig. 36 Effect of baicalein and scopoletin on latency time using rectangular maze test in AlCl3-induced learning impairment  
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Fig. 37 Effect of baicalein and scopoletin on escape latency time using Morris water maze test in AlCl3-induced learning 
impairment 
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Fig. 38 Effect of baicalein and scopoletin on locomotor activity in AlCl3-induced learning impairment 
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6.6.1.4 Conditioned avoidance response in AlCl3 treated mice 
In pole climbing method, the percentage of conditioned avoidance response 
(CAR) was calculated based on the number of successful events and number of errors 
produced by the animals. AlCl3 alone treated mice showed significantly (P<0.05) 
decreased percentage of CAR activity on 90th day (32.82±1.18) as compared to control 
group (66.28±0.76). Administration of baicalein (100 mg/kg and 200 mg/kg) resulted in 
significant (P<0.01) elevation of CAR values 89.52±0.74 and 93.43±0.46 and 
scopoletin (100 mg/kg and 200 mg/kg) significantly (P<0.01) increased the values to 
91.08±0.52 and 96.62±0.78 when compared to negative control. Donepezil treated mice 
significantly (P<0.01) increased percentage of CAR activity (84.45±0.82) compared to 
negative control group (Fig. 39). 
6.6.1.5 Effect of baicalein and scopoletin on response time in 5-choice serial 
reaction time task method  
5-CSRT is an operant based task used to study attention and impulse control in 
rodents. AlCl3 treated mice showed significantly (P<0.05) quicker response time 
(72.86±0.98) on the 91st day when compared to control group (35.24±0.68). Treatment 
with baicalein (100 mg/kg and 200 mg/kg) significantly (P<0.01) faster response time 
22.92±0.58 and 18.26±0.46 and scopoletin (100 mg/kg and 200 mg/kg) significantly 
(P<0.01) decreased the learning impairment values to 21.38±0.68 and 15.72±0.74 when 
compared to negative control. Donepezil treated mice significantly (P<0.01) decreased 
memory impairment to 19.56±0.76. 
From the behavioural assessments it has been evidenced that, the chronic 
administration of AlCl3 (3 months) resulted in the learning impairment in mice and the 
flavonoids (baicalein and scopoletin) treated mice significantly (P<0.01) reversed the 
learning impairment produced by AlCl3 (Fig. 40). Scopoletin (200 mg/kg) treated mice, 
effectively attenuated the learning impairment produced by AlCl3 when compared to all 
other groups and this further emphasized the neuroprotective role of scopoletin.  
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Fig. 39 Effect of baicalein and scopoletin on percentage of conditioned avoidance response in AlCl3-induced learning impairment 
 
 
 
 
139 
 
 
 
 
 
 
Fig. 40 Effect of baicalein and scopoletin on response time using 5-CSRT model in AlCl3-induced learning impairment 
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6.6.2 Biochemical evaluations in AlCl3-induced learning impairment in mice 
6.6.2.1 Estimation of AChE level in the brain 
AChE is an essential enzyme involved in cholinergic neurotransmission. 
Acetylcholine is broken into acetate and choline in the presence of AChE and thereby it 
act as a marker of extensive loss of cholinergic neurons in the brain. In the present 
study, a significant increase in AChE level was observed in the AlCl3 treated mice 
(Negative control). The percentage of the AChE inhibition in the brain homogenate was 
calculated for all the groups.  
The percentage of the AChE inhibition of the scopoletin (100 mg/kg and 200 
mg/kg) was found to be 68.25% and 78.41% and the values compared with AlCl3 alone 
treated group was found to be only 18.08% on the 91st day. The baicalein (100 mg/kg 
and 200 mg/kg) administered mice resulted in elevation of percentage of AChE 
inhibition 53.21% and 68.48%.  Donepezil (5 mg/kg, p.o.) increased the percentage of 
AChE inhibition to 58.38% (Fig. 41). These results clearly demonstrated that, 
scopoletin (200 mg/kg) effectively inhibited the AChE level and thereby it prevents the 
breakdown of acetylcholine.  
 
Fig. 41 Percentage of AChE inhibition in the mice brain in AlCl3-induced 
learning impairment 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control 
(One way ANOVA followed by Dunnett’s test). 
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6.6.2.2 Estimation of total protein content 
The total protein content was significantly (P<0.05) reduced to 0.28±1.24 
units/mg tissue protein in negative control group compared to control (1.24±0.81 
units/mg tissue protein). Administration of baicalein (100 mg/kg and 200 mg/kg) 
significantly (P<0.01) reversed the protein content values (1.21±1.12 and 1.25±0.84 
µmoles/min/mg protein) when compared to negative control and treatment with 
scopoletin (100 mg/kg and 200 mg/kg) significantly (P<0.01) increased the values 
(1.28±0.94 and 1.34±1.07 µmoles/min/mg protein) when compared to negative control.  
Donepezil (5 mg/kg, p.o.) increased the total protein level (1.26±1.04 µmoles/min/mg 
protein) (Table 9). The total protein content was greatly increased in higher dose of 
both scopoletin and baicalein (200 mg/kg) group compared to all other groups. 
Table 9: Effect of baicalein and scopoletin on protein content in AlCl3 
treated mice 
Groups Protein Content (mmoles/min/mg) 
Control 1.24±0.81 
Negative Control (AlCl3 50 mg/kg) 0.28±1.24* 
Baicalein (100 mg/kg) 1.21±1.12** 
Baicalein (200 mg/kg) 1.25±0.84** 
Scopoletin (100 mg/kg) 1.28±0.94** 
Scopoletin (200 mg/kg) 1.34±1.07** 
Standard (Donepezil) 1.26±1.04** 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control 
(One way ANOVA followed by Dunnett’s test). 
6.6.3 Measurement of enzymatic antioxidant levels  
6.6.3.1 Estimation of catalase level  
Chronic administration of AlCl3 caused marked oxidative stress, which led to 
decrease in the antioxidant enzyme levels. In the present study, a significant (P<0.05) 
decrease in the catalase level was found in AlCl3 treated group (0.98±0.34 
µmoles/min/mg protein) compared to the control (3.58±0.46 µmoles/min/mg protein). 
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Treatment with baicalein (100 mg/kg and 200 mg/kg) resulted in significant (P<0.01) 
increase in the catalase level (3.66±0.38 and 3.78±0.42 µmoles/min/mg protein) and 
scopoletin (100 mg/kg and 200 mg/kg) significantly (P<0.01) reversed the catalase 
level (3.76±0.66 and 3.88±0.42 µmoles/min/mg protein).  Donepezil (5 mg/kg) 
increased the catalase level (3.72±0.44 µmoles/min/mg protein) compared to the 
negative control group (Table 10).  
6.6.3.2 Evaluation of superoxide dismutase  
 
Table 10: Effect of baicalein and scopoletin on enzymatic and non-
enzymatic antioxidant level in AlCl3-induced mice 
Groups CAT SOD GPx GSSH GSH 
Control 3.58±0.46 2.74±0.38 1.82±0.42 25.38±0.94 3.24±0.36 
Negative 
Control 
(AlCl3) 
0.98±0.34* 0.62±0.74* 0.58±0.24* 16.25±1.31* 0.94±0.48* 
Baicalein  
(100 mg/kg) 3.66±0.38** 2.78±0.34** 1.90±0.48** 24.16±0.88** 3.34±0.44** 
Baicalein  
(200 mg/kg) 3.78±0.42** 2.94±0.64** 2.08±0.28** 26.58±0.97** 3.48±0.38** 
Scopoletin 
(100 mg/kg) 3.76±0.66** 2.92±1.02** 2.02±0.36** 26.48±1.08** 3.40±0.42** 
Scopoletin 
(200 mg/kg) 3.88±0.42** 3.12±0.48** 2.28±0.62** 28.35±0.94** 3.64±0.72** 
Standard 
(Donepezil) 3.72±0.44** 2.88±0.68** 1.96±0.52** 26.18±1.24** 3.42±0.38** 
Values are expressed as mean ± SEM; n = 6.  
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control 
(One way ANOVA followed by Dunnett’s test). 
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Superoxide dismutase scavenges the superoxide anion to hydrogen peroxide, 
hence diminishing the toxic effect caused by the radicals. The SOD level was 
significantly (P<0.05) decreased to 0.62±0.74 units/mg tissue protein in negative 
control group compared to control group (2.74±0.38 units/mg tissue protein). Donepezil 
(5 mg/kg, p.o.) resulted in a elevated SOD level (2.88±0.68 µmoles/min/mg protein) in 
the brain compared to negative control. In the baicalein (100 mg/kg and 200 mg/kg) 
treated mice, there was a significant (P<0.01) reversal in the level of SOD to 2.78±0.34 
and 2.94±0.64 µmoles/min/mg protein and scopoletin (100 mg/kg and 200 mg/kg) 
significantly (P<0.01) increased the SOD level (2.92±1.02 and 3.12±0.48 
µmoles/min/mg protein) emphasising the antioxidant potential of baicalein and 
scopoletin (Table 10). 
6.6.3.3 Determination of glutathione peroxidase level 
AlCl3 treated mice significantly (P<0.05) decreased the GPx level to 0.58±0.24 
when compared to the control group (1.82±0.42) and enzymatic activity of GPx in 
donepezil treated group was found to be 1.96±0.52. Administration with baicalein (100 
and 200 mg/kg) significantly (P<0.01) increased the level of GPx (1.90±0.48 and 
2.08±0.28) and scopoletin (100 mg/kg and 200 mg/kg) treated animals showed elevated 
levels of GPx to 2.02±0.36 and 2.28±0.62 when compared to negative control (Table 
10). Effective restoration of GPx level and the generation of free radicals and neuronal 
damage was reduced in the scopoletin (200 mg/kg) treated group.  
6.6.3.4 Estimation of glutathione reductase level 
The glutathione reductase level was significantly (P<0.01) decreased in negative 
control group to 16.25±1.31 when compared to the control group (25.38±0.94) and 
enzymatic activity in donepezil treated group was found to be 26.158±1.24. Baicalein 
treated (100 and 200 mg/kg) animals significantly (P<0.01) increased the level of 
glutathione reductase to 1.52±0.28 and 1.66±0.32 and treatment with scopoletin (100 
and 200 mg/kg) significantly (P<0.01) elevated the glutathione reductase level 
(1.58±0.40 and 1.76±0.36) (Table 10). Flavonoids treated animals showed increased 
level of antioxidant enzyme which in turn results in the improvement of 
neuroprotective potential of scopoletin and baicalein. 
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6.6.4 Non enzymatic antioxidant assay  
6.6.4.1 Determination of reduced glutathione  
Glutathione is a tripeptide which can remove the free radical species and 
maintain the membrane protein thiols and act as a substrate for GPx and glutathione 
transferase. Reduced glutathione level in brain of the negative control (AlCl3) group 
was significantly (P<0.05) reduced to 0.94±0.48 nmoles/min/mg tissue protein when 
compared to the control group. Donepezil (5mg/kg) treated animals significantly 
increased the reduced glutathione level 3.42±0.38 nmoles/min/mg tissue protein in the 
brain. Administration with baicalein (100 and 200 mg/kg) showed significantly 
(P<0.01) increased values 3.34±0.44 and 3.48±0.38 and scopoletin (100 and 200 
mg/kg) increased significantly (P<0.01) the levels of reduced glutathione to 3.40±0.42 
and 3.64±0.72 (Table 10).  
6.6.5 Estimation of DPPH assay 
Table 11: Effect of baicalein and scopoletin on DPPH and MDA level in AlCl3 
treated mice 
Groups MDA (nmoles/min/mg) DPPH (nmoles/min/mg) 
Control 0.98±0.36 16.22±0.86 
Negative Control (AlCl3) 4.12±0.48* 8.16±1.24* 
Baicalein (100 mg/kg) 0.72±0.54** 16.18±1.18** 
Baicalein (200 mg/kg) 0.60±1.08** 17.52±0.96** 
Scopoletin (100 mg/kg) 0.62±0.36** 18.08±1.08** 
Scopoletin (200 mg/kg) 0.54±0.28** 19.24±0.95** 
Standard (Donepezil) 0.66±0.62** 17.12±1.28** 
Values are expressed as mean ± SEM; n = 6. 
*P <0.05 when compared to vehicle control; **P <0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
 The DPPH scavenging activity was significantly decreased (P<0.05) in negative 
control group to 8.16±1.24 when compared to the control group (16.22±0.86). 
145 
 
Baicalein and scopoletin demonstrated remarkable H-donor activity. The highest DPPH 
radical scavenging activity was detected in the higher concentration of scopoletin (200 
mg/kg) 19.24±0.95, followed by the scopoletin 100 mg/kg, baicalein (200 mg/kg, 100 
mg/kg) exhibited lower DPPH scavenging activity compared to sscopoletin treated 
mice with the values of 18.08±1.08, 17.52±0.96 and 16.18±1.18 respectively. These 
activities were less than that of the standard, donepezil (17.12±1.28) (Table 11).  
6.6.6 Determination of lipid peroxidation level 
Increase in the level of lipid peroxides in the brain reflects the neuronal damage 
and thus leads to AD. Elevated level of MDA was observed in AlCl3-treated mice 
(4.12±0.48 nmoles/min/mg tissue protein), whereas it was significantly (P<0.05) 
reversed in flavonoids-treated groups. Donepezil (5 mg/kg, p.o) decreased the MDA 
level to 0.66±0.62 nmoles/min/mg tissue protein. Baicalein (100 and 200 mg/kg) 
treated mice showed significantly (P<0.05) decreased MDA level in brain to 0.72±0.54 
and 0.60±1.08 nmoles/min/mg tissue protein as compared to the negative control group 
and scopoletin (100 and 200 mg/kg) significantly (P<0.01) reduced the level of MDA 
(0.62±0.36 and 0.54±0.28) when compared to negative control group. The results 
suggested that scopoletin possibly has potent antioxidant property to reduce oxidative 
stress induced membrane lipid peroxidation (Table 11). 
6.6.7 Histopathological studies of the baicalien and scopoletin against chronic 
AlCl3 treatment in mice 
AlCl3 treated mice brain demonstrated severe degenerative changes and 
cytoplasmic vacuolation which in turn results in the cognitive impairment when 
compared to control group with normal histological architecture without any 
degenerative changes. Administration of donepezil exhibited mild congestion and less 
degenerative changes indicating the therapeutic efficacy. Mice treated with baicalein at 
a dose of 100 mg/kg presented moderate degenerative changes with cytoplasmic 
vacuolation and baicalein at higher dose of 200 mg/kg resulted in the intact histological 
structure with stray vacuolation and congested vessels. Treatment with scopoletin (100 
mg/kg) showed moderate neurodegenerative changes with vacuolation indicating the 
moderate therapeutic efficacy and high dose of scopoletin (200 mg/kg) resulted in 
normal histological features with appearance of normal glial cell population which 
further emphasize the therapeutic efficacy of the scopoletin (Fig. 42).  
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Fig. 42 The demonstration of the effects of baicalein and scopoletin  in AlCl3induced AD (A- Normal histological architecture without any 
degenerative changes; B-Severe neurodegenerative changes; C- Cytoplasmic vacuolation; D- Moderate degenerative changes; E- Cytoplasmic 
vacuolation; F- Stray vacuolation and congested vessels; G- Moderate neurodegenerative changes with vacuolation; H- Normal glial cell 
population; I-Mild congestion and less degenerative changes) 
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7. DISCUSSION 
Drug design is an important tool in the field of medicinal chemistry where new 
compounds are synthesized by molecular or chemical manipulation of the lead moiety 
in order to produce highly active compounds with minimum steric effect211. Docking of 
small molecules in the receptor binding site and estimation of binding affinity of the 
complex is a vital part of structure based drug design212, 213. A huge breakthrough in the 
process of drug design was the development of in silico method to predict the 
therapeutic efficacy of the molecule214.  
7.1 Evaluation of drug likeness properties 
The pharmacologically active substituents were characterized by calculating 
steric, hydrophobic, electronic, and hydrogen bonding properties as well as by the drug-
likeness score. The theory of drug-likeness score helps to optimize pharmaceutical and 
pharmacokinetic properties, for example, chemical stability, solubility, distribution 
profile and bioavailability. The molecular descriptors have developed as rationally 
predictive and informative, for example, the Lipinski's Rule-of-Five119. The better oral 
absorption of the ligands and drug likeness scores are constructed by the solubility, 
diffusion, Log P, molecular weight etc. Before the docking studies, the ligands were 
evaluated for its drug likeness properties. MedChem Designer software was used to 
evaluate the Lipinski’s rule of five for the flavonoids215. 
In the present study, lead optimization of the selected flavonoids was done by 
computation of druglikeness properties. Two hundred and forty five flavonoids were 
evaluated for its drug likeness properties with the help of MedChem Deisgner. All the 
245 flavonoids showed excellent drug likeness score which indicate that these 
compounds have no violations or acceptable violations in Lipinski’s Rule of 5. All the 
selected flavonoids were exhibiting considerable pharmacokinetic profile and were 
selected for in silico biological screening against AChE and BuChE using AutoDock 
4.2. 
7.2 In silico AChE and BuChE inhibition 
Molecular docking is a frequently used tool in computer-aided structure-based 
rational drug design. It evaluates how small molecules called ligands (flavonoids) and 
the target macromolecule fit together216.  The use of computers to predict the binding of 
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libraries of small molecules to known target structures is an increasingly important 
component in the drug discovery process217, 218. There is a wide range of software 
packages available for the conduct of molecular docking simulations like, AutoDock, 
GOLD, FlexX etc.122, 219. Among these, AutoDock 4.2 is the most recent version which 
has been widely employed for virtual screening, due to its enhanced docking speed220. 
Its default search function is based on Lamarckian Genetic Algorithm (LGA), a hybrid 
genetic algorithm with local optimization that uses a parameterized free-energy scoring 
function to estimate the binding energy221.  
AChE is a key enzyme in the central nervous system and inhibition of it leads to 
increase of neural acetylcholine levels which is one of the therapies for symptomatic 
relief of mild to moderate AD 222. Hence the inhibition of AChE is one of the central 
focuses for drug development to combat AD223.  
In the present study, 245 flavonoids were selected for the in silico docking 
studies. The docking studies were performed by the use of AutoDock4.2. Its principle is 
based on Monte carlo and Simulated annealing methods in combination with genetic 
algorithm which is used for the global optimization.  In the docking studies, if a 
compound shows lesser binding energy compared to the standard it proves that the 
compound has higher activity. The inhibition constant was correlated to half-maximal 
inhibitory concentration (IC50) at which 50% of the target was inhibited. This 
quantitative measure indicates the amount of a particular drug needed to inhibit a 
biological process. 
Based upon the chemical structure classification of our selected flavonoids, the 
AChE inhibitory activity was found to be, Flavones > Coumarin derivatives > 
Flavonones > Iso flavones > Flavonols. The minimum binding energy indicated that 
AChE and BuChE were successfully docked with selected flavonoids. These flavonoids 
showed an excellent binding mode when compared with the standard donepezil against 
AChE and BuChE. 
The amino acid residues are dynamically involved in the formation of 
hydrophilic and hydrophobic contacts and there were initiated to play important role in 
the binding site of target. Islam et al., studied the in silico QSAR analysis of quercetin 
and found that quercetin has higher binding score than the conventional drugs when 
allowed to bind at the same pocket of the AChE as conventional drugs224. The hydrogen 
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bonds formed by quercetin involve the same amino acid residues Tyr 124, Ser 293 and 
Tyr 341 as for conventional drugs. Moreover, different atoms of other amino acid 
residues such as Phe 295, Arg 296, Tyr 337 and Tyr 341 participate to form the 
hydrogen bonds225. 
While binding at the active site, a number of hydrogen bonds between different 
atoms of AChE and the inhibitors participate to interact with each other to make the 
binding affinity much stronger.  In the present study, the flavonoids showed the similar 
amino acid residues Tyr 124, Trp 286, Phe 295 and Tyr 341 against AChE as for the 
standard donepezil. Similarly, in case of BuChE flavonoids showed the binding 
interactive residues such as His 77, Lys 131, Val 204, Ser 287, Thr 346. This proves 
that the selected flavonoids possess potential AChE and BuChE inhibitory binding sites 
when compared to the standard.  
The presence of a benzopyran ring in their basic nucleus of the flavonoids 
would have contributed to its cholinesterase inhibitory activity. From these results, it 
was proved that all the selected flavonoids showed higher activity than the standard 
donepezil. This molecular docking analysis may further lead to the development of 
potent ChE inhibitors for the prevention and treatment of AD. 
7.3 In vitro AChE and BuChE inhibition 
Alzheimer’s disease (AD), a common type of progressive neurodegenerative 
disease, is characterized by low level of neurotransmitter (acetylcholine), oxidative 
stress and neuro-inflammation in brain stream226. Effective treatment strategies rely 
mostly on either enhancing the cholinergic function of the brain by stimulating the 
cholinergic receptors, improve the level of acetylcholine from being a breakdown by 
cholinesterase enzymes or induce antioxidant therapy and anti-inflammatory agents227. 
Acetylcholine (ACh) is the main neurotransmitter that is depleted in AD. This 
ACh plays an important role in learning things and in memory function. ACh is 
generally stored and released from the nerve terminals. In AD patients’ large amount of 
AChE and BuChE released in the system that makes the working half-life of ACh is too 
short. AChE enzyme hydrolyses ester bond of the ACh molecule to make it choline and 
ester. BuChE enzyme is prominent in glial cells, which have almost same activity on 
ACh228. 
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Till date the most promising target for the symptomatic treatment and slowing 
of AD progression is cholinesterase inhibitors. In AD the destruction of cholinergic 
neurones causes a depletion of ACh229. By inhibiting AChE, the enzyme which 
catalyses break down of ACh, levels of this neurotransmitter can be elevated and 
function improved. This approach has a particular success as these cholinergic neurones 
are found mainly in regions associated with learning and memory - spreading from the 
basal forebrain230 and hippocampus up to the cerebral cortex231, 232. Therefore, 
inhibition of AChE and BuChE level is an important strategy to treat AD. The enzyme 
inhibitory activity of the flavonoids was determined by Ellman’s method. This method 
based on the reaction between acetylthiocholine iodide or butyrylthiocholine iodide, 
DTNB, flavonoids and the enzyme solution. The enzymatic activity was measured 
spectrophotometrically, by the formation of a yellow coloured complex produced by 
reaction with DTNB ion.  
The selected flavonoids exhibited an excellent AChE and BuChE inhibitory 
activity than the standard. The results indicated that the flavonoids may be a potential 
source of cholinergic inhibition. In the current study, out of 245 flavonoids taken for in 
silico docking studies, 20 flavonoids were selected for the in vitro enzyme inhibitory 
assay. The selection of the flavonoids was based on high, moderate and low 
neuroprotective activity against the targets.  The absorbance of all the selected 
flavonoids decreased upon increasing concentrations in a dose dependent manner. The 
in vitro enzymatic activity of the flavonoids exhibited the potential AChE and BuChE 
inhibitory activity than the standard donepezil. The results validated the in silico 
docking studies and it further confirms that the selected flavonoids could be a 
promising remedy for the AD. 
7.4 Acute toxicity studies 
The acute toxicity studies were performed as per the OECD guidelines. Based on 
the acute toxicity studies, we had selected the two different doses of the selected 
flavonoids baicalein and scopoletin. The results of acute toxicity studies have revealed 
that, these compounds were considered non-toxic up to the dose of 2000 mg/kg and 
therefore 1/10th and 1/20th dose was used for the biological evaluation and the in vivo 
scopolamine and aluminium induced learning impairment studies were conducted at 
dose levels of 100 and 200 mg/kg body weight.   
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7.5 Acute scopolamine-induced amnesia 
Scopolamine is widely utilized as an experimental tool to study the anti-amnesic 
potential of new drugs233. Scopolamine hydrobromide is an anticholinergic drug, which 
produces dementia by reducing the levels of acetylcholine, which is considered to be an 
important neurotransmitter for learning and memory234.  
From the behavioral tests like, rectangular maze test and Morris water maze test, 
it is clearly seen that there was a significant decrease in the transfer latency in all the 
flavonoids treated groups compared to the scopolamine-treated group. The memory loss 
effect of scopolamine is more prominent compared to the control group. In comparison 
with Donepezil, the higher dose (200 mg/kg) of scopoletin and baicalein treated groups 
had excellent performance which indicates neuroprotective effect against scopolamine. 
Administration of scopoletin and baicalein at a dose of 200 mg/kg/p.o. for 7 days to 
animals successfully reversed the learning impairment produced by the scopolamine 
when compared to the lower doses of the selected flavonoids.  
There was a gradual increase in the locomotor activity and percentage of 
conditioned avoidance response in the flavonoids treated animals when compared to the 
standard. Thus, the potential neuroprotective behavioural changes in the flavonoids 
treated animals further augmented their role in the management of AD.      
The effect of the selected flavonoids in scopolamine-induced amnesia in mice 
was compared with donepezil, a known nootropic drug. It was observed that both the 
flavonoids showed significant improvement in conditional avoidance response (CAR) 
indicating protective effect of these flavonoids against scopolamine induced damage of 
memory. Along with behavioural parameters, the effect of flavonoids on the AChE 
activity, protein estimation enzymatic and non-enzymatic anti-oxidants were also 
evaluated. 
The selected flavonoids showed a reduction of the AChE level that was 
increased after administration of scopolamine. It was reported that a decrease in AChE 
activity can lead to improvement in learning and memory235. The non-enzymatic 
production of lipid peroxidation (LPO) is associated mostly with cellular damage as a 
result of oxidative stress. In this process, malanoldehyde is generated as secondary 
products. The increased generation of reactive oxygen species (ROS) is implicated in 
the pathogenesis of many diseases and in the toxicity of a wide range of compounds. 
Brain tissue is rich in polyunsaturated lipids, has high iron content, and critically 
dependent on aerobic metabolism and thus highly vulnerable to ROS mediated 
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oxidative damage. There are reports suggesting accumulation of LPO products in the 
brain of patients with Alzheimer's disease236.  
Our results also further emphasized the memory protective effect of the 
flavonoids. Scopoletin and baicalein significantly reduced brain AChE level, indicating 
the remarkable elevation of ACh level in the brain and thereby the flavonoids might 
possess anti-ChE activity. The selected flavonoids significantly improved antioxidant 
levels when compared to the scopolamine treated group. These results further 
augmented the potential effect of the selected flavonoids against the Alzheimer's 
disease.  Our study revealed that scopoletin and baicalein enhanced the oxygen species 
markers in most of the brain regions by improving antioxidant enzymes. Administration 
of scopoletin (200 mg/kg) exhibited the highest activity followed by the scopoletin (100 
mg/kg) and baicalein treated groups. It is well known that cholinergic neuronal systems 
play an important role in the cognitive deficits associated with AD, ageing and 
neurodegenerative diseases. Flavonoids treated animals showed potential in inhibition 
of oxidative stress-induced neuronal damage in the neurodegeneration and also in 
antioxidant assays and thus represents promising neuroprotective activities.   
Superoxide anion plays an important role in the formation of other reactive 
oxygen species such as hydrogen peroxide, hydroxyl radical and singlet oxygen in 
living systems. SOD is considered to be a stress protein which is synthesized in 
response to oxidative stress237. Glutathione peroxidase catalyses the oxidation of 
reduced glutathione (GSH) to oxidized glutathione (GSSG) at the expense of hydrogen 
peroxide238. Catalase primarily causes the decomposition of H2O2 to water at a much 
faster rate, in association with glutathione peroxidase. Thus, a decrease in the activities 
of both catalase and glutathione peroxidase leads to an accumulation of H2O2. A 
decrease in the activity of glutathione reductase is due to the depletion of thiol which 
leads to related pathologies239. 
Treatment with scopoletin and baicalein significantly (P<0.01) enhanced the 
total protein and enzymatic antioxidant levels in the brain. In scopolamine treated mice, 
significant (P<0.05) reduction in antioxidant enzyme level was observed in the mice 
brain. Higher dose (200 mg/kg) of scopoletin and baicalein treated mice significantly 
(P<0.05) increased the level of the enzymatic antioxidant enzymes such as superoxide 
dismutase, catalase, peroxidase and glutathione reductase, thus showing the 
neuroprotective beneficial effect against scopolamine treatment. 
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Glutathione is a major non-protein thiol in living organisms and protects the 
cellular defense system against the toxic effects of lipid peroxidation. Due to oxidative 
stress, the brain is unable to maintain the GSH redox state and oxidized glutathione 
(GSSG) is concentrated in some regions of the brain 240. The cellular levels of the 
active forms of vitamin C and α-tocopherol are also maintained by GSH by neutralizing 
the free radicals. A decrease in GSH level leads to a decrease in cellular levels of α-
tocopherol241. In the present study, a significant decrease in the levels of non-enzymatic 
antioxidants like GSH was observed in scopoletin and baicalein treated mice. This 
could be due to an increased utilization of GSH for scavenging the toxic products. Mice 
treated with higher dose of scopoletin and baicalein significantly restored the levels of 
GSH in the brain suggesting the involvement of GSH-dependent detoxification of free 
radical. These observations reveal that scopoletin and baicalein treated groups has 
enhanced the antioxidant potential.  
Increased lipid peroxidation in ethanol treated rats showed in a depletion of the 
cellular antioxidant defense system. Inhibition of SOD results in the generation of 
partially reduced oxygen species. When SOD activity is decreased, neurons are more 
vulnerable to oxyradical injury242. There was a significant elevation in MDA and a 
decrease in total protein and antioxidant enzymes in scopolamine treated mice (negative 
control) compared to normal control. These results suggest that scopoletin and baicalein 
can be used for the treatment of AD attributing to their antioxidant and neuroprotective 
activities.  In the histopathological studies, scopolmine treated mice indicated severe 
neurodegenerative changes and also resulted in the formation of neurofibrillary tangles 
and scopoletin (200 mg/kg) administered animals resulted in normal histological 
architecture with mild infiltration of inflammatory cells which indicates the effective 
repair mechanism of the high dose of scopoletin.  
7.6 Chronic in vivo aluminium chloride-induced dementia 
Based on the in vivo acute scopolamine studies, the flavonoids were selected for 
the chronic in vivo aluminium chloride induced dementia. Aluminium is a ubiquitous 
metal and has been associated in the etiology of Alzheimer’s disease where it 
intensifies brain oxidative damage. Based on the literatures AlCl3 is considered as a 
recognized etiological factor in a series of neurodegenerative disorders for many 
decades243. Several natural compounds such as curcumin and naringin exhibit 
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neuroprotective effect against AlCl3-induced cell damages in various experimental 
models181. Our current study explores the role of the selected flavonoids during chronic 
administration of AlCl3-induced neurotoxicity. 
AlCl3 is cholinotoxin, which produces functional alterations in the cholinergic 
and noradrenergic neurotransmission. AChE is a specific cholinergic indicator has 
received wide attention in the study of AlCl3 neurotoxicity. AChE is more accountable 
for acetylcholine metabolism whose modifications caused neurobehavioral fluctuations 
particularly in memory and cognitive function. AChE catalyzes the hydrolysis of 
acetylcholine into inactive metabolites, choline and acetate. Numerous literatures have 
shown that augmented AChE level is a prelude to oxidative stress244. Consistent with 
the previous discoveries, a substantial elevation in AChE activity was observed in 
AlCl3 exposure rats, which signifies impaired cholinergic function245.  
Scopoletin and baicalein at a dose of 200 mg/kg/p.o. for 90 days reversed the 
learning impairment produced by the AlCl3 in mice. Flavonoids treated animals 
significantly decreased the transfer latency time in rectangular maze test and escape 
latency time in Morris water maze test which results in improvement of the learning 
and memory. There was a substantial elevation of locomotor function and percentage of 
conditioned avoidance response in pole climbing method in scopoletin and baicaelin 
treated mice. These remarkable behavioural changes in the animals further highlight the 
role of scopoletin and baicalein in the management of AD.      
Catalase plays a major role in cellular antioxidant defense system by 
decomposing H2O2, thereby preventing the generation of hydroxyl radical through the 
Fenton reaction246. Accumulating evidence suggests that aluminium decreased the level 
of enzymatic antioxidants in the brain, such as catalase (CAT), superoxide dismutase 
(SOD) and glutathione (GSH). The effect of Al contact is consistent with the previous 
studies that result in the decreased levels of CAT and SOD in the brain247.  
Scopoletin and baicalein treated mice significantly elevated the level of total 
protein and enzymatic and non-enzymatic antioxidant levels and thus lead to a 
reduction of neural stress which enhances the synaptic communication. These results 
further augmented the long term potential effect of the selected flavonoids against the 
Alzheimer's disease. 
Our study demonstrated that, the selected flavonoids enhanced the oxygen 
species markers in most of the brain regions by improving the levels of antioxidant 
enzymes. Thus result implied that, because of elevated the level of antioxidant enzyme 
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by the selected flavonoids shows the reduction of neural stress, and enhances the 
synaptic communication. Our results also further emphasize the memory enhancing 
effect of the flavonoids against chronic administration of aluminium chloride. The 
selected flavonoids significantly improved antioxidant levels. These results further 
augmented the long term potential effect of the selected flavonoids against the 
Alzheimer's disease.   
In the histopathological studies, negative control group showed severe 
degenerative changes and cytoplasmic vacuolation results in cognitive impairment. 
Scopoletin (200 mg/kg) treated group resulted in normal histological features with 
appearance of normal glial cell population. The short and long-term administration of 
the scopoletin 200 mg/kg and baicalein 200 mg/kg exhibited prominent effect in the 
reversal of the both scopolamine and aluminium-induced learning impairment in both 
behavioural and biochemical estimations. 
The long term chronic neuroprotective effect of the scopoletin and baicalein was 
investigated against aluminium-induced learning impairment in mice. The long term 
administration of flavonoids (90 days) further improved the neuroprotective activities 
which further correlates with the results of acute scopolamine model. 
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8. CONCLUSION 
Alzheimer’s disease is a neurodegenerative disorder associated with a decline in 
cognitive abilities. The deficiency of acetylcholine is one of the characteristics of AD 
and responsible for most of its symptoms, such as a decline in memory and cognition. 
As a consequence of its role as a target for AD therapy, AChE is one of the most 
studied target in the Alzheimer’s field and the vast majority of reports in the field relate 
with treatment strategies associated with the use of AChE inhibitors. Despite the 
severity and high prevalence of this disease, the allopathic system of medicine is yet to 
provide a satisfactory drug candidate. Hence, the present study was focused on 
exploration of the memory enhancing activity of the flavonoids in scopolamine and 
aluminium-induced learning impairment in mice. 
The current study suggests that the flavonoids, baicalein and scopoletin 
possessed excellent binding interactions and docking score with AChE and BuChE 
enzymes than the standard (donepezil) in in silico studies. The in silico studies 
addressed the flavonoids stability against AChE and BuChE (protein-ligand complex) 
by molecular dynamic simulation. The in silico studies is actually an added advantage 
to screen the ChE enzyme inhibition. Two hundred and forty five compounds were 
selected and screened in the computational studies and among these compounds 20 
flavonoids have been selected for the in vitro enzyme inhibition studies based on their 
docking results.  
In vitro enzyme inhibition studies also proved that selected 20 flavonoids were 
effective in inhibiting ChE enzymes, which is considered to be related to the 
mechanism of memory dysfunction. The results of the in vitro studies were in 
correlation with the in silico predictions. Among the 20 selected flavonoids, scopoletin 
and baicalein demonstrated excellent inhibition constant (IC50) values in both 
computational and experimental studies towards AChE and BuChE and thereby these 
compounds possess potential ChE inhibitory activity. In the light of these findings, it 
can be concluded that scopoletin and baicalein showed less IC50 values against both 
enzyme targets (AChE and BuChE) and could be considered worthwhile to check its in 
vivo memory enhancing activity to be used in treatment of AD.  
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The results of acute toxicity studies have revealed that, baicalein and scopoletin 
were considered non-toxic up to the dose of 2000 mg/kg and therefore 1/10th and 1/20th 
dose was used for the biological evaluation and the in vivo scopolamine and aluminium 
induced learning impairment studies were conducted at dose levels of 100 and 200 
mg/kg body weight.   
The findings of acute model with scopolamine induced amnesia model 
suggested that the higher dose of scopoletin and baicalein (200 mg/kg) treated animals 
showed excellent neuroprotective activity in all the behavioural assessment studies 
performed. Administration of scopoletin and baicalein (200 mg/kg/p.o. for 7 days) to 
animals reversed the learning impairment produced by the scopolamine. Scopoletin and 
baicalein treated animals effectively decreased the transfer latency time in rectangular 
maze test, escape latency time in morris water maze test which emphasize the 
improvement of the learning and memory skills of the animals. There is a gradual 
increase in the locomotor function in actophotometer and percentage of conditioned 
avoidance response in pole climbing method was observed in the flavonoids treated 
animals. These potential neuroprotective behavioural changes in the flavonoids treated 
animals further proved the role of scopoletin and baicalein in the management of AD.      
It is well known that cholinergic neuronal systems play an important role in the 
cognitive deficits associated with AD, ageing and neurodegenerative diseases. In our 
study, scopoletin and baicalein significantly reduced brain AChE activity, indicating 
the stimulating actions of these drugs on the cholinergic system. Hence, the memory-
enhancing effect of the scopoletin and baicalein can be attributed to its anti-ChE 
activity. Flavonoids treated animals showed potential inhibition of oxidative stress-
induced neuronal damage in the neurodegeneration and also in antioxidant assays and 
represent promising neuroprotective activities.   
The end products of lipid peroxidation viz. malondialdehyde and lipid 
hydroperoxides and the levels of tissue protein, enzymatic and non-enzymatic 
antioxidants in the brain were estimated. Treatment with the scopoletin and baicalein 
significantly enhanced the total protein and enzymatic and non-enzymatic antioxidant 
levels in the brain. In scopolamine treated mice, significant (P<0.05) diminution was 
observed in brain antioxidant enzyme activity. Scopoletin and baicalein (200 mg/kg) 
treated mice significantly (P<0.05) increased the level of the antioxidant enzymes such 
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as superoxide dismutase, catalase, peroxidase and glutathione reductase. Glutathione 
which is widely distributed in cells is an intracelluar reductant and plays a major role in 
catalysis and metabolism. The selected flavonoids significantly (P<0.01) increased the 
level of non-enzymatic antioxidant GSH whereas in the negative control, the levels 
were decreased. 
In the histopathological studies, the brains of negative control group 
(scopolamine treated animals) showed severe neurodegenerative changes resulting in 
formation of neurofibrillary tangles which was reversed in the flavonoid treated groups. 
Scopoletin (200 mg/kg) treated group resulted in normal histological architecture with 
mild infiltration of inflammatory cells which indicates the effective repair mechanism 
at a high dose of scopoletin.  
The findings of chronic AlCl3 model suggested that the higher dose (200 mg/kg) 
of scopoletin and baicalein treated animals showed excellent neuroprotective activity in 
all the behavioural assessment studies performed. Scopoletin and baicalein (200 
mg/kg/p.o. for 90 days) treated animals reversed the learning impairment produced by 
the AlCl3. Scopoletin and baicalein treated animals significantly decreased the transfer 
latency time in rectangular maze test and escape latency time in morris water maze test 
which results in improvement of the learning and memory. There is a substantial 
elevation of locomotor function and percentage of conditioned avoidance response in 
pole climbing method was shown in the scopoletin and baicaelin treated mice. These 
remarkable behavioural changes in the animals further highlight the role of scopoletin 
and baicalein in the management of AD.      
Scopoletin and baicalein significantly reduced brain AChE level, indicating the 
remarkable elevation of ACh level in the brain and thereby the flavonoids possess anti-
ChE activity. Our study revealed that, high dose of scopoletin and baicalein improved 
antioxidant enzymes in most of the brain regions. Administration of scopoletin (200 
mg/kg) exhibited the highest activity followed by the scopoletin (100 mg/kg) and 
baicalein treated groups.  
AlCl3 treated mice showed significant reduction in total protein and enzymatic 
and non-enzymatic antioxidant levels which in turn results in cognitive impairment. 
Scopoletin and baicalein (200 mg/kg) treated mice significantly (P<0.05) increased the 
level of the antioxidant enzymes such as superoxide dismutase, catalase, peroxidase and 
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glutathione reductase. Scopoletin and baicalein treated mice significantly elevated the 
level of total protein and enzymatic and non-enzymatic antioxidant levels and thus lead 
to reduction of neural stress which enhances the synaptic communication. These results 
further augmented the long term potential effect of the selected flavonoids against the 
Alzheimer's disease. 
In the histopathological analysis, the brains of negative control group showed 
severe degenerative changes and cytoplasmic vacuolation which in turn results in the 
cognitive impairment which was recovered by the flavonoid treated groups so 
effectively than the standard drug. Scopoletin (200 mg/kg) treated group resulted in 
normal histological features with appearance of normal glial cell population. The short 
term (7 days) and long-term (90 days) administration of the scopoletin 200 mg/kg 
exhibited pronounced effect in the reversal of the both scopolamine and aluminium-
induced learning impairment in both behavioural and biochemical estimations. 
In conclusion, it has been clearly demonstrated that the approach utilized in this 
study is successful in finding novel anti-alzhiemer’s drugs. In particular, higher dose of 
scopoletin and baicalein, showed excellent neuroprotective effects against in silico, in 
vitro enzyme inhibitory and in vivo acute scopolamine and chronic AlCl3 induced 
learning impairment models.  Hence, scopoletin and baicalein could be considered as a 
therapeutic agent to prevent or slow down the development of neurodegenerative 
diseases such as AD. Further research is required to explore the detailed mechanism of 
action of the scopoletin and baicalein specifically targeting the pathogenetic 
mechanisms like amyloid deposition and tau hyperphosphorylation which might 
provide a definite therapeutic edge. Further extensive studies are needed to establish 
scopoletin and baicalein as potential drug candidates for clinical use in the prevention 
and treatment of Alzhiemer’s disease.  
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9. IMPACT OF THE STUDY 
Alzhiemer’s disease is a progressive neurodegenerative disorder characterized 
by a gradual decline in memory associated with shrinkage of brain tissue, with 
localized loss of neurons mainly in the hippocampus and basal forebrain, with 
diminished level of acetylcholine. It has also reported to be associated with 
accumulation of beta-amyloid and neurofibrillary tangles in the brain. WHO reports 
(2015) confirms that 47 million people are suffering from dementia globally and 4.1 
million people are living with dementia in India. Based on this alarming situation, the 
search for the identification of novel drug candidate with lesser toxicity and increased 
efficacy is essential. Clinical trials allow the health sector people to learn the symptoms 
and causes of AD and also to test new management strategies. Treatment with AChE 
inhibitors is one of the important treatment strategies for AD patients. In the 
management of AD, initiation of an AChE inhibitor is suggested as early as possible. 
Despite the issues of cost, it is important that AChE inhibitor therapy is deliberated for 
patients with mild to moderate AD. 
The prevalence of AD and dementia has increased significantly nowadays. As 
none of the available medications appears to be able to reduce the disease progression, 
there is enormous medical need for the development of novel therapeutic strategies that 
target the underlying pathogenic mechanisms in AD.  
The present study revealed that scopoletin and baicalein potentiates the 
neuroprotective activity in in silico, in vitro studies and in both acute scopolamine and 
chronic AlCl3-induced AD in mice. Scopoletin and baicalein possess significant 
advantages over existing drug candidates and these compounds may possess industrial 
acceptability. The observed neuroprotective and enhanced cognitive functions could be 
due to reducing the AChE level and antioxidant activities of the flavonoids in mice 
brain. Hence, this could be an effective drug of choice in the management of AD. 
Keeping in mind that scopoletin and baicalein has broad neuroprotective properties as 
observed in the current study. Its use might slow the progression of the multifactorial 
Alzhiemer’s disease. 
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1. INTRODUCTION 
1.1 
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NEURODEGENERATIVE DISORDERS 
Neurodegenerative disorders are categorized by progressive and irreversible loss of neurons 
from particular regions of the brain. Prototypical neurodegenerative disorders include Parkinson's 
disease (PD) and Huntington's disease (HD), results in deviations in the control of 
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drive due to the 
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loss of neurons from structures of the basal ganglia1, 2. Alzheimer's disease (AD), results in the 
loss of cortical and hippocampal neurons with impairment of memory and cognitive ability and 
amyotrophic lateral sclerosis (ALS), producing muscular weakness 
due to 
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degeneration of bulbar, spinal, and cortical motor neurons3, 4. 
Neurodegenerative disorders are comparatively common and represent a substantial societal 
and medical problem. They are 
principal disorders 
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of later life, developing in individuals who are neurologically normal, although childhood-onset 
forms of each of the disorders are known. PD is detected in more than 1% of population above 
the age of 655, 6, whereas AD affects as many as 10% of the same individuals7. HD, which is a 
genetically stable autosomal dominant disorder, is less common in the population as a whole but 
disturbs, on average, 50% of each generation in families booming the gene. ALS also is 
moderately rare but sometimes leads to disability and death8, 9. 
At present, the pharmacological therapy of neurodegenerative disorders is restricted mostly to 
symptomatic treatments that do not change the course of the underlying disease. Symptomatic 
management for PD, where the neurochemical deficit created by the disease is well defined. 
0: Lubhan Singh.doc 83% 
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The available treatments for AD, HD, and ALS are much more limited in effectiveness, and 
there is a need for new strategies10, 11. 
1.1.1 Overview of dementia 
Dementia is a depleting disorder, which gradually declines the cognitive functions including memory, 
language, speech, orientation, judgement and learning capacity. More than 47 million people are 
currently living with dementia worldwide and about 75% of this population that is, 27 million people, 
are estimated to be affected by AD12. It may be due to therapeutic drug use (atropine and 
phenytoin), metabolic disorders (hypoglycemia, acid base disorders, hematological disorders, 
hyperglycemia, hypopituitarism, pulmonary insufficiency, cardiac dysfunction and hepatolenticular 
degeneration), deficiency states (vitamin B12, niacin and folate deficiency), collagen (vascular 
disorders, systemic lupus erythematous, Behcet’s syndrome, temporal arteritis and sarcoidosis), 
intracranial disorders (tumor, epilepsy, neurosyphilis, encephalitis, multiple sclerosis and 
cerebrovascular insufficiency) and exogenous intoxication (alcohol, lead, carbon monoxide, 
organophosphates, mercury, manganese and toluene). It is not a part of normal aging and 
constantly turns as pathological process. Alzheimer’s is the most common cause of dementia13-15. 
1.2 TYPES OF DEMENTIA 
1.2.1 Alzheimer’s disease 
Alzheimer’s disease is a chronic, progressive and disabling organic brain disorder characterized by 
disturbances of multiple cortical functions including memory, comprehension, orientation, language 
and learning capacity16. AD is accompanied by three main structural changes in the brain including 
neuronal loss, formation and accumulation of hyperphosphorylated tau protein termed neurofibrillary 
tangles (NFT) and aggregation of β-amyloid (Aβ) peptides termed senile or amyloid plaques17. 
These changes are most protruding in the cholinergic system, primarily in cortex and hippocampus, 
which is closely associated with memory loss and cognitive dysfunction in AD18. 
1.2.2 Vascular dementia 
Earlier known as post stroke or multi-infract dementia, for about 10% of population associated with 
vascular dementia and it is less common as a cause of dementia than Alzheimer’s disease. In most 
of the cases, the infarct dementia co-occurs with Alzheimer’s pathology. Vascular dementia occurs 
most commonly from damage leading to infarcts or blood vessel blockages or bleeding in the 
brain19, 20. 
1.2.3 Dementia with Lewy bodies (DLB) 
Lewy bodies are abnormal aggregations of the protein alpha-synuclein that accumulate in neurons 
and dementia can result 
0: 107cd289-b95b-422a-b194-c980f3b9a6c7 52% 
when they develop in cortex region of the brain. Aggregation of alpha-synuclein in the brains of 
people with 
Parkinson’s disease (PD), in which it is produced by extreme neuronal loss in a part of the brain 
called the substantia nigra. While people with dementia with Lewy bodies DLB and PD both have 
4
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
Lewy bodies, the onset of the disease is marked by cognitive impairment in DLB and motor 
impairment in PD20. 
1.2.4 Fronto-temporal lobar degeneration (FTLD) 
0: 107cd289-b95b-422a-b194-c980f3b9a6c7 67% 
FTLD includes dementias such as behavioural-variant FTLD, 
0: thesis plagiarism check.docx 47% 
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primary progressive aphasia, corticobasal degeneration, Pick’s disease and progressive 
supranuclear palsy. Initial symptoms include marked changes in behaviour and personality and 
difficulty with 
comprehending language. Nerve cells in the frontal lobe and temporal lobes of the brain are 
affected, 
and these regions become significantly shrunken. 
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In addition, the upper layers of the cortex typically become spongy and soft and have protein 
insertions (tau protein or the transactive DNA-binding protein) 21. 
1.2.5 
Mixed dementia 
Mixed dementia is 
0: thesis plagiarism check.docx 79% 
1: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 79% 
characterized by the hallmark abnormalities of more than one cause of dementia most commonly 
Alzheimer’s combined with vascular dementia, followed by Alzheimer’s with DLB, and Alzheimer’s 
with vascular dementia and DLB. Vascular dementia with 
DLB is less common. 
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Recent studies suggest that mixed dementia is more common than previously 
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recognized, with about half of those with dementia having pathologic evidence of more than one 
cause of dementia 20, 22. 
1.2.6 Creutzfeldt-Jakob disease 
This is very rare fatal disorder and rapidly impairs memory and coordination and causes behaviour 
changes, results from a misfolding 
0: 107cd289-b95b-422a-b194-c980f3b9a6c7 96% 
protein (prion) that causes other proteins throughout the brain to misfold and malfunction. 
It may be hereditary sporadic or caused by a known infection. A specific form called 
0: thesis plagiarism check.docx 100% 
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variant Creutzfeldt-Jakob disease is believed to be caused by consumption of products from 
cattle affected by mad cow disease23. 
1.2.7 
Parkinson’s disease (PD) dementia 
Problems with movement (slowness, rigidity, tremor and changes in gait) are common symptoms of 
PD. In PD, 
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alpha-synuclein aggregates appear in an area deep in the brain called 
0: thesis plagiarism check.docx 100% 
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the substantia nigra. The aggregates are thought to cause degeneration of the nerve cells that 
produce dopamine. 
The incidence of PD is about one-tenth that of 
Alzheimer’s. As PD progresses, it often results in dementia secondary to the accumulation of Lewy 
bodies in the cortex (similar to DLB) or the accumulation of beta-amyloid clumps and tau tangles24, 
25. 
1.2.8 Normal pressure hydrocephalus 
0: thesis plagiarism check.docx 100% 
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Symptoms include difficulty in walking, memory loss and inability to control urination. 
Accounts for less than 5% of dementia cases and caused by impaired reabsorption of cerebrospinal 
fluid and the consequent build-up of fluid in the brain, increasing pressure in the brain. People with a 
history of brain haemorrhage (particularly subarachnoid haemorrhage) and meningitis are at 
increased risk. It 
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can sometimes be corrected with surgical installation of a shunt in the brain to drain excess 
fluid26. 
1.3 ALZHEIMER'S 
DISEASE ( 
AD) 
AD produces an impairment of cognitive abilities that is gradual in onset but relentless in 
progression. Impairment of short-term memory usually is the first clinical feature, whereas retrieval 
of distant memories is preserved relatively well into the course of the disease. As the condition 
progresses, additional cognitive abilities like, the ability to calculate, exercise visuospatial skills, and 
use common objects and tools (ideomotor apraxia) are impaired27. The level of arousal or alertness 
of the patient is not affected until the condition is very advanced, nor is there motor weakness, 
although muscular contractures are an almost universal feature of advanced stages of the disease. 
Death, most often from a complication of immobility such as pneumonia or pulmonary embolism, 
usually ensues within 6 to 12 years of onset. The diagnosis of AD is based on careful clinical 
assessment of the patient and appropriate laboratory tests to exclude other disorders that may 
mimic AD; at present, no direct antemortem confirmatory test exists28. 
1.3.1 History of Alzheimer’s disease 
AD, the most common form of dementia, is an increasing medical, social and public health 
concern29. AD is characterized by deficits in the cholinergic system and the deposition of β-amyloid 
(Aβ) protein30. The cholinergic system has been targeted for the design of anti-Alzheimer’s drugs. 
Cholinesterase inhibitors increase both the level and duration of action of acetylcholine. In addition, 
it has been demonstrated that both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) 
play an important role in Aβ-aggregation during plaque formation31. Many research papers 
published in the last decade have indicated that the structures of compounds that exhibit 
cholinesterase inhibitory activity are diverse32, 33. 
1.3.2 Neurotransmitters in AD 
The brain, in AD, shows the loss of cholinergic neurons in the basal forebrain, decreased 
acetylcholine (ACh) levels, and a decrease in the acetylcholine synthesizing enzyme choline 
acetyltransferase (CHAT) in the cerebral cortex. Animal models show that ACh plays a crucial role in 
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information processing and memory34. Although other neurotransmitters (noradrenaline, serotonin, 
somatostatin and other peptides) are also deficient in AD, the cognitive impairment correlates best 
with the loss of cholinergic input. AChE inhibitors (tacrine) and ACh receptor agonists, including 
nicotine, have been used to treat AD. The marginal success of this approach suggests that, in 
addition to ACh deficiency, there are other profound alterations that contribute to the cognitive 
dysfunction35. 
The relation between accumulation of plaques in brain and dementia was first identified by Dr. Alois 
Alzheimer in the year 1906. Later Emil Kraepelin, a German psychiatrist coined this disease as 
Alzheimer’s disease in 1910. Dr. Alois Alzheimer described the case of a 51-year-old woman, 
Auguste D in the year 1906. The patient was admitted to a hospital for 5 years with a cluster of 
unusual symptoms with loss of memory, inability to speak, disorientation, behavioral problems, and 
hallucinations. After the death, Dr. Alzheimer examined her brain tissue and found two hallmarks of 
Alzheimer’s disease (AD): Beta-amyloid plaques and neuroﬁbrillary tangles. Hence the name of this 
neurodegenerative disorder delivers his name36, 37. 
1.3.3 Signs of AD 
The first sign of AD is generally related to memory loss. The person may replicate the things many 
times, have trouble in naming items, may lose things like their wallet, glasses, keys, or get lost 
themselves. These changes may become more pronounced with time. Simple tasks can prove 
difficult for the person with Alzheimer’s, such as dressing, preparing meals, using the phone, or 
playing a game38. The Alzheimer's Association has identified ten warning signs concerned 
someone might have Alzheimer's or dementia: 
➢ Memory loss; 
➢ Problems with abstract thinking; 
➢ Difficulty performing familiar tasks; 
➢ Changes in mood or behavior; 
➢ Disorientation to time and place; 
➢ Misplacing things in unusual places; 
➢ Poor or decreased judgment; 
➢ Changes in personality; 
➢ Problems with language; and, 
➢ Loss of initiative. 
1.3.4 Clinical facts of AD 
The possibility of AD is 6% to 10% for men and 12% to 19% for women after 65 years of age. About 
47% of individuals develop AD beyond the age of 80 years. This disease last for 20 years and the 
persons would survive around 8 years after initial diagnosis39. 
1.3.5 Etiology of AD 
1.3.5.1 Genetic etiology of AD 
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The genetic etiology of AD includes apolipoprotein E gene polymorphism, amyloid-β protein 
precursor and presenilin I and II40. 
1.3.5.2 Non-genetic etiology of AD 
Non- genetic etiology of AD includes age, tauopathy and other risk factors like hyperlipidemia, 
hypertension, diabetes mellitus, stroke, smoking, traumatic head injury and familial history39, 41. 
1.3.6 Stages of AD 
Different stages of AD are: 
1. Mild cognitive decline 
2. Moderate cognitive decline 
3. Severe cognitive decline 
Fig 1: Brain image showing different stages of AD 
1.3.6.1 Mild cognitive decline 
People suffering from mild Alzheimer’s disease may appear to be healthy, but they actually have 
trouble making sense of their surroundings. Because mild Alzheimer’s is commonly mistaken for 
normal aging, it may take time to realize the condition of mild Alzheimer’s disease42. 
1.3.6.2 Moderate cognitive decline 
In the moderate stages of Alzheimer’s disease, the degeneration of the brain worsens and spreads 
to other areas that control language, reasoning, sensory processing and thought. The signs of the 
disease become more pronounced and behavioral problems often occur43. 
1.3.6.3 Severe cognitive decline 
Damage to the brain’s nerve cells is widespread in severe stages of AD. People may lose motor 
coordination and the ability to walk, speak, feed themselves, and recognize others (Fig. 1). Typically 
at this stage, full time care is required20, 43. 
Each of the three stages; mild, moderate and severe, can be further broken down into seven levels: 
Level 1 is considered to be a normal adult with no decline in function or of their memory. 
Level 2 is a slight decline from stage 1. A person in stage 2 will complain of deficits in recalling 
familiar names and places. This stage is often overlooked because forgetfulness is assumed to be a 
natural process associated with aging. 
Level 3 is characterized by a mild decline defined as early Alzheimer’s disease. In stage 3, anxiety 
and denial are large features under intensive interviews. Some signs include getting lost when 
traveling to unknown locations, low performance in the workplace and loss of words or vocabulary. 
Level 4 is identified when the person needs assistance in complicated tasks such as handling 
individual’s finances. In this stage people tend to exhibit problems remembering their past events 
such as family vacations. 
Level 5 brings a severe decline in a person’s ability to do everyday activities. In this stage one will 
need constant assistance by another individual to do simple tasks of picking out cloths, preparing 
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meals and even starting a car. They will have difficultly recalling current information, but will still 
remember major information involving themselves and their families. 
Level 6 is when there is a moderately severe decline in the disease. By this stage, Alzheimer’s 
patients forget significant amount of information including personal facts. When this stage 
approaches, a person needs assistance getting dressed and going to the bathroom, and has 
disturbed sleep patterns. The individual’s personality change becomes highly apparent and 
noticeable. Feeling frustrated and acting out with violence may occur because of the person’s 
inability to remember or process information long enough to react to their own thoughts. 
Level 7 is the last stage in Alzheimer’s disease. This is when there is a severe decline in vocabulary, 
emotions and the connection of the brain to body parts. Patients are now limited to six or seven 
words at a time. They lose the ability to walk, sit up straight, hold up their head, and even smile. In 
this stage there is no ability to have a hand-to-mouth motion, to place one foot in front of another, or 
even to urinate on their own. 
1.3.7 Pathophysiology of AD 
AD is driven by two processes: extracellular deposition of beta amyloid-Aβ and intracellular 
accumulation of tau protein. Both these compounds are insoluble. Aβ is the main component of 
senile plaques and tau is the component of neurofibrillary tangles. Aβ deposition is specific for AD 
and is thought to be primary. Tau accumulation is also seen in other degenerative diseases and is 
thought to be secondary44, 45. 
1.3.7.1 Beta Amyloid hypothesis 
Aβ is a 36 to 43 amino acid peptide, which is part of a larger protein, the Amyloid Precursor Protein 
(APP). APP is a transmembrane protein, made by neurons and other brain cells. It is also found in 
extraneural tissues and is especially abundant in platelets. Its function is unknown. The Aβ amyloid 
residue includes part of the transmembrane domain of APP and is derived from cleavage of APP by 
the enzymes β-and γ-secretase. Aβ monomers and oligomers are further degraded by other 
enzymes46. Defective clearance of Aβ from aberrant cleavage of APP and other mechanisms 
results in its accumulation (Fig. 2). Aβ monomers polymerize initially into soluble oligomers and then 
into larger insoluble fragments such as Aβ42, which precipitate as amyloid fibrils. 
Fig 2: Cascade of pathophysiological events in AD 
The beta amyloid hypothesis is the basis of a novel prevention and treatment method for AD that 
was reported recently in transgenic mice that overexpress a mutant APP and develop AD 
neuropathology. Active immunization of young animals with Aβ and passive immunization with Aβ 
antibodies prevented the development of AD; immunization of older animals reduced the extent and 
severity of AD pathology. Based on these findings, a human vaccine consisting of synthetic Aβ was 
developed. Phase I trials went uneventfully but phase II studies were terminated because some 
patients developed an autoimmune meningoencepalitis47, 48. 
1.3.7.2 Tau protein aggregation 
Neurofibrillary degeneration is characterized by the deposition in the neuronal body and processes 
of insoluble polymers of over-phosphorylated microtubule associated protein tau. Tau aggregates as 
pairs of filaments that are twisted around one another (paired helical filaments). These deposits 
interfere with cellular functions by displacing organelles (Fig. 3). 
Fig. 3: Aggregation of tau protein cascade events 
By distorting the spacing of microtubules, they impair the axonal transport thus affecting the nutrition 
of axon terminals and dendrites. No mutations of the tau gene occur in AD. Abnormal tau first 
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appears in the entorhinal cortex, then in the hippocampus, and at later stages in association cortex. 
Recent observations in transgenic mice suggest that the spread of the pathology to anatomically 
linked areas occurs by passage of abnormal tau across synapses49, 50. 
1.3.7.3 Cholinergic deficiency 
Neuronal and pharmacological evidences correlate the severity of memory impairment with 
cholinergic hypo function. Cholinergic neurotransmitter plays an important role in patients with AD. 
AChE is an enzyme that hydrolyzes the acetylcholine to acetate and choline at the cholinergic 
synapses51. Reduction in the level of acetylcholine in the brain produces memory and learning 
impairment. ACh binds to postsynaptic receptors such as muscarinic and nicotinic receptors (Fig. 4). 
Presynaptic nicotinic receptors are responsible for the release of neurotransmitters important for 
memory and mood (acetylcholine, glutamate, serotonin and norepinephrine). Loss of nicotinic 
receptor subtypes in the hippocampus and cortex has been observed in AD. Muscarinic receptors 
are not involved in the development of dementia, but blocking of this receptor produces 
confusion52, 53. 
Fig 4: Synthesis, release and binding of ACh to its receptors 
The function of BuChE is less clearly defined, and it can hydrolyze acetylcholine as well as other 
esters. Membrane bound form of AChE decreases the acetylcholine level in the brain of patients 
with AD whereas the BuChE remains unchanged or even increased. But ACh level can be 
maintained by selective BuChE inhibitors. Drugs that inhibit both enzymes may be preferably used 
for treating AD. In AD, there is an involvement of pyramidal neurons there by neuronal loss, synapse 
loss, reduced glutamate concentration and tangle formation leads to the formation of neurofibrillary 
tangles. Glutamate is the neurotransmitter of pyramidal neurons54-56. 
1.3.7.4 Glutamatergic pathway 
Glutamate is the primary excitatory neurotransmitter present in the brain. In the central nervous 
system, it is ubiquitous and involved roughly 66% of all brain synapse. Glutamatergic neurons are 
critical, because they form projections to other areas of brain including cholinergic neurons and the 
cholinergic neurons help for cognition and memory. (N-methyl-D-aspartate) (NMDA) receptor 
undergoes sustained low level activation in AD brains and produce sustained low level 
neurotransmission56. This dysregulation of NMDA glutamate receptor leads to neuronal damage 
and the continuous activation of the receptor leads to the chronic calcium influx within the neuron. 
This interfere the normal signal transduction pathway of glutamate and leads to increased 
production of amyloid precursor protein (APP). APP increases the plaque development and 
hyperphosporylation of tau protein (Neurofibrillary tangle (NFT) formation) followed by neuronal 
toxicity. AD patients appeared to have reduced number of glutamate reuptake receptor sites and 
abnormal expression of glutamate transporter leads to the formation of NFT and these tangles are 
pathogenic55. 
Other neurotransmitters like serotonin and norepinephrine levels become altered in brain which 
affect wide spread areas of cerebral cortex and produce behavioral and psychological symptoms of 
dementia57. 
1.3.7.5 Oxidative stress 
In AD brains, Aβ induces lipid peroxidation and generate reactive nitrogen and reactive oxygen 
species. The reactive nitrogen and oxygen molecules contain unpaired electrons in the outer shell. 
These unpaired electrons react with other molecules to achieve a stable configuration and produce 
free radicals. These free radicals cause cellular and molecular damage. This reaction is permanent 
and occurs in all types of neuronal macromolecules such as proteins, lipids, carbohydrates and 
nucleic acids. Brain is unprotected to damage from oxidative stress, because of high oxygen 
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consumption rate, high lipid content and relative loss (paucity) of anti-oxidant enzymes compared to 
other organs. Neuronal oxidation can cause numerous problems such as irreparable DNA damage 
and up-regulation of pro inflammatory cytokines57, 58. 
1.3.7.6 Chronic inflammation 
Senile plaques, NFT and damaged neurons may stimulate inflammation and leads to cell damage. 
Microglia is a type brain cells and it includes neurons, astrocytes and oligodendrocytes. These are 
involved in the infection or injury within the brain. Microglia gets activated and release cytotoxic 
molecules like pro-inflammatory cytokines, reactive oxygen species (ROS), complement proteins 
and proteinases during AD pathogenesis. Cytokines stimulate inflammatory process and promote 
apoptosis of neurons and oligodendrocytes and induce myelin damage55, 59. 
1.3.8 Acetylcholine 
Acetylcholine (ACh) is a neurotransmitter present in the cholinergic synapses and neuroeffector 
junctions in the central and peripheral nervous systems. Acetylcholine acts through muscarinic and 
nicotinic cholinergic receptors. With the help of these receptors, signals will transduce via different 
mechanisms. Cholinergic agonists are drugs, which mimics the effects of acetylcholine at these 
receptors60. 
. Cl- 
Fig 5: Structure of acetylcholine chloride 
1.3.9 Synthesis, storage and release of acetylcholine 
In the synthesis of acetylcholine, Acetyl CoA (Acetyl co-enzyme A) is derived from pyruvate via 
multistep pyruvate dehydrogenase reaction. Choline is taken up from the extracellular fluid into the 
axoplasm by active transport mechanism. In the presence of choline acetyltransferase, choline and 
acetyl CoA gets converted to acetylcholine. After its synthesis, ACh is taken up by storage vesicles 
present in the nerve terminals. The vesicles contain both ACh and ATP in the ratio of 10:1 and the 
release of ACh and other neurotransmitters takes place through calcium-mediated exocytosis. 
Release of ACh inhibited by botulinum and tetanus toxins from clostridium60, 61. 
1.3.10 Management of AD 
Several pathogenic pathways are involved in the progression of AD via senile plaques, NFT, 
oxidative stress, inflammatory cascade, glutamatergic and cholinergic deficiency. Based on the 
pathological mechanism, several pharmacological treatments are available. Currently available drug 
therapy for AD consist of cholinesterase inhibitors and NMDA receptor antagonists approved by the 
U.S. Food and Drug Administration (FDA) and some neuroprotective agents improve the 
psychological and behavioral symptoms of AD62. 
A major approach to the treatment of AD has involved attempts to augment the cholinergic function 
of the brain63. An early approach was the use of precursors of acetylcholine synthesis, such as 
choline chloride and phosphatidyl choline (lecithin). Physostigmine, a rapidly acting, reversible 
AChE inhibitor, produces improved responses in animal models of learning, and some studies have 
demonstrated mild transitory improvement in memory following physostigmine treatment in patients 
with AD. The use of physostigmine has been limited because of its short half-life and tendency to 
produce symptoms of systemic cholinergic excess at therapeutic doses64. 
Four inhibitors of AChE currently approved by the FDA for treatment of Alzheimer's disease are 
tacrine (1,2,3,4-tetrahydro-9-aminoacridine; COGNEX), donepezil (ARICEPT), rivastigmine 
(EXCELON), and galantamine (RAZADYNE)65. 
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Tacrine is a potent centrally acting inhibitor of AChE66. Studies of oral tacrine in combination with 
lecithin have confirmed that there is indeed an effect of tacrine on some measures of memory 
performance, but the magnitude of improvement observed with the combination of lecithin and 
tacrine is modest at best67. The side effects of tacrine often are significant and dose-limiting; 
abdominal cramps, anorexia, nausea, vomiting, and diarrhoea are observed in up to one-third of 
patients receiving therapeutic doses, and elevations of serum transaminases are observed in up to 
50% of those treated. Because of significant side effects, tacrine is not clinically widely used68. 
Donepezil is a selective inhibitor of AChE in the CNS with little effect on AChE in peripheral tissues. 
It produces modest improvement in cognitive scores in Alzheimer's disease patients and has a long 
half-life, allowing once-daily dosing. Rivastigmine and galantamine are dosed twice daily and 
produce a similar degree of cognitive improvement. Adverse effects associated with donepezil, 
rivastigmine, and galantamine are similar in character but generally less frequent and less severe 
than those observed with tacrine; they include nausea, diarrhea, vomiting, and insomnia. Donepezil, 
rivastigmine, and galantamine are not associated with the hepatotoxicity that limits the use of 
tacrine69. 
An alternative strategy for the treatment of AD is the use of the NMDA glutamate-receptor 
antagonist memantine. Memantine produces a use-dependent blockade of NMDA receptors. In 
patients with moderate to severe AD, use of memantine is associated with a reduced rate of clinical 
deterioration. Whether this is due to a true disease-modifying effect, possibly reduced excitotoxicity, 
or is a symptomatic effect of the drug is unclear. Adverse effects of memantine usually are mild and 
reversible and may include headache or dizziness70. 
1.3.10.1 Cholinesterase inhibitor 
Donepezil, rivastigmine, galantamine and tacrine are cholinesterase inhibitors. These drugs prevent 
the breakdown of acetylcholine in the brain by inhibition of acetylcholinesterase enzyme and 
increase the expression of nicotinic receptors. These drugs help in maintaining the acetylcholine 
level in brain and compensate the loss of functioning of brain cells. Cholinesterase inhibitors are 
used for the treatment of mild, moderate and severe AD and the side effects observed are nausea, 
vomiting, loss of appetite and increased frequency of bowel movement71. 
1.3.10.2 NMDA receptor antagonist 
Memantine is a NMDA receptor antagonist. It is used for the treatment of moderate to severe AD. 
Memantine restores the function of damaged nerve cells and reduce abnormal excitatory signals by 
modulating the NMDA receptor activity. Some compounds are mainly under preclinical and clinical 
evaluations based on the mechanism of β-amyloid (Aβ) cascade and tau protein 
hyperphosporylation72. 
1.3.10.2.1 Aβ-targeting strategies 
➢ α secretase activators/ modulators 
➢ β secretase inhibitors (GSK188909, PMS777) 
➢ γ secretase inhibitors/ modulators (BMS299897,MRK-560) 
➢ Aβ- aggregation inhibitors 
➢ M1 muscarinic agonists (AF102B, AF267B) 
➢ Immunotherapy 
➢ Apo lipoprotein (ApoE) promotes Aβ clearance 
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➢ Aβ-degrading enzyme 
➢ Drugs influencing Aβ blood- brain barrier transport 
1.3.10.2.2 Treatment based on tau pathology 
➢ Prevention of phosphorylation of tau 
➢ Prevention of the aggregation of tau 
➢ Tau immunotherapy 
➢ Prevent the misfolding of tau 
1.3.10.2.3 Non-steroidal anti-inflammatory drugs (NSAIDs) 
➢ Trials with COX-2 selective inhibitors 
1.3.10.2.4 Antioxidants nutrients and agents: Vitamins C and E, oestrogen, statins, omega-3 
polyunsaturated fatty acids. 
1.3.11 Alzheimer’s disease inducing agents 
Alzheimer’s disease or learning impairment was induced by drugs and chemicals such as: 
scopolamine, benzodiazepines, phencyclidine, monosodium glutamate, aluminium chloride and 
colchicines73. 
1.3.11.1 Scopolamine and neurotoxicity 
Scopolamine, a muscarinic cholinergic receptor antagonist, has been widely adopted to study 
cognitive deficits in experimental animals. After intraperitoneal (i.p.) injection of scopolamine, the 
cholinergic neurotransmission is blocked, leading to cholinergic dysfunction and impaired cognition 
in rats74. Recently, it has been reported that Indigofera tinctoria Linn (Fabaceae) attenuates 
cognitive and behavioral deficits in scopolamine-induced amnesic mice75. Munshi et al., 2016 
reported the efficacy of Brahmi ghrita against scopolamine induced amnesia in rats76. 
Fig. 6: Mechanism of scopolamine induced AD 
The administration of the antimuscarinic agent scopolamine to young human volunteers produces 
transient memory deficits77. Analogously, scopolamine has been shown to impair memory retention 
when given to mice shortly before training in a dark avoidance task78-80. The ability of a range of 
different cholinergic agonist drugs to reverse the amnesic effects of scopolamine is now well 
documented in animals and human volunteers. However, the neuropathology of dementia of the 
Alzheimer type is not confined to the cholinergic system81. 
Nabeshima et al., studied the antagonism against phencyclidine-induced retrograde amnesia in 
mice82. Lenegre et al., investigated the effects of piracetam on amnesia induced by scopolamine, 
diazepam and electroconvulsive shock83. Yamaoto et al., studied the effect of drugs on the 
impairment of working memory produced by scopolamine, ethylcholine aziridinium (AF64A) or 
cerebral ischemia using a repeated acquisition procedure in a three-panel runway apparatus84. 
Braida et al., investigated the short (120 min) and long-lasting (360 min) antagonism of 
scopolamine- induced amnesia in rats in an eight-arm radial maze by a cholinesterase inhibitor85. 
1.3.11.2 Aluminum and neurotoxicity 
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The hypothesis that there is a link between aluminum and Alzheimer's disease (AD) was first 
brought out in the 1960s by Terry and Pena and by Klatzo and collaborators in 196586. Early in 
1976, high levels of aluminum have been found in brain lesions, such as plaques and tangles, in 
patients with Alzheimer’s disease and also in other conditions such as Parkinson’s disease (PD), 
pre-senile dementia, amyotrophic lateral sclerosis, neuro fibrilar degeneration, dialysis 
encephalopathy syndrome and nigro striatal syndrome87 (Fig. 7). 
Fig. 7: Mechanism of Aluminium chloride induced AD 
Elevated aluminum levels have been reported in other less common neurological disorders such as 
the Guamanian Parkinsonian-amylotrophic lateral sclerosis constellation and Hallervorden-Spatz 
Disease. The most common neurostructural alterations induced by high levels of aluminum in the 
brain is: brain ventricle dilatation and thinning of the corpus callosum reduce neural cell density, 
degenerative changes like picnosis, vacuolization, chromatin condensation increase neural 
filaments in neuron from the spinal cord and brainstem, axonal cerebellar disorder with degeneration 
of the Purkinje cells. There is some experimental evidence that aluminium chloride exposure can 
adversely affect the dopaminergic system88. Extended exposure to 100 mM Al lactate increased 
striatal levels of the dopamine metabolite in turns, suggests that exposure to Al may cause 
increased turnover of dopamine. The development of an encephalopathy, characterized by cognitive 
deficits, in-coordination, tremor and spinocerebellar degeneration, among workers in the aluminum 
industry also indicates that exposure to the metal can be profoundly deleterious89. 
Abnormal neurological symptoms have been observed in several patients receiving intramuscular 
injections of Al-containing vaccines. There have been many experimental studies on animals and on 
isolated cells showing that aluminum has toxic effects on the nervous system. In 1991, Guy showed 
that the uptake of aluminum by human neuroblastoma cells display an epitope associated with 
Alzheimer's diseases. Chronic exposure of animals to aluminum is associated with behavioral, 
neuropathological and neurochemical changes90. Among them, deficits of learning and behavioral 
functions are most evident. Several metals interact with β-amyloid (Aβ) in senile plaques. It is 
interesting to note that, compared to other Aβ-metal complexes (Aβ-Fe, Aβ-Zn, Aβ-Cu), Aβ-Al is 
unique in promoting a specific form of Aβ oligomerization that has marked neurotoxic effects91. 
There are a lot of ways by which Al can damage neural cells: 
➢ Interfering with glucose metabolism, leading to low amounts of ACh precursors. 
➢ Inhibiting the binding of Ca++ ions 
➢ Increasing the production of cAMP 
➢ Changes in the cytoskeleton protein, leading to phosphorylation, proteolysis, transport and 
synthesis disruption 
➢ Inducing oxidative damage by lipid peroxidation 
➢ Interacting directly to genomic structures 
Being involved in the production of reactive oxygen species (ROS), aluminum may cause 
impairment in mitochondrial bioenergetics and may lead to the generation of oxidative stress which 
may lead to a gradual accumulation of oxidatively modified cellular proteins, lipids and affects 
endogenous antioxidant enzyme activity, leading to degeneration of neuronal cells92, 93. In this 
way, aluminum is a strong candidate for consideration as a subtle promoter of events typically 
associated with brain aging and neurodegenerative disorders. 
1.4 DRUG DISCOVERY AND DEVELOPMENT 
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Drug discovery process was started in the beginning of nineteenth century, by John Langley in the 
year of 1905. It is considered as the fastest developing directions of the high-tech investigations that 
depend on the achievements of molecular chemistry, information technologies, quantum physics, 
biology and bio-informatics94. 
Drug discovery process involves the identification of target, target validation, lead identification, lead 
optimisation, synthesis, screening for its therapeutic efficacy (Fig. 8). Once the testing is completed, 
drug development process will started prior to the clinical trials95, 96. 
Fig 8: Different phases of drug discovery cycle 
1.4.1 Drug design 
Rational drug design uses different computational methods to identify novel compounds. The 
compounds having maximum efficacy, safety and selectivity towards the target will be identified. In 
rational drug design the biological and physical properties of the target was studied97. 
1.4.2 Types of drug design 
There are two types of drug design: 
Structure based drug design 
Ligand based drug design 
1.4.2.1 Structure based drug design 
Structural based virtual screening is being with the identification of a potential ligand binding site on 
the target molecule (Fig. 9). Target site possesses a variety of hydrogen bond donors and 
acceptors, hydrophobic characteristics, and molecular adherence surfaces. The structure of a target 
protein is determined by NMR, X-ray crystallography and initialization of the target is the key steps 
in the structure based drug design98, 99. The experimental structures of ligands bound to the 
enzymes, provide ideas for analog design and intern useful for the docking studies100. 
Fig. 9 Various steps involved in structure based drug design 
1.4.2.2 Ligand based drug design 
It is a most effective method used in the absence of the structural information of the target. Ligand 
based method is used to know about the inhibitors of the target receptor101. The active lead 
molecule is detected by using structural properties or topological similarity properties. Several 
criteria for structure similarity comparisons are shape of an individual fragment or electrostatic 
properties of the molecule. The lead molecules are generated by ranked based on their function 
score obtained by using different algorithms98. 
In this method, the known active molecules (ligands) and the potential hit molecules are compared 
using pre-defined mathematical expressions (grids) to quantify molecular similarity (Fig. 10). These 
approaches essentially neglect any information about the target biomolecule as well as the 3D 
structure of the ligand compounds. Ligand based drug design is efficient method and applied in 
combination with structure-based approaches to identify potential bioactive leads that can be fed 
into docking experiments101. 
Fig. 10 Difference between structure based drug design and ligand based drug design 
1.4.3 Molecular docking 
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Molecular docking may be defined as an optimization problem, which would describe the “best-fit” 
orientation of a ligand that binds to a particular protein of interest. The aim of molecular docking is 
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to achieve an optimized conformation for both the protein and ligand and relative orientation 
between protein and ligand such that the free energy of the overall system is minimized102. 
0: 16_chapter10.pdf 88% 
In the field of molecular modeling, 
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docking is a method which predicts the preferred orientation of one molecule to a second when 
bound to each other to form a stable complex. Knowledge of the preferred orientation may be 
used to predict the binding affinity between two molecules 
or strength of association (scoring functions). During 
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the docking process, the ligand and the protein adjust their conformation to achieve an overall 
“best-fit” and this kind of conformational adjustments results in the overall binding 
and can be referred to as “induced-fit”103. 
1.4.4 Identification of right target and active site 
Target is a protein molecule and it is closely related to disease. It plays an important role in signal 
transduction pathway that often disrupted in the diseased condition. Enzymes are one of the targets 
as they have binding pockets for inhibition as well as substrates104. 
1.4.5 Lipinski’s rule of Five 
This rule was postulated by Christopher A. Lipinski in 1997, based on the observation that most of 
the drugs are relatively small and lipophilic in nature. Lipinski's rule of five is a rule of thumb to 
evaluate druglikeness. This rule states that, an orally active "drug-like" molecule has: 
• Partition coefficient (log P) less than 5 
• Molecular weight below 500 daltons 
• Not more than 10 hydrogen bond acceptors (O and Ngroup) 
• Not more than 5 hydrogen bond donors (OH and NH group) 
• Number of violations less than 5 
• All the numbers should be multiples of 5, which is the basis for the rules name. 
17
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
The rule describes about pharmacokinetic properties of a drug in the human body, including their 
absorption, distribution, metabolism, and excretion (ADME). But this rule does not predict if a 
compound is pharmacologically active or not105. This set of rules suggests that the necessary 
properties for good oral bioavailability and reflects the notion that pharmacokinetics, toxicity and 
other adverse effects are directly linked to the chemical structure of a drug106. 
1.4.6 Types of docking107 
1.4.6.1 Rigid docking 
The rigid docking is suitable position for the ligand in receptor environment obtained while 
maintaining its rigidity. 
1.4.6.2 Flexible docking 
In this process, receptor-ligand interaction was obtained by changing internal torsions of ligand into 
the active site while receptor remains fixed. 
1.4.7 Docking approaches108 
Two approaches mainly popular in molecular docking. 
1.4.7.1 Shape complementarity: This technique is used to describe the matching of ligand and 
protein as complementarity surfaces. 
1.4.7.2 Simulation: It is the actual docking process additionally calculating the interaction energies 
between ligand and protein molecule. 
1.4.8 Mechanics of docking 
To perform a docking screen, the first requirement is a structure of a protein. Protein structure has 
been determined by using x-ray crystallography or NMR spectroscopy. The protein structure and 
database of potential ligands serve as inputs to a docking programme. The success of docking 
program depends on: search algorithm and scoring function109. 
1.4.8.1 Search algorithm 
A strict search algorithm would completely elucidate all possible binding modes between ligand and 
receptor. Various searching algorithms have been developed and widely used in molecular docking 
software. But it would be too expensive to computationally generate all the possible conformations. 
Some commonly used searching algorithms are: Monte Carlo (MC) methods, fragment based 
method, distance geometry, matching method, ligand fit method, point complementarity method, 
blind docking, inverse docking, genetic algorithms and molecular dynamics110. 
1.4.8.2 Monte Carlo (MC) method 
MC methods are among the most established and widely used stochastic optimization techniques. 
These methods use sampling technique and are able to generate states of low energy 
conformations. The system makes random moves and accepts or rejects each conformation based 
on Boltzmann probability. Simulated annealing is a generalization of a Monte Carlo method for 
examining the equations of state and frozen states of n-body systems. The initial state of the system 
has random thermal motion within a specified potential force field. The effective temperature of the 
system (the degree of random motion) is decreased overtime, until a final stable docked position is 
obtained. The random motion of the ligand allows for exploration of the local search space, and the 
decreasing temperature of the system acts to drive it to a minimum energy111. One of the most 
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widely used simulated annealing procedures is the Metropolis Monte Carlo simulated annealing 
algorithm. 
1.4.8.3 Matching method 
This method focuses on complementarity. Ligand atom is placed at the ‘best’ position in the site, 
generating a ligand receptor configuration that may require optimization103. 
1.4.8.4 Distance geometry 
Many types of structural information can be expressed as intra or intermolecular distances. The 
distance geometry formalism allows these distance to be assembled and 3 dimensional structures 
consistent with them to be calculated. The fast sampling of the conformational space do not always 
results in reliable results. An example of a program using distance geometry in docking problem is 
Dock It102. 
1.4.8.5 Fragment based method 
Fragment based methods can be described as dividing the ligand into separate protons or 
fragments, docking the fragments and finally linking these fragments together with target protein. 
Some mainly used fragment based methods are FlexX104. 
1.4.8.6 Ligand fit method 
Ligand fit term provide a rapid accurate protocol for docking small molecules ligand into protein 
active sites for considering shape complimentarity between ligand and protein active sites103. 
1.4.8.7 Inverse docking 
This method uses computer for finding toxicity and side effects of protein targets on a small 
molecule. Knowledge of these targets combined with that of proteomics pharmacokinetic profile can 
facilitate the assessment of potential toxicities side effect of drug candidate. One of these protocols 
is selected for docking studies of particular ligand108. 
1.4.8.8 Genetic algorithm (GA) 
It is adaptive heuristic search technique premised on the evolutionary ideas of natural selection and 
genetics. The basic concept of GA is designed to simulate processes in natural system necessary 
for evolution. As such they represent an intelligent exploitation of a random search within a defined 
search space to solve a problem. In a genetic algorithm, there is a population of solutions that 
undergo mutation and crossover transformations. The algorithm maintains a selective pressure 
towards an optimal solution, with a randomized information exchange permitting exploration of the 
search space. A range of programs implements GA for docking110. 
1.4.8.9 Molecular dynamics (MD) 
Molecular dynamics (MD) is widely used as a powerful simulation method in many fields of 
molecular modeling. In the context of docking, by moving each atom separately in the field of the 
rest atoms, MD simulation represents the flexibility of both the ligand and protein more effectively 
than other algorithms. The disadvantage of MD simulations is that they progress in very small steps 
and thus have difficulties in stepping over high energy conformational barriers, which may lead to 
inadequate sampling. MD simulations are often efficient at local optimization. Thus a current 
strategy is to use random search in order to identify the conformation of the ligand, followed by the 
further subtle MD simulations106. 
1.4.9 Scoring functions 
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The purpose of the scoring function is to delineate the correct poses from incorrect poses, or 
binders from inactive compounds in a reasonable computation time. Scoring functions involve 
estimating, rather than calculating the binding affinity between the protein and ligand and through 
these functions, adopting various assumptions and simplifications104. Scoring functions can be 
divided into: 
i. Force-field-based 
scoring functions 
ii. Knowledge-based scoring functions. 
iii. Empirical based scoring functions 
1.4.9.1 Force-field- 
0: Dinesh_Thakkar_Pharmacy_Thesis.pdf 95% 
based scoring functions 
Classical force-field-based scoring functions assess the binding energy by calculating the sum of 
the non-bonded (electrostatics and van der Waals) interactions. The electrostatic terms are 
calculated by a Columbic formulation. 
0: Dinesh_Thakkar_Pharmacy_Thesis.pdf 100% 
Force-field-based scoring functions also have the problem of slow computational speed. Thus cut-
off distance is used to handle the non-bonded interactions106. 
0: Dinesh_Thakkar_Pharmacy_Thesis.pdf 100% 
Extensions of force-field-based scoring functions consider the hydrogen bonds, 
solvation’s 
0: Dinesh_Thakkar_Pharmacy_Thesis.pdf 100% 
and entropy contributions. Software programs, such as DOCK, GOLD and AutoDock, offer users 
such functions. 
They have some differences in the treatment of hydrogen bonds, the form of the energy function etc. 
The results of docking with force-field-based functions can be further refined with other techniques, 
such as linear interaction energy and free-energy perturbation methods (FEP) to improve the 
accuracy in predicting binding energies109. 
1.4.9.2 Knowledge-based scoring functions 
0: Dinesh_Thakkar_Pharmacy_Thesis.pdf 72% 
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Knowledge based scoring functions use statistical analysis of ligand-protein complexes crystal 
structures to obtain the inter-atomic contact frequencies and distances between the ligand and 
protein. 
The scoring is done by statistically observing the intermolecular relation between the ligand and the 
biological target protein using “Potential of Mean Force”. The intermolecular interactions are mainly 
taken into account for the functional group or atoms that occur frequently. The result of this method 
is evaluated based on the binding interactions. PMF, Drug Score, SMoG and Bleep are examples of 
knowledge-based functions110. 
1.4.9.3 Empirical scoring 
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functions 
In empirical scoring functions, binding energy decomposes into several energy components, such 
as hydrogen bond, ionic interaction, hydrophobic effect and binding entropy. Each component is 
multiplied by a coefficient and then summed up to give a final score. Coefficients are obtained from 
regression analysis fitted to a test set of ligand-protein complexes with known binding affinities. 
Empirical scoring functions 
may be treated in a different manner by different software, and the numbers of the terms included 
are also different. LUDI, PLP, Chem Score are examples derived from empirical scoring 
functions112. 
1.4.10 Various docking software’s used for molecular docking 
Over 60 docking software systems and more than 30 scoring functions are reported. Molecular 
docking is implemented as part of software packages for molecule design and simulation. More than 
one search method and scoring functions are provided in order to increase the accuracy of the 
simulations113. Only some of the software was made available and a limited number of them are 
widely used. Commonly used software’s are: 
1.4.10.1 DOCK 
DOCK is one of the oldest and best known ligand-protein docking programs. It systematically 
describes the geometries of ligands and binding sites by sets of spheres, attempting to fit each 
compound from a database into the binding site and the spheres could be overlapped by means of 
an approximate clique-detection procedure. The initial version used rigid ligands and edibility was 
later incorporated via incremental construction of the ligand in the binding pocket of the target 
protein. In the recent version of DOCK, steric matching-scores with electrostatic and molecular 
mechanics interaction energies are considered for the ligand-receptor complex. In scoring, the 
docked orientations of atomic hydrophobicity descriptors are being considered114, 115. 
1.4.10.2 GOLD (Genetic Optimization for Ligand Docking) 
GOLD uses a flexible docking mode for small molecules into protein binding site which utilizes 
genetic algorithm for the conformational search that forms a powerful tool for screening and 
identification of novel lead compounds. It provides docking of flexible ligand and protein with flexible 
hydroxyl groups. Otherwise the protein is considered to be rigid. This makes it a good choice when 
the binding pocket contains amino acids that form hydrogen bonds with the ligand. Gold is very 
highly regarded within the molecular modeling community for its accuracy and reliability and its 
genetic algorithm parameters are optimized for wide range of virtual screening applications. GOLD 
has one of the most comprehensive validation test sets114, 116. 
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1.4.10.3 GLIDE (Grid Based Ligand Docking with Energetics) 
GLIDE approximates a close and complete systematic search for the conformational, orientation 
and positional space of the docked ligand. Glide uses a series of hierarchical filters to search for 
possible locations of the ligand in the active-site region of the receptor. A grid representation for the 
shape and properties of the receptor is used that progressively scores for ligand posing114. 
1.4.10.4 FlexX (Future Leaders Exchange) 
A pose-clustering algorithm is used to classify the docked ligand conformers, where the placement 
of rigid core fragment is based on interaction geometry between fragment and receptor groups. Prior 
to docking, FlexX cuts the ligand at rotatable bonds into pieces, places a base fragment into the 
active site, and incrementally builds up the ligand again, using the other pieces. For a protein with 
known three dimensional structures and a small ligand molecule, FlexX predicts the geometry of the 
protein-ligand complex and estimates the binding affinity. It has a bit lower hit rate than DOCK but 
provides better estimates of Root Mean Square Distance for compounds with correctly predicted 
binding mode117. 
1.4.10.5 SLIDE (Screening for ligands by induced-fit docking) 
SLIDE represents a general approach to organic and peptidyl database screening. It can handle 
large binding-site templates and uses multi-stage indexing to identify feasible subsets of template 
points for ligand docking. An optimization approach based on mean-field theory is applied to model 
induced-fit complementarities, balancing flexibility between the ligand and the protein side chains. 
SLIDE can screen 100,000 compounds within a few days and returns a ranked list of sterically 
feasible ligand candidates, ranked by complementarities to the protein's binding site114. 
1.4.10.6 Hammerhead 
Hammerhead is suitable for screening large databases of flexible molecules by binding to a protein 
of known structure. It precisely docks a variety of known flexible ligands, and it spends an average 
of only a few seconds on each compound during a screen. The approach is completely automated, 
from the elucidation of protein binding sites, through the docking of molecules, to the final selection 
of compounds for assay114. 
1.4.10.7 FRED 
FRED takes a multi-conformer library or database of one or more ligands, a target protein structure, 
a box defining the active site of the protein and several optional parameters. Various options are 
available for optimization with respect to the built-in scoring functions: optimization of hydroxyl group 
rotamers, rigid body optimization, torsion optimization, and reduction of the number of poses that 
are passed on to the next scoring function. The ligand conformers and protein structure are treated 
as rigid during the majority of the docking process. FRED's docking strategy is to exhaustively score 
all possible positions of each ligand in the active site. The exhaustive search is based on rigid 
rotations and translations of each conformer. This novel strategy completely avoids the sampling 
issues associated with stochastic methods used by most other docking programs (such as Gold, 
FlexX, Dock and Glide). FRED jobs can also be easily distributed over multiple processors to further 
reduce docking time115. 
1.4.10.8 AutoDock 
AutoDock is a script driven flexible automated and random search docking technique operated by 
altering the ligand or a subset of ligand with several rotatable bonds to predict the binding interaction 
between small molecules to the known receptor three-dimensional structure. The robustness of 
AutoDock can be attributed to the 
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Monte Carlo simulated annealing, evolutionary, genetic and Lamarckian genetic algorithm 
methods. 
The prediction of bound conformations such as enzyme-inhibitor complexes, peptide-antibody 
complexes and even protein-protein interactions has shown a great success through AutoDock. 
Possible orientations are evaluated with AMBER force field model in conjunction with free energy 
scoring functions and a large set of protein-ligand complexes with known protein-ligand constants. 
The newest unreleased version 4 contains side chain flexibility. AutoDock has more informative web 
pages than its competitors; because of its free academic license118. 
1.4.10.9 AutoDock 4.2 
Auto Dock 4.2 uses a semi-empirical free energy force field to evaluate conformations during 
docking simulations. The force field evaluates binding in two steps. The ligand and protein start in 
an unbound conformation. In the first step, the intra molecular energies are estimated for the 
transition from these unbound states to the conformation of the ligand and protein in the bound 
state. The second step then evaluates the intermolecular energies of combining the ligand and 
protein in their bound conformations. The parameters are based on the amber force field119. 
Computer-aided drug design (CADD) is a key component in the process of drug discovery and 
development, as it offers great promise to drastically reduce cost and time120. It belongs to pre-
clinical phase and it plays a key role in identifying new investigational drug-likes and developing new 
potential inhibitors related to a determinate target. Computational strategy protocol characterized by 
the use of bioinformatics tools for lead optimization which reduce the cycle time and cost121. 
AutoDock 4.2 is the most recent version which has been widely used for virtual screening, due to its 
enhanced docking speed122. 
1.4.11 Applications of drug design 
Use of computational techniques in drug discovery and development process is rapidly gaining in 
implementation, popularity, and appreciation. Different terms are being applied to this area, including 
computer-aided drug design (CADD), computer-aided molecular modeling (CAMM), computational 
drug design, computer-aided molecular design (CAMD), computer-aided rational drug design, and in 
silico drug design. Both computational and experimental techniques have important roles in drug 
discovery and development and represent complementary approaches123, 124. CADD entails: 
➢ Streamline drug discovery and development process 
➢ Leverage of chemical and biological information about ligands and/or targets to identify and 
optimize new drugs 
➢ Design of in silico filters to eliminate compounds with undesirable properties (poor activity and/or 
poor absorption, distribution, metabolism, excretion and toxicity, ADMET) and develop most 
promising drug candidates. 
1.5 FLAVONOIDS 
Flavonoids are the large group of biologically active water-soluble plant compounds that include 
pigments present naturally in fruits, vegetables, and herbs. Flavonoids are inherent part of human 
and animal diet however, these are not synthesized within the body of animals including human125. 
Flavonoids are present in different parts of plant materials include leaves, fruits, vegetables, herbs 
and beverages such as tea and red wine. Flavonoids are associated with a broad spectrum of 
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health promoting effects126-128. They are an indispensable component in a variety of nutraceutical, 
pharmaceutical, medicinal and cosmetic applications129-130. Most of them are present in our 
everyday’s life. 
1.5.1 Structure of flavonoids 
Flavonoids occur in aglycones, glycosides and methylated derivatives131. Glycosylation makes it 
less active, more water soluble and permits its storage in the cell vacuole. Chemically flavonoids 
may be defined as a group of polyphenolic compounds consisting of two substituted benzene rings 
(Ring A and C) connected by the side chain of three carbon atoms and an oxygen bridge (Ring B)
132 (Fig. 11). 
Fig. 11 Basic structure of flavonoids 
All flavonoids share a basic C6-C3-C6 phenyl-benzopyran backbone. Ring A usually shows a 
phloroglucinol substitution pattern133. 
1.5.2 Classification of flavonoids 
Over 5000 naturally occurring flavonoids have been characterized from various plants sources134 
(Fig. 12). 
Fig. 12 Classification of flavonoids 
1.5.3 Pharmacological activity of flavonoids 
Flavonoids exhibit several biological effects such as: 
1.5.3.1 Antimicrobial activity 
Flavonoids are esters of phenolic acids; it has antibacterial, antifungal and antiviral activities. 
Naringin, quercetin, hesperetin and catechin possess various spectrum of antiviral activity. It affects 
the replication and infectivity of certain RNA and DNA viruses. Flavones selectively inhibit HIV-1 and 
HIV-2 or similar immunodeficiency virus infections. Quercetin and apigenin exhibit antibacterial 
activity135. 
1.5.3.2 Hepatoprotective activity 
Flavonoids have also been found to possess hepatoprotective activity. In a study carried out to 
investigate the flavonoid derivatives silymarin, apigenin, quercetin, and naringenin, as putative 
therapeutic agents against microcrystin LR-induced hepatotoxicity, silymarin was found to be the 
most effective one. The flavonoid, rutin and venoruton, showed regenerative and hepatoprotective 
effects in experimental cirrhosis131. 
1.5.3.3 Anti-oxidant activity 
Flavonoids possess antioxidant potential due to its structural characteristics. They protect cells 
against the damaging effects of reactive oxygen species. Anti-oxidant activity of flavonoids is due to 
their ability to reduce free radical formation, scavenge free radicals, and chelate metal ions. 
Flavonoids require a hydroxyl group at carbon 3 of the C- ring and two hydroxyl groups at carbons 3' 
and 4' of the B- ring for their anti-oxidant activity (Farooqui, 2012). Luteolin, genistein, daidzein, 
kaempferol, morin, naringenin, quercetin, apigenin, myricetin, robinin and cyanidin are possess 
antioxidant activity. Catechins are a most powerful flavonoid for protecting the body against reactive 
oxygen species131, 134. 
1.5.3.4 Antidiabetic activity 
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Flavonoids, especially quercetin, have been reported to possess antidiabetic activity. Quercetin 
brings about the regeneration of pancreatic islets and probably increases insulin release in 
streptozotocin-induced diabetic rats. Quercetin stimulates insulin release and enhanced Ca2+ 
uptake from isolated islets cell which suggest a place for flavonoids in noninsulin-dependent 
diabetes135. 
1.5.3.5 Anti-inflammatory activity 
Flavonoids possess the anti-inflammatory activity. Hesperidin possesses significant anti-
inflammatory and analgesic effect. Recently apigenin, luteolin and quercetin have been reported to 
exhibit anti-inflammatory activity. Kaempferol, quercetin, myricetin, fisetin can modulate arachidonic 
acid metabolism via the inhibition of cyclooxygenase (COX) and lipoxygenase activity (LOX) 
activities131. 
1.5.3.6 Antiulcer activity 
Flavonoids possess anti-ulcerogenic activity. Flavonoid glycosides decreased ulcer and inhibited 
gastric acid and pepsin secretions. Quercetin, rutin, and kaempferolare used for the treatment of 
peptic ulcer132, 134. 
1.5.3.7 Cardioprotective effects 
Flavonoids have been stimulated by the potential health benefits arising from the antioxidant activity. 
It results in the high propensity to transfer electrons, chelate ferrous ions, and scavenge reactive 
oxygen species. Because of these properties, flavonoids have been considered as potential 
protectors against chronic cardiotoxicity caused by the cytostatic drug doxorubicin. Doxorubicin is a 
very effective antitumor agent but its clinical use is limited by the occurrence of a cumulative dose-
related cardiotoxicity, resulting in, for example, congestive heart failure (negative inotropic effect) In 
a recent report, the cardiotoxicity of doxorubicin on the mouse left atrium has been inhibited by 
flavonoids, 7- monohydroxyethylrutoside and 7’,3’,4’-trihydroxyethylrutoside131. 
1.5.3.8 Anticancer effect 
Dietary flavonoid reduces the risk of cancer. Flavonoids are dietary antioxidants, which act as 
nutritional supplements during treatment of cancer or during inflammatory disorders. Flavonoids and 
their synthetic analogues are used in the treatment of ovarian, breast, cervical, pancreatic, and 
prostate cancer. Daidzein and genistein inhibit both hormonal and non-hormonal types of cancer. 
Tangeritin is a citrus flavonoid and inhibit cancer cell proliferation. Flavonoids such as 3-
hydroxyflavone, 3',4' dihydroxy flavone, 2',3'-dihydroxy flavone, fisetin, apigenin, and luteolin are 
potential inhibitors of tumour cell proliferation. Quercetin and apigenin inhibit melanoma growth. 
Kaempferol, catechin, toxifolin and fisetin also suppressed cell growth136. 
1.5.3.9 Immunomodulatory activity 
Certain flavonoids act as immune boosters. Flavonoids help in the homeostasis within the immune 
system and also affect the functions of inflammatory cells. Quercetin helps to inhibit several initial 
process of inflammation and stimulate immune functions137. 
1.5.3.10 Neuroprotective property 
Neurodegenerative disorders were developed by the combined effect of oxidative stress, 
inflammation and transition metal accumulation. Alzheimer’s and dementias are the major disorder 
of neurodegeneration. Flavonoids have attracted potential interest for their neuroprotective 
properties, because of their antioxidant, anti-inflammatory and metal chelating properties. Flavones 
and flavonones play an effective role in the treatment of neurodegenerative diseases138. 
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2. LITERATURE REVIEW 
2.1 RELATED TO DOCKING STUDIES 
Hamulakova et al., 2017 synthesized a novel series of acridine-coumarin hybrids and biologically 
evaluated their inhibitory potential of AChE and BuChE. The newly synthesized derivatives 9a-d 
have shown higher activity against human AChE compared with 7-MEOTA as the standard drug. 
Among them derivative 9b exhibited the most potent AChE inhibitory activity, with an IC50 value of 
5.85μM compared with 7-MEOTA (IC50=15μM). Molecular modelling studies were performed to 
predict the binding modes of compounds 9b, 9c and 9f with hAChE/hBuChE139. 
Park et al., 2017 studied the AChE and BuChE inhibitory potential of 3,4-dihydroquinazoline 
derivatives. In particular, compound 8b and 8d were the most active compounds in the series 
against BuChE with IC50 values of 45nM and 62nM, as well as 146- and 161-fold higher affinity to 
BuChE, respectively. Molecular docking simulations were performed to get better insights into the 
mechanism of binding of 3,4-dihydroquinazoline derivatives. As expected, compound 8b and 8d 
bind to both catalytic anionic site (CAS) and peripheral site (PS) of BuChE with better interaction 
energy values than AChE. Furthermore, the non-competitive/mixed-type inhibitions of both 
compounds confirmed their dual binding nature in kinetic studies140. 
Sehgal et al., 2016 carried out detailed screening analyses by 2-D similarity search against 
prescribed antidepressant drugs using their physicochemical properties. Ligand Scout was 
employed to ascertain novel molecules and pharmacophore properties. In this study, three novel 
compounds showed maximum binding affinity with HSPB8. Docking analysis elucidated that Met37, 
Ser57, Ser58, Trp60, Thr63, Thr114, Lys115, Asp116, Gly117, Val152, Val154, Leu186, Asp189, 
Ser190, Gln191, and Glu192 are their critical residues for ligand-receptor interactions. Site-directed 
mutagenesis could be significant for further analysis of the binding pocket. The novel findings based 
on an in silico approach may be momentous for potent drug design against depression and 
Charcoat Marie Tooth disease141. 
Sehgal et al., 2015 performed two-dimensional similarity search with selected inhibitor, keeping in 
view the physiochemical properties of the inhibitor. Docking studies revealed that Glu-53, Thr-54, 
Lys-58, Val-85, Ser-86, Tyr-87, Leu-88, Glu-90, Leu-95, Val-98, Ser-100, Glu-112, Tyr-116, Lys-120, 
Asp-121, and Arg-122 were critical residues for receptor-ligand interaction. The C-terminal of 
selected isoforms is conserved, and binding was observed on the conserved region of isoforms. 
Further analysis of this inhibitor through site-directed mutagenesis could be helpful for exploring the 
details of ligand-binding pockets142. 
Ahmad et al., 2014 generated the ligand based pharmacophore model using the Discovery studio 
2.0 software. In addition to this a structure based approach has been used to validate the developed 
pharmacophoric features to gain a deeper insight into its molecular recognition process. This 
validated pharmacophore and the docking model was then implemented as a query for 
pharmacophore based virtual screening to prioritize the probable hits for the caspase-3. Two 
ligands, ZINC12405015 and ZINC12405043 were finally selected on the basis of their fit values and 
docking scores. This study also reveals the vital amino acids His-121, Ser-205, Arg-207 which were 
found to be playing crucial role in the binding of the selected compounds within the active site of 
caspase-3143. 
Jalkute et al., 2013 performed molecular dynamics simulation of crystal structure complex of testis 
truncated version of ACE (tACE) and its inhibitor lisinopril along with Zn2+ to understand the 
dynamic behavior of active site residues of tACE. Root mean square deviation results revealed the 
stability of tACE throughout simulation. The residues Ala 354, Glu 376, Asp 377, Glu 384, His 513, 
Tyr 520 and Tyr 523 of tACE stabilized lisinopril by hydrogen bonding interactions. Using this 
information, in subsequent part of study, molecular docking of tACE crystal structure with Aβ-peptide 
was investigated and the interactions of Aβ-peptide with enzyme tACE was explored. The residues 
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Asp 7 and Ser 8 of Aβ-peptide were found in close contact with Glu 384 of tACE along with Zn2+. 
This study has demonstrated that the residue Glu 384 of tACE might play key role in the 
degradation of Aβ-peptide by cleaving peptide bond between Asp 7 and Ser 8 residues. Molecular 
basis generated by this attempt could provide valuable information towards designing of new 
therapies to control Aβ concentration in Alzheimer’s patient144. 
Spilovska et al., 2013 designed, synthesized and evaluated a structural series of 7-MEOTA-
adamantylamine thioureas as inhibitors of human AChE and human BuChE. The compounds were 
prepared based on the multi-target-directed ligand strategy with different linker lengths (n = 2–8) 
joining the well-known NMDA antagonist adamantine and the hAChE inhibitor 7-methoxytacrine (7-
MEOTA). Based on in silico studies, these inhibitors proved dual binding site character capable of 
simultaneous interaction with the peripheral anionic site (PAS) of human AChE and the catalytic 
active site (CAS). These structural derivatives exhibited very good inhibitory activity towards human 
BuChE resulting in more selective inhibitors of this enzyme. The most potent cholinesterase inhibitor 
was found to be thiourea analogue 14 (with an IC50 value of 0.47 µM for human AChE and an 
IC50value of 0.11 µM for hBuChE, respectively). Molecule 14 is a suitable novel lead compound for 
further evaluation proving that the strategy of dual binding site inhibitors might be a promising 
direction for development of novel AD drugs145. 
Grover et al., 2012 elucidated the ChE inhibitory potential of withanolide A and its associated 
binding mechanism. Binding interactions of the ligand to the receptor were predicted with the help of 
computational docking studies. Ligand interaction with the human AChE residues was found to be 
Thr78, Trp81, Ser120 and His442 as active sites, it could be responsible for its inhibitory activity. 
The study further proved the evidence for consideration of withanolide A as a potential molecule in 
prevention and management of AD146. 
Dayangac-Erden et al., 2009 found that (E)-resveratrol, inhibited histone deacetylase activity in a 
concentration-dependent manner and half-maximum inhibition was observed at 650 μm. Molecular 
docking studies showed that (E)-resveratrol had more favorable free energy of binding (−9.09 kcal/
mol) and inhibition constant values (0.219 μm) than known inhibitors. To evaluate the effect of (E)-
resveratrol on survival motor neuron (SMN2) expression, spinal muscular atrophy type I fibroblast 
cell lines was treated with (E)-resveratrol. The level of full-length SMN2 mRNA and protein showed 
1.2 to 1.3 fold increases after treatment with 100 μm (E)-resveratrol in only one cell line. These 
results indicated that response to (E)-resveratrol treatment was variable among cell lines. This data 
demonstrated a novel activity of (E)-resveratrol and that it could be a promising candidate for the 
treatment of spinal muscular atrophy147. 
Tatar et al., 2009 tested 33 carboxylic acid derivatives to understand the structural requirements for 
histone deacetylase (HDAC) inhibition activity. Several modifications were applied to develop the 
structure–activity relationships of carboxylic acid HDAC inhibitors. HDAC inhibition activities were 
investigated in vitro by using HeLa nuclear extract in a fluorimetric assay. Molecular docking was 
also carried out for the human HDAC8 enzyme in order to predict inhibition activity and the 3D 
poses of inhibitor–enzyme complexes. Among the compounds tested caffeic acid derivatives 
chlorogenic acid and curcumin were found to be highly potent compared to sodium butyrate, a well-
known HDAC inhibitor148. 
2.2 ENZYME INHIBITION ASSAY 
Lan et al., 2017 developed novel family of cinnamic acid derivatives and evaluated cholinesterase 
inhibitory activity by fusing N-benzyl pyridinium moiety and different substituted cinnamic acids. In 
vitro studies showed that most compounds were endowed with a noteworthy ability to inhibit 
cholinesterase, self-induced Aβ (1-42) aggregation, and to chelate metal ions. Especially, compound 
5l showed potent cholinesterase inhibitory activity (IC50, 12.1 nM for eeAChE, 8.6 nM for human 
AChE, 2.6 μM for eqBuChE and 4.4 μM for hBuChE) and the highest selectivity toward AChE over 
BuChE. It also showed good inhibition of Aβ (1-42) aggregation (64.7% at 20 μM) and good 
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neuroprotection on PC12 cells against amyloid-induced cell toxicity. Finally, compound 5l could 
penetrate the BBB, as forecasted by the PAMPA-BBB assay and proved in OF1 mice by ex vivo 
experiments. Overall, compound 5l seems to be a promising lead compound for the treatment of 
Alzheimer's disease149. 
Saeedi et al., 2017 evaluated the in vitro ChEI activity of various plants including betel nuts (Areca 
catechu L.), clove buds (Syzygium aromaticum L.), aerial parts of dodder (Cuscuta chinensis Lam.), 
common polypody rhizomes (Polypodium vulgare L.) and turpeth roots (Ipomoea turpethum R. Br.) 
which were recommended for the treatment of AD symptoms in Iranian traditional medicine (ITM). 
Among them, aqueous extract of A. catechu L. was found to be potent anti-AChE (IC50 = 32.00 μg/
mL) and anti-BuChE (IC50 = 48.81 ± 0.1200 μg/mL) agent150. 
Singh et al., 2016 evaluated the anti-amnesic effect of Ocimum basilicum L., Ocimum sanctum L. 
and Ocimum gratissimum L. extracts using in-vitro and in-vivo models. In-vitro AChE inhibitory and 
antioxidant activities of hydro-methanol extracts of plants were evaluated using Ellman and DPPH 
and FRAP assays, respectively. Brain AChE activity, oxidative profile and histopathological studies 
were assessed to outline the anti-amnesic mechanism of the extract. Significant antioxidant and 
AChE inhibition activity was observed with all prepared extracts and however, Ocimum basilicum 
extract (OBE) showed most marked free radical scavenging, reducing power and AChE inhibition 
(IC50 0.65±0.15mg/ml) activity. The in-vivo studies showed that OBE pre-treatment (200 and 400 
mg/kg, p.o.) reversed the memory deficit induced by scopolamine in mice, evident by significant 
(p>0.05) decrease in the transfer latency time and increase in step down latency in elevated plus 
maze and passive shock avoidance task, respectively. These biochemical changes were 
responsible for the anti-amnesic and neuroprotective activities of Ocimum basilicum which may be 
attributed to the presence of phenolic and flavonoid compounds and can be developed as an 
effective anti-amnesic drug151. 
Hajlaoui et al., 2016 investigated the chemical composition and evaluated the antioxidant, 
antimicrobial, cytotoxic and anti-acetylcholinesterase properties of Tunisian Origanum majorana 
essential oil. The findings showed that the oil exhibited high activity, particularly in terms of reducing 
power and β-carotene bleaching, inducing higher IC50 values than butylated hydroxyl toluene. The 
oil showed an important antimicrobial activity against 25 bacterial and fungal strains. In fact, the 
inhibitory zone, minimum inhibitory concentration and minimum bactericidal concentration values 
were recorded. A low cytotoxic effect was observed against cancer (Hep-2 and HT29) and 
continuous cell lineage (Vero), with cytotoxic concentration (CC50) values ranging from 13.73 to 
85.63 mg/mL. The oil was also evaluated for anti-AChE effects, which showed that it exhibited 
significant activity with IC50 values reaching 150.33 ± 2.02 μg/mL152. 
Formagio et al., 2015 investigated the in vitro antiproliferative and anticholinesterase activities of 11 
extracts from 5 Annonaceae species. Antiproliferative activity was assessed using 10 human cancer 
cell lines. Thin-layer chromatography and a microplate assay were used to screen the extracts for 
AChE inhibitory activity. The chemical compositions of the active extracts were investigated using 
high performance liquid chromatography. Eleven extracts obtained from five Annonaceae plant 
species were active and were particularly effective against the UA251, NCI-470 lung, HT-29, NCI/
ADR, and K-562 cell lines with growth inhibition (GI50) values of 0.04-0.06, 0.02-0.50, 0.01-0.12, 
0.10-0.27, and 0.02-0.04 mg/mL, respectively. The Annona cacans extract displayed the lowest 
activity. Based on the microplate assay, the percent AChE inhibition of the extracts ranged from 12 
to 52%, and the Annona coriacea seed extract resulted in the greatest inhibition (52%). Caffeic acid, 
sinapic acid, and rutin were present at higher concentrations in the Annona crassiflora seed 
samples153. 
Ali-Shtayeh et al., 2014 investigated the in vitro AChEI in herbal medicines traditionally used in 
Palestine to treat cognitive disorders. The effect on AChE activity of 92 extracts belonging to 47 
medicinal plants were evaluated using micro-well plate AChE activity (NA-FB) and Ellman’s assays 
and antioxidant activity using DPPH assay.67.4% and 37% of extracts inhibited AChE by <50% 
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using the NA-FB and Ellman’s assays. Using NA-FB assay, 84 extracts interacted reversibly with the 
enzyme, of which Mentha spicata (94.8%), Foeniculum vulgare (89.81), and Oxalis pes-caprae 
(89.21) were most potent, and 8 showed irreversible inhibitions of leaves of Lupinus pilosus 
(92.02%) were most active. Antioxidant activity was demonstrated by 73 extracts Majorana syriaca 
(IC50 0.21mg/ml), and Rosmarinus officinalis (0.38) were the most active. Palestinian flora has 
shown to be a rich source for, new and promising agents (AChEIs) for the treatment of AD154. 
Liu et al., 2014 focused on the synthesis and anti-cholinesterase evaluation of new donepezil like 
analogs. A new series of phthalimide derivatives (compounds 4a-4j) were synthesized via Gabriel 
protocol and subsequently amidation reaction was performed using various benzoic acid derivatives. 
Then, the corresponding anti-acetylcholinesterase activity of the prepared derivatives (4a-4j) was 
assessed by utilization of the Ellman’s test and obtained results were compared to donepezil. 
Besides, docking study was also carried out to explore the likely in silico binding interactions. 
According to the obtained results, electron withdrawing groups (Cl, F) at position 3 and an electron 
donating group (methoxy) at position 4 of the phenyl ring enhanced the AChE inhibitory activity. 
Compound 4e (m-Fluoro, IC50 = 7.1 nM) and 4i (p-Methoxy, IC50 = 20.3 nM) were the most active 
compounds in this series and exerted superior potency than donepezil (410 nM). Moreover, a similar 
binding mode was observed in silico for all ligands in superimposition state with donepezil into the 
active site of AChE155. 
Alipour et al., 2013 synthesised a novel series of coumarin and 3-coumaranone derivatives 
encircling the phenacyl pyridinium moiety and assessed their AChE and BuChE inhibitory activity by 
Ellman's method. All compounds exhibited AChE and BuChE inhibitory activity in the µM 
concentrations. The computational docking studies revealed that the selected compounds were 
inhibitors of AChE dual binding site. A kinetic study was carried out and mixed type of enzyme 
inhibition was found. The compounds were evaluated for their antioxidant activity and no significant 
activity was witnessed156. 
2.3 SCOPOLAMINE INDUCED AMNESIA 
Akinyemi et al., 2017 assessed the combined pretreatment effect of curcumin, the major 
polyphenolic compound of turmeric (Curcuma longa) rhizomes, with donepezil, a ChE inhibitor, on 
cognitive function in scopolamine-induced memory impairment in rats. Rats were pretreated with 
curcumin (50 mg/kg) and/or donepezil (2.5 mg/kg) via oral administration (p.o.) for seven successive 
days. Dementia was induced at the end of the treatment period by a single i.p. injection of 
scopolamine (1 mg/kg). Thereafter, the changes in spatial and episodic memory were conducted; 
then, the estimation of some biochemical parameters associated with cognitive function was 
determined. Scopolamine-treated rats showed impaired learning and memory and increased 
activities of AChE and BuChE, adenosine deaminase (ADA), and lipid peroxidation with a 
concomitant decrease in levels of nitric oxide (NO) and reduced glutathione (GSH), superoxide 
dismutase (SOD), and catalase when compared with control. Thus, the observed anti-amnestic 
effect could be linked to their inhibitory effect on key enzyme of cholinergic system associated with 
memory function157. 
Erfanparast et al., 2017 investigated the effects of microinjection of vitamin B12 into the 
hippocampus on the orofacial pain and memory impairments induced by scopolamine and orofacial 
pain. The memory impairment induced by orofacial pain was improved by vitamin B12 and 
physostigmine used alone. Naloxone prevented, whereas physostigmine enhanced the memory 
improving effect of vitamin B12 in the pain-induced memory impairment. All the above-mentioned 
chemicals did not alter locomotor activity. The results of the present study showed that at the level of 
the dorsal hippocampus, vitamin B12 modulated orofacial pain through a mu-opioid receptor 
mechanism. In addition, vitamin B12 contributed to hippocampal cholinergic system in processing of 
memory. Moreover, cholinergic and opioid systems may be involved in improving effect of vitamin 
B12 on pain-induced memory impairment158. 
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Imam et al., 2017 investigated the neuro-cognitive implications of oral cannabis use in rats. 
Cannabis significantly reduced rearing frequencies in the OFT and EPM, and increased freezing 
period in the OFT. It also reduced percentage alternation similar to scopolamine in the Y maze, and 
these effects were coupled with alterations in the cortico-hippocampal neuronal architectures. These 
results pointed the detrimental impacts of cannabis on cortico-hippocampal neuronal architecture 
and morphology, and consequently cognitive deficits159. 
Rahmati et al., 2017 studied the effects of L. officinalis extract in scopolamine-induced memory 
impairment, anxiety and depression-like behaviour. Memory impairment was assessed by Y-maze 
task, while, elevated plus maze and forced swimming test were used to measure anxiolytic and 
antidepressive-like activity. Spontaneous alternation percentage in Y maze is reduced by 
scopolamine (36.42 ± 2.60) (p ≤ 0.001), whereas lavender (200 and 400 mg/kg) enhanced it (83.12 
± 5.20 and 95 ± 11.08, respectively) (p ≤ 0.05). Also, lavender pretreatment in 200 and 400 mg/kg 
enhanced time spent on the open arms (15.4 ± 3.37 and 32.1 ± 3.46, respectively) (p ≤ 0.001). On 
the contrary, while immobility time was enhanced by scopolamine (296 ± 4.70), 100, 200 and 
400 mg/kg lavender reduced it (193.88 ± 22.42, 73.3 ± 8.25 and 35.2 ± 4.22, respectively) in a dose-
dependent manner (p ≤ 0.001). Lavender extracts improved scopolamine-induced memory 
impairment and also reduced anxiety and depression-like behaviour in a dose-dependent 
manner160. 
Kim et al., 2016 investigated the cognition-enhancing effects of aqueous extract of Indigofera 
tinctoria Linn. (ITE, Fabaceae) in experimental amnesic mice. The cognitive-enhancing activity of 
the ITE (5, 10 and 20 μg/mL) was studied by passive avoidance response, elevated plus maze and 
Y-maze behavioral paradigm in normal and scopolamine-induced amnesic mice. Antioxidant 
activities were also determined based on the ability of ITE to inhibit lipid peroxide, superoxide and 
hydroxyl radicals. Scopolamine-induced cognitive deficits were significantly reversed by ITE (p > 
0.001 at 20 mg/kg) in a dose-dependent fashion in all the behavioral paradigms tested. 
Furthermore, ITE dose dependently scavenged lipid peroxide, superoxide and hydroxyl free radicals 
with 50 % inhibition concentration (IC50) of 7.28 ± 0.37, 5.25 ± 0.28 and 7.62 ± 0.43 μg/mL, 
respectively. ITE possesses cognitive-enhancing properties in amnesic mice due to its potent 
antioxidant action75. 
Pandareesh et al., 2016 evaluated the cognition-enhancing activity of Bacopa monniera extract 
(BME) against scopolamine-induced amnesic rats by novel object recognition test (NOR), elevated 
plus maze (EPM) and Morris water maze (MWM) tests. BME administration also ameliorated 
scopolamine effect by down-regulating AChE and up-regulating BDNF, muscarinic M1 receptor and 
CREB expression in brain hippocampus confirms the potent neuroprotective role and these results 
are in corroboration with the earlier in vitro studies. BME administration showed significant 
protection against scopolamine-induced toxicity by restoring the levels of antioxidant and lipid 
peroxidation. These results indicate that, cognition-enhancing and neuromodulatory propensity of 
BME is through modulating the expression of AChE, BDNF, MUS-1, CREB and also by altering the 
levels of neurotransmitters in hippocampus of rat brain161. 
Setorki, 2016, observed the effect of Ziziphus spina-christi extract against anxiety related behavior 
induced by scopolamine. Experimental groups received Z. spina-christi extract (50, 100 and 200 mg/
kg IP) 30 min after scopolamine injection. Anxiety related behaviors were assessed using the 
elevated plus maze. The rotarod test was used to evaluate motor coordination. Administration of Z. 
spina-christi extract (200 mg/kg) significantly increased the time spent in the open arm of elevated 
plus maze. The extract also reduced the percentage of closed arms entries and time spent in the 
closed arms. Different concentration of Z. spina-christi extract didn’t affect motor coordination and 
balance. Hydro-alcoholic extract of Z. spina-christi significantly ameliorated scopolamine-induced 
anxiety162. 
He et al., 2015 examined the effect on scopolamine-induced memory impairment mice and APP/
PS1 transgenic mice using Morris water maze test. Results showed that harmine (20 mg/kg) 
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administered by oral gavage for 2 weeks could effectively enhance the spatial cognition of C57BL/6 
mice impaired by intraperitoneal injection of scopolamine (1 mg/kg). Meanwhile, long-term 
consumption of harmine (20 mg/kg) for 10 weeks also slightly benefited the impaired memory of 
APP/PS1 mice. Furthermore, harmine could pass through blood brain barrier, penetrate into the 
brain parenchyma shortly after oral administration, and modulate the expression of Egr-1, c-Jun and 
c-Fos. Molecular docking assay disclosed that harmine molecule could directly dock into the 
catalytic active site of acetylcholinesterase, which was partially confirmed by its in vivo inhibitory 
activity on AChE. Results suggested that harmine impaired memory by enhancement of cholinergic 
neurotransmission via inhibiting the activity of AChE, which may contribute to its clinical use in the 
therapy of neurological diseases characterized with AChE deficiency163. 
Lee et al., 2015 evaluated the neuropharmacological effects of 30% ethanolic pine needle extract 
(PNE) on memory impairment caused by scopolamine injection in mice hippocampus. Mice were 
orally pretreated with PNE (25, 50, and 100 mg/kg) or tacrine (10 mg/kg) for 7 days, and 
scopolamine (2 mg/kg) was injected intraperitoneally, 30 min before the Morris water maze task on 
first day. To evaluate memory function, the Morris water maze task was performed for 5 days 
consecutively. Scopolamine increased the escape latency and cumulative path-length but decreases 
the time spent in target quadrant, which were ameliorated by pre-treatment with PNE. These 
findings suggest that PNE could be a potent neuro pharmacological drug against amnesia, and its 
possible mechanism might be modulating cholinergic activity via CREB-BDNF pathway164. 
2.4 ALUMINIUM CHLORIDE INDUCED AMNESIA 
Lee et al., 2017 investigated the effect of the ethanol extract of Acanthopanax koreanum (EEAK) on 
cholinergic blockade-induced memory impairment in mice. The phosphorylation levels of both Akt 
and CaMKII were significantly increased by approximately two-fold compared with the control group 
because of the administration of EEAK (100 or 200 mg/kg) (p > 0.05). Moreover, the 
phosphorylation level of CREB was also significantly increased compared with the control group by 
the administration of EEAK (200 mg/kg) (p > 0.05). The study suggested that EEAK ameliorates the 
cognitive dysfunction induced by the cholinergic blockade, in part, via several memory-associated 
signalling molecules and may hold therapeutic potential against cognitive dysfunction, such as that 
presented in neurodegenerative diseases165. 
Pahaye et al., 2017 assessed memory improvement and neuroprotective and antioxidant effects of 
Mitragyna inermis leaf decoction on the central nervous system. Oxidative stress enzymes-catalase, 
superoxide dismutase, and the thiobarbituric acid reactive substance, a product of lipid peroxidation-
were quantified. The time spent in target quadrant in morris water maze increased while the transfer 
latency decreased in mice treated by M. inermis at the dose of 196.5 mg/kg. The activity levels of 
superoxide dismutase and catalase were significantly increased, whereas the thiobarbituric acid 
reactive substance was significantly decreased after 8 consecutive days of treatment with M. 
inermis at the dose of 393 mg/kg. These results suggest that M. inermis leaf extract possess 
potential anti-amnesic effects166. 
Thenmozhi et al., 2017 reported that hesperidin, a citrus bioflavonoid reversed memory loss caused 
by aluminium intoxication through attenuating acetylcholine esterase activity and the expression of 
amyloid β biosynthesis related markers. Intraperitoneal injection of AlCl3 (100 mg/kg., b.w.) for 60 
days significantly enhanced the learning and memory deficits, levels of thiobarbituric acid reactive 
substances and diminished the levels of reduced glutathione, activities of enzymatic antioxidants 
and the expression of B-cell lymphoma-2 as compared to control group in the hippocampus, cortex, 
and cerebellum. Co administration of hesperidin (100 mg/kg., b.w. oral) for 60 days prevented the 
cognitive deficits, biochemical anomalies and apoptosis induced by AlCl3 treatment. Results of the 
study demonstrated that hesperidin could be a potential therapeutic agent in the treatment of 
oxidative stress and apoptosis associated neurodegenerative diseases including AD18. 
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Al-Amin et al., 2016 investigated the effect of astaxanthin on AlCl3-exposed behavioral brain 
function and neuronal oxidative stress. Aluminum exposed group showed a significant reduction in 
spatial memory performance and anxiety-like behavior. Moreover, aluminium group exhibited a 
marked deterioration of oxidative markers; lipid peroxidation (MDA), nitric oxide (NO), glutathione 
(GSH) and advanced oxidation of protein products (AOPP) in the brain. To the contrary, co-
administration of astaxanthin and aluminium has shown improved spatial memory, locomotor 
activity, and reduced OS. These results indicate that astaxanthin improves aluminium-induced 
impaired memory performances presumably by the reduction of OS in the distinct brain regions167. 
Azza et al., 2016 evaluated the influence of caffeine and nicotine co-administration against 
aluminium-induced neurotoxicity that mimics AD in rats. Five groups of rats were used and received 
daily for five weeks: Saline for control, aluminium chloride (AlCl3) (70 mg/kg, i.p.) for AD mimic 
group, while treated groups received together with AlCl3, either caffeine (5 mg/kg, i.p.), nicotine (1 
mg/kg, s.c.) or their combination. Three behavioral experiments were performed: Forced swimming 
test (FST), Morris water maze (MWM) task and conditioned-avoidance and learning (CAL) test. 
Histo pathological changes in the brain and biochemical changes in AChE as well as oxidative 
parameters; malondialdehyde (MDA), superoxide dismutase (SOD), total antioxidant capacity (TAC) 
were also evaluated for all groups. Results of the behavioral tests showed that caffeine and nicotine 
co-administration had more pronounced protecting effect from learning and memory impairment 
induced by AlCl3 than each one alone. Caffeine and nicotine co-administration also prevented 
neuronal degeneration in the hippocampus and the eosinophilic plagues in the striatum induced by 
AlCl3 while nicotine alone showed mild gliosis in striatum. The marked protection of caffeine and 
nicotine co-administration was also confirmed by the significant increase in TAC and SOD and 
decrease in MDA and AChE in brain tissue. Co-administration of caffeine and nicotine reduced the 
risk of neuronal degeneration in the hippocampus and attenuated the impairment of learning and 
memory associated with AD16. 
Jayant et al., 2016 investigated the ameliorative role of selective modulator of cannabinoid receptor 
type 2 (CB2), 1-phenylisatin in experimental AD condition. Intra cerebro ventricular (i.c.v.) 
administration of streptozotocin (STZ) and AlCl3+d-galactose were given to animals. Morris water 
maze (MWM) and attentional set shifting test (ASST) were used to assess learning and memory. 
Hematoxylin-eosin and Congo red staining were used to examine the structural variation in brain. 
Brain oxidative stress (thiobarbituric acid reactive substance and glutathione), nitric oxide levels 
(nitrites/nitrates), AChE activity, myeloperoxidase and calcium levels were also estimated. i.c.v. STZ 
as well as AlCl3+d-galactose have impaired spatial and reversal learning with executive functioning, 
increased brain oxidative and nitrosative stress, cholinergic activity, inflammation and calcium levels. 
Furthermore, these agents have also enhanced the burden of Aβ plaque in the brain. Treatment with 
1-phenylisatin and donepezil attenuated i.c.v. STZ as well as AlCl3+d-galactose induced impairment 
of learning-memory, brain biochemistry and brain damage. Hence, this study concludes that CB2 
receptor modulation can be a potential therapeutic target for the management of AD168. 
Kiuji et al., 2016 explored the neuroprotective effect of CA on chronic aluminium chloride (AlCl3) 
exposure induced neurotoxicity in rat brain regions (cerebral cortex, striatum, hypothalamus and 
hippocampus). Wistar albino rats were segregated into four groups: group 1-control rats, group 2- 
rats received AlCl3 (300 mg/kg b.w. every day orally) for 60 days, rats in group 3-received CA (500 
mg/kg b.w. orally) and group 4 rats were initiated with both AlCl3 and CA treatment. Administration 
of AlCl3 developed behavioral deficits, triggered lipid peroxidation (LPO), compromised 
acetylcholine esterase (AChE) activity, and reduced the levels of superoxide dismutase (SOD), 
catalase (CAT), reduced glutathione (GSH) and glutathione-S-transferase (GST) and caused 
histologic aberrations. AlCl3–induced alterations in the activities of SOD, CAT, GSH and GST, levels 
of LPO, activity of AChE, behavioral deficits and histologic aberrations were attenuated on treatment 
with CA. Results of the study demonstrate neuroprotective potential of CA against AlCl3- induced 
oxidative damage and cognitive dysfunction169. 
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de Vargas et al., 2016 evaluated the in vitro antioxidant and anti-peroxidases potential of the ethanol 
extracts of five plants from the Brazilian Amazon. 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, 2,2’-
azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assay, superoxide anion radical, singlet 
oxygen and the β-carotene bleaching methods were employed for characterization of free radical 
scavenging activity and total polyphenols were determined. Antioxidant activities were evaluated 
using murine fibroblast NIH3T3 cell. The stem bark extracts of Calycophyllum spruceanum and 
Mytella guyanensis provided the highest free radical scavenging activities. C. spruceanum exhibited 
IC50 = 7.5 ± 0.9, 5.0 ± 0.1, 18.2 ± 3.0 and 92.4 ± 24.8 μg/mL for DPPH(•), ABTS(+•), O2 (-•) and O2 
assays, respectively. Ptychopetalum olacoides and C. spruceanum extracts also inhibited free 
radicals formation in the cell-based assay. At a concentration of 100 μg/mL, the extracts of C. 
spruceanum, Byrsonima japurensis inhibited horseradish peroxidase by 62 and 50 %, respectively. 
C. spruceanum, M. guyanensis, B. japurensis also inhibited myeloperoxidase in 72, 67 and 56 %, 
respectively170. 
Kasbe et al., 2016 studied protective effect of mangiferin against AlCl3-induced neurotoxicity and 
cognitive impairment in male Swiss albino mice. AlCl3 (100 mg/kg) was administered once daily 
through oral gavage for 42 days. Mangiferin (20 and 40 mg/kg, p.o.) was given to mice for last 21 
days of the study. Cognitive dysfunction in AlCl3-treated group was assessed by Morris water maze 
test, and novel object recognition test. AlCl3-treated group showed elevated level of oxidative stress 
markers, proinflammatory cytokines level and lowered hippocampal brain-derived neurotrophic 
factor (BDNF) content. Mangiferin (40 mg/kg) prevented the cognitive deficits, hippocampal BDNF 
depletion, and biochemical anomalies induced by AlCl3-treatment. Mangiferin offered 
neuroprotection in AlCl3-induced neurotoxicity and reduced oxido-nitrosative stress and 
inflammation-associated neurotoxicity171. 
Li et al., 2016 explored the therapeutic effect of ginseng protein (GP) on Alzheimer's disease and its 
correlation with the PI3K/Akt signaling pathway to understand the mechanism underlying the 
neuroprotective effect of ginseng. The expression of mRNAs and proteins of PI3K, Akt, 
phosphorylated Akt (p-Akt), Bcl-2, and Bax in the hippocampus was detected by real-time 
quantitative reverse transcription polymerase chain reaction and Western blot assay. GP was found 
to significantly improve the memory ability of AD rats and prolong the times of crossing the platform 
and the percentage of residence time in the original platform quadrant of spatial probe test. GP also 
reduced the content of Aβ1-42 and p-tau and improved the mRNA and protein expression of PI3K, 
p-Akt/Akt, and Bcl-2/Bax in the hippocampus. GP improved the memory ability and reduced the 
content of Aβ1-42 and p-tau in AD rats. The anti-AD effects of GP were in part mediated by PI3K/
Akt signaling pathway activation172. 
Mahboob et al., 2016 evaluated the neuroprotective effect of alpha-lipoic acid (ALA) in AlCl3-
induced neurotoxicity mouse model. Effect of ALA (25mg/kg/day) was evaluated in the AlCl3-
induced neurotoxicity (AlCl3 150 mg/kg/day) mouse model on learning and memory using behaviour 
tests and on the expression of muscarinic receptor genes (using RT-PCR), in hippocampus and 
amygdala. ALA enhanced fear memory (p>0.01) and social novelty preference (p>0.001) 
comparative to the AlCl3-treated group. Fear extinction memory was remarkably restored (p>0.001) 
in ALA-treated group demonstrated by reduced freezing response as compared to the AlCl3-treated 
group which showed higher freezing. In-silico analysis showed that racemic mixture of ALA has 
higher binding affinity for M1 and M2 compared to acetylcholine. These novel findings highlight the 
potential role of ALA in cognitive functions and cholinergic system enhancement thus presenting it 
an enviable therapeutic candidate for the treatment of neurodegenerative disorders173. 
Prema et al., 2016 explored the neuroprotective effect of fenugreek seed powder (FSP) against 
AlCl3-induced experimental AD model. Administration of germinated FSP (2.5, 5 and 10% mixed 
with ground standard rat feed) protected AlCl3 induced memory and learning impairments, Al 
overload, AChE hyperactivity, amyloid β (Aβ) burden and apoptosis via activating Akt/GSK3β 
pathway. Further these results could lead a possible therapeutics for the management of 
neurodegenerative diseases including AD in future12. 
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Huma et al., 2013 analyzed thirteen plant-derived alkaloids, namely pleiocarpine, kopsinine, 
pleiocarpamine, oliveroline, noroliveroline, liridonine, isooncodine, polyfothine, darienine and 
eburnamine, eburnamonine, eburnamenine and geissoschizol for their anti-cholinergic action 
through docking with AChE as target. Among the alkaloids, pleiocarpine showed promising anti-
cholinergic potential, while its amino derivative showed about six-fold higher anti-cholinergic 
potential than pleiocarpine. Pleiocarpine and its amino derivative were found to be better inhibitors 
of AChE, as compared to commonly used drugs tacrine and rivastigmine, suggesting development 
of these molecules as potential therapeutics in future174. 
Lakshmi et al., 2015 evaluated the effect of selenium on AlCl3-induced Alzheimer's disease in rats. 
The animals showed increase in time to reach platform in Morris water maze and decreased step-
down latencies in passive avoidance test indicating learning and memory impairment in AlCl3-
treated group, but administration of selenium decreased time to reach platform in Morris water 
maze, increased step-down latencies, and strengthened its memory action in drug-treated animals. 
There was decrease in muscle strength measured by rotarod test indicating motor incoordination 
and decrease in locomotor activity assessed by actophotometer test in AlCl3 control group, whereas 
in selenium-AlCl3 group, there was improvement in muscle strength and locomotion. Biochemical 
analysis of the brain revealed that chronic administration of AlCl3 significantly increased lipid 
peroxidation and decreased levels of AChE, catalase, reduced glutathione and glutathione 
reductase, an index of oxidative stress process. Administration of selenium attenuated lipid 
peroxidation and ameliorated the biochemical changes. There were marked changes at subcellular 
level observed by histopathology studies in AlCl3 group, and better improvement in these changes 
was observed in selenium + AlCl3 group. Therefore, this study strengthened the hypothesis that 
selenium helped to combat oxidative stress produced by accumulation of AlCl3 in the brain and 
helped in prophylaxis of Alzheimer's diseases175. 
Thippeswamy et al., 2013 evaluated the synergistic activity of Bacopa monniera with rivastigmine 
against AlCl3-induced cognitive impairment in rats. Chronic administration of AlCl3 caused 
significant memory impairment associated with increased RL in the Morris water maze task and 
increased TL in the elevated plus maze test. Interestingly, animals treated with oral administration of 
B. monniera (100 and 200 mg/kg), rivastigmine (5 mg/kg) or a combination of B. monniera (100 mg/
kg) with rivastigmine (5 mg/kg) showed significant protection against AlCl3-induced memory 
impairment compared to animal treated with AlCl3 alone. Additionally, the neuroprotective effect of 
B. monniera (100 and 200 mg/kg) was significantly improved when supplemented with rivastigmine 
(5 mg/kg). These findings suggest that treatment with a combination of B. monniera with 
rivastigmine highly beneficial compared to their AlCl3 alone treated animals176. 
Thirunavukkarasu et al., 2012 examined the neuroprotective effect of Manasamitra vatakam (MMV) 
against aluminum (Al)-induced memory impairment and oxidative damage in rats. Neurotoxicity was 
induced by the administration of Al [100 mg/kg body weight (b.w.) per oral (p.o.)/day] to Wistar 
albino rats for 90 days. It was observed that the administration of MMV (100 mg/kg b.w./p.o./day) 
along with AlCl3 improved memory performance and antioxidant activity against Al-induced 
neurotoxicity in rats. These data suggest that MMV can prevent brain damage from Al-induced 
neurotoxicity in rats and thus can be used as a neuroprotective agent177. 
Kumar et al., 2011 explored the possible role of carvedilol, an adrenergic antagonist against AlCl3-
induced neurotoxicity in rats. AlCl3 (100 mg/kg) administered daily for six weeks, significantly 
increased cognitive dysfunction in the Morris water maze and oxidative damage as indicated by a 
rise in lipid peroxidation and nitrite concentration and depleted reduced glutathione, superoxide 
dismutase, catalase and glutathione S-transferase activity compared to sham treatment. Chronic 
aluminium chloride treatment also significantly increased acetylcholinesterase activity and the 
aluminium concentration in brain compared to sham. Chronic administration of carvedilol (2.5 and 5 
mg/kg, po) daily to rats for a period of 6 weeks significantly improved the memory performance 
tasks of rats in the Morris water maze test, attenuated oxidative stress (reduced lipid peroxidation, 
nitrite concentration and restored reduced glutathione, superoxide dismutase, catalase and 
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glutathione S-transferase activity), decreased acetylcholinesterase activity and aluminium 
concentration in aluminium-treated rats compared to control rats (p > 0.05). Results of this study 
demonstrated the neuroprotective potential of carvedilol in aluminium chloride-induced cognitive 
dysfunction and oxidative damage178. 
Butler et al., 2010 tested tubastatin A, in primary cortical neuron cultures in which it was found to 
induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity. 
Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against 
glutathione depletion-induced oxidative stress. Importantly, when given alone at all concentrations 
tested, this hydroxamate-containing HDAC6-selective compound displayed no neuronal toxicity, 
thus, forecasting the potential application of this agent and its analogues to neurodegenerative 
conditions179. 
Bihaqi et al., 2009 investigated neuroprotective effects of aqueous extract from Convolvulus 
pluricaulis (CP) against AlCl3-induced neurotoxicity in rat cerebral cortex. Daily administration of CP 
(150 mg/kg) for 3 months along with AlCl3 (50 mg/kg) decreased the elevated enzymatic activity of 
AChE and also inhibited the decline in Na+/K+ATPase activity which resulted from aluminium intake. 
Oral administration of CP preserved the mRNA levels of muscarinic receptor 1 (M1 receptor), 
choline acetyltransferase (ChAT) and Nerve growth factor-tyrosine kinase A receptor (NGF-TrkA). 
The potential of CPE to inhibit aluminium induced toxicity was compared with rivastigmine tartrate (1 
mg/kg), which was taken as standard. The potential of the extract to prevent aluminium-induced 
neurotoxicity was also reflected at the microscopic level, indicative of its neuroprotective effects. C. 
pluricaulis possesses neuroprotective potential, thus validating its use in alleviating toxic effects of 
aluminium180. 
Kumar et al., 2009 demonstrated the protective effect of chronic curcumin administration against 
aluminium-induced cognitive dysfunction and oxidative damage in rats. AlCl3 (100 mg/kg, p.o.) was 
administered to rats daily for 6 weeks. Rats were concomitantly treated with curcumin (per se; 30 
and 60 mg/kg, p.o.) daily for a period of 6 weeks. On the 21st and 42nd day, behavioral studies to 
evaluate memory (Morris water maze and elevated plus maze task) and locomotion 
(actophotometer) were done. The rats were sacrificed on 43rd day following the last behavioral test 
and various biochemical tests were performed to assess the extent of oxidative damage. Chronic 
aluminium chloride administration resulted in poor retention of memory in Morris water maze, 
elevated plus maze task paradigms and caused marked oxidative damage. It also caused a 
significant increase in the acetylcholinesterase activity and aluminium concentration in aluminium 
treated rats. Chronic administration of curcumin significantly improved memory retention in tasks, 
attenuated oxidative damage, AChE activity and aluminium concentration in aluminium treated rats 
(P > 0.05). Curcumin has neuroprotective effects against aluminium-induced cognitive dysfunction 
and oxidative damage181. 
3. AIM & OBJECTIVES 
In the light of literature review, the study was aimed to evaluate the possible neuroprotective effects 
of commercially available flavonoids using in silico, in vitro and in vivo approaches. 
The objectives of the present study are to 
• Evaluate drug likeness properties of the flavonoids 
• Carry out in silico docking studies of the selected flavonoids using AutoDock 4.2 
• Perform in vitro AChE and BuChE enzyme inhibitory assay for the selected flavonoids 
• Carry out the acute toxicity studies for the selected flavonoids 
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• Assess the selected flavonoids against scopolamine and aluminium chloride induced Alzheimer 
models 
• Carry out various behavioural studies using selected flavonoids using in vivo models 
• Explore the biochemical alterations after induction of learning impairment and correction of 
biochemical parameters after drug treatment. 
• Perform histopathological studies to corroborate the results of in vivo studies. 
• To correlate the results obtained using statistical tools using GraphPad Prism software. 
4. PLAN OF WORK 
STEP I 
Selection of flavonoids and determination of acetylcholinesterase inhibitory activity. 
STEP II 
Determination of drug likeness score by using MedChem Designer software. 
STEP III 
To carry out the molecular docking studies using AutoDock 4.2 against AChE and BuChE based on 
the bioactive score. 
STEP IV 
Selection of flavonoids based on their docking score and drug likeness properties. 
STEP V 
In vitro screening of selected flavonoids by AChE and BuChE inhibitory assay. 
STEP VI 
Acute toxicity studies following OECD guidelines-420 (fixed dose procedure) for selected flavonoids 
based on the in vitro results. 
STEP VII 
In vivo screening of the flavonoids by acute scopolamine-induced learning impairment in mice. 
STEP VIII 
In vivo screening of the flavonoids by chronic aluminium chloride-induced learning impairment in 
mice. 
STEP IX 
Assessment of neuroprotective activity using various behavioral experiments. 
STEP X 
Dissection and preparation of tissue homogenates using brain for biochemical estimations. 
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STEP XI 
Histopathological studies for both scopolamine and aluminium chloride-induced models. 
STEP XII 
Tabulation, compilation of results and statistical analysis of data obtained. 
Scopolamine-induced amnesia Aluminium Chloride-induced amnesia 
Fig.13 Schematic representation of the plan of work 
5. MATERIALS AND METHODS 
5.1 Evaluation of drug likeness properties 
The pharmacologically active substituents are characterized by calculating steric, hydrophobic, 
electronic, and hydrogen bonding properties as well as by the drug-likeness score. The theory of 
drug-likeness score helps to optimize pharmaceutical and pharmacokinetic properties, for example, 
chemical stability, solubility, distribution profile and bioavailability. The molecular descriptors have 
developed as rationally predictive and informative, for example, the Lipinski's Rule-of-Five182. 
The better oral absorption of the ligands and drug likeness scores are constructed by getting 
information about the solubility, diffusion, log P, molecular weight etc. The theory of drug-likeness 
score helps to optimize pharmaceutical and pharmacokinetic properties. Lipinski’s rule of five 
describes the important molecular properties required for the drug’s pharmacokinetics183. Lipinski’s 
rule states that, the drug to have good pharmacokinetic profile, should not have more than one 
violation of the following criteria: 
• Not more than 5 hydrogen-bond donors 
• Not more than 10 hydrogen-bond acceptors 
• Molecular weight should be less than 500 daltons 
• The partition coefficient (log P) not greater than 5 
Two hundred and forty five flavonoids were evaluated for their pharmacokinetic profile based on 
Lipinski’s rule of five using MedChem Designer software. 
5.1.1 Lipinski’s rule of five calculations 
• Open the MedChem designer home page. 
• Click calculation of molecular properties of drug likeness 
• Draw the structure of flavonoids in the active window. 
• Click and calculate properties. 
• Save the properties. 
5.2 In silico docking binding interaction studies 
5.2.1 Softwares used 
• AutoDock 4.2 which combines 
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➢ AutoDock Tools 1.5.4 
➢ Python Molecule Viewer 1.5.4 
➢ Vision 1.5.4 
• Python 2.7 
• Cygwin 
• Accerlys discovery studio viewer 
• ChemSketch 
• RCSB protein data bank 
• Online SMILES translator 
5.2.2 In silico docking study on AChE enzyme using AutoDock 4.2 
5.2.2.1 Identification of target enzyme and selection of flavonoids and related compounds 
The crystal structures of acetylcholinesterase (AChE) (PDB ID: 5HCU) and butyrylcholinesterase 
(BuChE) (PDB ID: 4BDS) were obtained from the research collaboratory for structural bioinformatics 
(RCSB) protein data bank and refined proteins were further used for in silico studies. 
Fig. 14 Refined crystal structure of mouse acetylcholinesterase (5HCU) 
A total of 245 flavonoids were taken for the study and the structures were drawn using ChemSketch 
and optimized using “Prepare Ligands” in the AutoDock 4.2 for docking studies184. 
Fig. 15 Human butyrylcholinesterase in complex with tacrine (4BDS) 
5.2.2.2 Docking studies for the selected flavonoids185 
Step I - Protein structure refinement 
The proteins downloaded from PDB have to be refined for docking. The steps involved in the protein 
structure refinement are, 
• Open Accelrys discovery studio viewer 
• Select Target protein PDB file 
• Click View, and then click Hierarchy. 
• Click water molecules 
• Ctrl + shift and click the last water molecule (select all water molecules) 
• Give right click and cut 
• Select ligand, which is unnecessary, give right click and cut. 
• Save the molecule in our desired area. 
Step II - Ligand file format conversion 
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• The ligands which are desired are drawn in Chem Sketch. 
• Select tools and click generate, finally click SMILES notation [simplified molecular input line entry 
system, which is a file format] 
• Save the SMILES in a word document 
• Open the online smiles translator – cactus.nci.nih.gov/services/translate/ 
• Upload the SMILES. 
• By choosing the required file format we can save the file (pdb file). 
Online smiles translator allows the user to convert SMILES format into PDB, MOL, SDF and smile 
text file format. Thus the selected ligand molecule of canonical smile formats was converted to pdb 
formats. The protein and ligand files which are prepared by above said procedures are selected for 
docking. 
Step III - Docking with AutoDock 4.2 
Docking calculation in AutoDock 4.2 was performed using the refined protein and the desired ligand 
in pdb format. 
Preparing the protein 
• At first give the right click on the PMV molecules for to open the file. 
• Choose the particular refined enzyme file. 
• Click under atom to give color to the atoms. 
• The elimination of the water is carried by the following steps. 
• press select option 
• click select from string option 
• then write HOH* in the residue line & * in the atom line 
• click add and then dismiss. 
• After that click edit option and delete and then delete atom set. 
• Addition of hydrogens is take placed by, 
• Press edit option 
• Click the hydrogens 
• Then click add 
• Finally choose hydrogens and no bond order, and finally yes to renumbering. 
• Next add the Kollmann charges which is present in the edit option 
• For to hide the protein click on the gray under show molecules. 
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Preparing the ligand 
• Confirm that all the hydrogens are added in the ligand. 
• Toggle the Autodock tools button 
• For to open the ligand file press the Input option and click open and then all files finally choose the 
suitable ligand file and finally open 
• AutoDock tools itself computes Gasteiger charges, and merges nonpolar hydrogens, and finally 
assigns AutoDock type to each atom. 
• The torsions are designed by following steps, 
• In the ligand option select torsion tree 
• Select detect root option 
• Click torsion tree 
• Then select the choose torsions option 
• Amide bonds should not be active. 
• After that click the torsion tree and select set number of torsions. 
• Number of rotatable bonds is choosen. 
• Finally save the ligand files by selecting the output option (pdbqt file). 
• Hide the ligand. 
Conversion of pdb files of protein into pdbqt file 
• Select the grid option and open the macromolecule pdb file 
• AutoDock adds the charges and itself merges the hydrogens. 
• Save the object as pdbqt in desired area. 
Running AutoGrid Calculation (glg file) 
• Open the grid and click macromolecule option and choose the rigid protein then yes to preserve 
the existing charges. 
• The preparation of grid parameter file is carried out by, 
• Open grid 
• Select the set map types 
• Choose ligand 
• Accept it. 
• Setting of grid properties 
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• Open grid 
• Select the grid box 
• Set the proper grid dimensions 
• Adjust the spacing 
• Select the file and click close saving current. 
• Save the grid settings as gpf file in the output option (gpf file). 
• Make sure the AutoGrid is in the same directory as like of the other input files. 
• Select the run option and click run AutoGrid for to launch. 
• It will be saved as glg file. 
Running AutoDock (dlg file) 
• The rigid molecule specification is carried out by, 
• Select the docking option 
• Click the macromolecule 
• Set rigid file name. 
• The ligand specification is carried out by, 
• Click the docking option 
• Select the ligand 
• And then accept it. 
• In the next step, click docking option and select search parameters in that click genetic algorithm 
and finally accept it. 
• In the docking options select docking parameters and choose the defaults. 
• After that, in the docking option clicks output and adds Lamarckian genetic algorithm. 
• The confirmation is required that whether all the files (macromolecule, ligand, gpf, dpf ) are in the 
same directory. 
• Finally select the run command and click run AutoDock and then launch. 
Step IV - Viewing docking results 
Reading the docking log file .dlg 
• Toggle the AutoDock tools button 
• Click analyze and dockings then open it. 
• In the next step, click analyze option and conformations then load. 
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• Double click on the conformation for to view it. 
Visualizing docked conformations 
• Click analyze and dockings then play. 
• Load dlg file 
• Choose the suitable conformations 
• In the next step, click analyze and docking then show interactions. 
Obtaining snap shots of docked pose 
• Open the file and read the molecule 
• Open analyze option click dockings and open dlg file 
• Open analyze option click macromolecule and choose pdbqt file. 
• Open analyze option click conformations and load 
• Double click the desired conformation 
• In the next step, click analyze and docking then show interactions. 
Lamarckian genetic algorithm (LGA) for ligand conformational searching is used for the docking, 
which is a hybrid of genetic algorithm and local search algorithm. This algorithm first builds a 
population of individuals, each being a different random conformation of the docked molecule. Each 
individual is then mutated to acquire a slightly different translation and rotation and the local search 
algorithm then performs energy minimizations on a user-specified proportion of the individuals. The 
individuals with the low resulting energy are transferred to the next generation and the process is 
then repeated. The algorithm is called lamarckian genetic algorithm because every new generation 
of individuals is allowed to inherit the local search adaptations of their parents186. 
The preparation of the target protein 5HCU and 4 BDS with the AutoDock tools software involved 
adding all hydrogen atoms to the macromolecule, which is a step necessary for correct calculation 
of partial atomic charges (Calderone et al. 2000). Gasteiger charges are calculated for each atom of 
the macromolecule in AutoDock 4.2 instead of kollman charges which were used in the previous 
versions of the program. Three-dimensional affinity grids of size 277 × 277 × 277 Å with 0.6 Å 
spacing were centered on the geometric center of the target protein and were calculated for each of 
the following atom types: HD, C, A, N, OA, and SA, representing all possible atom types in a protein. 
Additionally, an electrostatic map and a desolvation map were also calculated187. 
Rapid energy evaluation was achieved by precalculating atomic affinity potentials for each atom in 
the ligand molecule. In the AutoGrid procedure, the target enzyme was embedded on a three 
dimensional grid point. The energy of interaction of each atom in the ligand was encountered. The 
selected important docking parameters for the LGA as follows: population size of 150 individuals, 
2.5 million energy evaluations, maximum of 27000 generations, number of top individuals to 
automatically survive to next generation of 1, mutation rate of 0.02, crossover rate of 0.8, 10 docking 
runs, and random initial positions and conformations. The probability of performing local search on 
an individual in the population was set to 0.06. AutoDock was run several times to get various 
docked conformations, and used to analyze the predicted docking energy. The binding sites for 
these molecules were selected based on the ligand-binding pocket of the templates. AutoDock Tools 
provide various methods to analyze the results of docking simulations such as, conformational 
similarity, visualizing the binding site and its energy and other parameters like intermolecular energy 
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and inhibition constant. For each ligand, ten best poses were generated and scored using AutoDock 
4.2 scoring functions188. 
5.3 REAGENTS AND CHEMICALS 
Donepezil, acetylcholinesterase, butyrylcholinesterase, apigenin, baicalein, catechin, chrysin, 
diosmin, epigallocatechin, hesperetin, hesperidin, kaempferol, morin, myrecetin, naringenin, 
robinetin, rutin, scopoletin, silibinin, taxifolin, tetra hydroflavone, theaflavin and tricetin were 
purchased from Sigma Aldrich, St. Louis, MO. All other drugs and chemicals used in the study were 
obtained commercially and were of analytical grade. Bovine serum albumin (BSA), p-nitro 
benzaldehyde, p- fluro benzaldehyde, p-chloro benzaldehyde, p-methyl benzaldehyde, p-methoxy 
benzaldehyde, p-hydroxy benzaldehyde ethanol, potassium phosphate, Folin phenol reagent, 5,5'-
dithiobis-2-nitro benzoic acid, acetylthiocholine iodide, carboxy methyl cellulose and tris 
hydrochloride were purchased from Hi Media Laboratories, Mumbai. Sodium thiosulphate, sodium 
hydroxide, hydrochloric acid, sodium potassium tartarate, sodium carbonate, copper sulphate, 
hydrogen peroxide, potassium dichromate, glacial acetic acid and sodium citrate were purchased 
from SD Fine chem limited, Mumbai. Scopolamine and aluminium chloride were purchased from 
Sigma Aldrich, USA. All other chemicals and solvents used were of AR grade. 
5.4 INSTRUMENTS USED 
Digital Balance (Sartorius Ltd., USA), Eppendorff minispin, incubator (Technico), Jasco FTIR-420 
series, Mass spectrometer, Shimadzu-Jasco V-530 UV/Vis spectrophotometer, ELCO 1/27 pH 
meter. 
5.5 In vitro enzyme inhibition assay 
5.5.1 In vitro acetylcholinesterase inhibition 
Based on in silico results, twenty compounds were selected for their AChE inhibitory activities189. 
About 1.3 ml of the Tris-HCl buffer (pH 8.0; 50 mM) was treated with 0.4 ml of different 
concentrations (2 to 128 µg/ml) of the compounds and 0.1 ml of the AChE (0.28 U/ml) was added. 
This mixture was incubated for 15 minutes and 0.3 ml of acetylthiocholine iodide (0.023mg/ml) and 
1.9 ml (5,5'-dithiobis-(2-nitrobenzoic acid) DTNB (3 mM) solution were added. This final reaction 
mixture (4.0 ml) was kept for further incubation 
0: Lubhan Singh.doc 71% 
1: Lubhan Singh With references.doc 71% 
2: Lubhan Singh without references.doc 71% 
at room temperature for 30 minutes and the absorbance of the reaction mixture was measured at 
405 nm. 
The assay was done in triplicate and the results were expressed as mean±SEM. Donepezil was 
used as standard190. The percentage inhibition was calculated for the selected flavonoids using the 
following formula, 
A0= Absorbance of the control 
A1= Absorbance of the standard/compounds. 
43
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
5.5.2 In vitro butyrylcholinesterase inhibition 
In our work, 20 flavonoids were examined for their BuChE inhibitory activities at various 
concentrations (1 to 128 µg/ml) and were dissolved in 1.3 ml of the Tris-HCl buffer (pH 8.0; 50 mM) 
following the spectrophotometric method189. In this method, 0.1 ml of the BuChE (0.377 U/ml) 
solution were added to the initial mixture, to start the reaction and then the absorbance was 
determined. 0.3 ml of s-butyrylthiocholine iodide (1.5 mM) and 1.9 ml DTNB (3 mM) solution and 0.4 
ml of drug solution at the different concentrations evaluated, which were mixed and incubated for 15 
min at 30ºC. Then, the mixture was monitored spectrophotometrically at 405 nm. The control 
sample contained all components except the test compounds and rivastigmine was used as 
standard190. The percentage of BuChE inhibitory activity was calculated by using the following 
equation: 
A0 = Absorbance of the control 
A1 = Absorbance of the standard/ compounds. 
5.6 ACUTE TOXICITY STUDIES 
5.6.1 Experimental animals 
Acute toxicity studies were performed for the baicalein and scopoletin according to organization for 
economic co-operation and development (OECD) guidelines 420 (fixed dose procedure) 191. 
Healthy young adult female rats (200-250 g) used for the acute toxicity studies were procured from 
Kerala Veterinary and Animal Sciences University, Mannuthy, Thrissur, Kerala, India. Animals were 
8-12 weeks old and weight was not deviated from ± 20%. CPCSEA approval number for 
experimental protocols for the toxicological studies was COPSRIPMS/IAEC/PhD/P’CHEMISTRY/ 
03/ 2012-2013. 
5.6.2 Acute toxicity study procedure 
Due to absence of toxicity information for flavonoids, in the sighting study, one animal was 
administered with 5 mg/kg dose and in the absence of toxicity 50mg/kg dose was given to second 
animal to check for toxicity. If no mortality was observed for 50mg/kg dose then the next dose of 300 
mg/kg was given to third animal and if no mortality was observed then the fourth animal was 
administered with 2000 mg/kg dose. If no mortality was observed for upper dose limit of 2000 mg/
kg, then the specific dose was selected for main study. Keen observations were done to determine 
the onset of signs, onset of recovery and time to death. 
In main study a total of 5 animals of one sex was used. The 5 animals would be made of one animal 
from the sighting study dosed at the selected dose level together with an additional four animals. 
Dose of 2000 mg/kg dose of the drug was administered and food was withheld for further 3-4 hours. 
0: Thesis Final Work 27062017.docx 71% 
Animals were observed individually at least once during the first 30 minutes after dosing, 
periodically during the first 24 hours (with special attention during the first 4 hours) and daily 
thereafter for a 
period of 14 days. Once daily cage side observations included changes in skin and fur, eyes and 
mucous membrane (nasal), and also changes in respiratory rate, circulatory parameters (heart rate 
and blood pressure), autonomic parameters (salivation, lacrimation, perspiration, piloerection, 
urinary incontinence and defecation) and CNS parameters (ptosis, drowsiness, gait, tremors and 
convulsions)192. 
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5.7 IN VIVO EXPERIMENTAL DESIGN 
5.7.1 Experimental animals 
Male swiss albino mice (20-25 g) were procured from Kerala Veterinary and Animal Sciences 
University, Mannuthy, Thrissur, Kerala, India. Animals were fed with commercial pellet diet and 
drinking water ad libitum and maintained at an ambient temperature of 22 ± 2°C with a 12-h light: 
dark cycle. The experiments were conducted in accordance with guidelines of Institutional animal 
ethical committee (IAEC) governed 
0: Thesis Final Work 27062017.docx 100% 
by Committee for the Purpose of Control and Supervision of Experiments on Animals ( 
CPCSEA) guidelines, Government of India. All the readings were taken during the same time of the 
day that is between 10.00 am and 2.00 pm. CPCSEA approval number for experimental protocols 
for the pharmacological studies was COPSRIPMS/IAEC/PhD/P’CHEMISTRY/ 03/ 2012-2013. 
5.7.2 In vivo scopolamine-induced amnesia model 
Animals were classified into six groups (n=6, Swiss albino mice). Treatments were given p.o. for 
seven successive days. Group I served as control received only normal saline (10ml/kg). Animals in 
group II were treated with baicalein (100 mg/kg/day) and group III mice were treated with baicalein 
(200 mg/kg/day). Animals in group IV received scopoletin (100 mg/kg/day) and group V mice were 
administered with scopoletin (200 mg/kg/day). Group VI mice were treated with donepezil (5 mg/kg, 
p.o.). For all the groups, treatments were given for 7 consecutive days. One hour after the last dose 
of test agents, all animals were i.p. injected with scopolamine hydrobromide (1 mg/kg) except the 
control group193. The values for the negative control group were taken from archives163. The 
neuroprotective effects of the selected flavonoids were studied using various behavioral 
assessments such as rectangular maze test, Morris water maze, gross behavioral activity, 5 choice 
serial reaction time task and pole climbing test during the treatment period. 
On day 8, after behavioral assessments, animals were sacrificed by excess of anesthesia. The brain 
was removed and each brain had been separately kept after rinsing with ice-cold isotonic saline. A 
(10% w/v) homogenate was prepared with 0.1 M phosphate buffer (pH 7.4) and centrifuged at 
3000 rpm for 15 minutes and aliquots of supernatant had separated and used for the various 
biochemical estimations {cholinesterase activity, protein estimation, enzymatic (Catalase activity, 
2,2-diphenyl-1-picrylhydrazyl assay, superoxide dismutase assay, glutathione reductase, glutathione 
peroxidase) and non-enzymatic antioxidant activities (reduced glutathione) and lipid peroxidation 
indices with thiobarbituric acid reactive substances assay}. 
5.7.3 Aluminium-induced learning impairment 
Swiss albino mice were divided into 6 different groups, each comprising of six animals. Group I 
served as control which received normal saline. In group II mice were treated with baicalein (100 
mg/kg/day) and group III were administered with baicalein (200 mg/kg/day). In group IV mice 
received scopoletin (100 mg/kg/day), group V received scopoletin (200 mg/kg/day). Group VI mice 
were treated with donepezil (5 mg/kg, p.o.) for 3 months. All the groups were treated for a period of 
3 months. Groups III to VII received Aluminum chloride (AlCl3) dissolved in water at a dose of 50 
mg/kg/day194, 195, for a period of 3 months. The values for the negative control group were taken 
from archives. The values for the negative control group were taken from archives18. The effects of 
the selected flavonoids were studied using various behavioral assessments such as rectangular 
maze test, Morris water maze, gross behavioral activity, 5 choice serial reaction time task and pole 
climbing test during the treatment period. 
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After treatment period, animals were sacrificed by excess of anesthesia. The brain of the each 
animal was removed and rinsed with ice-cold isotonic saline. A (10% w/v) homogenate was 
prepared with 0.1 M phosphate buffer (pH 7.4) and centrifuged at 3000 rpm for 15 minutes and 
aliquots of supernatant separated and used for various biochemical estimations {cholinesterase 
activity, protein estimation, enzymatic (Catalase activity, 2,2-diphenyl-1-picrylhydrazyl assay, 
superoxide dismutase assay, glutathione reductase, glutathione peroxidase} and non-enzymatic 
antioxidant activities (reduced glutathione) and lipid peroxidation by thiobarbituric acid reactive 
substances assay}. 
5.8 BEHAVIORAL ASSESSMENTS 
5.8.1 Rectangular maze test 
The maze consists of completely enclosed rectangular box with an entry and reward chamber 
partitioned with wooden slots into blind passages leaving just twisting corridor leading from the entry 
to the reward chamber (Fig. 16). All the mice were familiarized with the rectangular maze. Well 
trained animals were taken for the experiment. The time taken for the mouse to reach the reward 
chamber was taken as the transfer latency. Lower scores of assessment indicate efficient learning 
while higher scores indicate poor learning in animals. The time taken by the animals to reach the 
reward chamber from the entry chamber was tabulated196. All the values were calculated in 
seconds. 
Fig. 16 Rectangular maze 
5.8.2 Morris water maze test 
This test was carried out in circular pool (150 cm in diameter and 60 cm in height) of water with ten 
centimeter hidden platform (Fig. 17). In the water maze experiments, the day prior to the experiment 
the animals were trained to swim for 60 s in the absence of the platform. In the following days, the 
mice were given the trial session each day for four consecutive days. During each trial, the escape 
latencies of mice were recorded. The point of entry of the mouse into the pool and the location of the 
platform for escape between trials changed each day thereafter. During acquisition, trial escape 
latency time (ELT), measure to locate the hidden platform, was noted as an index of acquisition. 
Escape latency time was calculated in seconds. All mice were tested for spatial memory 30 minutes 
after the last dose of the treatment197. 
Fig. 17 Morris water maze 
5.8.3 Assessment of gross behavioral activity (Locomotor activity) 
Most of the CNS drugs influence the locomotor activity in man and animals. The locomotor activity 
of drug was studied using actophotometer which operates on photoelectric cells which are 
connected in circuit with a counter (Fig. 18). When the beam of light falling on photocell was cut off 
by the animal, then a count was recorded. Animals were placed individually in the activity cage for 
10 min and the activity was monitored. The photo cell count was noted and a decrease or increase 
in locomotor activity was calculated198. 
Fig. 18 Actophotometer 
5.8.4 Pole climbing test 
This test was used to study the neuroprotective and nootropic effect of test drugs. The mice were 
trained for conditioned avoidance response (CAR) by using pole climbing apparatus. Prior to the 
experiment, animals were trained in a 25 × 25 × 40 cm chamber that was enclosed in a dim light, 
sound attenuated box (Fig. 19). Each mouse was allowed to acclimatize for 2 min and then exposed 
to a buzzer noise. After 10 sec of putting on the buzzer, mild electric shocks were given through the 
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grid floor. The magnitude of the voltage was adequate (30v) to stimulate the mice to escape from 
the floor and climb the pole. As soon as the mice climbed the pole, both the buzzer and foot-shock 
were switched off. At least 10 such trails were given to each mouse at an interval of 1 min. per day 
for 3 days. After training schedule, most of the mice learned to climb the pole within 10 sec of 
starting the buzzer to avoid the electric foot shocks. On the test days, after 2 min of acclimatization 
period, each mouse was exposed to the buzzer for 10 sec; ten such trails were given at an interval 
of 1 min, without giving any shock. Mice, responding by climbing the pole when exposed to the 
buzzer noise, were considered to have retained the conditional avoidance response198. 
Fig. 19 Pole climbing apparatus 
5.8.5 Attention in a 5 choice serial reaction time task (5-CSRT) 
The 5 choice serial reaction time task (5-CSRT) tests specific types of attention, including sustained, 
divided, and selected attention. The 5-CSRT was implemented in a specifically designed operant 
chamber with multiple response locations using light source (Fig. 20). The usual paradigm requires 
the mice to detect brief flashes of light presented in a pseudorandom order in one of five locations 
over a large number of trials. The response time of the animals were calculated in seconds199. 
Fig. 20 Five choice serial reaction time task apparatus 
5.9 BIOCHEMICAL ESTIMATIONS 
5.9.1 Estimation of AChE in mice brain 
The cholinergic marker, acetylcholinesterase, was estimated in the whole brain using Ellman 
method. Ellman’s reagent is 5,5’-dithiobis(2-nitrobenzoate) and is also abbreviated as DTNB. 
Ellman’s reagent is the mixture of 19.8 mg of DTNB in 100 ml of 0.1% sodium citrate solution. About 
0.1 ml of brain homogenate was incubated for 5 min with 2.7 ml of phosphate buffer and 0.1 ml of 
DTNB. Then, 0.1 ml of freshly prepared acetylthiocholine iodide (pH 8) was added and the 
absorbance was measured at 412 nm200. 
5.9.2 Estimation of total protein content 
The amount of total protein present in the tissue homogenate was estimated using bovine serum 
albumin as the standard. To 0.1 ml of tissue homogenate, 4.0 ml of alkaline copper tartarate solution 
was added and allowed to stand for 10 min. To the mixture 0.4 ml of phenol reagent was added 
rapidly, mixed quickly and incubated at room temperature for 30 min for colour development. 
Reading was taken against blank prepared with distilled water at 610 nm in an UV-visible 
spectrophotometer. The protein content was calculated from the standard curve prepared with 
bovine serum albumin (BSA) (1 mg/ml) and expressed as mmoles/min/mg brain tissue201. 
5.9.3 Enzymatic anti-oxidants 
5.9.3.1 Estimation of catalase 
Catalase (hydrogen peroxide oxidoreductase) enzyme is involved in the decomposition of hydrogen 
peroxide into water and oxygen molecules. Catalase activity is measured either by decomposition of 
H2O or by liberation of O2. The decrease in the absorbance by H2O2 as a function of time is used 
to follow the hydrogen-peroxide reaction. The spectral region for hydrogen peroxide is 210-240 nm. 
The difference in absorbance per minute is a measure of catalase activity. Catalase plays a major 
role in cellular antioxidant defense system by decomposing H2O2, thereby preventing the 
generation of hydroxyl radical through the Fenton reaction202. 
About 0.1 ml of tissue homogenate was added to 1.0 ml of 0.01 M phosphate buffer of pH 7.0 and 
was incubated at 37C for 15 min. The reaction was started by the addition of 0.4 ml of 2M H2O2. 
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The reaction was then stopped by the addition of 2 ml of dichromate - acetic acid reagent (a mixture 
of 5% potassium dichromate and glacial acetic acid in a ratio of 1:3). CAT was assayed 
colorimetrically at 620 nm. Unit of catalase activity is expressed as the amount of enzyme causing 
the decomposition of µmoles H2O2/mg protein/min203. 
5.9.3.2 Estimation of superoxide dismutase (SOD) 
The first enzyme involved in the antioxidant defense is superoxide dismutase. It is a metalloprotein 
found in both prokaryotic and eukaryotic cells. The oxygen-derived free radicals generated by the 
interaction of Fe2+ and H2O2 are the species responsible for the oxidation of epinephrine and they 
were strongly inhibited by the enzyme, superoxide dismutase204. 
About 0.1 ml of tissue homogenate was mixed with sodium pyrophosphate buffer, and nitroblue 
tetrazolium (NBT). 
0: Lubhan Singh.doc 83% 
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The reaction was initiated by the addition of NADH. The reaction mixture 
was incubated at 30°C for 90 seconds and it was stopped by the addition of 1 ml of glacial acetic 
acid. The absorbance of the chromogen formed was measured at 560nm. SOD activity is expressed 
as nmoles/min/mg protein205. 
5.9.3.3 Estimation of glutathione reductase (GSSH) 
The reaction mixture contained 2.1 ml of 0.25 mM potassium phosphate buffer of pH 7.6, 0.1ml of 
0.001M NADPH, 0.2 ml of 0.0165 M oxidized glutathione and 0.1 ml of bovine serum albumin (10 
mg/ml). The reaction was started by the addition of 0.2 ml of tissue homogenate with mixing and the 
decrease in the absorbance at 340 nm was measured for 3 minutes against the blank. Glutathione 
reductase activity is expressed as nmoles NADPH oxidized /min/mg protein205. 
5.9.3.4 Estimation of glutathione peroxidase (GPx) 
Glutathione peroxidase (GPx) has a major role in degrading the levels of H2O2 in cells. Since GPx 
acts on the hydroperoxides of unsaturated fatty acids, this enzyme plays an important role in 
protecting membrane lipids, and thus the cell membranes from oxidative disintegration206. 
The reaction mixture consisted of 0.2 ml of 0.4 M Tris-HCl buffer, 0.1 ml of sodium azide, 0.1 ml of 
hydrogen peroxide, 0.2 ml of glutathione and 0.2 ml of supernatant. The mixture was incubated at 
37C for 10 min. The reaction was arrested by the addition of 10 % trichloro acetic acid and the 
absorbance was measured at 340 nm. GPx activity is expressed as nmoles/min/mg protein207. 
5.9.4. Non-enzymatic antioxidants 
5.9.4.1 Estimation of reduced glutathione (GSH) 
The most widely used method for the determination of GSH in biological samples is by Ellman 
reagent (DTNB), which reacts with sulfydryl compounds to give a relatively stable yellow colour. 
About 1 ml of supernatant was treated with 0.5 ml of Ellman’s reagent (19.8 mg of 5, 5’-dithiobis-(2-
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nitro) benzoic acid (DTNB) in 100 ml of 0.1% sodium citrate solution) and 3.0 ml of 0.2 M phosphate 
buffer of pH 8.0. The absorbance was read at 412 nm using a spectrophotometer. The activity of 
GSH was expressed as nmoles/min/mg protein204. 
5.9.5 Estimation of lipid peroxidation (LPO) 
Lipid peroxidation as evidenced by the formation of malondialdehyde was measured by the method 
of Niehaus and Samuelson, 1986. About 0.1 ml of tissue homogenate was treated with 2 ml of 
(1:1:1 ratio) TBA-TCA-HCl reagent (0.37% thiobarbituric acid, 15% trichloroacetic acid and 0.25 N 
hydrochloric acid) placed in a water bath for 15 min, cooled and centrifuged at room temperature for 
10 min at 3000 rpm. The absorbance of the clear supernatant was measured against a reference 
blank at 535 nm. The values are expressed as nmoles of MDA formed /min/mg protein208. 
5.9.6 (2,2-Diphenyl-1-picrylhydrazyl) (DPPH) assay 
DPPH is a stable, nitrogen-centered free radical which produces violet colour in ethanol solution. It 
was reduced to a yellow colored product, diphenylpicryl hydrazine, with the addition of the fractions 
in a concentration-dependent manner. The reduction in the number of DPPH molecules can be 
correlated with the number of available hydroxyl groups. About 1 ml of tissue homogenate was 
mixed with 4 ml of 0.004% methanolic solution of DPPH solution. After 30 min incubation, 
absorbance was read at 517 nm. Percentage of inhibition was calculated 209. 
5.10 Histopathological studies 
Brain of animals in different groups was perfusion-fixed with 4% paraformaldehyde in 0.1 M 
phosphate buffer. The brain was removed and post fixed in the same fixative overnight. The brain 
was embedded in paraffin and stained with hematoxylin-eosin. The hippocampal lesions were 
assessed microscopically at 40 X magnification210. 
5.11 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 4.0 by 
0: Thesis Final Work 27062017.docx 90% 
One-way Analysis of Variance (ANOVA) followed by Dunnett’s test. 
Results are expressed as mean±SEM from six mice in each group. P values > 0.05 were considered 
significant. 
6. RESULTS 
6.1 Drug likeness properties of the flavonoids 
In the present study, two hundred and forty five flavonoids were identified and the structures were 
drawn with the help of MedChem designer. The drug likeness properties of the flavonoids were 
evaluated with the help of MedChem designer. All the 245 flavonoids showed excellent score 
(partition coefficient, molecular weight, hydrogen bond donors and acceptors) which indicate that 
these compounds have no violations or acceptable violations in Lipinski’s rule of 5 (Fig. 21). Based 
on the drug likeness score, all the 245 flavonoids exhibited considerable pharmacokinetic profile and 
were selected for in silico biological screening against AChE and BuChE using AutoDock 4.2. 
Fig. 21 Drug likeness properties of the flavonoids 
6.2 In silico docking studies against AChE and BuChE 
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Totally 245 flavonoids selected were subjected to in silico docking studies based on drug likeness 
properties. In the docking studies of the flavonoids, the following docking parameters such as 
binding energy, inhibition constant and intermolecular energy were evaluated against AChE and 
BuChE enzymes. The selected flavonoids showed excellent docking parameters and orientations 
when compared with the standard (donepezil) against AChE and BuChE. 
All the selected flavonoids when docked with AChE target protein showed binding energy ranging 
between -6.95 kcal/mol to -3.90 kcal/mol as compared to donepezil (standard) which showed 
binding energy of -3.87 kcal/mol (Table 1). Scopoletin and baicalein showed remarkably excellent 
binding energy (-6.95 kcal/mol and -6.93 kcal/mol) when compared to other flavonoids (Fig. 22). The 
minimum binding energy indicated that the selected flavonoids have excellent inhibitory potential 
toward AChE protein. 
Inhibition constant is an important score to consider, by which the effectiveness of the compounds 
were evaluated through both virtual screening and in vitro pharmacological experimental studies. In 
silico studies proved that, the flavonoids could exhibit excellent inhibition constant toward the AChE 
ranging between 8.37 µM to 990.45 µM when compared with standard (994.14 µM). Scopoletin and 
baicalein showed remarkably excellent inhibition constant (8.37 µM and 8.32 µM) when compared to 
other flavonoids. 
Intermolecular energy is also directly proportional to binding energy. We found a decrease in 
intermolecular energy of all the flavonoids with a simultaneous decrease in binding energy. The 
flavonoids showed intermolecular energy towards the AChE ranging from -8.94 kcal/mol to -5.51 
kcal/mol when compared with standard (-5.46 kcal/mol). Scopoletin and baicalein showed 
remarkably excellent intermolecular energy (-8.94 kcal/mol and -8.91 kcal/mol) when compared to 
other flavonoids. This further proved the inhibitory potential of scopoletin and baicalein against 
AChE. 
The ligand scopoletin interacted with the binding sites of AChE at the amino acid residues Tyr 124, 
Trp 286, Leu 289, Ser 293, Ile 294, Phe 295, Tyr 341 and it was in correlation with the donepezil Tyr 
72, Tyr 124, Trp 286, Phe 295 and Tyr 341 (Fig. 23). 
Fig. 22 Binding energy of the flavonoids against AChE 
Table 1: In silico molecular interactions scores of the flavonoids against AChE and BuChE 
Flavonoids Acetylcholinesterase Butyrylcholinesterase Binding Energy (kcal/mol) Inhibition constant 
(µM) Intermolecular Energy (kcal/mol) Binding Energy (kcal/mol) Inhibition constant (µM) 
Intermolecular Energy (kcal/mol) Acacatechin -4.84 287.59 -7.37 -2.97 134.85 -4.81 Acacetin -4.54 
335.28 -6.92 -2.79 156.98 -4.54 Afzelechin -5.26 136.28 -7.80 -3.20 71.63 -5.09 Angoletin -5.14 
162.14 -7.73 -3.12 80.92 -5.06 Annulatin -4.86 282.94 -7.40 -2.98 131.50 -4.85 Apigenin -6.33 39.87 
-8.67 -3.88 19.08 -5.68 Apometzgerin -5.31 114.42 -7.87 -3.26 54.77 -5.16 Aromadedrin, Dihydro 
Kaempferol -5.37 90.21 -7.96 -3.29 43.32 -5.23 Aurantinidin -5.46 84.04 -8.10 -3.35 39.25 -5.25 
Aureusidin -5.54 80.12 -8.19 -3.40 37.76 -5.37 Ayanin -5.63 74.78 -8.24 -3.45 35.09 -5.41 Azaleatin 
-4.24 730.98 -6.30 -2.60 342.77 -4.11 Baicalein -6.93 8.32 -8.91 -4.51 2.12 -6.11 Baicalin mono 
hydrate -3.94 964.84 -5.64 -2.41 459.96 -3.66 Baptigenin -5.34 98.84 -7.94 -3.26 51.69 -5.21 
Bavachinin -4.04 914.52 -5.84 -2.47 439.08 -3.77 Biochanin A -4.36 368.66 -6.62 -2.68 170.41 -4.33 
Bis Hydroxy Coumarin -5.68 70.32 -8.35 -3.48 33.11 -5.46 Bracteatin -5.46 83.74 -7.99 -3.33 39.69 
-5.25 Buceracidin-B -5.54 80.56 -8.18 -3.40 37.96 -5.36 Butein -4.92 276.36 -7.45 -3.02 126.27 
-4.87 Calycopterin -4.30 581.36 -6.41 -2.63 320.78 -4.20 Calycosin -4.67 321.84 -7.14 -2.85 150.65 
-4.66 Candidone -5.05 200.12 -7.62 -3.09 102.49 -4.95 Cannflavin -4.77 298.34 -7.30 -2.92 142.95 
-4.77 Capensinidin -4.50 339.68 -6.89 -2.75 160.72 -4.50 Carajuflavone -4.23 729.36 -6.24 -2.60 
341.73 -4.07 Carpachromene -3.96 954.36 -5.71 -2.42 451.12 -3.68 Casticin -4.69 315.64 -7.16 
-2.87 150.86 -4.69 Catechin -5.34 136.44 -6.99 -3.28 45.30 -5.21 Chrysin -6.30 45.39 -8.64 -3.83 
25.37 -5.65 Chrysoeriol -4.59 328.45 -6.97 -2.79 157.16 -4.54 Chrysosplenetin -5.43 84.68 -7.99 
-3.33 40.58 -5.23 Cirsililol -4.16 832.21 -6.01 -2.52 399.50 -3.91 Cirsilineol -5.63 74.86 -8.24 -3.45 
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35.76 -5.40 Cirsimaritin -5.72 69.92 -8.38 -3.49 32.93 -5.48 Cladrin -5.80 68.84 -8.44 -3.53 32.46 
-5.53 Combretol -4.23 729.64 -6.23 -2.59 339.48 -4.07 Cyanidin -4.50 338.64 -6.87 -2.75 160.37 
-4.49 Cyclocommunol -4.77 298.81 -7.29 -2.92 142.72 -4.77 Daidzein -5.04 218.24 -7.58 -3.08 
109.86 -4.95 Datin -5.31 118.42 -7.86 -3.26 54.04 -5.15 Datiscetin -4.24 731.26 -6.30 -2.60 343.07 
-4.10 Delphinidin -3.94 962.38 -5.61 -2.41 459.45 -3.64 Demethylbellidifolin -4.64 321.62 -7.12 -2.83 
151.89 -4.59 Desmethoxycentaureidin -5.58 79.05 -8.20 -3.42 37.00 -5.38 Dihydrobaicalein -5.84 
67.86 -8.50 -3.57 31.99 -5.55 Dihydroflavonol -4.77 298.72 -7.27 -2.91 143.73 -4.77 
Dihydrokaempferide -5.04 218.64 -7.54 -3.08 108.39 -4.94 Dihydromyricetin -5.31 116.84 -7.86 
-3.24 57.58 -5.14 Dihydrorobinetin -5.58 78.94 -8.20 -3.42 36.88 -5.38 Dihydrotricetin -4.54 334.98 
-6.92 -2.77 157.71 -4.53 Dihydrowogonin -4.34 396.44 -6.55 -2.65 197.60 -4.27 Diosmetin -6.03 
60.86 -8.57 -3.66 29.87 -5.61 Diosmin -6.03 36.86 -7.84 -3.69 28.66 -5.61 Dorsilurin-F -5.68 70.26 
-8.34 -3.52 32.57 -5.51 Epicatechin -5.74 69.64 -8.42 -3.52 32.64 -5.53 Epicatechin Gallate -5.80 
68.98 -8.44 -3.17 73.26 -5.09 Epigallocatechin -5.24 124.12 -7.04 -3.24 58.29 -5.13 
Epigallocatechin Gallate -5.31 115.28 -7.84 -3.40 37.56 -5.38 Eriocitrin -5.58 78.68 -8.20 -3.57 
31.95 -5.55 Eriodictyol -5.84 67.24 -8.48 -2.68 172.81 -4.35 Ermanin -4.37 357.45 -6.67 -2.69 
164.74 -4.42 Esculetin -4.38 354.98 -6.75 -3.12 79.86 -5.05 Eupafolin -5.09 168.42 -7.72 -3.39 
38.31 -5.34 Eupalitin -5.53 81.12 -8.17 -3.44 36.51 -5.39 Eupatilin -5.60 77.94 -8.21 -3.47 33.24 
-5.44 Eupatolitin -5.67 70.64 -8.32 -3.52 32.59 -5.52 Eupatorin -5.75 69.24 -8.43 -3.42 36.85 -5.38 
Europetin -5.60 77.89 -8.21 -3.38 38.42 -5.32 Europinidin -5.52 81.72 -8.13 -3.30 42.29 -5.23 
Farobin-A -5.39 89.12 -7.97 -3.23 63.88 -5.12 Fisetin -5.28 122.84 -7.83 -3.15 76.00 -5.07 
Fisetinidol -5.17 156.28 -7.75 -3.09 102.30 -4.98 Flavoxate -5.05 198.89 -7.67 -3.02 126.66 -4.88 
Formononetin -4.94 264.69 -7.45 -2.95 136.96 -4.79 Fustin -4.82 290.86 -7.32 -2.87 148.82 -4.69 
Galangin -4.71 312.28 -7.18 -2.81 155.39 -4.56 Gallocatechin -4.60 326.54 -6.97 -3.36 38.85 -5.32 
Gallocatechin Gallate -5.51 81.96 -8.11 -3.44 36.53 -5.39 Ganhuangenin -5.62 76.28 -8.23 -3.51 
32.78 -5.50 Gardenin B -5.74 69.47 -8.39 -3.56 32.27 -5.54 Gartanin -5.82 68.24 -8.46 -2.65 197.10 
-4.22 Genistein -4.32 421.54 -6.50 -2.50 412.75 -3.87 Genistin -4.08 886.24 -5.94 -2.58 338.97 
-4.06 Geraldone -4.22 724.23 -6.20 -2.97 134.81 -4.84 Gericudranin-B -4.86 283.16 -7.40 -2.77 
157.50 -4.53 Glabridin -4.54 334.20 -6.92 -2.69 165.22 -4.40 Glaziovianin-A -4.38 352.12 -6.74 
-2.91 144.53 -4.75 Glycitein -4.76 304.95 -7.27 -2.38 464.27 -3.62 Gnetifolin E -3.92 981.25 -5.58 
-2.98 132.73 -4.86 Gomphrenol -4.88 278.98 -7.42 -2.96 136.34 -4.81 Gossypetin -4.84 289.64 
-7.34 -2.50 413.84 -3.86 Guibourtinidol -4.08 884.16 -5.93 -2.63 311.37 -4.19 Helmon -4.28 698.28 
-6.41 -3.70 27.38 -5.63 Herbacetin -6.08 57.96 -8.58 -3.22 25.63 -5.11 Hesperedin -5.28 148.38 
-7.08 -4.15 8.09 -5.72 Hesperetin -6.72 17.02 -8.81 -3.83 24.67 -5.64 Hibiscetin -6.28 48.42 -8.63 
-3.56 32.33 -5.54 Hirsutidin -5.82 68.16 -8.45 -3.52 32.56 -5.51 Hispudulin -5.74 69.53 -8.41 -3.35 
38.98 -5.32 Homoeriodictyol -5.48 82.87 -8.10 -3.26 53.63 -5.17 Homoorientin -5.32 110.28 -7.94 
-2.82 153.96 -4.58 Hydrangenol -4.61 324.03 -6.99 -2.73 163.43 -4.48 Hypolaetin -4.46 345.24 
-6.84 -2.63 316.01 -4.20 Icaritin -4.30 561.28 -6.41 -2.69 164.18 -4.40 Irigenin -4.38 350.92 -6.74 
-2.93 140.03 -4.77 Isalpinin -4.77 298.36 -7.30 -2.97 135.77 -4.82 Isoetin -4.86 284.31 -7.38 -2.50 
413.50 -3.88 Isoimperatorin -4.11 852.26 -5.96 -2.58 338.62 -4.06 Isokaempferide -4.23 728.14 
-6.22 -2.74 161.83 -4.49 Isookanin -4.48 344.23 -6.85 -2.76 158.74 -4.51 Isopongaflavone -4.52 
336.45 -6.90 -2.65 196.09 -4.22 Isoquercitrin -4.32 421.28 -6.48 -3.73 27.17 -5.63 Isorhamnetin 
-6.22 57.28 -8.58 -3.06 114.78 -4.92 Isosakuranetin -5.02 236.24 -7.54 -3.04 119.75 -4.90 
Isoscutellarein -4.98 244.87 -7.50 -2.95 136.61 -4.81 Isosilybin -4.84 287.31 -7.34 -3.03 124.07 
-4.89 Isothymusin -4.96 252.36 -7.48 -2.65 195.11 -4.21 Isovitexin -4.32 420.84 -6.46 -2.74 161.80 
-4.48 Isoxanthohumol -4.48 342.86 -6.85 -2.99 130.77 -4.87 Jaceidin -4.92 272.38 -7.44 -3.11 85.53 
-5.04 Kaempferide -5.08 172.63 -7.71 -3.85 22.70 -5.68 Kaempferol -6.32 42.90 -8.65 -3.06 112.98 
-4.92 Kumatakenin -5.02 234.36 -7.54 -2.68 171.17 -4.33 Ladanein -4.36 364.28 -6.61 -2.71 163.76 
-4.43 Laricitrin -4.42 349.84 -6.81 -2.50 412.54 -3.85 Leptosidin -4.08 882.14 -5.91 -2.69 166.40 
-4.43 Leucoanthocyanidin -4.42 349.21 -6.79 -3.14 77.49 -5.07 Leucocyanidin -5.16 160.76 -7.74 
-2.71 163.99 -4.47 Leucodelphinidin -4.46 345.18 -6.83 -2.69 164.29 -4.40 Leucofisetinidin -4.38 
351.44 -6.73 -2.60 341.89 -4.10 Leucomalvidin -4.24 731.04 -6.30 -2.90 145.70 -4.75 
Leucopelargonidin -4.76 304.46 -7.27 -2.93 139.86 -4.79 Leucopeonidin -4.81 291.44 -7.32 -2.99 
130.04 -4.86 Leucorobinetinidin -4.92 270.21 -7.43 -2.83 152.19 -4.58 Leukoefdin -4.64 321.38 
-7.10 -2.62 346.13 -4.18 Licoflavonol -4.28 674.16 -6.40 -2.63 327.32 -4.21 Limocitrin -4.31 454.26 
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-6.42 -2.67 180.12 -4.33 Limocitrol -4.36 362.18 -6.61 -2.69 165.06 -4.42 Liquiritigenin -4.42 349.12 
-6.77 -2.71 163.69 -4.46 Luteoforol -4.46 345.02 -6.83 -2.66 188.85 -4.29 Luteolin -4.35 384.26 
-6.59 -2.58 338.73 -4.06 Luteolinidin -4.23 729.02 -6.20 -2.48 428.68 -3.83 Maesopsin -4.08 880.54 
-5.89 -2.50 415.43 -3.90 Malvidin -4.12 842.15 -5.99 -2.60 342.02 -4.09 Maritimetin -4.24 731.24 
-6.26 -2.61 343.32 -4.14 Matteucinol -4.26 734.22 -6.34 -2.65 197.27 -4.24 Mearnsitrin -4.33 402.89 
-6.53 -2.69 164.10 -4.39 Meciadanol -4.38 352.46 -6.70 -2.58 339.12 -4.06 Melacacidin -4.21 
722.38 -6.19 -2.71 163.65 -4.44 Melanoxetin -4.45 348.65 -6.82 -2.68 170.76 -4.34 Mesquitol -4.37 
359.12 -6.67 -4.44 3.92 -5.74 Morin -6.92 8.29 -8.90 -3.88 18.69 -5.69 Myricetin -6.34 38.96 -8.68 
-4.21 6.18 -5.72 Naringenin -6.76 17.26 -8.84 -3.59 31.52 -5.57 Naringin -5.88 65.86 -8.51 -3.45 
35.05 -5.41 Natsudaidain -5.64 72.68 -8.28 -3.31 41.78 -5.23 Negletein -5.42 86.56 -7.97 -3.12 
78.95 -5.07 Nepetin -5.16 160.32 -7.73 -2.97 134.68 -4.82 Nobiletin -4.86 280.53 -7.38 -2.89 146.38 
-4.71 Nodifloretin -4.73 310.83 -7.23 -2.68 167.55 -4.38 Norathyriol -4.38 350.25 -6.70 -2.84 151.38 
-4.66 Norwogonin -4.67 321.15 -7.14 -2.93 140.07 -4.79 Okanin -4.80 292.19 -7.30 -2.50 414.45 
-3.89 Ombuin -4.12 840.14 -5.98 -2.60 341.32 -4.08 Ononin -4.24 731.88 -6.25 -2.48 427.71 -3.82 
Orientin -4.08 882.85 -5.88 -2.64 212.93 -4.21 Orobol -4.32 420.48 -6.43 -2.55 390.10 -3.95 
Oroxylin-A -4.18 784.46 -6.13 -2.68 168.34 -4.38 Osajin -4.38 350.48 -6.70 -2.87 150.54 -4.69 
Pachypodol -4.68 318.65 -7.15 -2.62 346.42 -4.16 Patuletin -4.28 684.33 -6.39 -2.43 447.36 -3.75 
Pectolinarigenin -4.04 912.44 -5.82 -2.43 448.38 -3.73 Pedalitin -4.02 934.27 -5.76 -2.64 263.10 
-4.21 Pelargonidin -4.32 418.33 -6.43 -2.53 394.76 -3.94 Penduletin -4.18 782.15 -6.12 -3.94 17.01 
-5.70 Peonidin -6.42 36.28 -8.71 -2.60 342.65 -4.14 Persicarin -4.26 735.08 -6.33 -2.75 161.36 
-4.50 Persicogenin -4.52 336.01 -6.90 -2.81 155.24 -4.56 Petunidin -4.61 324.68 -6.98 -2.74 161.73 
-4.48 Pinoquercetin -4.48 342.12 -6.84 -2.87 149.37 -4.69 Platanetin -4.71 311.88 -7.19 -2.64 
272.51 -4.21 Pomiferin -4.32 416.24 -6.42 -2.53 393.82 -3.92 Pratensein -4.18 780.14 -6.03 -2.65 
197.48 -4.25 Pratol -4.34 398.78 -6.55 -2.42 452.27 -3.70 Primetin -4.02 936.71 -5.74 -2.61 344.17 
-4.16 Propolin B -4.28 664.26 -6.38 -2.21 488.27 -2.92 Prosogerin E -3.92 980.16 -5.55 -2.18 
508.27 -2.82 Prunetin -3.90 990.45 -5.51 -2.47 437.94 -3.78 Prunin -4.08 880.08 -5.86 -2.79 157.02 
-4.54 Pulchellidin -4.58 331.18 -6.95 -2.82 153.07 -4.58 Quercetagetin -4.63 322.94 -7.10 -2.57 
367.72 -4.02 Quercetagetinidin -4.21 722.62 -6.18 -3.26 55.51 -5.16 Ranupetin -5.32 108.12 -7.90 
-3.09 102.36 -4.99 Retusin -5.06 182.46 -7.68 -2.93 139.85 -4.79 Rhamnazin -4.81 291.25 -7.31 
-3.04 118.74 -4.89 Rhamnetin -4.98 241.02 -7.50 -2.66 185.83 -4.30 Rhusflavanone -4.36 363.55 
-6.60 -2.76 159.23 -4.52 Rhynchosin -4.54 334.89 -6.91 -1.25 231.18 -2.41 Robinetin -6.45 24.25 
-8.73 -3.96 11.37 -5.71 Robinetinidin -5.66 70.96 -8.30 -3.45 34.93 -5.42 Robinetinidol -5.02 231.24 
-7.52 -3.04 118.29 -4.91 Rosinidin -5.08 170.15 -7.69 -3.10 93.23 -5.04 Rutin -6.51 23.27 -8.76 
-4.03 9.23 -5.72 Sakuranetin -4.96 255.46 -7.47 -3.02 129.54 -4.89 Salvigenin -4.84 287.68 -7.33 
-2.95 136.52 -4.80 Santal -5.08 170.36 -7.69 -3.10 93.81 -5.00 Santin -5.28 124.36 -7.82 -3.20 
70.46 -5.10 Scopoletin -6.95 8.37 -8.94 -4.62 1.29 -6.23 Scutellarein -5.72 69.87 -8.38 -3.49 32.96 
-5.48 Scutevulin -5.12 165.31 -7.72 -3.12 79.76 -5.05 Selagin -4.96 253.31 -7.45 -3.02 127.68 -4.88 
Silibinin -5.66 70.92 -7.45 -3.46 34.07 -5.44 Silybin -5.74 69.48 -8.40 -3.51 32.75 -5.50 Sinensetin 
-5.04 218.36 -7.60 -3.08 110.74 -4.95 Skullcapflavone Ii -4.75 306.62 -7.26 -2.90 145.79 -4.73 
Sorbifolin -4.37 358.98 -6.64 -2.68 169.77 -4.34 Sternbin -4.26 736.24 -6.32 -2.60 342.78 -4.14 
Sterubin -4.42 349.36 -6.75 -2.69 164.49 -4.42 Syringetin -4.36 365.16 -6.59 -2.66 186.93 -4.30 
Tamarixetin -4.68 317.48 -7.15 -2.85 150.76 -4.67 Tambulin -4.74 308.32 -7.24 -2.89 146.19 -4.72 
Tanetin -4.58 331.49 -6.95 -2.79 156.66 -4.54 Tangeritin -6.24 56.62 -8.59 -3.82 26.19 -5.63 
Taxifolin -5.22 150.32 -7.01 -3.17 75.36 -5.08 Tectorigenin -4.21 723.14 -6.18 -2.57 366.63 -4.02 
Tephrosin -4.92 269.38 -7.42 -2.98 132.63 -4.86 Teracacidin -4.72 311.02 -7.20 -2.88 147.96 -4.70 
Ternatin -4.88 277.42 -7.40 -2.98 133.27 -4.85 Tetra Hydroflavone -6.38 37.08 -8.70 -3.89 18.26 
-5.70 Texasin -5.34 96.64 -7.94 -3.26 50.68 -5.19 Theaflavin -5.88 66.25 -8.52 -3.59 31.81 -5.58 
Theaflavin-3-Gallate -5.58 78.62 -8.20 -3.42 37.05 -5.38 Thunberginol A -4.27 738.41 -6.36 -2.61 
345.11 -4.15 Tomentin -4.21 723.46 -6.18 -2.57 365.69 -3.96 Topazolin -4.38 350.08 -6.68 -2.68 
168.27 -4.36 Tricetin -4.27 739.02 -6.06 -2.61 344.57 -4.16 Tricin -5.36 92.42 -7.96 -3.28 46.33 
-5.21 Veronicoside -4.25 732.41 -6.31 -2.60 342.68 -4.14 Viscidulin Ii -5.46 83.16 -8.10 -3.35 39.39 
-5.32 Vitexin -5.96 63.72 -8.54 -3.61 30.87 -5.59 Vitexycarpin -6.01 61.15 -8.54 -3.61 31.05 -5.59 
Wogonin -6.86 9.48 -8.87 -4.25 4.81 -5.73 Wogonoside -5.54 80.98 -8.17 -3.39 38.03 -5.36 
Xanthohumol -5.21 152.82 -7.75 -3.17 75.15 -5.07 Donepezil -3.87 994.14 -5.46 -3.47 33.26 -5.45 
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Fig. 23 Molecular interactions of scopoletin and donepezil against AChE 
In silico studies with BuChE revealed that all the flavonoids showed good binding energy ranging 
between -4.62 to -2.18 kcal/mol. The scopoletin binding energy was found to be -4.62 kcal/mol as 
compared to donepezil (standard) -1.25 kcal/mol (Fig. 24). In case of BuChE target, inhibition 
constant of the flavonoids were found to be 1.29 µM to 508.27 µM when compared to the standard 
(231.18 µM). The results of inhibition constant coincide with the binding energy scores (Table 1). 
Fig. 24 Binding energy of the flavonoids against BuChE 
The flavonoid molecules having 2D structure were converted to energy minimized 3D structures and 
were further used for in silico protein–ligand docking. The active pocket of the BuChE for the 
scopoletin was found to be His 77, Lys 131, Gln 279, Val 204, Ile 272, Ser 287, Thr 346, Pro 449, 
Arg 515 and for donepezil were His 77, Pro 102, Lys 131, Val 204, Ser 287, Thr 346 (Fig. 25). 
Fig. 25 Molecular interactions of scopoletin and donepezil against BuChE 
These amino acid residues were dynamically involved in the formation of hydrophilic and 
hydrophobic contacts and they were initiated to play an important role in the binding site of target. 
This proves that the flavonoids possess potential ChE inhibitory binding sites when compared to the 
standard. These molecular docking analyses could lead to the further development of potent 
acetylcholinesterase inhibitors for the treatment of AD. 
The in silico ChE (AChE and BuChE) inhibitory activities of the 245 flavonoid compounds decreased 
in the order of Scopoletin < Baicalein < Morin < Wogonin < Naringenin < Hesperetin < Rutin < 
Robinetin < Peonidin < Tetra Hydroflavone < Myricetin < Apigenin < Kaempferol < Chrysin < 
Hibiscetin < Tangeritin < Isorhamnetin < Herbacetin < Diosmin < Diosmetin < Vitexycarpin < Vitexin 
< Theaflavin < Naringin < Dihydrobaicalein < Eriodictyol < Gartanin < Hirsutidin < Cladrin < 
Epicatechin Gallate < Eupatorin < Epicatechin < Hispudulin < Silybin < Gardenin B < Scutellarein < 
Cirsimaritin < Bis Hydroxy Coumarin < Dorsilurin-F < Eupatolitin < Silibinin < Robinetinidin < 
Natsudaidain < Ayanin < Cirsilineol < Ganhuangenin < Eupatilin < Europetin < Theaflavin-3-Gallate 
< Desmethoxycentaureidin < Dihydrorobinetin < Eriocitrin < Aureusidin < Buceracidin-B < 
Wogonoside < Eupalitin < Europinidin < Gallocatechin Gallate < Homoeriodictyol < Viscidulin II < 
Aurantinidin < Bracteatin < Chrysosplenetin < Negletein < Farobin-A < Aromadedrin < Tricin < 
Catechin < Baptigenin < Texasin < Homoorientin < Ranupetin < Apometzgerin < Datin < 
Dihydromyricetin < Epigallocatechin Gallate < Fisetin < Hesperedin < Santin < Afzelechin < 
Epigallocatechin < Taxifolin < Xanthohumol < Fisetinidol < Leucocyanidin < Nepetin < Angoletin < 
Scutevulin < Eupafolin < Kaempferide < Rosinidin < Santal < Retusin < Flavoxate < Candidone < 
Sinensetin < Daidzein < Dihydrokaempferide < Isosakuranetin < Kumatakenin < Robinetinidol < 
Isoscutellarein < Rhamnetin < Isothymusin < Sakuranetin < Selagin < Formononetin < Butein < 
Jaceidin < Leucorobinetinidin < Tephrosin < Gomphrenol < Ternatin < Annulatin < Gericudranin-B < 
Isoetin < Nobiletin < Acacatechin < Gossypetin < Isosilybin < Salvigenin < Fustin < Leucopeonidin < 
Rhamnazin < Okanin < Isalpinin < Cannflavin < Cyclocommunol < Dihydroflavonol < Glycitein < 
Leucopelargonidin < Skullcapflavone II < Tambulin < Nodifloretin < Teracacidin < Platanetin < 
Galangin < Casticin < Pachypodol < Tamarixetin < Calycosin < Norwogonin < Demethylbellidifolin < 
Leukoefdin < Quercetagetin < Hydrangenol < Petunidin < Gallocatechin < Chrysoeriol < Pulchellidin 
< Tanetin < Acacetin < Dihydrotricetin < Glabridin < Rhynchosin < Isopongaflavone < Persicogenin < 
Capensinidin < Cyanidin < Isookanin < Isoxanthohumol < Pinoquercetin < Hypolaetin < 
Leucodelphinidin < Luteoforol < Melanoxetin < Laricitrin < Leucoanthocyanidin < Liquiritigenin < 
Sterubin < Esculetin < Glaziovianin-A < Irigenin < Leucofisetinidin < Meciadanol < Norathyriol < 
Osajin < Topazolin < Ermanin < Mesquitol < Sorbifolin < Biochanin A < Ladanein < Limocitrol < 
Rhusflavanone < Syringetin < Luteolin < Dihydrowogonin < Pratol < Mearnsitrin < Genistein < 
Isoquercitrin < Isovitexin < Orobol < Pelargonidin < Pomiferin < Limocitrin < Icaritin < Calycopterin < 
Helmon < Licoflavonol < Patuletin < Propolin B < Tricetin < Thunberginol A < Matteucinol < 
Persicarin < Sternbin < Veronicoside < Azaleatin < Datiscetin < Leucomalvidin < Maritimetin < 
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Ononin < Carajuflavone < Combretol < Isokaempferide < Luteolinidin < Geraldone < Melacacidin < 
Quercetagetinidin < Tectorigenin < Tomentin < Oroxylin-A < Penduletin < Pratensein < Cirsililol < 
Malvidin < Ombuin < Isoimperatorin < Genistin < Guibourtinidol < Leptosidin < Maesopsin < Orientin 
< Prunin < Bavachinin < Pectolinarigenin < Pedalitin < Primetin < Carpachromene < Delphinidin < 
Gnetifolin E < Prosogerin E < Prunetin < Donepezil. 
6.3 In vitro AChE and BuChE inhibitory assay 
An increase in AChE leads to an increase in breakdown of ACh to acetate and choline, leading to 
the development of AD. Recent findings suggest that the occurrence of AD is increasing worldwide, 
possibly due to life style modifications. AChE inhibitors are commonly employed in the treatment of 
AD. Inhibition of AChE results in a decreased breakdown of acetylcholine into acetate and choline, 
when measured spectroscopically. Out of 245 flavonoids taken for in silico docking studies, 20 
flavonoids were selected for the in vitro enzyme inhibitory assay. The selection of the flavonoids was 
based upon the predicted docked score and the compounds were divided conventionally into those 
of high, moderate and low neuroprotective activity against the targets. 
Hence, to prove the reliability of in silico studies the fourteen flavonoids with highest activity 
(Scopoletin < Baicalein < Morin < Diosmin < Naringenin < Catechin < Hesperetin < Silibinin < Rutin 
< Robinetin < Taxifolin < Tetra hydroflavone < Hesperidin < Myrecetin), three with moderate 
(Apigenin < Kaempferol < Tricetin) and three with lowest (Chrysin < Epigallocatechin < Theaflavin) 
neuroprotective activities were selected for the in vitro enzyme inhibition studies (Fig. 26). 
Fig. 26 Selection of flavonoids for in vitro enzyme inhibition studies 
The absorbance of all the selected flavonoids decreased upon increasing the concentrations in a 
dose dependent manner. The percentage inhibition was calculated for all the flavonoids and for 
standard. A dose dependent increase in percentage of inhibition was observed for standard. 
6.3.1 Role of flavonoids in AChE inhibitory activity 
Among the different flavonoids tested, scopoletin and baicalein exhibited the highest AChE inhibitory 
activity. The inhibition constant (IC50) of scopoletin was 
found to be 10.18 ± 0.68 µg/ml and for baicalein 10.92 ± 0.38 µg/ml when compared to the standard 
donepezil showed 22.14 ± 0.56 µg/ml. All the selected flavonoids showed AChE inhibitory activity at 
a concentration below 100 µg/ml, with IC50 values ranging from 10.18 to 21.48 µg/ml (Fig. 27). 
. 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 considered as significant (One way ANOVA followed by Dunnett’s test). 
Fig. 27 In vitro AChE enzyme inhibitory assay of the selected flavonoids 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 considered as significant (One way ANOVA followed by Dunnett’s test). 
Fig. 28 In vitro BuChE enzyme inhibitory assay of the selected flavonoids 
6.3.2 Role of flavonoids in BuChE inhibitory activity 
The inhibitory activity of the flavonoids against BuChE was determined by Ellman’s method with 
some modifications. This method estimates BuChE using s-butyrylythiocholine iodide (substrate) 
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and DTNB. The enzymatic activity was measured by the yellow color compound produced by 
thiocholine when it reacts with dithiobisnitro benzoate ion. The inhibitory activity of the flavonoids 
increased with increasing concentration. All the flavonoids selected showed BuChE inhibitory 
activity at a concentration below 100 µg/ml, with IC50 values ranging from 28.18 to 6.12 µg/ml. 
Noteworthy IC50 values were found for scopoletin and baicalein against BuChE. Scopoletin showed 
the IC50 value 28.18 ± 0.92 µg/ml and for baicalein 31.24 ± 1.12 µg/ml against BuChE when 
compared to that of donepezil was found to be 64.38± 0.42 µg/ml (Fig. 28). 
The order of potency of flavonoids to ChE (AChE and BuChE) inhibitory activities of the compounds 
decreased in the order of Scopoletin < Baicalein < Morin < Diosmin < Naringenin < Catechin < 
Hesperetin < Silibinin < Rutin < Robinetin < Taxifolin < Tetra hydroflavone < Hesperidin < Myrecetin 
< Apigenin, Kaempferol < Tricetin < Chrysin < Epigallocatechin < Theaflavin < Donepezil. 
Among the selected flavonoids, scopoletin and baicalein showed excellent inhibition constant (IC50) 
values against AChE and BuChE and thereby proved that these compounds possess potential 
cholinesterase inhibitory activity. The inhibitory activity of scopoletin and baicalein against 
cholinesterase enzymes were found to be greater than the standard, donepezil (22±0.56 µg/ml). 
Hence, the compounds scopoletin and baicalein were further selected for the in vivo studies to 
prove its neuroprotective activity against scopolamine and aluminium induced learning impairment in 
mice. 
6.4 Acute toxicity studies and selection of dose for in vivo studies 
Among the twenty compounds selected for in vitro AChE inhibitory assay two flavonoids (scopoletin 
and baicalein) were found to possess excellent activity in inhibiting the AChE and BuChE enzymes 
and these compounds were selected and used for further in vivo studies. Acute toxicity was 
determined as per OECD guidelines (420) employing fixed dose procedure for selecting the dose for 
biological activity. For acute toxicity studies 10 female Wistar rats weighing 150-200 g were used 
and they were fasted overnight before the experimental day. 
Table 2: Observations done for the acute oral toxicity study- Baicalein 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 Day 4&5 Day 6&7 Day 8&9 Day 10&11 Day 
12&13 Day 14 Respiratory Dyspnea - - - - - - - - - - - - Apnea - - - - - - - - - - - - Nostril discharges - - - 
- - - - - - - - - Motor activity Tremor - - - - - - - - - - - - Hyper activity - - - - - - - - - - - - Hypo activity - - - - 
- - - - - - - - Ataxia - - - - - - - - - - - - Jumping - - - - - - - - - - - - Catalepsy - - - - - - - - - - - - Locomotor 
activity - - - - - - - - - - - Reflexes Corneal reflex - - - - - - - - - - - - Pinna reflex - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - Convulsion Tonic and clonic convulsion - - - - - - - - - - - - Muscle tone 
Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - Ocular sign Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - Mydriasis - - - - - - - - - - - - Ptosis - - - - - - - - - - - - Skin Edema - - - - - - - - - - 
- - Skin and fur - - - - - - - - - - - - Erythema - - - - - - - - - - - - Cardiovascular signs Bradycardia - - - - - 
- - - - - - - Tachycardia - - - - - - - - - - - - Piloerection Contraction of erectile tissue of hair - - - - - - - - - 
- - - - - - - - - - - - - - - Gastro intestinal signs Diarrhoea - - - - - - - - - - - - 
Live phase animals Observations Body weight every day Normal Food consumption daily Normal 
Water consumption daily Normal Home cage activity Normal 
Note: Acute toxicity study of baicalein and scopoletin was performed and it was non-toxic up to 2000 
mg/kg dose 
Table 3: Mortality record for baicalein in acute oral toxicity study 
Dose Sighting study Main study (2000 mg/kg) 5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg No. of 
animals 1 2 3 4 5 6 7 8 9 Body weight (g) 170 174 168 172 172 196 186 170 184 Sex Female 
Female Female Female Female Female Female Female Female 30 min Nil Nil Nil Nil Nil Nil Nil Nil 
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Nil 1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 2 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 3 h Nil Nil Nil Nil Nil Nil Nil Nil 
Nil 4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 2 Nil Nil Nil Nil Nil Nil 
Nil Nil Nil Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 4 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 5 Nil Nil Nil 
Nil Nil Nil Nil Nil Nil Day 6 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 8 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 10 Nil Nil Nil Nil Nil Nil Nil Nil 
Nil Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 12 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 13 Nil Nil Nil Nil 
Nil Nil Nil Nil Nil Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil Mortality 0/1 0/1 0/1 0/1 0/5 Note: Acute 
toxicity study of baicalein compound was performed and it was non-toxic up to 2000 mg/kg dose 
Table 4: Observations done for the acute oral toxicity study- Scopoletin 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 Day 4&5 Day 6&7 Day 8&9 Day 10&11 Day 
12&13 Day 14 Respiratory Dyspnea - - - - - - - - - - - - Apnea - - - - - - - - - - - - Nostril discharges - - - 
- - - - - - - - - Motor activity Tremor - - - - - - - - - - - - Hyper activity - - - - - - - - - - - - Hypo activity - - - - 
- - - - - - - - Ataxia - - - - - - - - - - - - Jumping - - - - - - - - - - - - Catalepsy - - - - - - - - - - - - Locomotor 
activity - - - - - - - - - - - Reflexes Corneal reflex - - - - - - - - - - - - Pinna reflex - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - Convulsion Tonic and clonic convulsion - - - - - - - - - - - - Muscle tone 
Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - Ocular sign Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - Mydriasis - - - - - - - - - - - - Ptosis - - - - - - - - - - - - Skin Edema - - - - - - - - - - 
- - Skin and fur - - - - - - - - - - - - Erythema - - - - - - - - - - - - Cardiovascular signs Bradycardia - - - - - 
- - - - - - - Tachycardia - - - - - - - - - - - - Piloerection Contraction of erectile tissue of hair - - - - - - - - - 
- - - - - - - - - - - - - - - Gastro intestinal signs Diarrhoea - - - - - - - - - - - - 
Live phase animals Observations Body weight every day Normal Food consumption daily Normal 
Water consumption daily Normal Home cage activity Normal 
Note: Acute toxicity study of baicalein and scopoletin was performed and it was non-toxic up to 2000 
mg/kg dose 
Table 5: Mortality record for scopoletin in acute oral toxicity study 
Dose Sighting study Main study (2000 mg/kg) 5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg No. of 
animals 1 2 3 4 5 6 7 8 9 Body weight (g) 184 166 182 174 196 168 172 196 183 Sex Female 
Female Female Female Female Female Female Female Female 30 min Nil Nil Nil Nil Nil Nil Nil Nil 
Nil 1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 2 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 3 h Nil Nil Nil Nil Nil Nil Nil Nil 
Nil 4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 2 Nil Nil Nil Nil Nil Nil 
Nil Nil Nil Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 4 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 5 Nil Nil Nil 
Nil Nil Nil Nil Nil Nil Day 6 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 8 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 10 Nil Nil Nil Nil Nil Nil Nil Nil 
Nil Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 12 Nil Nil Nil Nil Nil Nil Nil Nil Nil Day 13 Nil Nil Nil Nil 
Nil Nil Nil Nil Nil Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil Mortality 0/1 0/1 0/1 0/1 0/5 Note: Acute 
toxicity study of scopoletin compound was performed and it was non-toxic up to 2000 mg/kg dose 
The animals were observed no toxic effect and after sufficient interval of time (2-3 days) the second 
animal was administered with 50 mg/kg dose of test flavonoids. Similar observations were made as 
before and since the dose was non-toxic the third animal was administered with 300 mg/kg. This 
dose also did not exhibit any toxic effects or morbidity and therefore the last and highest dose in 
fixed dose procedure of 2000 mg/kg was administered to fourth animal and no toxicity was noticed 
for highest dose (Table 2, 3). 
Signs and symptoms of toxicity and death if any were observed individually for each rat at 0, 0.5, 1, 
2, 3 and 4h for first 24 h and thereafter daily for 14 days. Food was given to the animals after 4 h of 
dosing. The animals were observed twice daily for 14 days and body weight changes, food and 
water consumption, etc., were noted. In acute toxicity studies, it was found that the animals were 
56
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
safe up to a maximum dose of 2000 mg/kg of body weight. There were no changes in normal 
behavioural pattern and no signs and symptoms of toxicity and mortality were observed (Table 4, 5). 
As per the OECD 420 guidelines, selected flavonoids can be included in the category 5 or 
unclassified category of globally harmonized classification system (GHS). Hence, based on these 
results, the flavonoids baicalein and scopoletin were considered non-toxic and 1/10th and 1/20th of 
the maximum tolerated (2000 mg/kg) dose was used for the biological evaluation (memory 
enhancing activity) and thus the studies were conducted at dose levels of 100 and 200 mg/kg body 
weight. 
6.5 NEUROPROTECTIVE EFFECTS OF BAICALEIN AND SCOPOLETIN IN SCOPOLAMINE-
INDUCED MODEL 
6.5.1 Behavioural assessment of baicalein and scopoletin in scopolamine treated mice 6.5.1.1 Effect 
on transfer latency in the rectangular maze 
In this test, baicalein and scopoletin treated mice showed significant (P>0.01) decrease in latency 
time (LT) when compared to scopolamine treated group on the 7th day. Moreover the higher LT 
induced by scopolamine was significantly reversed by scopoletin and baicalein treated groups than 
the standard donepezil treated group. Administration of scopolamine resulted in learning impairment 
as evidenced by a significant (P>0.05) increase in the LT from 124.45±1.15 on the 1st day to 174.88
±0.76 on the 7th day in the negative control group when compared to the control group 
(120.34±1.18 on 1st day and 118.34±0.68 on the 7th day). Treatment with the scopoletin and 
baicalein for seven days reversed the LT significantly (P>0.01) when compared with negative control 
group (Fig. 29). The potency of the reduction in LT was produced by the scopoletin 200mg/kg 
followed by baicalein 200 mg/kg among the flavonoids treated groups (77.92±0.63 sec, 82.35±0.78 
sec on the 7th day). Donepezil, at a dose of 10 mg/kg treated for successive 7 days acts as positive 
control, elicited a significant (P>0.01) reduction in LT from 122.44±1.05 sec to 92.81±0.67 sec 
compared to the negative control group using Dunnet’s test. 
Fig. 29 Effect of baicalein and scopoletin on latency time using rectangular maze test in 
scopolamine-induced amnesia 
Fig. 30 Effect of baicalein and scopoletin on escape latency time using Morris water maze test in 
scopolamine-induced amnesia 
6.5.1.2 Effect on escape latency time in the Morris water maze 
The Morris water maze (MWM) plays an important role in the validation of rodent models for 
neurocognitive disorders such as Alzheimer’s disease. In MWM, escape latency time (ETL) was 
calculated, i.e., the time taken by an animal to find the platform. The scopolamine administration 
group showed increased ELT from 64.53±0.94 sec to 86.78±1.14 sec, whereas the control group 
was found to be 56.35±0.84. This relative increase in ELT when compared to the control group 
indicated a spatial memory deficit in the scopolamine treated mice. It was found that baicalein and 
scopoletin treated mice significantly (P>0.01) reduced ELT when compared with the scopolamine 
treated group. 
In the treatment groups, higher dose of scopoletin and baicalein successfully reversed the 
scopolamine-induced memory deficits compared to other flavonoids treated groups and standard. 
The significant reduction of ELT was produced by the scopoletin and baicalein (200 mg/kg) among 
the flavonoids treated groups on the 7th day was found to be 24.18±0.63 sec, 31.26±1.18. 
Donepezil (10 mg/kg) treated animals, produced a significant (P>0.01) decrease in ELT 36.42±0.84 
sec on the 7th day compared to the negative control group (Fig. 30). 
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6.5.1.3 Locomotor activity in scopolamine treated mice 
Reduction of metabolic rate occurs in rodents in response to intoxication with several neurotoxic 
agents. Scopolamine decreased locomotor activity as compared to control mice indicating locomotor 
deficits. Scopolamine-treated group showed lower locomotion values on the 7th day 164.85±0.82 
sec when compared to control group 280.46±0.64 sec which in turn replicate the learning 
impairment in negative control group. 
The locomotor activity of the flavonoids treated groups significantly (P>0.01) increased when 
compared to the negative control group. A significant (P>0.01) increase in the values of locomotion 
346.17±1.04 sec on the 7th day was observed in the standard group. In the treatment groups, 
scopoletin (200 mg/kg and 100 mg/kg) treated mice significantly increased the locomotor values 
(P>0.01), 380.78±0.82 sec and 368.52±1.02 sec respectively and baicalein (200 mg/kg and 100 mg/
kg) significantly elevated locomotor values 356.32±0.78 and 352.43±0.62 on the 7th day compared 
to the scopolamine-treated group (Fig. 31). 
Fig. 31 Effect of baicalein and scopoletin on locomotor activity using Actophotometer in 
scopolamine-induced amnesia 
Fig. 32 Effect of baicalein and scopoletin on percentage of conditioned avoidance response using 
Pole climbing test in scopolamine-induced amnesia 
6.5.1.4 Conditioned avoidance response in scopolamine treated mice 
In pole climbing method, the percentage of conditioned avoidance response (CAR) were calculated 
based on the number of successful events and number of errors produced by each groups. 
Scopolamine treated mice showed significantly decreased percentage of CAR activity 48.21±0.51 
sec as compared to control group 74.15±0.58 sec on the 7th day and donepezil treated animals 
exhibited significant (P>0.05) increase in percentage of CAR activity 88.92±0.38. Scopoletin (100 
mg/kg and 200 mg/kg) treated animals significantly (P>0.01) increased CAR activity to 92.15±0.26 
and 96.84±0.62 and baicalein (100 mg/kg and 200 mg/kg) significantly (P>0.01) elevated CAR 
values to 88.08±0.64 and 92.62±0.82 compared to negative control group (Fig. 32). 
6.5.1.5 Effect of scopoletin and baicalein response time in 5-choice serial time task method 
Five-choice serial reaction time task (5-CSRTT) is an operant based task and was used to study 
attention and impulse control in rodents. The 5-CSRTT can be used to explore aspects of both 
attentional and inhibitory control mechanisms. The basic test design involves training animals to 
respond to a brief visual stimulus presented unpredictably in one of five locations. Increasingly, the 
test is also used to examine aspects of response control. Increasingly this test is being applied in 
drug discovery efforts, primarily to identify novel drug treatments for conditions associated with 
attention deficits. 
Administration of scopolamine resulted in learning impairment as evidenced by significant delayed 
response values (68.24±0.84) when compared to control group (36.18±0.44). In treatment groups, 
scopoletin (100 mg/kg and 200 mg/kg) showed quicker responses (23.12±1.08 and 18.54±0.72) and 
baicalein (100 mg/kg and 200 mg/kg) treated animals also showed significant (P>0.01) improved 
responses time (25.74±0.56 and 22.32±0.44). Standard drug, donepezil administered animals 
exhibited significantly improved responses (19.42±0.63) (Fig. 33). 
These observations made the scopolamine-induced mice as a useful learning impairment model for 
studying neuroprotective effects of the baicalein and scolpoletin. It has been found that higher dose 
of scopoletin followed by baicalein treated mice effectively reversed the cognitive impairments 
produced by the scopolamine when 
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Fig. 33 Effect of baicalein and scopoletin on response time using 5 CSRT model in scopolamine-
induced amnesia 
compared to the lower dose of flavonoids treated animals. These results further augmented the 
neuroprotective effect of the scopoletin against the Alzheimer's disease. 
6.5.2 Biochemical estimations in scopolamine induced mice 
6.5.2.1 Estimation of AChE activity in the brain 
Fig. 34 Percentage of AChE inhibition in the mice brain in scopolamine-induced amnesia 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
AChE is a key enzyme involved in cholinergic neurotransmission and is a marker of extensive loss 
of cholinergic neurons in the brain. A significant increase (P>0.01) in the level of AChE was 
observed in the scopolamine treated mice. Administration of baicalein and scopoletin significantly 
(P>0.01) attenuated AChE levels and no change was observed in control group. 
Scopoletin (100 mg/kg and 200 mg/kg) exhibited the percentage AChE inhibition in the brain 
homogenate as 70.48% and 85.22%, which were significantly (P>0.01) increased values when 
compared to scopolamine treated mice (22.14%). Administration of baicalein (100 mg/kg and 
200mg/kg) exhibited the percentage AChE inhibition as 57.18% and 72.14%. Donepezil significantly 
(P>0.05) reduced the level of AChE into 66.72%. Scopoletin (200 mg/kg) effectively inhibited the 
AChE and thereby it increased the level of acetylcholine in the brain (Fig. 34). 
6.5.2.2 Determination of total protein content 
The total protein content was significantly reduced to 0.34±1.32 units/mg tissue protein in negative 
control group compared to control (1.08±1.26 units/mg tissue protein). Scopoletin (100 mg/kg and 
200 mg/kg, p.o.) treated mice significantly reversed the protein content values (1.22±1.08 and 1.31
±0.82 µmoles/min/mg protein) and administration of baicalein (100 mg/kg and 200 mg/kg, p.o.) 
significantly increased the values (1.16±0.84 and 1.25±1.23 µmoles/min/mg protein) when 
compared to negative control. Treatment with donepezil (5 mg/kg, p.o.) resulted in a significant 
increased protein content level (1.12±0.96 µmoles/min/mg protein) in the brain (Table 6). The total 
protein content was greatly increased in higher dose of scopoletin (200 mg/kg) treated group when 
compared to all other groups. 
Table 6: Effect of baicalein and scopoletin on protein content in scopolamine treated mice 
Groups Protein Content (mmoles/min/mg) Control 1.08±1.26 Negative Control (Scopolamine) 0.34
±1.32* Baicalein (100 mg/kg) 1.16±0.84** Baicalein (200 mg/kg) 1.25±1.23** Scopoletin (100 mg/kg) 
1.22±1.08** Scopoletin (200 mg/kg) 1.31±0.82** Standard (Donepezil) 1.12±0.96** 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.5.2.3 Enzymatic antioxidant levels 
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Administration of scopolamine caused marked oxidative stress, which was evident by the decrease 
in the antioxidant enzyme levels marking the occurrence of AD. The role of baicalien and scopoletin 
in the antioxidant level (CAT, SOD, GSSH, GPx and GSH) in the brain homogenate were estimated. 
6.5.2.3.1 Estimation of catalase 
A significant (P>0.05) reduction in the catalase level was found in scopolamine treated mice (1.24
±0.48 µmoles/min/mg protein) compared to the control group (3.18±0.62 µmoles/min/mg protein). 
Scopoletin (100 mg/kg and 200 mg/kg, p.o.) treated mice resulted in significant (P>0.01) increase in 
the level of catalase (3.34±1.08 and 3.46±0.38 µmoles/min/mg protein) and administration of 
baicalein (100 mg/kg and 200 mg/kg, p.o.) significantly (P>0.01) increased the catalase level to 3.26
±0.72 and 3.38±0.64 µmoles/min/mg protein when compared to negative control. Treatment with 
donepezil (5 mg/kg) showed significant (P>0.05) increased in the level of catalase to 3.30±0.52 
µmoles/min/mg protein in the brain (Table 7). The catalase level was greatly increased in higher 
dose of scopoletin treated group animals compared to other groups used in the study. 
6.5.2.3.2 Estimation of superoxide dismutase 
Superoxide dismutase is an enzymatic antioxidant which scavenges the superoxide anion to 
hydrogen peroxide, hence diminishing the toxic effect caused by this radical. The SOD level was 
significantly (P>0.01) reduced to 0.98±1.08 units/mg tissue protein in negative control when 
compared to control (2.96±0.58 units/mg tissue protein). Scopoletin (100 mg/kg and 200 mg/kg, 
p.o.) treated group significantly (P>0.01) increased the SOD level to 3.28±0.82 and 3.42±0.74 
µmoles/min/mg protein and treatment with baicalein (100 mg/kg and 200 mg/kg, p.o.) significantly 
(P>0.01) elevated the SOD level to 3.08±0.64 and 3.36±1.12 µmoles/min/mg protein when 
compared to negative control. Donepezil treated mice (5 mg/kg, p.o.) resulted in a significant 
(P>0.05) elevation of SOD level (3.28±0.88 µmoles/min/mg protein) in the brain (Table 7). The SOD 
level was greatly increased in higher dose of scopoletin group treated animals compared to all other 
groups. 
6.5.2.3.3 Estimation of glutathione peroxidase 
The GPx level was significantly decreased (P>0.05) in negative control group to 0.42±0.48 when 
compared to the control group (1.48±0.36) and enzymatic activity of GPx in donepezil treated group 
showed elevation of GPx level (1.62±0.34). It reveals that in baicalein treated mice (100 and 200 
mg/kg) restoration of the activity of the glutathione peroxidase enzyme was noticed to 1.52±0.28 
and 1.66±0.32 and scopoletin (100 and 200 mg/kg) treatment elevated GPx values significantly to 
1.58±0.40 and 1.76±0.36 respectively and possibly this could be due to reduced generation of free 
radicals and subsequent neuronal damage (Table 7). This suggests that the higher dose of 
scopoletin has greater capability to restore level of GPx and reduced formation of free radicals and 
associated oxidative stress. 
Table 7: Effect of baicalein and scopoletin on enzymatic and non-enzymatic antioxidant level in 
scopolamine treated mice 
Groups CAT SOD GSSH GPx GSH Control 3.18±0.62 2.96±0.58 22.45±1.32 1.48±0.36 3.88±0.46 
Negative Control (Scopolamine) 1.24±0.48* 0.98±1.08* 11.31±1.43* 0.42±0.48* 1.28±0.28* 
Baicalein (100 mg/kg) 3.26±0.72** 3.08±0.64** 21.08±1.61** 1.52±0.28** 3.74±0.24** Baicalein (200 
mg/kg) 3.38±0.64** 3.36±1.12** 24.82±1.17** 1.66±0.32** 3.98±0.48** Scopoletin (100 mg/kg) 3.34
±1.08** 3.28±0.82** 25.03±1.72** 1.58±0.40** 4.14±0.54** Scopoletin (200 mg/kg) 3.46±0.38** 3.42
±0.74** 27.21±1.54** 1.76±0.36** 4.32±1.08** Standard (Donepezil) 3.30±0.52** 3.28±0.88** 23.13
±1.38** 1.62±0.34** 3.96±0.32** 
Values are expressed as mean ± SEM; n = 6. 
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*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.5.2.3.4 Estimation of glutathione reductase (GSSH) 
The glutathione reductase level was significantly reduced (P>0.05) in negative control group to 
11.31±1.43 when compared to control group (22.45±1.32) and enzymatic activity in donepezil 
resulted in an increased level of glutathione reductase (23.13±1.38). Administration of baicalein (100 
and 200 mg/kg) could reverse the level of the glutathione reductase to 21.08±1.61 and 24.82±1.17 
and scopoletin (100 and 200 mg/kg) increased GR significantly (P>0.01) to 25.03±1.72 and 27.21
±1.54 respectively (Table 7). This suggests that the higher dose of scopoletin has the capability to 
reverse the level of glutathione reductase. 
6.5.2.4 Non enzymatic antioxidant activity 
6.5.2.4.1 Estimation of reduced glutathione 
Glutathione is an important tripeptide which can remove the free radical species such as H2O2, O2·, 
alkoxy radical and maintain the membrane protein thiols and acts as a substrate for glutathione 
peroxidase and glutathione transferase. The level of reduced glutathione in the brain was reduced in 
the negative control group (1.28±0.28 nmoles/min/mg tissue protein) when compared to the control 
(1.28±0.28 nmoles/min/mg tissue protein). Treatment with baicalein (100 and 200 mg/kg) resulted in 
a significant (P>0.01) elevation of reduced glutathione level to 3.74±0.24 and 3.98±0.48 and 
administration of scopoletin (100 and 200 mg/kg) significantly (P>0.01) elevated the reduced 
glutathione levels to 4.14±0.54 and 4.32±1.08 respectively. Donepezil (5mg/kg, p.o.) significantly 
(P>0.01) increased the level (3.96±0.32 nmoles/min/mg tissue protein) of reduced glutathione in the 
brain (Table 7). The present research depicts that scopoletin (100 mg and 200 mg/kg) reduced 
oxidative stress by replenishing the levels of catalase, SOD, GPx, and GSH in mice. 
6.5.2.5 DPPH assay 
DPPH is a stable, nitrogen-centered free radical which produces violet colour. It was reduced to a 
yellow colored product, diphenylpicryl hydrazine, with the addition of the fractions in a concentration-
dependent manner. The reduction in the number of DPPH molecules can be correlated with the 
number of available hydroxyl groups. The DPPH scavenging activity was significantly decreased 
(P>0.05) in negative control group to 7.24±1.89 when compared to the control group (12.18±1.58). 
The highest DPPH radical scavenging activity was detected in the higher concentration of scopoletin 
(200 mg/kg) 15.48±1.15, followed by the scopoletin 100 mg/kg, baicalein (200 mg/kg, 100mg/kg) 
showed the values 14.12±0.84, 13.98±1.06 and 12.48±0.81 respectively. These activities were less 
than that of the standard, donepezil (13.08±0.98) (Table 8). Scopoletin and baicalein treated mice 
showed significantly (P>0.01) higher DPPH scavenging values compared to negative control group. 
Table 8: Effect of baicalein and scopoletin on DPPH and MDA level in scopolamine treated mice 
Groups DPPH (nmoles/min/mg) MDA (nmoles/min/mg) Control 12.18±1.58 5.86±0.24 Negative 
Control (Scopolamine) 7.24±1.89* 13.88±0.64* Baicalein (100 mg/kg) 12.48±0.81** 5.63±0.34** 
Baicalein (200 mg/kg) 13.98±1.06** 5.48±0.28** Scopoletin (100 mg/kg) 14.12±0.84** 4.52±0.46** 
Scopoletin (200 mg/kg) 15.48±1.15** 4.03±0.38** Standard (Donepezil) 13.08±0.98** 6.26±0.73** 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.5.2.6 Estimation of lipid peroxidation 
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Lipid peroxidation (LPO) is one of the main manifestations of oxidative damage, which implicates 
free radical oxidative cell injury in mediating the toxicity of scopolamine. Effect of baicalein and 
scopoletin on the levels of malondialdehyde (MDA) during scopolamine-induced neurotoxicity was 
observed. Increase in the level of lipid peroxides in the brain reflects the neuronal damage. Elevated 
level of MDA was observed in scopolamine-treated mice (13.88±0.64 nmoles/min/mg tissue 
protein), whereas it was significantly (P>0.01) reversed in flavonoids-treated groups (scopoletin and 
baicalein). 
Administration of baicalein (100 and 200 mg/kg) significantly (P>0.01) decreased (5.63±0.34 and 
5.48±0.28 nmoles/min/mg tissue protein) MDA level in brain and scopoletin (100 and 200 mg/kg) 
treated group also reduced the level of MDA significantly to 4.52±0.46 and 4.03±0.38 when 
compared to the negative control group. Donepezil (5 mg/kg, p.o) significantly (P>0.01) decreased 
the level (6.26±0.73 nmoles/min/mg tissue protein) of MDA in the brain (Table 8). The results 
revealed that scopoletin and baicalein possess antioxidant property with concentration gradient and 
thereby it reduces the oxidative stress induced membrane lipid peroxidation. 
6.5.3 Histopathological studies of the baicalien and scopoletin in acute scopolamine induced 
amnesia in mice 
The results for the histopathological studies in the brains (H&E x 400) of control group showed 
normal histological architecture without any degenerative changes and scopolmine induced mice 
indicated severe neurodegenerative changes and also resulted in the formation of neurofibrillary 
tangles. Administration of baicalein (100 mg/kg) with scopolamine showed faintly appearing 
neurofibrillary tangles suggesting moderate therapeutic efficacy of the flavonoids and baicalein (200 
mg/kg) resulted in mild infiltration of inflammatory cells indicating the repair mechanism. Treatment 
with scopoletin (100 mg/kg) showed moderately appearing neurofibrillary tangles representing the 
minimal efficacy and scopoletin (200 mg/kg) resulted in normal histological architecture with mild 
infiltration of inflammatory cells which indicates the effective repair mechanism at the high dose of 
scopoletin. Administration of standard donepezil exhibited minimal neuro degenerative changes 
indicating neuroprotective effect of the standard drug (Fig. 35). 
Fig. 35 The demonstration of the effects of baicalein and scopoletin in scopolamine-induced 
amnesia (SCP-scopolamine)(A-Normal histological architecture without any degenerative changes; 
B-Severe neurodegenerative changes; C-Formation of neurofibrillary tangles; D-Faintly appearing 
neurofibrillary tangles; E-Mild infiltration of inflammatory cells indicating the repair mechanism; F-
Moderately appearing neurofibrillary tangles; G-normal histological architecture with mild infiltration 
of inflammatory cells; H-minimal neuro degenerative changes) 
6.6 NEUROPROTECTIVE EFFECT OF BAICALEIN AND SCOPOLETIN ON BEHAVIOURAL 
CHANGES IN AlCl3-INDUCED MODEL 
6.6.1 Effect of baicalein and scopoletin on behavioural changes in AlCl3 treated mice 
6.6.1.1 Evaluation of transfer latency in the rectangular maze 
In this test, latency time (LT) of the animals was calculated for all (Group I to VII) the groups. 
Administration of AlCl3 to mice for 3 months resulted in learning impairment by a significant 
(P>0.05) increase in the LT (175.32±0.98) in the negative control group when compared to the 
control group (112.21±0.54). Baicalein and scopoletin treated mice resulted in reversal of LT 
significantly (P>0.01) when compared with negative control. 
The LT was effectively decreased by scopoletin (200 mg/kg, 100 mg/kg) treated mice among the all 
other groups tested showing the values of 46.72±0.38 and 54.48 ±0.82 respectively. Donepezil 
resulted in significant (P>0.01) decrease in LT 72.54±0.64 compared to the negative control group 
using Dunnet’s test (Fig. 36). 
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6.6.1.2 Estimation of escape latency time in the Morris water maze 
In MWM, escape latency time (ETL) was calculated, which was the time taken by an animal to find 
the platform. AlCl3 treated animals showed significantly (P>0.01) increased ETL values on 90th day 
(76.38±1.18) as compared to control group (49.48±0.72) and it indicates the impairment in learning 
and memory. Baicalein (100 mg/kg and 200 mg/kg) treated mice significantly (P>0.01) decreased 
ETL, 31.54±0.84 and 27.06±0.78 and scopoletin (100 mg/kg and 200 mg/kg) significantly (P>0.01) 
decreased ETL, 30.82±1.02 and 21.42±0.62 when compared to negative control. Administration of 
donepezil significantly (P>0.01) decreased ETL values (32.18±0.48). Among the treatment groups, 
scopoletin (200 mg/kg) treated mice effectively reduced ETL values when compared to all other 
groups (Fig. 37). 
Fig. 36 Effect of baicalein and scopoletin on latency time using rectangular maze test in AlCl3-
induced learning impairment 
Fig. 37 Effect of baicalein and scopoletin on escape latency time using Morris water maze test in 
AlCl3-induced learning impairment 
Fig. 38 Effect of baicalein and scopoletin on locomotor activity in AlCl3-induced learning impairment 
6.6.1.3 Locomotor activity in AlCl3 treated mice 
AlCl3 treated mice exhibited significantly (P>0.05) decreased locomotor activity on 90th day (176.46
±1.38) as compared to control group (286.53±0.82) and it indicates the learning and memory 
impairment in mice. Baicalein (100 mg/kg and 200 mg/kg) treated mice significantly (P>0.01) 
elevated locomotor values 386.76±0.46 and 448.54±0.68 and scopoletin (100 mg/kg and 200 mg/
kg) significantly (P>0.01) increased the locomotion to 426.34±0.92 and 492.54±1.08 when 
compared to negative control. Donepezil significantly (P>0.01) elevated the locomotor values 
(394.38±0.62) on the 90th day. Higher dose of scopoletin resulted in effective increase in locomotor 
activity which in turns results in its neuroprotective activity (Fig. 38). 
6.6.1.4 Conditioned avoidance response in AlCl3 treated mice 
In pole climbing method, the percentage of conditioned avoidance response (CAR) was calculated 
based on the number of successful events and number of errors produced by the animals. AlCl3 
alone treated mice showed significantly (P>0.05) decreased percentage of CAR activity on 90th day 
(32.82±1.18) as compared to control group (66.28±0.76). Administration of baicalein (100 mg/kg and 
200 mg/kg) resulted in significant (P>0.01) elevation of CAR values 89.52±0.74 and 93.43±0.46 and 
scopoletin (100 mg/kg and 200 mg/kg) significantly (P>0.01) increased the values to 91.08±0.52 and 
96.62±0.78 when compared to negative control. Donepezil treated mice significantly (P>0.01) 
increased percentage of CAR activity (84.45±0.82) compared to negative control group (Fig. 39). 
Fig. 39 Effect of baicalein and scopoletin on percentage of conditioned avoidance response in 
AlCl3-induced learning impairment 
Fig. 40 Effect of baicalein and scopoletin on response time using 5-CSRT model in AlCl3-induced 
learning impairment 
6.6.1.5 Effect of baicalein and scopoletin on response time in 5-choice serial reaction time task 
method 
5-CSRT is an operant based task used to study attention and impulse control in rodents. AlCl3 
treated mice showed significantly (P>0.05) quicker response time (72.86±0.98) on the 91st day 
when compared to control group (35.24±0.68). Treatment with baicalein (100 mg/kg and 200 mg/kg) 
significantly (P>0.01) faster response time 22.92±0.58 and 18.26±0.46 and scopoletin (100 mg/kg 
and 200 mg/kg) significantly (P>0.01) decreased the learning impairment values to 21.38±0.68 and 
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15.72±0.74 when compared to negative control. Donepezil treated mice significantly (P>0.01) 
decreased memory impairment to 19.56±0.76. 
From the behavioural assessments it has been evidenced that, the chronic administration of AlCl3 
(3 months) resulted in the learning impairment in mice and the flavonoids (baicalein and scopoletin) 
treated mice significantly (P>0.01) reversed the learning impairment produced by AlCl3 (Fig. 40). 
Scopoletin (200 mg/kg) treated mice, effectively attenuated the learning impairment produced by 
AlCl3 when compared to all other groups and this further emphasized the neuroprotective role of 
scopoletin. 
6.6.2 Biochemical evaluations in AlCl3-induced learning impairment in mice 
6.6.2.1 Estimation of AChE level in the brain 
AChE is an essential enzyme involved in cholinergic neurotransmission. Acetylcholine is broken into 
acetate and choline in the presence of AChE and thereby it act as a marker of extensive loss of 
cholinergic neurons in the brain. In the present study, a significant increase in AChE level was 
observed in the AlCl3 treated mice (Negative control). The percentage of the AChE inhibition in the 
brain homogenate was calculated for all the groups. 
The percentage of the AChE inhibition of the scopoletin (100 mg/kg and 200 mg/kg) was found to be 
68.25% and 78.41% and the values compared with AlCl3 alone treated group was found to be only 
18.08% on the 91st day. The baicalein (100 mg/kg and 200 mg/kg) administered mice resulted in 
elevation of percentage of AChE inhibition 53.21% and 68.48%. Donepezil (5 mg/kg, p.o.) increased 
the percentage of AChE inhibition to 58.38% (Fig. 41). These results clearly demonstrated that, 
scopoletin (200 mg/kg) effectively inhibited the AChE level and thereby it prevents the breakdown of 
acetylcholine. 
Fig. 41 Percentage of AChE inhibition in the mice brain in AlCl3-induced learning impairment 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.6.2.2 Estimation of total protein content 
Table 9: Effect of baicalein and scopoletin on protein content in AlCl3 treated mice 
Groups Protein Content (mmoles/min/mg) Control 1.24±0.81 Negative Control (AlCl3 50 mg/kg) 
0.28±1.24* Baicalein (100 mg/kg) 1.21±1.12** Baicalein (200 mg/kg) 1.25±0.84** Scopoletin (100 
mg/kg) 1.28±0.94** Scopoletin (200 mg/kg) 1.34±1.07** Standard (Donepezil) 1.26±1.04** 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
The total protein content was significantly (P>0.05) reduced to 0.28±1.24 units/mg tissue protein in 
negative control group compared to control (1.24±0.81 units/mg tissue protein). Administration of 
baicalein (100 mg/kg and 200 mg/kg) significantly (P>0.01) reversed the protein content values 
(1.21±1.12 and 1.25±0.84 µmoles/min/mg protein) when compared to negative control and 
treatment with scopoletin (100 mg/kg and 200 mg/kg) significantly (P>0.01) increased the values 
(1.28±0.94 and 1.34±1.07 µmoles/min/mg protein) when compared to negative control. Donepezil (5 
mg/kg, p.o.) increased the total protein level (1.26±1.04 µmoles/min/mg protein) (Table 9). The total 
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protein content was greatly increased in higher dose of both scopoletin and baicalein (200 mg/kg) 
group compared to all other groups. 
6.6.3 Measurement of enzymatic antioxidant levels 
6.6.3.1 Estimation of catalase level 
Chronic administration of AlCl3 caused marked oxidative stress, which led to decrease in the 
antioxidant enzyme levels. In the present study, a significant (P>0.05) decrease in the catalase level 
was found in AlCl3 treated group (0.98±0.34 µmoles/min/mg protein) compared to the control (3.58
±0.46 µmoles/min/mg protein). Treatment with baicalein (100 mg/kg and 200 mg/kg) resulted in 
significant (P>0.01) increase in the catalase level (3.66±0.38 and 3.78±0.42 µmoles/min/mg protein) 
and scopoletin (100 mg/kg and 200 mg/kg) significantly (P>0.01) reversed the catalase level (3.76
±0.66 and 3.88±0.42 µmoles/min/mg protein). Donepezil (5 mg/kg) increased the catalase level 
(3.72±0.44 µmoles/min/mg protein) compared to the negative control group (Table 10). 
6.6.3.2 Evaluation of superoxide dismutase 
Superoxide dismutase scavenges the superoxide anion to hydrogen peroxide, hence diminishing 
the toxic effect caused by the radicals. The SOD level was significantly (P>0.05) decreased to 0.62
±0.74 units/mg tissue protein in negative control group compared to control group (2.74±0.38 units/
mg tissue protein). Donepezil (5 mg/kg, p.o.) resulted in a elevated SOD level (2.88±0.68 µmoles/
min/mg protein) in the brain compared to negative control. In the baicalein (100 mg/kg and 200 mg/
kg) treated mice, there was a significant (P>0.01) reversal in the level of SOD to 2.78±0.34 and 2.94
±0.64 µmoles/min/mg protein and scopoletin (100 mg/kg and 200 mg/kg) significantly (P>0.01) 
increased the SOD level (2.92±1.02 and 3.12±0.48 µmoles/min/mg protein) emphasising the 
antioxidant potential of baicalein and Scopoletin (Table 10). 
Table 10: Effect of baicalein and scopoletin on enzymatic and non-enzymatic antioxidant level in 
AlCl3 treated mice 
Groups CAT SOD GPx GSSH GSH Control 3.58±0.46 2.74±0.38 1.82±0.42 25.38±0.94 3.24±0.36 
Negative Control (AlCl3) 0.98±0.34* 0.62±0.74* 0.58±0.24* 16.25±1.31* 0.94±0.48* Baicalein (100 
mg/kg) 3.66±0.38** 2.78±0.34** 1.90±0.48** 24.16±0.88** 3.34±0.44** Baicalein (200 mg/kg) 3.78
±0.42** 2.94±0.64** 2.08±0.28** 26.58±0.97** 3.48±0.38** Scopoletin (100 mg/kg) 3.76±0.66** 2.92
±1.02** 2.02±0.36** 26.48±1.08** 3.40±0.42** Scopoletin (200 mg/kg) 3.88±0.42** 3.12±0.48** 2.28
±0.62** 28.35±0.94** 3.64±0.72** Standard (Donepezil) 3.72±0.44** 2.88±0.68** 1.96±0.52** 26.18
±1.24** 3.42±0.38** 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.6.3.3 Determination of glutathione peroxidase level 
AlCl3 treated mice significantly (P>0.05) decreased the GPx level to 0.58±0.24 when compared to 
the control group (1.82±0.42) and enzymatic activity of GPx in donepezil treated group was found to 
be 1.96±0.52. Administration with baicalein (100 and 200 mg/kg) significantly (P>0.01) increased the 
level of GPx (1.90±0.48 and 2.08±0.28) and scopoletin (100 mg/kg and 200 mg/kg) treated animals 
showed elevated levels of GPx to 2.02±0.36 and 2.28±0.62 when compared to negative control 
(Table 10). Effective restoration of GPx level and the generation of free radicals and neuronal 
damage was reduced in the scopoletin (200 mg/kg) treated group. 
6.6.3.4 Estimation of glutathione reductase level 
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The glutathione reductase level was significantly (P>0.01) decreased in negative control group to 
16.25±1.31 when compared to the control group (25.38±0.94) and enzymatic activity in donepezil 
treated group was found to be 26.158±1.24. Baicalein treated (100 and 200 mg/kg) animals 
significantly (P>0.01) increased the level of glutathione reductase to 1.52±0.28 and 1.66±0.32 and 
treatment with scopoletin (100 and 200 mg/kg) significantly (P>0.01) elevated the glutathione 
reductase level (1.58±0.40 and 1.76±0.36) (Table 10). Flavonoids treated animals showed increased 
level of antioxidant enzyme which in turn results in the improvement of neuroprotective potential of 
scopoletin and baicalein. 
6.6.4 Non enzymatic antioxidant assay 
6.6.4.1 Determination of reduced glutathione 
Glutathione is a tripeptide which can remove the free radical species and maintain the membrane 
protein thiols and act as a substrate for GPx and glutathione transferase. Reduced glutathione level 
in brain of the negative control (AlCl3) group was significantly (P>0.05) reduced to 0.94±0.48 
nmoles/min/mg tissue protein when compared to the control group. Donepezil (5mg/kg) treated 
animals significantly increased the reduced glutathione level 3.42±0.38 nmoles/min/mg tissue 
protein in the brain. Administration with baicalein (100 and 200 mg/kg) showed significantly (P>0.01) 
increased values 3.34±0.44 and 3.48±0.38 and scopoletin (100 and 200 mg/kg) increased 
significantly (P>0.01) the levels of reduced glutathione to 3.40±0.42 and 3.64±0.72 (Table 10). 
6.6.5 Estimation of DPPH assay 
The DPPH scavenging activity was significantly decreased (P>0.05) in negative control group to 
8.16±1.24 when compared to the control group (16.22±0.86). Baicalein and scopoletin 
demonstrated remarkable H-donor activity. The highest DPPH radical scavenging activity was 
detected in the higher concentration of scopoletin (200 mg/kg) 19.24±0.95, followed by the 
scopoletin 100 mg/kg, baicalein (200 mg/kg, 100 mg/kg) exhibited lower DPPH scavenging activity 
compared to sscopoletin treated mice with the values of 18.08±1.08, 17.52±0.96 and 16.18±1.18 
respectively. These activities were less than that of the standard, donepezil (17.12±1.28) (Table 11). 
Table 11: Effect of baicalein and scopoletin on DPPH and MDA level in AlCl3 treated mice 
Groups MDA (nmoles/min/mg) DPPH (nmoles/min/mg) Control 0.98±0.36 16.22±0.86 Negative 
Control (AlCl3) 4.12±0.48* 8.16±1.24* Baicalein (100 mg/kg) 0.72±0.54** 16.18±1.18** Baicalein 
(200 mg/kg) 0.60±1.08** 17.52±0.96** Scopoletin (100 mg/kg) 0.62±0.36** 18.08±1.08** Scopoletin 
(200 mg/kg) 0.54±0.28** 19.24±0.95** Standard (Donepezil) 0.66±0.62** 17.12±1.28** 
Values are expressed as mean ± SEM; n = 6. 
*P >0.05 when compared to vehicle control; **P >0.01 when compared to negative control (One way 
ANOVA followed by Dunnett’s test). 
6.6.6 Determination of lipid peroxidation level 
Increase in the level of lipid peroxides in the brain reflects the neuronal damage and thus leads to 
AD. Elevated level of MDA was observed in AlCl3-treated mice (4.12±0.48 nmoles/min/mg tissue 
protein), whereas it was significantly (P>0.05) reversed in flavonoids-treated groups. Donepezil (5 
mg/kg, p.o) decreased the MDA level to 0.66±0.62 nmoles/min/mg tissue protein. Baicalein (100 
and 200 mg/kg) treated mice showed significantly (P>0.05) decreased MDA level in brain to 0.72
±0.54 and 0.60±1.08 nmoles/min/mg tissue protein as compared to the negative control group and 
scopoletin (100 and 200 mg/kg) significantly (P>0.01) reduced the level of MDA (0.62±0.36 and 0.54
±0.28) when compared to negative control group. The results suggested that scopoletin possibly 
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has potent antioxidant property to reduce oxidative stress induced membrane lipid peroxidation 
(Table 11). 
Fig. 42 The demonstration of the effects of baicalein and scopoletin in AlCl3induced AD (A- Normal 
histological architecture without any degenerative changes; B-Severe neurodegenerative changes; 
C- Cytoplasmic vacuolation; D- Moderate degenerative changes; E- Cytoplasmic vacuolation; F- 
Stray vacuolation and congested vessels; G- Moderate neurodegenerative changes with 
vacuolation; H- Normal glial cell population; I-Mild congestion and less degenerative changes) 
6.6.7 Histopathological studies of the baicalien and scopoletin against chronic AlCl3 treatment in 
mice 
AlCl3 treated mice brain demonstrated severe degenerative changes and cytoplasmic vacuolation 
which in turn results in the cognitive impairment when compared to control group with normal 
histological architecture without any degenerative changes. Administration of donepezil exhibited 
mild congestion and less degenerative changes indicating the therapeutic efficacy. Mice treated with 
baicalein at a dose of 100 mg/kg presented moderate degenerative changes with cytoplasmic 
vacuolation and baicalein at higher dose of 200 mg/kg resulted in the intact histological structure 
with stray vacuolation and congested vessels. Treatment with scopoletin (100 mg/kg) showed 
moderate neurodegenerative changes with vacuolation indicating the moderate therapeutic efficacy 
and high dose of scopoletin (200 mg/kg) resulted in normal histological features with appearance of 
normal glial cell population which further emphasize the therapeutic efficacy of the scopoletin (Fig. 
42). 
7. DISCUSSION 
Drug design is an important tool in the field of medicinal chemistry where new compounds are 
synthesized by molecular or chemical manipulation of the lead moiety in order to produce highly 
active compounds with minimum steric effect211. Docking of small molecules in the receptor binding 
site and estimation of binding affinity of the complex is a vital part of structure based drug 
design212, 213. A huge breakthrough in the process of drug design was the development of in silico 
method to predict the therapeutic efficacy of the molecule214. 
7.1 Evaluation of drug likeness properties 
The pharmacologically active substituents were characterized by calculating steric, hydrophobic, 
electronic, and hydrogen bonding properties as well as by the drug-likeness score. The theory of 
drug-likeness score helps to optimize pharmaceutical and pharmacokinetic properties, for example, 
chemical stability, solubility, distribution profile and bioavailability. The molecular descriptors have 
developed as rationally predictive and informative, for example, the Lipinski's Rule-of-Five119. The 
better oral absorption of the ligands and drug likeness scores are constructed by the solubility, 
diffusion, Log P, molecular weight etc. Before the docking studies, the ligands were evaluated for its 
drug likeness properties. MedChem Designer software was used to evaluate the Lipinski’s rule of 
five for the flavonoids215. 
In the present study, lead optimization of the selected flavonoids was done by computation of 
druglikeness properties. Two hundred and forty five flavonoids were evaluated for its drug likeness 
properties with the help of MedChem Deisgner. All the 245 flavonoids showed excellent drug 
likeness score which indicate that these compounds have no violations or acceptable violations in 
Lipinski’s Rule of 5. All the selected flavonoids were exhibiting considerable pharmacokinetic profile 
and were selected for in silico biological screening against AChE and BuChE using AutoDock 4.2. 
7.2 In silico AChE and BuChE inhibition 
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Molecular docking is a frequently used tool in computer-aided structure-based rational drug design. 
It evaluates how small molecules called ligands (flavonoids) and the target macromolecule fit 
together216. The use of computers to predict the binding of libraries of small molecules to known 
target structures is an increasingly important component in the drug discovery process217, 218. 
There is a wide range of software packages available for the conduct of molecular docking 
simulations like, AutoDock, GOLD, FlexX etc.122, 219. Among these, AutoDock 4.2 is the most 
recent version which has been widely employed for virtual screening, due to its enhanced docking 
speed220. Its default search function is based on Lamarckian Genetic Algorithm (LGA), a hybrid 
genetic algorithm with local optimization that uses a parameterized free-energy scoring function to 
estimate the binding energy221. 
AChE is a key enzyme in the central nervous system and inhibition of it leads to increase of neural 
acetylcholine levels which is one of the therapies for symptomatic relief of mild to moderate AD 222. 
Hence the inhibition of AChE is one of the central focuses for drug development to combat AD223. 
In the present study, 245 flavonoids were selected for the in silico docking studies. The docking 
studies were performed by the use of AutoDock4.2. Its principle is based on Monte carlo and 
Simulated annealing methods in combination with genetic algorithm which is used for the global 
optimization. In the docking studies, if a compound shows lesser binding energy compared to the 
standard it proves that the compound has higher activity. The inhibition constant was correlated to 
half-maximal inhibitory concentration (IC50) at which 50% of the target was inhibited. This 
quantitative measure indicates the amount of a particular drug needed to inhibit a biological process. 
Based upon the chemical structure classification of our selected flavonoids, the AChE inhibitory 
activity was found to be, Flavones < Coumarin derivatives < Flavonones < Iso flavones < Flavonols. 
The minimum binding energy indicated that AChE and BuChE were successfully docked with 
selected flavonoids. These flavonoids showed an excellent binding mode when compared with the 
standard donepezil against AChE and BuChE. 
The amino acid residues are dynamically involved in the formation of hydrophilic and hydrophobic 
contacts and there were initiated to play important role in the binding site of target. Islam et al., 
studied the in silico QSAR analysis of quercetin and found that quercetin has higher binding score 
than the conventional drugs when allowed to bind at the same pocket of the AChE as conventional 
drugs224. The hydrogen bonds formed by quercetin involve the same amino acid residues Tyr 124, 
Ser 293 and Tyr 341 as for conventional drugs. Moreover, different atoms of other amino acid 
residues such as Phe 295, Arg 296, Tyr 337 and Tyr 341 participate to form the hydrogen bonds225. 
While binding at the active site, a number of hydrogen bonds between different atoms of AChE and 
the inhibitors participate to interact with each other to make the binding affinity much stronger. In the 
present study, the flavonoids showed the similar amino acid residues Tyr 124, Trp 286, Phe 295 and 
Tyr 341 against AChE as for the standard donepezil. Similarly, in case of BuChE flavonoids showed 
the binding interactive residues such as His 77, Lys 131, Val 204, Ser 287, Thr 346. This proves that 
the selected flavonoids possess potential AChE and BuChE inhibitory binding sites when compared 
to the standard. 
The presence of a benzopyran ring in their basic nucleus of the flavonoids would have contributed to 
its cholinesterase inhibitory activity. From these results, it was proved that all the selected flavonoids 
showed higher activity than the standard donepezil. This molecular docking analysis may further 
lead to the development of potent ChE inhibitors for the prevention and treatment of AD. 
7.3 In vitro AChE and BuChE inhibition 
Alzheimer’s disease (AD), a common type of progressive neurodegenerative disease, is 
characterized by low level of neurotransmitter (acetylcholine), oxidative stress and neuro-
inflammation in brain stream226. Effective treatment strategies rely mostly on either enhancing the 
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cholinergic function of the brain by stimulating the cholinergic receptors, improve the level of 
acetylcholine from being a breakdown by cholinesterase enzymes or induce antioxidant therapy and 
anti-inflammatory agents227. 
Acetylcholine (ACh) is the main neurotransmitter that is depleted in AD. This ACh plays an important 
role in learning things and in memory function. ACh is generally stored and released from the nerve 
terminals. In AD patients’ large amount of AChE and BuChE released in the system that makes the 
working half-life of ACh is too short. AChE enzyme hydrolyses ester bond of the ACh molecule to 
make it choline and ester. BuChE enzyme is prominent in glial cells, which have almost same 
activity on ACh228. 
Till date the most promising target for the symptomatic treatment and slowing of AD progression is 
cholinesterase inhibitors. In AD the destruction of cholinergic neurones causes a depletion of 
ACh229. By inhibiting AChE, the enzyme which catalyses break down of ACh, levels of this 
neurotransmitter can be elevated and function improved. This approach has a particular success as 
these cholinergic neurones are found mainly in regions associated with learning and memory - 
spreading from the basal forebrain230 and hippocampus up to the cerebral cortex231, 232. 
Therefore, inhibition of AChE and BuChE level is an important strategy to treat AD. The enzyme 
inhibitory activity of the flavonoids was determined by Ellman’s method. This method based on the 
reaction between acetylthiocholine iodide or butyrylthiocholine iodide, DTNB, flavonoids and the 
enzyme solution. The enzymatic activity was measured spectrophotometrically, by the formation of a 
yellow coloured complex produced by reaction with DTNB ion. 
The selected flavonoids exhibited an excellent AChE and BuChE inhibitory activity than the 
standard. The results indicated that the flavonoids may be a potential source of cholinergic 
inhibition. In the current study, out of 245 flavonoids taken for in silico docking studies, 20 flavonoids 
were selected for the in vitro enzyme inhibitory assay. The selection of the flavonoids was based on 
high, moderate and low neuroprotective activity against the targets. The absorbance of all the 
selected flavonoids decreased upon increasing concentrations in a dose dependent manner. The in 
vitro enzymatic activity of the flavonoids exhibited the potential AChE and BuChE inhibitory activity 
than the standard donepezil. The results validated the in silico docking studies and it further 
confirms that the selected flavonoids could be a promising remedy for the AD. 
7.4 Acute toxicity studies 
The acute toxicity studies were performed as per the OECD guidelines. Based on the acute toxicity 
studies, we had selected the two different doses of the selected flavonoids baicalein and scopoletin. 
The results of acute toxicity studies have revealed that, these compounds were considered non-
toxic up to the dose of 2000 mg/kg and therefore 1/10th and 1/20th dose was used for the biological 
evaluation and the in vivo scopolamine and aluminium induced learning impairment studies were 
conducted at dose levels of 100 and 200 mg/kg body weight. 
7.5 Acute scopolamine-induced amnesia 
Scopolamine is widely utilized as an experimental tool to study the anti-amnesic potential of new 
drugs233. Scopolamine hydrobromide is an anticholinergic drug, which produces dementia by 
reducing the levels of acetylcholine, which is considered to be an important neurotransmitter for 
learning and memory234. 
From the behavioral tests like, rectangular maze test and Morris water maze test, it is clearly seen 
that there was a significant decrease in the transfer latency in all the flavonoids treated groups 
compared to the scopolamine-treated group. The memory loss effect of scopolamine is more 
prominent compared to the control group. In comparison with Donepezil, the higher dose (200 mg/
kg) of scopoletin and baicalein treated groups had excellent performance which indicates 
neuroprotective effect against scopolamine. Administration of scopoletin and baicalein at a dose of 
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200 mg/kg/p.o. for 7 days to animals successfully reversed the learning impairment produced by the 
scopolamine when compared to the lower doses of the selected flavonoids. 
There was a gradual increase in the locomotor activity and percentage of conditioned avoidance 
response in the flavonoids treated animals when compared to the standard. Thus, the potential 
neuroprotective behavioural changes in the flavonoids treated animals further augmented their role 
in the management of AD. 
The effect of the selected flavonoids in scopolamine-induced amnesia in mice was compared with 
donepezil, a known nootropic drug. It was observed that both the flavonoids showed significant 
improvement in conditional avoidance response (CAR) indicating protective effect of these 
flavonoids against scopolamine induced damage of memory. Along with behavioural parameters, 
the effect of flavonoids on the AChE activity, protein estimation enzymatic and non-enzymatic anti-
oxidants were also evaluated. 
The selected flavonoids showed a reduction of the AChE level that was increased after 
administration of scopolamine. It was reported that a decrease in AChE activity can lead to 
improvement in learning and memory235. The non-enzymatic production of lipid peroxidation (LPO) 
is associated mostly with cellular damage as a result of oxidative stress. In this process, 
malanoldehyde is generated as secondary products. The increased generation of reactive oxygen 
species (ROS) is implicated in the pathogenesis of many diseases and in the toxicity of a wide 
range of compounds. Brain tissue is rich in polyunsaturated lipids, has high iron content, and 
critically dependent on aerobic metabolism and thus highly vulnerable to ROS mediated oxidative 
damage. There are reports suggesting accumulation of LPO products in the brain of patients with 
Alzheimer's disease236. 
Our results also further emphasized the memory protective effect of the flavonoids. Scopoletin and 
baicalein significantly reduced brain AChE level, indicating the remarkable elevation of ACh level in 
the brain and thereby the flavonoids might possess anti-ChE activity. The selected flavonoids 
significantly improved antioxidant levels when compared to the scopolamine treated group. These 
results further augmented the potential effect of the selected flavonoids against the Alzheimer's 
disease. Our study revealed that scopoletin and baicalein enhanced the oxygen species markers in 
most of the brain regions by improving antioxidant enzymes. Administration of scopoletin (200 mg/
kg) exhibited the highest activity followed by the scopoletin (100 mg/kg) and baicalein treated 
groups. It is well known that cholinergic neuronal systems play an important role in the cognitive 
deficits associated with AD, ageing and neurodegenerative diseases. Flavonoids treated animals 
showed potential in inhibition of oxidative stress-induced neuronal damage in the neurodegeneration 
and also in antioxidant assays and thus represents promising neuroprotective activities. 
Superoxide anion plays an important role in the formation of other reactive oxygen species such as 
hydrogen peroxide, hydroxyl radical and singlet oxygen in living systems. SOD is considered to be a 
stress protein which is synthesized in response to oxidative stress237. Glutathione peroxidase 
catalyses the oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG) at the expense 
of hydrogen peroxide238. Catalase primarily causes the decomposition of H2O2 to water at a much 
faster rate, in association with glutathione peroxidase. Thus, a decrease in the activities of both 
catalase and glutathione peroxidase leads to an accumulation of H2O2. A decrease in the activity of 
glutathione reductase is due to the depletion of thiol which leads to related pathologies239. 
Treatment with scopoletin and baicalein significantly (P>0.01) enhanced the total protein and 
enzymatic antioxidant levels in the brain. In scopolamine treated mice, significant (P>0.05) reduction 
in antioxidant enzyme level was observed in the mice brain. Higher dose (200 mg/kg) of scopoletin 
and baicalein treated mice significantly (P>0.05) increased the level of the enzymatic antioxidant 
enzymes such as superoxide dismutase, catalase, peroxidase and glutathione reductase, thus 
showing the neuroprotective beneficial effect against scopolamine treatment. 
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Glutathione is a major non-protein thiol in living organisms and protects the cellular defense system 
against the toxic effects of lipid peroxidation. Due to oxidative stress, the brain is unable to maintain 
the GSH redox state and oxidized glutathione (GSSG) is concentrated in some regions of the brain 
240. The cellular levels of the active forms of vitamin C and α-tocopherol are also maintained by 
GSH by neutralizing the free radicals. A decrease in GSH level leads to a decrease in cellular levels 
of α-tocopherol241. In the present study, a significant decrease in the levels of non-enzymatic 
antioxidants like GSH was observed in scopoletin and baicalein treated mice. This could be due to 
an increased utilization of GSH for scavenging the toxic products. Mice treated with higher dose of 
scopoletin and baicalein significantly restored the levels of GSH in the brain suggesting the 
involvement of GSH-dependent detoxification of free radical. These observations reveal that 
scopoletin and baicalein treated groups has enhanced the antioxidant potential. 
Increased lipid peroxidation in ethanol treated rats showed in a depletion of the cellular antioxidant 
defense system. Inhibition of SOD results in the generation of partially reduced oxygen species. 
When SOD activity is decreased, neurons are more vulnerable to oxyradical injury242. There was a 
significant elevation in MDA and a decrease in total protein and antioxidant enzymes in scopolamine 
treated mice (negative control) compared to normal control. These results suggest that scopoletin 
and baicalein can be used for the treatment of AD attributing to their antioxidant and neuroprotective 
activities. In the histopathological studies, scopolmine treated mice indicated severe 
neurodegenerative changes and also resulted in the formation of neurofibrillary tangles and 
scopoletin (200 mg/kg) administered animals resulted in normal histological architecture with mild 
infiltration of inflammatory cells which indicates the effective repair mechanism of the high dose of 
scopoletin. 
7.6 Chronic in vivo aluminium chloride-induced dementia 
Based on the in vivo acute scopolamine studies, the flavonoids were selected for the chronic in vivo 
aluminium chloride induced dementia. Aluminium is a ubiquitous metal and has been associated in 
the etiology of Alzheimer’s disease where it intensifies brain oxidative damage. Based on the 
literatures AlCl3 is considered as a recognized etiological factor in a series of neurodegenerative 
disorders for many decades243. Several natural compounds such as curcumin and naringin exhibit 
neuroprotective effect against AlCl3-induced cell damages in various experimental models181. Our 
current study explores the role of the selected flavonoids during chronic administration of AlCl3-
induced neurotoxicity. 
AlCl3 is cholinotoxin, which produces functional alterations in the cholinergic and noradrenergic 
neurotransmission. AChE is a specific cholinergic indicator has received wide attention in the study 
of AlCl3 neurotoxicity. AChE is more accountable for acetylcholine metabolism whose modifications 
caused neurobehavioral fluctuations particularly in memory and cognitive function. AChE catalyzes 
the hydrolysis of acetylcholine into inactive metabolites, choline and acetate. Numerous literatures 
have shown that augmented AChE level is a prelude to oxidative stress244. Consistent with the 
previous discoveries, a substantial elevation in AChE activity was observed in AlCl3 exposure rats, 
which signifies impaired cholinergic function245. 
Scopoletin and baicalein at a dose of 200 mg/kg/p.o. for 90 days reversed the learning impairment 
produced by the AlCl3 in mice. Flavonoids treated animals significantly decreased the transfer 
latency time in rectangular maze test and escape latency time in Morris water maze test which 
results in improvement of the learning and memory. There was a substantial elevation of locomotor 
function and percentage of conditioned avoidance response in pole climbing method in scopoletin 
and baicaelin treated mice. These remarkable behavioural changes in the animals further highlight 
the role of scopoletin and baicalein in the management of AD. 
Catalase plays a major role in cellular antioxidant defense system by decomposing H2O2, thereby 
preventing the generation of hydroxyl radical through the Fenton reaction246. Accumulating 
evidence suggests that aluminium decreased the level of enzymatic antioxidants in the brain, such 
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as catalase (CAT), superoxide dismutase (SOD) and glutathione (GSH). The effect of Al contact is 
consistent with the previous studies that result in the decreased levels of CAT and SOD in the 
brain247. 
Scopoletin and baicalein treated mice significantly elevated the level of total protein and enzymatic 
and non-enzymatic antioxidant levels and thus lead to a reduction of neural stress which enhances 
the synaptic communication. These results further augmented the long term potential effect of the 
selected flavonoids against the Alzheimer's disease. 
Our study demonstrated that, the selected flavonoids enhanced the oxygen species markers in most 
of the brain regions by improving the levels of antioxidant enzymes. Thus result implied that, 
because of elevated the level of antioxidant enzyme by the selected flavonoids shows the reduction 
of neural stress, and enhances the synaptic communication. Our results also further emphasize the 
memory enhancing effect of the flavonoids against chronic administration of aluminium chloride. The 
selected flavonoids significantly improved antioxidant levels. These results further augmented the 
long term potential effect of the selected flavonoids against the Alzheimer's disease. 
In the histopathological studies, negative control group showed severe degenerative changes and 
cytoplasmic vacuolation results in cognitive impairment. Scopoletin (200 mg/kg) treated group 
resulted in normal histological features with appearance of normal glial cell population. The short 
and long-term administration of the scopoletin 200 mg/kg and baicalein 200 mg/kg exhibited 
prominent effect in the reversal of the both scopolamine and aluminium-induced learning impairment 
in both behavioural and biochemical estimations. 
The long term chronic neuroprotective effect of the scopoletin and baicalein was investigated 
against aluminium-induced learning impairment in mice. The long term administration of flavonoids 
(90 days) further improved the neuroprotective activities which further correlates with the results of 
acute scopolamine model. 
8. CONCLUSION 
Alzheimer’s disease is a neurodegenerative disorder associated with a decline in cognitive abilities. 
The deficiency of acetylcholine is one of the characteristics of AD and responsible for most of its 
symptoms, such as a decline in memory and cognition. As a consequence of its role as a target for 
AD therapy, AChE is one of the most studied target in the Alzheimer’s field and the vast majority of 
reports in the field relate with treatment strategies associated with the use of AChE inhibitors. 
Despite the severity and high prevalence of this disease, the allopathic system of medicine is yet to 
provide a satisfactory drug candidate. Hence, the present study was focused on exploration of the 
memory enhancing activity of the flavonoids in scopolamine and aluminium-induced learning 
impairment in mice. 
The current study suggests that the flavonoids, baicalein and scopoletin possessed excellent 
binding interactions and docking score with AChE and BuChE enzymes than the standard 
(donepezil) in in silico studies. The in silico studies addressed the flavonoids stability against AChE 
and BuChE (protein-ligand complex) by molecular dynamic simulation. The in silico studies is 
actually an added advantage to screen the ChE enzyme inhibition. Two hundred and forty five 
compounds were selected and screened in the computational studies and among these compounds 
20 flavonoids have been selected for the in vitro enzyme inhibition studies based on their docking 
results. 
In vitro enzyme inhibition studies also proved that selected 20 flavonoids were effective in inhibiting 
ChE enzymes, which is considered to be related to the mechanism of memory dysfunction. The 
results of the in vitro studies were in correlation with the in silico predictions. Among the 20 selected 
flavonoids, scopoletin and baicalein demonstrated excellent inhibition constant (IC50) values in both 
computational and experimental studies towards AChE and BuChE and thereby these compounds 
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possess potential ChE inhibitory activity. In the light of these findings, it can be concluded that 
scopoletin and baicalein showed less IC50 values against both enzyme targets (AChE and BuChE) 
and could be considered worthwhile to check its in vivo memory enhancing activity to be used in 
treatment of AD. 
The results of acute toxicity studies have revealed that, baicalein and scopoletin were considered 
non-toxic up to the dose of 2000 mg/kg and therefore 1/10th and 1/20th dose was used for the 
biological evaluation and the in vivo scopolamine and aluminium induced learning impairment 
studies were conducted at dose levels of 100 and 200 mg/kg body weight. 
The findings of acute model with scopolamine induced amnesia model suggested that the higher 
dose of scopoletin and baicalein (200 mg/kg) treated animals showed excellent neuroprotective 
activity in all the behavioural assessment studies performed. Administration of scopoletin and 
baicalein (200 mg/kg/p.o. for 7 days) to animals reversed the learning impairment produced by the 
scopolamine. Scopoletin and baicalein treated animals effectively decreased the transfer latency 
time in rectangular maze test, escape latency time in morris water maze test which emphasize the 
improvement of the learning and memory skills of the animals. There is a gradual increase in the 
locomotor function in actophotometer and percentage of conditioned avoidance response in pole 
climbing method was observed in the flavonoids treated animals. These potential neuroprotective 
behavioural changes in the flavonoids treated animals further proved the role of scopoletin and 
baicalein in the management of AD. 
It is well known that cholinergic neuronal systems play an important role in the cognitive deficits 
associated with AD, ageing and neurodegenerative diseases. In our study, scopoletin and baicalein 
significantly reduced brain AChE activity, indicating the stimulating actions of these drugs on the 
cholinergic system. Hence, the memory-enhancing effect of the scopoletin and baicalein can be 
attributed to its anti-ChE activity. Flavonoids treated animals showed potential inhibition of oxidative 
stress-induced neuronal damage in the neurodegeneration and also in antioxidant assays and 
represent promising neuroprotective activities. 
The end products of lipid peroxidation viz. malondialdehyde and lipid hydroperoxides and the levels 
of tissue protein, enzymatic and non-enzymatic antioxidants in the brain were estimated. Treatment 
with the scopoletin and baicalein significantly enhanced the total protein and enzymatic and non-
enzymatic antioxidant levels in the brain. In scopolamine treated mice, significant (P>0.05) 
diminution was observed in brain antioxidant enzyme activity. Scopoletin and baicalein (200 mg/kg) 
treated mice significantly (P>0.05) increased the level of the antioxidant enzymes such as 
superoxide dismutase, catalase, peroxidase and glutathione reductase. Glutathione which is widely 
distributed in cells is an intracelluar reductant and plays a major role in catalysis and metabolism. 
The selected flavonoids significantly (P>0.01) increased the level of non-enzymatic antioxidant GSH 
whereas in the negative control, the levels were decreased. 
In the histopathological studies, the brains of negative control group (scopolamine treated animals) 
showed severe neurodegenerative changes resulting in formation of neurofibrillary tangles which 
was reversed in the flavonoid treated groups. Scopoletin (200 mg/kg) treated group resulted in 
normal histological architecture with mild infiltration of inflammatory cells which indicates the 
effective repair mechanism at a high dose of scopoletin. 
The findings of chronic AlCl3 model suggested that the higher dose (200 mg/kg) of scopoletin and 
baicalein treated animals showed excellent neuroprotective activity in all the behavioural 
assessment studies performed. Scopoletin and baicalein (200 mg/kg/p.o. for 90 days) treated 
animals reversed the learning impairment produced by the AlCl3. Scopoletin and baicalein treated 
animals significantly decreased the transfer latency time in rectangular maze test and escape 
latency time in morris water maze test which results in improvement of the learning and memory. 
There is a substantial elevation of locomotor function and percentage of conditioned avoidance 
response in pole climbing method was shown in the scopoletin and baicaelin treated mice. These 
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remarkable behavioural changes in the animals further highlight the role of scopoletin and baicalein 
in the management of AD. 
Scopoletin and baicalein significantly reduced brain AChE level, indicating the remarkable elevation 
of ACh level in the brain and thereby the flavonoids possess anti-ChE activity. Our study revealed 
that, high dose of scopoletin and baicalein improved antioxidant enzymes in most of the brain 
regions. Administration of scopoletin (200 mg/kg) exhibited the highest activity followed by the 
scopoletin (100 mg/kg) and baicalein treated groups. 
AlCl3 treated mice showed significant reduction in total protein and enzymatic and non-enzymatic 
antioxidant levels which in turn results in cognitive impairment. Scopoletin and baicalein (200 mg/kg) 
treated mice significantly (P>0.05) increased the level of the antioxidant enzymes such as 
superoxide dismutase, catalase, peroxidase and glutathione reductase. Scopoletin and baicalein 
treated mice significantly elevated the level of total protein and enzymatic and non-enzymatic 
antioxidant levels and thus lead to reduction of neural stress which enhances the synaptic 
communication. These results further augmented the long term potential effect of the selected 
flavonoids against the Alzheimer's disease. 
In the histopathological analysis, the brains of negative control group showed severe degenerative 
changes and cytoplasmic vacuolation which in turn results in the cognitive impairment which was 
recovered by the flavonoid treated groups so effectively than the standard drug. Scopoletin (200 mg/
kg) treated group resulted in normal histological features with appearance of normal glial cell 
population. The short term (7 days) and long-term (90 days) administration of the scopoletin 200 
mg/kg exhibited pronounced effect in the reversal of the both scopolamine and aluminium-induced 
learning impairment in both behavioural and biochemical estimations. 
In conclusion, it has been clearly demonstrated that the approach utilized in this study is successful 
in finding novel anti-alzhiemer’s drugs. In particular, higher dose of scopoletin and baicalein, showed 
excellent neuroprotective effects against in silico, in vitro enzyme inhibitory and in vivo acute 
scopolamine and chronic AlCl3 induced learning impairment models. Hence, scopoletin and 
baicalein could be considered as a therapeutic agent to prevent or slow down the development of 
neurodegenerative diseases such as AD. Further research is required to explore the detailed 
mechanism of action of the scopoletin and baicalein specifically targeting the pathogenetic 
mechanisms like amyloid deposition and tau hyperphosphorylation might provide a definite 
therapeutic edge and thereby extensive clinical trials are needed to identify a potential chemical 
entity for clinical use in the prevention and treatment of alzhiemer’s disease. 
9. IMPACT OF THE STUDY 
Alzhiemer’s disease is a progressive neurodegenerative disorder characterized by a gradual decline 
in memory associated with shrinkage of brain tissue, with localized loss of neurons mainly in the 
hippocampus and basal forebrain, with diminished level of acetylcholine. It has also reported to be 
associated with accumulation of beta-amyloid and neurofibrillary tangles in the brain. WHO reports 
(2015) confirms that 47 million people are suffering from dementia globally and 4.1 million people 
are living with dementia in India. Based on this alarming situation, the search for the identification of 
novel drug candidate with lesser toxicity and increased efficacy is essential. Clinical trials allow the 
health sector people to learn the symptoms and causes of AD and also to test new management 
strategies. Treatment with AChE inhibitors is one of the important treatment strategies for AD 
patients. In the management of AD, initiation of an AChE inhibitor is suggested as early as possible. 
Despite the issues of cost, it is important that AChE inhibitor therapy is deliberated for patients with 
mild to moderate AD. 
The prevalence of AD and dementia has increased significantly nowadays. As none of the available 
medications appears to be able to reduce the disease progression, there is enormous medical need 
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for the development of novel therapeutic strategies that target the underlying pathogenic 
mechanisms in AD. 
The present study revealed that scopoletin and baicalein potentiates the neuroprotective activity in 
in silico, in vitro studies and in both acute scopolamine and chronic AlCl3-induced AD in mice. 
Scopoletin and baicalein possess significant advantages over existing drug candidates and these 
compounds may possess industrial acceptability. The observed neuroprotective and enhanced 
cognitive functions could be due to reducing the AChE level and antioxidant activities of the 
flavonoids in mice brain. Hence, this could be an effective drug of choice in the management of AD. 
Keeping in mind that scopoletin and baicalein has broad neuroprotective properties as observed in 
the current study. Its use might slow the progression of the multifactorial Alzhiemer’s disease. 
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that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
21: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 78% 
In addition, the upper layers of the cortex typically become spongy 
and soft and have protein insertions (tau protein or the transactive 
DNA-binding protein) 21. 
1.2.5 
21: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 78% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
23: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 79% 
characterized by the hallmark abnormalities of more than one cause 
of dementia most commonly Alzheimer’s combined with vascular 
dementia, followed by Alzheimer’s with DLB, and Alzheimer’s with 
vascular dementia and DLB. Vascular dementia with 
23: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 79% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
27: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 27: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 
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variant Creutzfeldt-Jakob disease is believed to be caused by 
consumption of products from cattle affected by mad cow disease23. 
1.2.7 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
30: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 
the substantia nigra. The aggregates are thought to cause 
degeneration of the nerve cells that produce dopamine. 
30: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
33: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 
Symptoms include difficulty in walking, memory loss and inability to 
control urination. 
33: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 100% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
35: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 94% 
can sometimes be corrected with surgical installation of a shunt in 
the brain to drain excess fluid26. 
1.3 ALZHEIMER'S 
35: D Sheeja Malar Ph.D Thesis 501 2012-13.docx 94% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
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Instances from: Lubhan Singh without references.doc 
3: Lubhan Singh without references.doc 71% 
NEURODEGENERATIVE DISORDERS 
Neurodegenerative disorders are categorized by progressive and 
irreversible loss of neurons from particular regions of the brain. 
Prototypical neurodegenerative disorders include Parkinson's 
disease (PD) and Huntington's disease (HD), results in deviations in 
the control of 
3: Lubhan Singh without references.doc 71% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
6: Lubhan Singh without references.doc 58% 
loss of neurons from structures of the basal ganglia1, 2. Alzheimer's 
disease (AD), results in the loss of cortical and hippocampal neurons 
with impairment of memory and cognitive ability and amyotrophic 
lateral sclerosis (ALS), producing muscular weakness 
6: Lubhan Singh without references.doc 58% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
9: Lubhan Singh without references.doc 54% 
degeneration of bulbar, spinal, and cortical motor neurons3, 4. 
Neurodegenerative disorders are comparatively common and 
represent a substantial societal and medical problem. They are 
9: Lubhan Singh without references.doc 54% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
12: Lubhan Singh without references.doc 72% 
of later life, developing in individuals who are neurologically normal, 
although childhood-onset forms of each of the disorders are known. 
PD is detected in more than 1% of population above the age of 655, 
12: Lubhan Singh without references.doc 72% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
89
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
6, whereas AD affects as many as 10% of the same individuals7. 
HD, which is a genetically stable autosomal dominant disorder, is 
less common in the population as a whole but disturbs, on average, 
50% of each generation in families booming the gene. ALS also is 
moderately rare but sometimes leads to disability and death8, 9. 
At present, the pharmacological therapy of neurodegenerative 
disorders is restricted mostly to symptomatic treatments that do not 
change the course of the underlying disease. Symptomatic 
management for PD, where the neurochemical deficit created by the 
disease is well defined. 
15: Lubhan Singh without references.doc 83% 
The available treatments for AD, HD, and ALS are much more 
limited in effectiveness, and 
15: Lubhan Singh without references.doc 83% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
52: Lubhan Singh without references.doc 71% 
at room temperature for 30 minutes and the absorbance of the 
reaction mixture was measured at 405 nm. 
52: Lubhan Singh without references.doc 71% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
57: Lubhan Singh without references.doc 83% 
The reaction was initiated by the addition of NADH. The reaction 
mixture 
57: Lubhan Singh without references.doc 83% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
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Instances from: 16_chapter10.pdf 
38: 16_chapter10.pdf 100% 
to achieve an optimized conformation for both the protein and ligand 
and relative orientation between protein and ligand such that the free 
energy of the overall system is minimized102. 
38: 16_chapter10.pdf 100% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
40: 16_chapter10.pdf 88% 
In the field of molecular modeling, 
docking is a method which predicts the preferred orientation of one 
molecule to a second when bound to each other to form a stable 
complex. Knowledge of the preferred orientation may be used to 
predict the binding affinity between two molecules 
40: 16_chapter10.pdf 88% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
41: 16_chapter10.pdf 89% 
the docking process, the ligand and the protein adjust their 
conformation to achieve an overall “best-fit” and this kind of 
conformational adjustments results in the overall binding 
41: 16_chapter10.pdf 89% 
The source document can not be shown. The most likely reason is 
that the submitter has opted to exempt the document as a source in 
Urkund's Archive. 
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Instances from: Thesis Final Work 27062017.docx 
53: Thesis Final Work 27062017.docx 71% 
Animals were observed individually at least once during the first 30 
minutes after dosing, periodically during the first 24 hours (with 
special attention during the first 4 hours) and daily thereafter for a 
53: Thesis Final Work 27062017.docx 71% 
animals were observed individually after dosing atleast once during 
the first 30 minutes periodically and during the first 24 hours with 
special attention given during the first 4 hours and daily thereafter for 
a 
54: Thesis Final Work 27062017.docx 100% 
by Committee for the Purpose of Control and Supervision of 
Experiments on Animals ( 
54: Thesis Final Work 27062017.docx 100% 
by committee for the purpose of control and Supervision of 
Experiments on Animals ( 
58: Thesis Final Work 27062017.docx 90% 
One-way Analysis of Variance (ANOVA) followed by Dunnett’s test. 
58: Thesis Final Work 27062017.docx 90% 
one-way analysis of variance (ANOVA), which was followed by 
Dunnett’s test. 
92
U R K N DU Madeswaran Final Thesis.doc (D29512176) 
Instances from: 107cd289-b95b-422a-b194-c980f3b9a6c7 
16: 107cd289-b95b-422a-b194-c980f3b9a6c7 52% 
when they develop in cortex region of the brain. Aggregation of 
alpha-synuclein in the brains of people with 
16: 107cd289-b95b-422a-b194-c980f3b9a6c7 52% 
When they develop in a part of the brain called the cortex, dementia 
can result. Alpha-synuclein also aggregates in the brains of people 
with 
17: 107cd289-b95b-422a-b194-c980f3b9a6c7 67% 
FTLD includes dementias such as behavioural-variant FTLD, 
primary progressive aphasia, corticobasal degeneration, Pick’s 
disease and progressive supranuclear palsy. Initial symptoms 
include marked changes in behaviour and personality and difficulty 
with 
17: 107cd289-b95b-422a-b194-c980f3b9a6c7 67% 
FTLD Includes dementias such as behavioral-variant FTLD, primary 
progressive aphasia, Pick’s disease, and progressive supranuclear 
palsy. 
Typical symptoms include changes in personality and behavior, and 
difficulty with 
24: 107cd289-b95b-422a-b194-c980f3b9a6c7 100% 
Recent studies suggest that mixed dementia is more common than 
previously 
24: 107cd289-b95b-422a-b194-c980f3b9a6c7 100% 
Recent studies suggest that mixed dementia is more common than 
previously 
25: 107cd289-b95b-422a-b194-c980f3b9a6c7 96% 
protein (prion) that causes other proteins throughout the brain to 
misfold and malfunction. 
25: 107cd289-b95b-422a-b194-c980f3b9a6c7 96% 
protein (prion) that causes other proteins throughout the brain to 
misfold and thus malfunction. 
28: 107cd289-b95b-422a-b194-c980f3b9a6c7 100% 28: 107cd289-b95b-422a-b194-c980f3b9a6c7 100% 
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variant Creutzfeldt-Jakob disease is believed to be caused by 
consumption of products from cattle affected by mad cow disease23. 
1.2.7 
Variant Creutzfeldt-Jakob disease is believed to be caused by 
consumption of products from cattle affected by mad cow disease. 
31: 107cd289-b95b-422a-b194-c980f3b9a6c7 92% 
alpha-synuclein aggregates appear in an area deep in the brain 
called 
the substantia nigra. The aggregates are thought to cause 
degeneration of the nerve cells that produce dopamine. 
The incidence of PD is about one-tenth that of 
31: 107cd289-b95b-422a-b194-c980f3b9a6c7 92% 
Alpha-synuclein aggregates are likely to begin in an area deep in the 
brain called the substantia nigra. The aggregates are thought to 
cause degeneration of the nerve cells that produce dopamine. 
The incidence of PD is about one-tenth that of 
36: 107cd289-b95b-422a-b194-c980f3b9a6c7 95% 
can sometimes be corrected with surgical installation of a shunt in 
the brain to drain excess fluid26. 
1.3 ALZHEIMER'S 
DISEASE ( 
36: 107cd289-b95b-422a-b194-c980f3b9a6c7 95% 
Can sometimes be corrected with surgical installation of a shunt in 
the brain to drain excess fluid. Abbreviations: AD, Alzheimer’s 
disease; 
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The current  objective  of the  study is to  identify  inhibitory  afﬁnity  potential of  the  certain commer-
cially  available  ﬂavonoids, against  crystal structure  of acetylcholinesterase (AChE)  enzyme using in silico
and in vitro  studies.  The inhibitory  proﬁles of the compounds  have  been  compared with  standard  AChE
inhibitor  donepezil.  In  the  docking  studies,  conformational site analysis  and  docking  parameters  like
binding  energy,  inhibition  constant and  intermolecular energy  were  determined using  AutoDock  4.2.
Docking  studies  conducted  with  diosmin,  silibinin, scopoletin, taxifolin and  tricetin exhibited  tight bind-
ing  forces prevailing  with  the enzyme  than between donepezil.  Based on the  in silico studies, compounds
were selected  for the  in  vitro AChE  inhibitory assay. In vitro  results showed  that  all the  selected  ﬂavonoids
displayed  excellent concentration-dependant  inhibition  of AChE.  Scopoletin was  found to be  the  most
potent  and  speciﬁc inhibitor of  the  enzyme  with  IC50  values  of 10.18 ± 0.68  M. Scopoletin  showed  sev-
eral strong hydrogen bonds  to several important amino acid  residues against  target  enzyme. A  number  of
hydrophobic  interactions  could also  explain  the  potency of the  compounds  to inhibit AChE. These molec-
ular docking and in  vitro  analyses  could  lead to  the  further development  of  potent  acetylcholinesterase
inhibitors for the treatment  of Alzheimer’s  disease.
© 2016 Elsevier B.V.  All  rights  reserved.
1.  Introduction
Drug design is  an important tool  in  the ﬁeld of medicinal
chemistry where new compounds are  synthesized by molecular
or chemical manipulation of the lead moiety in order to produce
highly active compounds with minimum steric effect [1]. Docking
of small molecules in  the receptor binding site and estimation of
binding afﬁnity of the complex is a vital part of structure based drug
design [2,3].
Alzheimer’s disease (AD), a common type of progressive neu-
rodegenerative disease, is characterized by  low level of neurotrans-
mitter (acetylcholine), oxidative stress and neuro-inﬂammation in
brain stream [4]. Effective treatment methodologies rely mostly on
either increasing the cholinergic function of the brain by stimulat-
ing the cholinergic receptors, improving the level of acetylcholine
∗ Corresponding author at:  Department of Pharmacology, College of  Pharmacy, Sri
Ramakrishna Institute of Paramedical Sciences, Coimbatore, 641 044, Tamil Nadu,
India.
E-mail address: madeswaran2@gmail.com (M.  Arumugam).
(ACh), preventing breakdown by cholinesterase enzymes and anti-
inﬂammatory agents [5].
ACh is  the major neurotransmitter located at all autonomic
ganglia, at various autonomically innervated organs, at the neuro-
muscular junction, and also found in various synapses in  central
nervous system. In central nervous system, ACh is  found pre-
dominantly in interneurons, and a  few vital long-axon cholinergic
pathways have also been recognized. Degeneration of this pathway
is one of the pathologies associated with AD [6].  During neuro-
transmission, ACh is  released from the nerve into the synaptic
cleft and binds to ACh receptors (nicotinic and muscarinic) on
the post-synaptic membrane, relaying the signal from the nerve.
Acetylcholinesterase (AChE), also located on the post-synaptic
membrane, terminates the signal transmission by hydrolyzing ACh
[7].
AChE is found in several types of conducting tissue such as nerve
and muscle, motor and sensory ﬁbers, central and peripheral tis-
sues, and cholinergic and noncholinergic ﬁbers. The activity of AChE
is higher in motor neurons than in sensory neurons [8–10].  Pseu-
docholinesterase (BuChE), also known as plasma cholinesterase
or  butyrylcholinesterase, is primarily found in the liver. Different
http://dx.doi.org/10.1016/j.ijbiomac.2016.11.062
0141-8130/© 2016 Elsevier B.V. All rights reserved.
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from AChE, BuChE hydrolyzes butyrylcholine faster than ACh [11].
AChE enzyme hydrolyzes ester bond of the ACh to breakdown into
choline and ester. BuChE enzyme is rich in  glial cells, which have
similar action on ACh. In AD  enhanced concentration of AChE and
BuChE results into the decreased half-life of ACh [12].
Currently the most favourable target for the symptomatic treat-
ment and slowing of AD development is cholinesterase inhibitors
[13]. Cholinergic neurones are  located mainly in regions associated
with learning and memory – spreading from the basal forebrain
[14] and hippocampus [15].  By inhibiting acetylcholinesterase
(AChE), the enzyme which catalyses break down of ACh, levels of
this neurotransmitter can be elevated and thus improve the learn-
ing and memory function.
Flavonoids and their related compounds are  a  group of
natural products which exhibits various biological and phar-
macological activities like  antibacterial, antiviral, antioxidant,
anti-inﬂammatory, anti-allergic, hepatoprotective, antithrombotic,
antiviral and antimutagenic effects and inhibition of several
enzymes [16,17]. Flavonoids can be  a  promising remedy to treat
AD by inhibiting AChE and thereby it can increase the ACh level.
Hence, the objective of the current study is to identify the  AChE
inhibitory afﬁnity potential of the certain commercially available
ﬂavonoids using in silico and in vitro studies.
2. Materials and methods
2.1. Software used
Python 2.7 – language was downloaded from www.python.
com [18],  Cygwin (a data storage) c:\program and Python 2.5
were simultaneously downloaded from www.cygwin.com [19],
Molecular graphics laboratory (MGL) tools and AutoDock 4.2
was downloaded from www.scripps.edu [20],  Discovery stu-
dio visualizer 2.5.5 was downloaded from www.accelerys.com
[21], Chemsketch was downloaded from www.acdlabs.com [22].
Online smiles translatory notation was carried out using cac-
tus.nci.nih.gov/translate/ [23].
2.2. Chemicals used
Donepezil, acetylcholinesterase, diosmin, silibinin, scopoletin,
and taxifolin were purchased from Sigma Aldrich, St.  Louis, MO.
All other drugs and chemicals used in the study were obtained
commercially and were of analytical grade.
2.3. Preparation of target enzyme
The crystal structure of mouse acetylcholinesterase (5HCU) pro-
tein database was downloaded from  the research collaboratory
for structural bioinformatics (RCSB) protein data bank (Fig. 1).
The preparation of the target protein 5HCU with the AutoDock
Tools involved adding all hydrogen atoms to  the macromolecule,
which is a step necessary for correct calculation of partial atomic
charges. Three-dimensional afﬁnity grids of size 277 × 277 ×  277 Å
with 0.6 Å spacing were centered on the geometric center of the
target protein and were calculated for  each  of the following atom
types: HD, C, A, N,  OA, and SA,  representing all possible atom types
in a protein [24].
2.4. Drug likeness properties of the ligands
The ﬂavonoid ligands like diosmin, silibinin, scopoletin, taxi-
folin, tricetin, and donepezil were built using ChemSketch (Fig. 2)
and optimized using “Prepare Ligands” in  the AutoDock 4.2  for
docking studies [25].
Fig. 1.  Reﬁned crystal structure of mouse acetylcholinesterase (5HCU).
2.5. In silico acetylcholinesterase inhibition
Lamarckian genetic algorithm (LGA) was used for ligand confor-
mational searching, which is  a hybrid of a genetic algorithm and a
local search algorithm. This algorithm ﬁrst builds a  population of
individuals (genes), each being a  different random conformation of
the docked molecule. Each individual is  then mutated to acquire
a slightly different translation and rotation and the local  search
algorithm then performs energy minimizations on a  user-speciﬁed
proportion of the population of individuals. The individuals with
the low resulting energy are transferred to the next generation and
the process is  then repeated. The algorithm is  called Lamarckian
because every new generation of individuals is  allowed to  inherit
the local search adaptations of their parents. Gasteiger charges are
calculated for each atom of the macromolecule in AutoDock 4.2
instead of Kollman charges which were used in  the previous ver-
sions of this program [26].
Docking calculation in  AutoDock 4.2 was performed using the
reﬁned protein and the desired ligand in pdb format. Running Auto-
Grid calculation is  carried out by the .glg ﬁle. Running AutoDock
is carried out by the .dlg ﬁle. Finally 10 different docked con-
formations were studied for a single compound. The parameters
like binding energy, intermolecular energy and inhibition constant
were studied for all the selected ﬂavonoids [27]. For each lig-
and, 10 best docking simulations were obtained against the target
molecule. AutoDock 4.2 was  run  numerous times to get different
docked conformational poses [28]. Based upon the docking param-
eters obtained using AutoDock 4.2, the ﬂavonoids was selected for
further in vitro studies.
2.6. In vitro  acetylcholinesterase inhibition
The assay for the measurement of the enzyme inhibition was
carried out based on  Ellman method [29].  About 1.3 ml  of the Tris-
HCl buffer (pH 8.0; 50 mM)  was treated with 0.4  ml of  different
concentrations of the drug solution and to  it 0.1 ml of the AChE
(0.28 U/ml) was added. This mixture was  incubated for 15 min  and
to it 0.3 ml of Acetylthiocholine iodide (0.023 mg/ml) and 1.9 ml
(5,5′-dithiobis-(2-nitrobenzoic acid) [DTNB] (3  mM) solution were
added. This ﬁnal reaction mixture was  kept for further incubation
at room temperature for 30 min  and the absorbance of the reaction
mixtures was taken at 405 nm.  The assay was done in triplicate
and the results were expressed as mean ± SEM. The percentage
inhibition was calculated for the selected ﬂavonoids [30].
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Fig. 2. The optimized ligand molecules (A–Diosmin, B–Silibinin, C–Scopoletin, D–Taxifolin, E–Tricetin, and F–Donepezil).
2.7. Statistical analysis
Statistical analysis of the results was carried out using Graph-
Pad by one way analysis of variance followed by Dunnett’s test. All
results are expressed as  mean ±  standard deviation (SD) and values
average from 3 independent experiments.
3. Results
3.1. In silico acetylcholinesterase inhibitory profiling
In  silico AChE inhibitory proﬁling were evaluated based on the
binding energy, inhibition constant, intermolecular energy and root
mean square deviation (RMSD) of the starting and the ﬁnal docked
conformation against AChE enzyme. All  the selected ﬂavonoids
showed the excellent docking parameters when compared with
the standard against AChE.
As shown in Table 1, the selected compounds had lesser bind-
ing energy when compared to  the standard (−3.87 kcal/mol).
The binding energy of ﬂavonoids ranged from −6.93 kcal/mol to
−4.27 kcal/mol. Thus proving those ﬂavonoids has potential AChE
inhibitory binding sites when compared to donepezil.
All the selected compounds had lesser inhibition constant when
compared to  the standard (529.73 M).  Inhibition constant is
directly proportional to binding energy. We found a  decrease in
inhibition constant of all the selected compounds with a  simultane-
ous decrease in the binding energy. Flavonoids showed inhibition
constant ranging from 8.37 M  to 739.02 M.  The  selected com-
pounds had lesser intermolecular energy when compared to the
standard (994.14 M).
We  found a  decrease in intermolecular energy of all the selected
compounds with a progressive decrease in  the binding energy.
Flavonoids showed intermolecular energy ranging from −8.72 to
−6.06. Root mean square deviation is indirectly proportional to
binding energy. We  found an increase in RMSD of all the compounds
with an increase in the binding energy. Flavonoids showed RMSD
ranging from 26.46 to 35.19. The selected compounds had excel-
lent RMSD when compared to the standard (42.19). The in silico
AChE inhibitory activities of the compounds were in  the order of
scopoletin > diosmin >  silibinin >  taxifolin >  tricetin >  donepezil.
3.2. Amino acid interactions in the molecular docking studies
The ﬂavonoids showed the excellent binding sites when com-
pared with the standard against AChE. These amino acid residues
play an important role  in the binding site  of target enzyme. This
proves that the ﬂavonoids possess potential AChE inhibitory bind-
ing sites when compared to the standard.
The aminoacid residues responsible for the binding interactions
of the Scopoletin (Fig. 3) with the enzyme AChE were Tyr  124, Trp
Fig. 3. Docked pose of AChE with scopoletin and  donepezil.
286, Leu 289, Ser  293, Ile 294, Phe 295, Tyr 341 and the binding
site  of the Donepezil (Fig. 3) was  found to possess, Tyr 72, Tyr
124, Trp 286, Phe 295 and Tyr  341 amino acid residues. This result
proves that  the effective binding orientations were present in  the
Diosmin when compared with the standard Donepezil. Based on
the most stable conformations, we predict that the interactions
observed with molecular docking calculations of the ﬂavonoids lead
to  reversible AChE inhibitors.
Hydrogen bonding between a  protein and its ligands delivers
a directionality and speciﬁcity of interaction that is  a fundamen-
tal part of molecular recognition. The energetics and kinetics of
hydrogen bonding therefore require to allow the rapid sampling
and kinetics of folding, conferring stability to  the target structure
and providing the speciﬁcity needed for selective macromolecular
interactions.
Hydrophobic interactions make the major contribution to the
stability of 5HCU (AChE) and the major contributors are: Ile  294
(4.5), Leu 289 (3.8), and Phe 295 (2.8) (Table 2). The globular con-
formation of proteins is stabilized predominately by hydrophobic
interactions.
3.3. In vitro acetylcholinesterase inhibitory assay
From the in silico docking studies the ﬂavonoids were selected
for the in vitro cholinesterase inhibitory studies based on the dock-
ing parameters. The in vitro enzymatic activity of the ﬂavonoids
exhibited the potential AChE inhibitory activity than the standard
donepezil (Fig. 4).  The results further validated the in silico dock-
ing studies and it further conﬁrms that the ﬂavonoids could be a
promising remedy for the AD.
An increase in AChE leads to an increase in  breakdown of ACh
to acetate and choline, leading to the development of  AD. Recent
ﬁndings suggest that the occurrence of AD is  increasing world-
wide, possibly due to life style modiﬁcations. AChE inhibitors are
commonly employed in  the treatment of AD.
Inhibition of AChE resulted in  a  decreased breakdown of
acetylcholine into acetate and choline, when measured spectro-
scopically. Among the selected ﬂavonoids, scopoletin was  found
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Table  1
Molecular docking scores of the ﬂavonoids against AChE.
Name of  the Compound Binding Energy(Kcal/mol) Inhibition Constant (kI) (M)  Intermolecular Energy (Kcal/mol) RMSD a
Diosmin −6.03 36.86 −7.84 27.00
Silibinin −5.66 70.92 −7.45 22.59
Scopoletin −6.95 8.37 −8.72 26.46
Taxifolin −5.22 150.32 −7.01 25.01
Tricetin −4.27 739.02 −6.06 35.19
Donepezil −3.87 994.14 −5.46 42.19
a The root mean square deviation of the starting and the ﬁnal docked conformation.
Table 2
Hydrophobic interactions and interacting residues of the AChE with ﬂavonoids.
Amino acid Residue Name of the amino acid Hydrophobicity Average Isotropic Displacement
TYR72 Tyrosine −1.3 60.989
TYR124 Tyrosine −1.3 49.835
TRP286 Tryptophan −0.9 64.389
LEU289 Leucine 3.8 101.06
SER293  Serine −0.8 136.315
ILE294  Isoleucine 4.5 112.474
PHE295 Phenylalanine 2.8 91.122
TYR341 Tyrosine −1.3 87.133
Fig. 4.  in vitro AChE inhibitory activity of the ﬂavonoids (Values are Mean ± SEM of
three parallel measurements).
to possess highest activity (IC50 10.18 ±  0.68 g/ml). The activ-
ity of scopoletin was found to  be greater than the standard,
donepezil (22 ±  0.56 g/ml). All the compounds demonstrated
AChE inhibitory activity at a concentration below 100 g/ml,
with IC50 values ranging from 10.18 to  18.28 g/ml. The AChE
inhibitory activities of the compounds were in the order of scopo-
letin > Diosmin > silibinin >  Taxifolin > Tricetin >  Donepezil.
4. Discussion
AD is a complex neurodegenerative disorder of the central ner-
vous system, characterized by amyloid- deposits, tau-protein
aggregation, oxidative stress and reduced levels of acetylcholine in
the brain [31]. AD is a progressive neurodegenerative disorder clin-
ically characterized by loss of memory and cognition. Cholinergic
deﬁcit and oxidative stress have been implicated in  the patho-
genesis of AD. Therefore, inhibition of acetylcholinesterase and
oxidation are the two promising strategies in the development of
drug for  AD [32,33].
The functionalized piperidine were evaluated in vitro for their
AChE inhibitory activity, and in silico studies for all the target com-
pounds were carried out using pharmacophore mapping, molecular
docking and quantitative structure-activity relationship analysis in
order to know the structural features needed for interaction with
the AChE enzyme and the essential active site residues involved in
the intermolecular interactions [34].
AChE that  has been covalently inhibited by  organophosphate
compounds (OPCs), such as nerve agents and pesticides, has tra-
ditionally been reactivated by using nucleophilic oximes. The
recognized need for new classes of compounds with the ability
to reactivate inhibited AChE with improved in vivo efﬁcacy. Katz
et al.,  2015 described the discovery of new functional groups-
Mannich phenols and general bases-that are  capable of reactivating
OPC-inhibited AChE more efﬁciently than standard oximes and the
cooperative mechanism by which these functionalities are deliv-
ered to the active site [35].
Ali et al. [36] evaluated the tea polyphenols of green tea and
reported its AChE and BChE inhibitory potential and its use in
the management of AD. The  molecular docking analysis revealed
that polyphenols exhibited binding interactions with AChE and
BChE. The amount of energy to bind with AChE and BChE required
by Epigallocatechin-3-gallate was  lowest at  about −14.45 and
−13.30 kcal/mol, respectively.
Phyllanthus acidus is  used in  traditional medicine to treat sev-
eral inﬂammatory, pain and oxidative stress related diseases such
as rheumatism, respiratory disorder, and its potential to pro-
mote intellect and memory enhancement, thus supporting its
anti-Alzheimer’s properties. The methanolic extract of  P. acidus
exhibited inhibition of rat brain AChE and human blood BuChE in
a  dose dependent manner and the inhibition constant value was
found to  be 1009.87 g/ml and 449.51 g/ml respectively [37].
In the  present study, we  had investigated the AChE-drug com-
plexes, ligand-binding sites calculation within the active site of  the
enzyme, pharmacophore perception of ﬂavonoids and in vitro AChE
inhibitory activity of the ﬂavonoids. The ﬂavonoids showed the
better binding modes when compared with the standard against
AChE. These amino acid residues are dynamically involved in  the
formation of hydrophilic and hydrophobic contacts and there were
initiated to play important role in the binding site of target. This
proves that the ﬂavonoids possess potential AChE inhibitory bind-
ing sites when compared to the standard. All the selected ﬂavonoids
contributed AChE inhibitory activity because of  its structural prop-
erties.
In in vitro study, a  dose dependent AChE inhibitory activity was
observed for all the selected ﬂavonoids. These molecular dock-
ing and in vitro analyses could lead to the further development of
potent acetylcholinesterase inhibitors for  the treatment of AD. The
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in vitro results were in  corroboration with the in silico studies as
evidenced by  the docking orientations and the parameters. Based
on the in silico and in vitro AChE inhibitory studies, scopoletin was
found to be potential lead in the management of AD.
5. Conclusions
AChE inhibitors provide symptomatic beneﬁt in AD across key
symptom domains. From the in silico docking studies it is concluded
that ﬂavonoids possess the potential binding sites  and the dock-
ing parameters against the AChE. This in silico studies is actually an
added advantage to  screen the AChE inhibition. The results from the
in vitro study emphasise the ﬂavonoids inhibitory potential against
AChE. The stronger effect of scopoletin than the other ﬂavonoids
and donepezil, is  interesting and merits further characterization.
Scopoletin showed a  particularly favourable AChE inhibitory pro-
ﬁle and thus could be a great potential candidate for AD treatment.
Further investigations on the above compound and in vivo stud-
ies  are necessary to develop clinical useful AChE inhibitor in  the
prevention and management of AD.
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